docetaxel anhydrous has been researched along with Breast Cancer in 2571 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 205 (7.97) | 18.2507 |
| 2000's | 973 (37.85) | 29.6817 |
| 2010's | 1152 (44.81) | 24.3611 |
| 2020's | 241 (9.37) | 2.80 |
| Authors | Studies |
|---|---|
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Arya, GC; Jaitak, V; Kaur, K | 1 |
| Chitkara, D; Mittal, A; Pukale, S; Sahel, DK; Sharma, S; Singh, P | 1 |
| Gilbar, PJ; Hurvitz, SA; Van Belle, H; Wildiers, H | 1 |
| Gao, YY; Kong, FL; Lan, XY; Li, S; Sun, ZW; Xi, YL | 1 |
| Alsherbiny, MA; Bhuyan, DJ; Chang, D; Li, CG; Low, MN | 1 |
| Chen, S; Dong, Z; Liu, Z; Xiao, J; Zhang, C; Zhou, X | 1 |
| Ligtenberg, M; Steegers, M; van den Heuvel, S; van Haren, F; Vissers, K | 1 |
| Cheung, P; Chiu, JW; Kwok, G; Kwong, A; Leung, R; Li, B; Suen, D; Tsang, J; Wong, TT; Yau, T | 1 |
| Banda, K; Gadi, VK; Indorf, A; Jung, L; Miske, A; Nelson, K | 1 |
| Bastos, JK; Conte, FL; Conti, BJ; de Assis Golim, M; de Oliveira Cardoso, E; Rainho, CA; Romagnoli, GG; Santiago, KB; Sforcin, JM; Tasca, KI | 1 |
| Je, NK; Ku, M | 1 |
| Chang, CS; Chang, YY; Hsiao, LC; Lin, HJ; Lin, YF; Liu, DZ | 1 |
| Chen, B; Guo, J; Jiang, J; Li, D; Li, Y; Sui, Y; Xu, H | 1 |
| Albanell, J; Cristóbal, I; de la Fuente, L; Eroles, P; Luque, M; Madoz-Gúrpide, J; Mínguez, P; Rojo, F; Rovira, A; Santamaría, A; Sanz-Álvarez, M; Zazo, S | 1 |
| Li, W; Lu, RH; Shih, CW | 1 |
| He, F; Li, G; Li, Q; Liu, J; Shen, X; Wang, Z | 1 |
| Ahn, JS; Chae, BJ; Im, YH; Kim, JY; Kim, SW; Lee, JE; Lee, SK; Nam, SJ; Park, YH; Ryu, JM; Yu, J | 1 |
| Ahlgren, J; Auvinen, P; Bono, P; Huovinen, R; Joensuu, H; Jukkola, A; Junnila, J; Kataja, V; Kellokumpu-Lehtinen, PL; Lahdenperä, O; Lindman, H; Nilsson, G; Nyandoto, P; Poikonen-Saksela, P; Tanner, M; Villman, K | 1 |
| Ahn, JS; Im, YH; Kim, H; Kim, JY; Lee, MS; Lee, YP; Park, YH | 1 |
| Ben Abdallah, I; Berrazega, Y; Boussen, H; Daoud, N; Mejri, N; Neji, H; Rachdi, H | 1 |
| Beijnen, JH; Huitema, ADR; van Eijk, M; van Werkhoven, E; Vermunt, MAC; Wilthagen, EA | 1 |
| Adamchuk, H; Blayney, DW; Chen, M; Du, L; Ginn, G; Huang, L; Kirtbaya, DV; Mohanlal, R; Ogenstad, S; Zhang, Q | 1 |
| Al-Husban, A; Asir, N; Hegab, M; Horani, M; Kafa, G; Musa, F | 1 |
| Brugman, W; de Boo, LW; Hauptmann, M; Joensuu, H; Jóźwiak, K; Kluin, RJC; Kok, M; Lauttia, S; Lindman, H; Linn, SC; Nederlof, PM; Opdam, M; Schouten, PC; van Steenis, C | 1 |
| Bu, H; Cao, S; Chen, F; Lei, T; Li, L; Shen, M; Xiao, L; Yang, L; Ye, F; Zhang, P | 1 |
| Chen, X; Liu, Z; Lu, Z; Qiao, J; Sun, X; Wang, C; Wang, H; Wang, Y; Xia, Q; Yan, M; Zhou, Y; Zhu, J | 1 |
| Aruga, T; Doihara, H; Hara, Y; Ishida, T; Kaneko, K; Ohtake, T; Saji, S; Taira, T; Takeshita, T; Tsurutani, J; Tsuyuki, S; Uehara, K; Yamaguchi, Y; Yamashita, T; Yanagita, Y | 1 |
| Berger, M; Collins, S; Le, D; Palettas, M; Vargo, C; Williams, N | 1 |
| Cai, W; Lu, H; Zhou, Y | 1 |
| Ahern, TP; Cronin-Fenton, D; Damkier, P; Ejlertsen, B; Feddersen, S; Hamilton-Dutoit, S; Hjorth, CF; Lash, TL; Rørth, M; Stage, TB; Sørensen, HT | 1 |
| Coleman, IM; Corey, E; DeSarkar, N; Haffner, MC; Li, D; Morrissey, C; Nelson, PS; Roudier, MP; Sayar, E; Xin, L | 1 |
| Álvarez, MM; Gallegos-Martínez, S; García-Lara, S; López-Castillo, LM; Trinidad-Calderón, PA; Trujillo-de Santiago, G | 1 |
| Anderson, JD; Bhangoo, RS; Cheng, TW; DeWees, TA; Halyard, MY; Patel, SH; Petersen, MM; Schild, SE; Thorpe, CS; Vargas, CE; Wong, WW | 1 |
| Chen, W; Deng, Q; Dong, M; Duan, S; Gao, N; He, X; Li, F; Liu, S; Liu, T; Liu, Y; Ma, W; Sheng, D; Tu, J; Wang, D; Zhang, F; Zhang, L; Zhang, R; Zhou, L | 1 |
| Basta, P; Chen, W; Crea, F; Czesnikiewicz-Guzik, M; Dikalov, S; Dikalova, A; Dobosz, AM; Dobrzyn, A; Dormer, J; Dziewulska, A; Gara, K; Grodzicki, T; Guzik, TJ; Harrison, DG; Hodorowicz-Zaniewska, D; Jozefczuk, E; Krolczyk, J; Laksa, I; Maffia, P; Mikolajczyk, TP; Moslehi, J; Nosalski, R; Saju, B; Siedlinski, M; Streb, J; Sulicka-Grodzicka, J; Szczepaniak, P; Tomaszewski, M | 1 |
| Ishida, T; Koseki, T; Tada, H; Takahashi, N; Tanda, N; Washio, J | 1 |
| Alacacioglu, A; Atci, MM; Avci, O; Ayhan, M; Aykan, MB; Cabuk, D; Cakar, B; Cevik, GT; Coban, E; Demir, A; Demir, H; Diker, O; Dincer, M; Dogan, I; Esen, SA; Garbioglu, DB; Gülbagci, BB; Gulmez, A; Gursoy, P; Hacibekiroglu, I; Inal, A; Kalkan, NO; Karadurmus, N; Karatas, F; Kemal, Y; Nayir, E; Özdemir, Ö; Ozden, E; Paydas, S; Pilanci, KN; Sakalar, T; Salim, DK; Sari, M; Sönmez, ÖU; Taskaynatan, H; Tasli, F; Telli, TA; Uluç, BO; Vatansever, S; Yildirim, ME; Yildiz, Y; Yilmaz, C; Yilmaz, M; Zengel, B | 1 |
| Chen, Y; Cheng, M; Gao, HF; Ji, F; Li, J; Shen, B; Wang, K; Yang, C; Yang, M; Zhang, J; Zhang, L; Zhang, T; Zhu, T | 1 |
| Ahn, HK; Ahn, JH; Chae, H; Choi, YL; Im, SA; Jeong, JH; Jung, KH; Kim, JH; Kim, JY; Kim, MH; Lee, DW; Lee, KH; Lee, KS; Park, YH; Sim, SH; Sohn, JH; Suh, KJ | 1 |
| Chan, AL; Leung, JH; Tai, YS; Tsung-Chin, H; Wang, SY; Yip Fion, HT | 1 |
| Gabata, T; Kozaka, K; Sai, Y; Takamatsu, A; Toshima, F; Yamamoto, N; Yoshida, K | 1 |
| Chakrabarti, P; Dehghani, M; Gholamzadeh, MJ; Kamali, AM; Mousavi, SZ; Nami, M; Owrangi, M; Vasaghi Gharamaleki, M | 1 |
| Aas, T; Aase, HS; Deng, W; Eikesdal, HP; Engebrethsen, C; Geisler, J; Geisler, S; Hovig, E; Iversen, GT; Knappskog, S; Lønning, PE; Meza-Zepeda, LA; Myklebost, O; Nakken, S; Seyedzadeh, M; Steinskog, ES; Venizelos, A; Vodak, D | 1 |
| Etminan, M; Maberley, D; Mikelberg, F; Sodhi, M; Yeung, SN | 1 |
| Eckl, T; Grafe, A; Klare, P; Luedtke-Heckenkamp, K; Reichert, D; Schneeweiss, A; Thill, M; Wimberger, P; Zaiss, M; Ziegler-Löhr, K | 1 |
| Amrita, PNA; Ashariati, A; Bintoro, UY; Diansyah, MN; Hendrata, WM; Looi, SS; Mahmudin, AA; Romadhon, PZ; Savitri, M; Wijaya, AY | 1 |
| Del Mar Conde-Crespo, M; Guevara-Cuellar, CA; Nuñez-Castro, JM; Parody-Rúa, E; Rengifo-Mosquera, MP | 1 |
| Behroozaghdam, M; Bishayee, A; De Greef, D; Dehghani, M; Hasani Sadi, F; Hashemi, M; Javanshir, S; Kamali, D; Mirzaei, S; Rashidi, M; Tabari, T; Zabolian, A; Zarepour, A; Zarrabi, A | 1 |
| Chan, LL; Kwok, CCH; Tse, SLA; Wang, F; Wong, MCS; Wong, SPY; Wong, WH | 1 |
| Dilawari, A; Graham, D; Isaacs, C; Kurian, S; Lynce, F; Mainor, C; McNamara, D; Mohebtash, M; Ottaviano, Y; Pohlmann, PR; Rao, S; Swain, SM; Swanson, N; Tan, M; Warren, R; Wu, T | 1 |
| Accetta, C; Carbognin, L; D'Angelo, T; Di Giorgio, D; Di Leone, A; Fabi, A; Franceschini, G; Fuso, P; Garganese, G; Giannarelli, D; Magno, S; Masetti, R; Muratore, M; Paris, I; Pavese, F; Sanchez, AM; Scambia, G; Terribile, DA; Tiberi, G | 1 |
| Cao, M; Li, H; Lv, Z; Ma, F; Mo, H; Pan, B; Song, G; Sun, X; Teng, Y; Xu, B; Yan, X; Zhai, J; Zhao, F; Zhao, J | 1 |
| Itagaki, T; Kimura, Y; Shigematsu, H | 1 |
| Chen, Q; Chen, Y; Guo, J; Li, X; Lin, J; Lin, M; Lin, W; Weng, Y; Yu, X; Zeng, S; Zheng, X | 1 |
| Chen, LC; Chen, M; Cheng, WJ; Chuang, KH; Ho, HO; Hsieh, CM; Lin, SY; Sheu, MT | 1 |
| Aoki, Y; Hamada, K; Han, Q; Hoffman, RM; Hozumi, C; Kubota, Y; Masaki, N; Obara, K; Tsunoda, T | 1 |
| Feng, J; Knott, A; Li, H; Li, Q; Li, W; Macharia, H; Siddiqui, A; Sun, T; Wang, X; Xu, B; Yin, Y; Zhang, Q; Zheng, H; Zhu, H | 1 |
| Eto, T; Hara, M; Ijichi, H; Koga, C; Misumi, N; Nakamura, Y; Okamoto, M; Tajiri, W; Tokunaga, E | 1 |
| Bernardo, MCC; Braojo, IMP; Caballero, BB; Carrasco, JM; Fernández, BM; Guerrero, OV; Gutiérrez, ZA; Medina, EAG; Miguel, KL; Montero, YC; Ortiz, MR; Prado, YID; Rodríguez, LEM; Rubio, MC; Torres, KP; Tul, LEA; Varela, IGS | 1 |
| Eguchi, S; Hidaka, M; Kuba, S; Matsumoto, M; Morita, M; Nagayasu, T; Otsubo, R; Sakimura, C; Yamanouchi, K; Yano, H | 1 |
| Fu, P; Huang, J; Jiang, Z; Lin, X; Liu, Q; Liu, Y; Liu, Z; Tang, J; Wang, C; Wang, H; Wang, K; Wang, S; Wang, Y; Wu, F; Wu, J; Yang, B; Yang, H; Zhang, S; Zhen, L; Zhu, X; Zou, J | 1 |
| Chen, XM; Fan, MH; Huang, GZ; Liu, J; Liu, Z; Ma, L; Xuan, XJ | 1 |
| Armirotti, A; Bono, L; Decuzzi, P; Felici, A; Ferreira, M; Gawne, PJ; Mascolo, DD; Moore, TL; Palange, AL; Salerno, M; Spanò, R | 1 |
| Trapani, D | 1 |
| Beijnen, JH; Huitema, ADR; van Eijk, M | 1 |
| Liang, Q; Liu, Y; Thakur, A; Xu, Z; Yan, Y; Zeng, S; Zhou, S | 1 |
| Hakamada, K; Igawa, A; Nishimura, A; Suzuki, T; Yamamoto, T | 1 |
| Ikeda, M; Kataoka, Y; Nakagoshi, H; Suwa, H; Taji, T | 1 |
| Hung, CC; Hung, CS; Kuo, YL; Li, CL; Lin, CY; Tsai, JH; Yeh, DC | 1 |
| Chen, R; He, J; Huang, X; Li, X; Ma, L; Shi, W; Wan, X; Wang, J; Wang, L; Wang, Y; Xu, L; Xu, Y; Zha, X; Zhang, W; Zheng, R | 1 |
| André Di Ricco, B; Martins Medeiros, E; Miyasaki Piovesana, M; Peron, V; Teixeira Liutti, V | 1 |
| Guo, Z; Liu, D; Liu, Y; Wang, L; Zhang, S; Zhang, X | 1 |
| Cathcart-Rake, EJ; Friday, BB; Lacouture, M; Loprinzi, CL; McCue, S; O'Connor, A; Piens, J; Register, T; Smith, D; Thomé, S; Young, S; Zahrieh, D | 2 |
| Anusca Martins, K; Costa Marinho, ED; Di Pietro, PF; Dias Custódio, ID; Freitas-Junior, R; Frenzel, AP; Godinho-Mota, JCM; Gonzalez, MC; Mota, JF; Paiva Maia, YC; Rodrigues Vilella, P; Schroeder de Souza, J; Vaz-Gonçalves, L; Verde, SMML | 1 |
| Ahn, HK; Ha, JY; Ji, JH; Kang, JH; Kim, CK; Kim, HY; Kim, JY; Kim, SB; Koh, SJ; Koo, DH; Kwon, JH; Lee, DW; Lee, KH; Lee, KS; Maeng, CH; Oh, SY; Sohn, J; Won, YW | 1 |
| Heibloem, RE; Ilozumba, OUC; Komen, MMC; van den Hurk, CJG | 1 |
| Cao, Y; Gong, J; Kou, F; Li, J; Li, Y; Liu, D; Lu, M; Lu, Z; Shen, L; Wang, X; Wang, Z; Xu, R; Zhang, X; Zhou, J; Zhu, X; Zou, J | 1 |
| Aksoy, S; Arslan, C; Basaran, G; Bilici, A; Cakar, B; Cicin, I; Cubukcu, E; Demirci, U; Erdem, D; Gumus, M; Harputluoglu, H; Kaplan, MA; Karadag, I; Karadurmus, N; Oksuzoglu, B; Olmez, OF; Selcukbiricik, F; Sendur, MAN; Sezer, A; Sezgin Goksu, S; Shbair, ATM; Sumbul, AT | 1 |
| El-Naggar, A; Ferrarotto, R; Wotman, M | 1 |
| Bian, W; Chu, J; Kong, L; Lin, X; Liu, J; Wei, F | 1 |
| Dang, CT; Du Toit, Y; Hurvitz, SA; Knott, A; Polito, L; Restuccia, E; Sanglier, T; Shim, J; Swain, SM | 1 |
| Angiolini, V; Bei, R; Benvenuto, M; Di Meo, C; Frajese, GV; Mancini, P; Masuelli, L; Matricardi, P; Nalli, M; Nardozi, D; Paoletti, L; Zoratto, N | 1 |
| Dimitsaki, S; Jaulent, MC; Natsiavas, P | 1 |
| Hayash, M; Hirata, A; Kimura, K; Morita, S; Takashima, Y; Terasawa, R | 1 |
| Ahn, MJ; An, HJ; Choi, YJ; Jung, HA; Kang, EJ; Kim, JJ; Kim, JW; Kim, MK; Kim, SB; Lee, J; Lee, KW; Lee, SH; Oh, SY; Park, LC; Park, S; Seo, S; Shim, BY; Shin, SH | 1 |
| Arteaga, CL; Chu, F; Gagea, M; Hanash, S; Hanker, AB; Liu, S; Liu, W; Marchese, A; Neelapu, SS; Nguyen, N; Singareeka Raghavendra, A; Tripathy, D; Xie, SM; Yang-Kolodji, G; Zimmermann, J | 1 |
| Kanno, R; Oshino, T; Saito, Y; Sugawara, M; Takekuma, Y; Takeshita, T | 1 |
| Ding, K; Ding, X; Ding, Y; Gu, X; He, X; Liang, C; Mo, W; Qin, C; Wang, O; Xie, X; Yang, H; Zhao, S | 1 |
| Ah, YM; Cha, SH; Choi, HD; Shin, KH | 1 |
| Oshino, T; Saito, Y; Sugawara, M; Takekuma, Y; Takeshita, T | 1 |
| Ahn, JH; Gong, G; Hwang, I; Jeong, JH; Jung, KH; Kim, HH; Kim, JE; Kim, SB; Lee, HJ; Shin, J; Son, BH | 1 |
| Deo, S; Gogia, A; Gupta, A; Mathur, S; Sagiraju, HKR; Sharma, DN | 1 |
| Araya, J; Hirano, S; Konishi, K; Nagabuchi, M; Ogino, J; Sakamoto, T | 1 |
| Abe, K; Ait-Oufella, H; Alacamli, G; Alacamli, OG; Amir, O; Antar, S; Ashour, H; Azimonti, G; Baba, Y; Balogun, MM; Bampidis, V; Bastos, ML; Ben Hamouda, N; Bickel Haase, T; Bjornsson, R; Bostan, M; Braik, R; Brantom, P; Briggs, S; Bujor, I; Canbek, TD; Cherecheanu, AP; Chesson, A; Choudhary, RJ; Christensen, H; Chung, HR; Clavier, T; Dahman, NBH; Dani, S; Demailly, Z; Devine, LD; Ding, G; Duan, X; Durjava, M; Dusemund, B; Edebali, S; Elbaz Greener, G; Elnoby, AS; Fang, Q; Fares, AM; Fashola, MB; Fawzy, MS; Fouad, FM; Fu, SZ; Fujita, S; Furusawa, S; Gallagher, AM; Gao, J; Goyal, N; Guo, J; Hamuda, N; Han, Y; Hariri, G; Heist, EK; Hill, AJ; Homoud, M; Hu, Q; Hu, Z; Huang, L; Ide, T; Ikeda, M; Ishimaru, K; Jiang, C; Kaderli, ST; Kanamura, T; Karalezli, A; Kaur, P; Kazatsker, M; Kobo, O; Kouba, M; Kumar, R; Lavillegrand, JR; Leshem, E; Li, A; Li, S; Liu, R; López Puente, S; López-Alonso, M; Ma, M; Madias, C; Manini, P; Marcon, F; Margolis, G; Matsushima, S; Mayo, B; Miller, JE; Miyake, R; Miyamoto, HD; Naumann-Gola, S; Ortner, E; Pandit, R; Pang, Y; Pechová, A; Petkova, M; Pîrvulescu, R; Popa-Cherecheanu, A; Ramos, F; Roguin, A; Rozen, G; Ruskin, JN; Sanz, Y; Schweiggert-Weisz, U; Shafie, AAA; Sharma, H; Shi, X; Stoicescu, EA; Stopyra, W; Suh, JD; Sul, S; Tamion, F; Tiu, C; Tohyama, T; Tsutsui, H; Tsutsui, Y; Vandestienne, M; Villa, RE; Wang, P; Watanabe, M; Westendorf, J; Woutersen, R; Xia, J; Xing, W; Xu, X; Yang, L; Yang, N; Yu, J; Yu, M; Yu, X; Zhang, L; Zhao, Y; Zhao, Z; Zhou, X; Zorn, H | 1 |
| Cai, X; Fang, Z; Li, L; Sui, F; Wan, X; Zhang, Y | 1 |
| Chen, L; Kong, LJ; Lin, W; Mo, CQ; Wu, KL; Wu, X | 1 |
| Li, J; Liu, J; Meng, L; Sun, L; Wang, J; Zhang, H; Zhou, Q | 1 |
| Blayney, DW; Cummings Joyner, AK; Huang, L; Jarvis, J; Kuderer, NM; Lyman, GH; Monhanlal, R; Nunag, D; Wells, J | 1 |
| Chen, R; He, J; Huang, X; Shi, W; Wan, X; Wang, J; Wang, Y; Xu, L; Xu, Y; Zha, X; Zhang, W | 1 |
| Brufsky, AM; Ding, Y; Gomez Marti, JL; Nasrazadani, A; Normolle, D | 1 |
| Cheng, J; Cheng, Y; Dong, F; Geng, C; Li, H; Li, W; Liu, H; Liu, Q; Luo, T; Ma, F; Mo, Q; Nie, J; Ouyang, Q; Sun, T; Teng, Y; Tong, Z; Wang, S; Wang, X; Wang, Y; Wu, S; Wu, X; Xu, B; Yan, M; Yang, J; Ye, C; Zeng, X; Zhang, Q; Zhong, J; Zhu, X | 1 |
| Abraham, DT; Backianathan, S; Balakrishnan, R; Chacko, RT; Cherian, AJ; George, TK; Georgy, JT; Joel, A; John, AO; Manipadam, MT; Patole, S; Paul, MJ; Ramnath, N; Rebekah, G; Sebastian, P; Sharma, P; Sigamani, E; Singh, A; Thumaty, DB | 1 |
| Ahn, JS; Chae, BJ; Cho, WK; Im, YH; Kim, H; Kim, JY; Kim, N; Kim, SW; Kim, TG; Lee, JE; Lee, SK; Nam, SJ; Park, W; Park, YH; Ryu, JM; Yu, J | 1 |
| Bago-Horvath, Z; Balic, M; Bartsch, R; Birnleitner, H; Brostjan, C; Egle, D; Exner, R; Filipits, M; Fitzal, F; Frantal, S; Gnant, M; Oehler, R; Ramos, C; Rudas, M; Sachet, M; Singer, CF; Wimmer, K | 1 |
| Ambroggi, M; Bisagni, G; Bria, E; Campanini, N; Carbognin, L; Casarini, C; Cretella, E; Fiorio, E; Frassoldati, A; Gianni, L; Gori, S; Maglietta, G; Missale, G; Montemurro, F; Mura, A; Musolino, A; Pellegrino, B; Serra, O; Silini, EM; Todeschini, R; Tognetto, M; Tommasi, C; Zamagni, C; Zambelli, A | 1 |
| Chen, X; Huang, X; Lin, G; Liu, G; Ma, J; Mei, L; Shu, X; Wang, X; Wang, Y; Yang, Y; Ying, Y; Zhao, Y; Zuo, A | 1 |
| Alonso-González, C; Cos, S; García Nieto, E; Gómez-Arozamena, J; González, A; González-González, A; Martínez-Campa, C; Menéndez-Menéndez, J; Sánchez-Fernández, C | 1 |
| Chworos, A; Janaszewska, A; Klajnert-Maculewicz, B; Marcinkowska, M; Sobierajska, E; Stanczyk, M | 1 |
| Anazodo, A; Dickinson, JE; Li, Z; Lui, K; Safi, N; Sullivan, EA; Wang, AY | 1 |
| Cheng, R; Deng, C; Fang, H; Gu, X; Sun, H; Zhao, X; Zhong, Z | 1 |
| Chan, YN; Chen, CY; Jheng, YW; Lin, MW; Wang, PJ; Wang, YJ | 1 |
| Ben Kridis, W; Khanfir, A | 3 |
| Li, J; Liang, X; Shen, Q; Sun, L; Yang, J; Zhang, J; Zuo, T | 1 |
| Ban, L; Cui, X; Wang, D; Zhang, B; Zhang, X; Zhao, J | 1 |
| Abrams, J; Albain, KS; Badve, SS; Berenberg, JL; Brufsky, AM; Dees, EC; Desbiens, C; Ellis, MJ; Geyer, CE; Goetz, MP; Goggins, TF; Gomez, HL; Gray, RJ; Hayes, DF; Kaklamani, VG; Keane, MM; Lively, T; Mahalcioiu, C; Makower, DF; Mayer, IA; Olson, JA; Paik, S; Reddy, PS; Saphner, TJ; Sledge, GW; Sparano, JA; Toppmeyer, DL; Wagner, LI; Wood, WC | 1 |
| An, N; Liu, YC; Ma, Y; Sun, C; Sun, P; Wang, Y | 1 |
| Chen, SC; Hsu, YH; Lin, YF; Shen, WC; Wang, CH | 1 |
| Coonrod, SA; Li, F; Liu, X; Miao, L; Mondal, S; Qin, H; Thompson, PR; Xue, T; Zhang, X | 1 |
| Bland, KA; Bovard, J; Campbell, KL; Davis, MK; Gelmon, KA; Kirkham, AA; McKenzie, DC; Shenkier, T; Zucker, D | 1 |
| Barbano, R; Copetti, M; Esteller, M; Fazio, VM; Fontana, A; Graziano, P; Maiello, E; Mazza, T; Morritti, M; Murgo, R; Parrella, P; Pasculli, B; Rendina, M; Valori, VM | 1 |
| Ghassami, E; Jahanian-Najafabadi, A; Minaiyan, M; Noorbakhsh, A; Varshosaz, J | 1 |
| Chen, S; Feng, Z; Liang, Y; Wang, M | 1 |
| Chung, S; Cooper, J; Dadwal, S; Jung, J; Kruper, L; Mortimer, JE; Stewart, D; Wong, L; Yu, KW; Yuan, Y | 1 |
| Althaus, B; Chang, YC; Cui, S; Eng-Wong, J; Jiang, Z; Kang, SY; Laohawiriyakamol, S; Li, J; Li, W; Liao, N; Mao, Y; Pang, D; Seo, JH; Shao, Z; Shen, K; Wang, C; Wang, H; Wang, S; Wang, Y; Yang, H; Zhou, J | 1 |
| Bernatz, S; Braun, Y; Devraj, K; Halder, R; Harter, PN; Ilina, EI; Jennewein, L; Kleber, S; Mischo, A; Mittelbronn, M; Mueller, K; Penski, C; Pestalozzi, BC; Renner, C; Solbach, C; Thorsen, F | 1 |
| Ding, T; Dong, L; Jiang, YF; Li, JB; Xie, BJ; Zhu, LN; Zhu, ZN | 1 |
| Fujii, T; Horiguchi, J; Inoue, K; Kurosumi, M; Kurozumi, S; Matsumoto, H; Oyama, T; Shirabe, K | 1 |
| Ahn, JH; Jeong, JH; Jung, KH; Kim, JE; Kim, SB; Koh, SJ; Lee, KS; Seo, JH; Sohn, BS; Sohn, JH | 1 |
| Ozturker, C; Tas, F | 1 |
| Duan, W; Ha-Lien Tran, P; Tran, TTD; Wang, T; Yang, C | 1 |
| Bouganim, N; Fuson, A; Joshi, AS; Khalife, S; Mascarella, MA; Ramanakumar, AV; Richardson, K; Sadeghi, N; Siegel, R; Taheri, R | 1 |
| Bi, PD; Duan, WJ; Liu, NQ; Ma, Y; Zhen, X | 1 |
| Belevich, YV; Dudnikova, EA; Dygai, AM; Goldberg, AV; Goldberg, VE; Goncharova, NM; Grigor'ev, EG; Polyakova, TY; Popova, NO; Simolina, EI; Vysotskaya, VV | 1 |
| Ali, AA; Alqhtani, H; Balkrishnan, R; de Lima Lopes, G; Diaby, V; Ko, Y; Palacio, S; van Boemmel-Wegmann, S; Wang, CY | 1 |
| Baas, IO; van der Wall, E; van Dooijeweert, C | 1 |
| Albain, KS; Atkins, JN; Boileau, JF; Borges, VF; Cecchini, RS; Costantino, JP; Crown, JP; Fehrenbacher, L; Flynn, PJ; Geyer, CE; Mamounas, EP; Moore, TD; Paik, S; Polikoff, J; Provencher, L; Rastogi, P; Robidoux, A; Stokoe, C; Swain, SM; Wolmark, N | 1 |
| Kaneko, K; Kashiwaba, M; Masuda, N; Matsunami, N; Morita, S; Ohno, S; Ohtani, S; Sato, N; Takahashi, M; Takano, T; Toi, M; Ueno, T; Yamamura, J | 1 |
| Chan, SK; Chin, CHY; Chong, G; Kwan, MW; Lee, CF; Lee, SF; Leung, K; Ma, VYM; Ng, TY; So, KH; Tang, W; Tsang, HT; Wong, CS; Wong, LKM; Yeung, A; Yip, YTE; Young, WM; Zhou, K | 1 |
| Hoshina, H; Takei, H | 1 |
| Ahmad, FJ; Ahmad, I; Akhter, S; Alam Rizvi, MM; Hafeez, Z; Jain, GK; Zafar, S | 1 |
| Bengtsson, NO; Bergh, J; Foukakis, T; Gnant, M; Greil, R; Hedayati, E; Hellström, M; Hübbert, L; Johansson, H; Loibl, S; Malmström, P; Matikas, A; Moebus, V; Papakonstantinou, A; Steger, G; Untch, M | 1 |
| Chang, J; Chen, T; He, M; Hong, W; Li, F; Li, H; Li, J; Liu, L; Luo, D; Ran, L; Shan, L; Song, Y; Wang, B; Wang, H | 1 |
| Bouquet, F; Carre, M; Ciccolini, J; Fanciullino, R; Giacometti, S; Lacarelle, B; Maia, T; Rodallec, A; Savina, A; Sicard, G; Valette, M | 1 |
| Emami, J; Hasanzadeh, F; Kazemi, M; Lavasanifar, A; Minaiyan, M; Mirian, M | 1 |
| Ahmad, FJ; Akhter, S; Garg, N; Kumar Jain, G; Selvapandiyan, A; Zafar, S | 1 |
| Goping, IS; Kirschenman, R; Lemieux, H; Mann, J; Montpetit, R; Yang, N | 1 |
| Awan, A; Basulaiman, B; Bedard, D; Brunet, MC; Clemons, M; Fergusson, D; Hutton, B; Kehoe, A; MacDonald, F; Mallick, R; Mazzarello, S; Robinson, A; Saunders, D; Stober, C; Vandermeer, L | 1 |
| Barres, B; Chanchou, M; Coudert, B; Durando, X; Gadéa, E; Ginzac, A; Merlin, C; Molnar, I; Thivat, E | 1 |
| Gao, J; Liu, J; Lu, Y; Shen, X; Xie, F; Yin, C | 1 |
| Chang, ED; Kim, JS; Kim, YS; Lee, DS; Na, SJ; Whang, IY; Won, HS | 1 |
| Cheng, L; Li, L; Lu, Y; Majumdar, A; Stover, D; Wu, S | 1 |
| Andrade, BYG; Báo, SN; da Rocha, MCO; da Silva, PB; de Oliveira, JV; Estrela-Lopis, I; Longo, JPF; Merker, C; Radicchi, MA; Venus, T | 1 |
| Fujisawa, T; Higaki, K; Ishiguro, H; Kadoya, T; Kaneko, K; Masuda, N; Matsunami, N; Mizutani, M; Morimoto, T; Morita, S; Ohno, S; Ohtani, S; Sato, N; Takahashi, M; Takano, T; Tanaka-Mizuno, S; Toi, M; Yamamoto, Y; Yanagita, Y | 1 |
| Lambertini, M; Vaz-Luis, I | 1 |
| Burstein, HJ; Hassett, MJ; Li, H; Punglia, RS | 1 |
| Hou, L; Huang, M; Ling, R; Meng, H; Wang, Z; Yan, C; Yang, L; Zhang, C; Zhang, J; Zhang, M | 1 |
| Faridi-Majidi, R; Jaafari, MR; Rezayat, SM; Sadri, K; Vakili-Ghartavol, R | 1 |
| Bergh, J; Brandberg, Y; Foukakis, T; Gnant, M; Greil, R; Hellström, M; Johansson, H; Möbus, V | 1 |
| Eguchi, S; Iwata, T; Kanetaka, K; Kuba, S; Maeda, S; Matsumoto, M; Morita, M; Nagayasu, T; Otsubo, R; Sakimura, C; Sato, S; Yamanouchi, K; Yano, H | 1 |
| Chan, KKW; Earle, CC; Eisen, A; Gong, IY; Trudeau, ME; Yan, AT | 1 |
| Aoishi, Y; Hirai, Y; Kawaji, M; Miyasaka, M; Nishiguchi, H; Nishimura, Y; Oura, S; Shima, A | 1 |
| Albain, KS; Carlos, RC; Cella, D; Dees, EC; Garcia, SF; Geyer, CE; Goetz, MP; Gray, RJ; Hayes, DF; McCaskill-Stevens, WJ; Minasian, LM; Olson, JA; Pritchard, KI; Sledge, GW; Sparano, JA; Tevaarwerk, AJ; Wagner, LI; Whelan, TJ; Yanez, B | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Fujiwara, Y; Hasegawa, J; Hashimoto, K; Ikeda, K; Kawabata, H; Nishizawa, D; Ozaki, Y; Shimizu, C; Shimomura, A; Shiraishi, S; Takano, T; Tamura, K; Tamura, N; Tanabe, Y; Yonemori, K; Yunokawa, M | 1 |
| Rong, G; Song, Z; Xiang, L | 1 |
| Alizadeh, N; Darjani, A; Mirpour, SH; Mohammadhoseini, M; Rafiei, E; Rafiei, R | 1 |
| Tribukait, B | 1 |
| Ahn, SH; Gong, G-; Han, W; Jung, YS; Kim, HJ; Kim, LS; Lee, ES; Nam, SJ; Noh, WC | 1 |
| Allen, RJ; Bishop, RT; Capulli, M; Carrasco, G; Idris, AI; Li, B; Marino, S; Mollat, P; Ottewell, PD; Sims, AH; Sparatore, A; Wang, N | 1 |
| Bergan, R; Cao, M; Liu, B; Liu, Y; Luoh, SW; Mori, M; Zhang, X; Zhang, Z | 1 |
| Kogure, A; Ochiya, T; Prieto-Vila, M; Shimomura, I; Takahashi, RU; Usuba, W; Yamamoto, Y | 1 |
| Bathara, M; Chaudhari, D; Date, T; Ghadi, R; Jain, S; Kuche, K | 1 |
| Bueno, C; Carolla, RL; Chen, B; Hillman, DW; Jenkins, RB; Johnson, DB; Leon-Ferre, RA; Moreno-Aspitia, A; Northfelt, DW; Perez, AT; Perez, EA; Zon, RT | 1 |
| Albuquerque, L; Guerreiro, C; Reimão, S | 1 |
| Feng, J; Lei, G; Li, H; Li, Q; Li, W; Restuccia, E; Shao, Z; Sun, T; Wang, X; Xu, B; Yin, Y; Zhang, H; Zhang, Q; Zheng, H | 1 |
| Fan, ZM; Ma, L; Zhang, DG; Zheng, LH | 1 |
| Biganzoli, E; Clatot, F; Crown, J; de Azambuja, E; De Bortoli, D; Demicheli, R; Desmedt, C; Di Leo, A; Fornili, M; Francis, PA; Piccart, M; Sotiriou, C; Viale, G | 1 |
| Chowdhury, R; Roy, A; Sharma, S; Swetha, KL | 1 |
| Ball, S; Elmassry, M; Jahan, N; Quirch, M; Rehman, S; Sultan, A; Wongsaengsak, S | 1 |
| Babalola, C; Ibraheem, A; Karrison, T; Kotila, O; Ntekim, AI; Olopade, CO; Sofoluwe, AA | 1 |
| Cheng, MY; Gao, HF; Hu, MX; Ji, F; Li, WP; Wang, K; Xu, FP; Yang, CQ; Yang, M; Zhang, LL; Zhu, T | 1 |
| Endo, M; Hashishita, H; Takada, S; Uno, K | 1 |
| Bhat, G; Chawla, S; Cobb, PW; Hasal, SJ; Láng, I; Mezei, K; Moon, YW; Schwartzberg, LS | 1 |
| Ismail, F; Kang, IH; Lee, DW | 1 |
| Bermejo, B; de la Torre-Montero, JC; Del Monte-Millán, M; García-Sáenz, JÁ; González-Neira, A; Herraez, B; Lluch, A; Martín, M; Núñez-Torres, R; Peiró-Chova, L; Pinilla, K; Pita, G; Rodrigo-Faus, M; Tejera-Pérez, H | 1 |
| Anisimov, VN; Artemyeva, AS; Baldueva, IA; Belyaev, AM; Golubev, AG; Kireeva, GS; Kruglov, SS; Maydin, MA; Panchenko, AV; Tyndyk, ML | 1 |
| Bi, Z; Chen, P; Liu, YB; Song, XR; Sun, X; Wang, YS; Zhao, T | 1 |
| Han, M; Hong, Y; Liu, Y; Ma, J; Shan, B; Wang, L; Zhang, S | 1 |
| Barrett, JA; Chawla, S; Greene, D; Kolli, P; Lakshmikanthan, S; Lebel, F | 1 |
| Aldaz-Pastor, A; Burgos-San José, A; Garrido-Siles, M; González-Haba-Peña, E; Mangues-Bafalluy, I; Martínez-Bautista, MJ | 1 |
| Coe, F; Ekholm, M; Horsley, L; Howell, SJ; Wang, X | 1 |
| Alsafar, N; Batra, A; Hannouf, MB; Lupichuk, S | 1 |
| Asakawa, T; Ikeda, M; Ishida, K; Ito, Y; Komoike, Y; Masuda, N; Matsumoto, S; Nagai, SE; Nakayama, T; Ohtani, S; Osako, T; Shimizu, D; Takahashi, M; Takashima, S; Takashima, T; Tsuneizumi, M; Yamaguchi, M | 1 |
| Chen, Q; Cong, S; Dong, J; Jiang, D; Jin, L; Li, F; Luo, H; Wang, X | 1 |
| Cheon, C; Ko, SG | 1 |
| Akpa, AA; Bathily, M; Berthe, D; Cisse, HL; Dao, S; Dembele, JP; Diabate, K; Diakite, A; Diallo, DA; Diarra, B; Diarra, IM; Fofana, Y; Guindo, I; Konate, M; Kone, AA; Kone, AC; Kone, AS; Kone, J; Minta, D; Ouattara, BZ; Sidibe, A; Sidibe, FM; Sidibe, S; Soumare, MD; Toloba, Y; Toure, BA | 1 |
| Hao, C; Jia, Y; Li, S; Meng, W; Tong, Z; Xie, X; Zhang, J | 1 |
| Arai, K; Best, D; Brown, A; Dash, C; Eton, EO; Goldman, A; Goldman, D; Khiste, S; Kohandel, M; Mondal, J; Natarajan, SK; Pellowe, M; Rahman, M; Ramadurai, N; Saha, T; Sengupta, S; Shanthappa, B; Smalley, JL; Smalley, M; Thayakumar, A | 1 |
| Gao, C; Song, C; Wang, Z; Zhao, J | 1 |
| Cai, D; Chen, F; Diao, L; Hu, Y; Jin, H; Shen, A; Tao, J; Wang, S | 1 |
| Alkhatib, MH; Bawadud, RS; Gashlan, HM | 1 |
| Andergassen, U; Bauer, E; Beckmann, MW; Bekes, I; Blohmer, JU; Brucker, SY; de Gregorio, A; de Gregorio, N; Deniz, M; Fasching, PA; Fehm, TN; Fink, V; Forstbauer, H; Friedl, TWP; Häberle, L; Heinrich, G; Janni, W; Lato, K; Lorenz, R; Mahner, S; Müller, V; Rack, B; Schneeweiss, A; Schrader, I; Tesch, H | 1 |
| Eguchi, S; Kanetaka, K; Kuba, S; Matsumoto, M; Morita, M; Nagayasu, T; Otsubo, R; Sakimura, C; Yamanouchi, K; Yano, H | 1 |
| Dai, Y; Hu, G; Huang, T; Luo, X; Peng, P; Qiu, H; Wu, B; Yuan, X | 1 |
| Ishiyama, T; Jinguu, A; Matsumoto, H; Yamaya, H | 1 |
| Bao, B; Chen, Y; Lv, Y; Sun, D; Wang, J; Zhang, L; Zhao, W | 1 |
| Emi, A; Kadoya, T; Kimura, Y; Masumoto, N; Okada, M; Sasada, S | 1 |
| Lee, KE | 1 |
| Choi, JH; Jeon, CW; Jung, S; Kim, YO | 1 |
| Mandal, B; Mukherjee, B; Panda, J; Sarkar, R; Satapathy, BS; Sen, R; Tudu, B | 1 |
| Joerger, M; Kloft, C; Muth, M; Ojara, FW | 1 |
| Ito, T; Iwasaki, A; Nohara, Y; Ono, S; Tanaka, M; Yamashita, S; Yoshinaga, Y | 1 |
| Bienkowska, J; Bonato, V; Ching, KA; Cho, SY; Choi, YL; Deng, S; Ding, Y; Fernandez, D; Hwang, S; Kan, Z; Kang, ES; Kim, J; Kim, JY; Kim, SW; Kim, YJ; Lal, S; Lee, JE; Lee, SH; Lee, SK; Nam, JY; Nam, SJ; Park, S; Park, WY; Park, YH; Powell, E; Ram, S; Rejto, PA; Shin, H; Wang, S; Wen, J; Yu, JH | 1 |
| Ayadi, M; Bahri, O; Berjeb, KK; Braham, M; Chakroun, N; Chtourou, S; Debbabi, L; Fadhlaoui, A; Hamdoun, M; Hannachi, H; Kacem, K; Zemni, Z; Zhioua, F | 1 |
| Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A | 1 |
| Pisoni, R; Ramagopalan, SV; Rathore, LS; Ray, J; Sammon, C | 1 |
| Maruo, K; Nishimori, T; Sakurai, Y; Takemura, S | 1 |
| Chen, R; Chen, X; Huang, X; Li, S; Li, Y; Shi, X; Wang, J; Xu, H; Xu, L; Xu, Y; Zha, X; Zhang, W; Zhu, Q | 1 |
| Amant, FCH; Beijnen, JH; Bekkers, R; Boere, I; Dorlo, TPC; Drochytek, V; Fruscio, R; Halaska, MJ; Huitema, ADR; Janssen, JM; Ottevanger, P; Painter, RC; Schröder, CP; Van Calsteren, K; Witteveen, PO | 1 |
| Banerjee, SK; Chaudhari, D; Jain, S; Katare, PB; Katiyar, SS; Kuche, K; Kumar, Y; Swami, R | 1 |
| Chaudhari, D; Deore, SV; Ghadi, R; Jain, S; Katiyar, SS; Kuche, K | 1 |
| Aziz, MIA; Cheng, LJ; Lim, EH; Loke, L; Ng, K; Pearce, F | 1 |
| Chen, W; Hong, M; Shen, Y; Tang, K; Tu, Q | 1 |
| Garrison, LP; Jiao, B | 1 |
| Hayama, S; Itami, M; Miyaki, T; Nakamura, R; Sonoda, I; Yamamoto, N | 1 |
| Abraham, J; Benyunes, M; Cardona-Huerta, S; Hitre, E; Itrych, B; Juárez-Ramiro, A; Karaszewska, B; Kuemmel, S; Martín, M; Monturus, E; Morales-Vásquez, F; Nowecki, Z; Pérez-García, JM; Restuccia, E; Sequi, M; Tondini, CA | 1 |
| Bago-Horvath, Z; Balic, M; Bartsch, R; Bjelic-Radisic, V; Dubsky, PC; Egle, D; Exner, R; Filipits, M; Fitzal, F; Frantal, S; Gnant, M; Greil, R; Hubalek, M; Jakesz, R; Muy-Kheng, TM; Petru, E; Petzer, AL; Pfeiler, G; Pichler, A; Rudas, M; Sevelda, P; Singer, CF; Stoeger, H; Tinchon, C; Wette, V | 1 |
| Chaudhari, D; Desai, MR; Jain, S; Katiyar, SS; Kuche, K; Nallamothu, B | 1 |
| Achilefu, S; Bakewell, SJ; Cordell, E; Dang, HX; Davis, JL; Esser, AK; Fitzpatrick, JAJ; Fontana, F; Fox, GC; Kwakwa, KA; Lanza, GM; Maher, CA; Pagliai, K; Ross, MH; Sharma, V; Sivapackiam, J; Stewart, SA; Su, X; Veis, DJ; Weilbaecher, KN; Xiang, J; Xu, Y | 1 |
| Batra, A; Hannouf, M; Lupichuk, S | 1 |
| Bender, BC; Friberg, LE; Krishnan, SM; Laarif, SS; Quartino, AL | 1 |
| Adamchuk, H; Bondarenko, I; Hu, X; Li, W; Shparyk, Y; Sun, T; Teng, Y; Tong, Z; Trukhin, D; Wang, Q; Wang, S; Xu, B; Zhang, L; Zhang, Q; Zheng, H | 1 |
| Gajbhiye, KR; Gajbhiye, V; Garg, NK; Jadon, RS; Katare, OP; Salve, R; Sharma, G; Sharma, M; Sharma, U; Tandel, N; Tyagi, RK | 1 |
| Awan, A; Basulaiman, B; Clemons, M; Fergusson, D; Hiller, JP; Hilton, JF; Hutton, B; Ibrahim, MFK; Joy, AA; Mackey, J; Meza-Junco, J; Ng, T; Nixon, NA; Pitre, L; Pond, G; Saunders, D; Sienkiewicz, M; Thavorn, K; Vandermeer, L; Zhu, X | 1 |
| Abbaspour-Ravasjani, S; Haghbin Nazarpak, M; Hamishehkar, H; Mahoutforoush, A; Solouk, A | 1 |
| Du, Q; Li, H; Liu, H; Ye, X; Yu, B; Zhai, Q; Zhang, J; Zhang, Z | 1 |
| Chung, WB; Lee, JE; Lee, M; Park, CS; Park, WC; Song, BJ; Youn, HJ | 1 |
| Asleh, K; Balslev, E; Gao, D; Jensen, MB; Leung, S; Lænkholm, AV; Nielsen, D; Nielsen, LB; Nielsen, TO; Riaz, N; Stovgaard, ES | 1 |
| Honda, H; Ishioka, C; Kanbe, M; Kawai, S; Murakawa, Y; Ohori, H; Otsuka, K; Ouchi, K; Saijo, K; Sakamoto, Y; Shimodaira, H; Shindo, Y; Takahashi, H; Takahashi, M; Tanaka, Y; Yamaguchi, T; Yoshioka, T | 1 |
| Girgis-Gabardo, A; Gwynne, WD; Hassell, JA; Shakeel, MS | 1 |
| Buckley, DL; Dall, BJ; Dodwell, D; Farrow, IM; Georgiou, L; Hanby, AM; Hughes, TA; Perren, TJ; Sharma, N; Stevens, W; Wilson, DJ; Windel, LM | 1 |
| Chen, J; Gong, Q; Gu, Z; Li, Z; Luo, K; Pan, D; Wang, W; Zhang, H; Zhang, X; Zhu, H | 1 |
| Adra, J; Agartz, S; Andersson, A; Azavedo, E; Bergh, J; Bjöhle, J; Bosch, A; Brandberg, Y; Carlsson, L; Dreifaldt, AC; Einbeigi, Z; Elinder, E; Foukakis, T; Fredholm, H; Grybäck, P; Hartman, J; Hatschek, T; Hellström, M; Isaksson-Friman, E; Johansson, H; Lekberg, T; Lindman, H; Maes, C; Pekar, G; Schiza, A; Zerdes, I | 1 |
| Ademuyiwa, FO; Akintola-Ogunremi, O; Anurag, M; Bagegni, N; Basu, A; Bose, R; Chen, I; Church, SE; Clifton, K; Davis, J; Ellis, MJ; Ferrando-Martinez, S; Fisk, B; Frith, A; Gao, F; Gillanders, W; Griffith, M; Griffith, OL; Hagemann, IS; Hernandez-Aya, LF; Jeffers, G; Lee, BH; Luo, J; Ma, CX; Opyrchal, M; Peterson, LL; Rearden, TP; Richters, M; Rigden, CE; Rimawi, MF; Roshal, A; Skidmore, ZL; Suresh, R; Weilbaecher, K | 1 |
| Alibolandi, M; Andisheh, F; Hadizadeh, F; Khodaverdi, E; Nassirli, H; Oroojalian, F; Ramezani, M; Shakour, N; Shamsara, J | 1 |
| Barros, LRC; Capelozzi, VL; Machado-Rugolo, J; Mangone, FR; Nagai, MA; Pavanelli, AC | 1 |
| Iwata, H; Mizutani, T; Sasaki, K; Sawaki, M; Sekino, Y; Shibata, T; Shien, T; Shimomura, A; Tamura, K; Tanaka, K | 1 |
| Azzopardi, N; Coudert, B; Desvignes, C; Mouret-Reynier, MA; Navarro-Teulon, I; Paintaud, G; Petitcollin, A; Pierga, JY; Ternant, D | 1 |
| Boso, S; Freire-Garabal, M; Gago, P; García, C; Martínez, MC; Novio, S; Núñez-Iglesias, MJ; Pérez-Muñuzuri, ME; Santiago, JL | 1 |
| Beyer, U; Bruno, R; Friberg, LE; Jin, JY; Karlsson, MO; Krishnan, SM | 1 |
| Chen, H; Liu, B; Liu, F; Liu, Z; Mao, C; Miao, Z; Shi, T; Wan, M; Wang, X; Wang, Y; Wei, J; Zhang, H | 1 |
| Karlas, A; Klemm, U; Liapis, E; Ntziachristos, V | 1 |
| Abdel Rahman, H; Abdelghany, EM; Ahmad, I; Allithy, A; Dada, R; Deibas, MY; Farag, K; Ibrahim, RB; Kamel, MK; Nawaz, A; Rasool, H; Zekri, J | 1 |
| Chen, R; Chen, W; Feng, J; Hu, K; Liu, M; Ni, S | 1 |
| Li, J; Liang, X; Shen, Q; Wang, Y; Wusiman, Z; Yin, Y; Zhang, J | 1 |
| Gerber, NK; Perez, C; Tam, MM; Wu, SP | 1 |
| Aitken, S; Artibani, M; Brunton, VG; Del-Pozo, J; Hastie, ND; Hohenstein, P; Katz, E; Morrison, LR; Muir, M; Sims, AH; Slight, J; Thornburn, A | 1 |
| Antoun, J; Arej, N; Chelala, E; El Karak, F; Farhat, F; Haddad, FG; Kattan, J; Kourie, HR; Zaarour, K | 1 |
| Fan, J; Ling, R; Wang, L; Yan, CY; Yun, J | 1 |
| Ahn, JS; Awada, A; Cortés, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C | 1 |
| Liu, Y; Sun, G; Sun, L; Wang, K; Xing, H | 1 |
| Inoue, Y; Maehara, Y; Oki, E; Saeki, H; Tanaka, K; Tokunaga, E; Ueo, H; Yamamoto, H; Yamashita, N | 1 |
| Abba, Y; Hammadi, NI; Hezmee, MNM; Isa, T; Jaji, AZ; Mahmood, SK; Razak, ISA; Zakaria, MZAB | 1 |
| Asmar, L; Blum, JL; Brufsky, AM; Colangelo, LH; Dang, CT; Fehrenbacher, L; Flynn, PJ; Geyer, CE; Gómez, HL; Hopkins, JO; Jacobs, SA; Jeong, JH; Jones, SE; Lyss, AP; Mamounas, EP; O'Shaughnessy, JA; Paul, D; Robert, NJ; Swain, SM; Vukelja, SJ; Wolmark, N; Yothers, G | 1 |
| Li, Y; Wang, T; Zhao, G | 1 |
| Abraham, JE; Ahmad, R; Bartlett, JMS; Blenkinsop, C; Caldas, C; Cameron, DA; Chan, S; Dunn, JA; Earl, HM; Gounaris, I; Grybowicz, L; Hayward, RL; Hickish, T; Hiller, L; Hughes-Davies, L; McAdam, K; Provenzano, E; Rea, D; Thomas, J; Vallier, AL | 1 |
| Ahn, JS; Im, YH; Kim, JY; Lee, SH; Ok, ON; Park, YH; Seo, JJ | 1 |
| Freedman, RA; Gross, C; Haddad, TC; Hashmi, SK; Herrin, J; Jemal, A; Mougalian, S; Ruddy, KJ; Sangaralingham, LR; Shah, N; Thompson, CA; Van Houten, HK | 1 |
| Becker, G; Gourieux, B; Levêque, D | 1 |
| Dyck, JRB; Fresco, R; Fung, H; Mackey, JR; Paterson, I; Pituskin, E; Spera, G | 1 |
| Bonnefoi, H; Breton-Callu, C; Cameron, D; Gillon, P; Slaets, L; Touati, N | 1 |
| Furue, M; Ito, T; Maehara, E; Mitoma, C; Oda, Y; Tsuji, G; Uchi, H | 1 |
| Fujiuchi, N; Hasebe, T; Hirokawa, E; Matsuura, K; Misumi, M; Osaki, A; Saeki, T; Sakurai, T; Shigekawa, T; Shimada, H; Sugitani, I; Takahashi, T; Takeuchi, H; Ueda, S | 1 |
| Annuar, MABA; Ho, GF; Jabir, RS; Stanslas, J | 2 |
| Azarenko, O; Jordan, MA; LaPointe, NE; Miller, H; Rifkind, A; Smiyun, G; Wilson, L | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Alshaker, H; Arafat, T; Böhler, T; Kawano, Y; Mills, R; Pchejetski, D; Wang, Q; Winkler, M | 1 |
| Chia, SK; LeVasseur, N | 1 |
| Agelaki, S; Boukovinas, I; Christophylakis, C; Fountzilas, G; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kentepozidis, N; Mavroudis, D; Papakotoulas, P; Rigas, G; Saloustros, E; Varthalitis, I; Ziras, N | 1 |
| Boon, E; Flucke, UE; van Boxtel, W; van den Hoogen, FJA; van Herpen, CML; Weijs, WLJ | 1 |
| Alshaker, H; Chao, Y; Cooper, C; Pchejetski, D; Srivats, S; Wang, Q | 1 |
| Dong, XY; Lang, TQ; Li, YP; Yin, Q; Zhang, PC | 1 |
| Carey, LA; Dusetzina, SB; Hinton, SP; Meng, K; Meyer, AM; Reeder-Hayes, KE | 1 |
| Chiu, L; Chiu, N; Chow, E; Chow, R; DeAngelis, C; Dent, R; Gallo-Hershberg, D; Giotis, A; Lam, H; Pasetka, M; Stacey, E; Stinson, J; van Draanen, J; Verma, S; Wan, BA; Zhang, L | 1 |
| Li, Y; Pan, H; Pan, W; Yang, X; Zhu, Z | 1 |
| Tian, T; Ye, J; Zhou, S | 1 |
| Burugu, S; Chen, B; Gao, D; Gelmon, KA; Kos, Z; Leung, S; Liu, S; Nielsen, TO; Parulekar, WR; Shepherd, L; Virk, S | 1 |
| Breathnach, O; Carr, A; Crown, J; Duke, D; Eustace, AJ; Fay, J; Gallagher, W; Grogan, L; Gullo, G; Hambly, N; Hennessy, BT; Hill, AD; Kay, EW; Kelly, C; Kennedy, MJ; Madden, SF; Milewska, M; Moulton, B; O'Donovan, N; Power, C; Sheehan, KM; Teiserskiene, A; Toomey, S; Walshe, J | 1 |
| Chanrion, M; Dewson, G; Geneste, O; Giner, G; Gong, JN; Gräsel, J; Herold, MJ; Huang, DCS; Lalaoui, N; Lessene, G; Li, X; Lindeman, GJ; Liu, K; Maragno, AL; Merino, D; Pal, B; Schneider, E; Segal, D; Serrano, A; Smyth, GK; Vaillant, F; Visvader, JE; Whittle, JR | 1 |
| Clowes, M; Coleman, R; Kaltenthaler, E; Pandor, A; Squires, H; Stevens, JW; Thokala, P; Wyld, L | 1 |
| Choi, JS; Park, JS | 1 |
| Brindley, DN; Chen, X; Joy, AA; Parissenti, AM; Tuszynski, J; Wang, RC; Wang, Z | 1 |
| Moeller, M; Moore, HCF; Mustafa Ali, M; Rybicki, L | 1 |
| Adachi, Y; Ando, Y; Hayashi, H; Inaishi, T; Kikumori, T; Maeda, O; Matsuoka, A; Mizutani, T; Morita, S; Nakanishi, K; Ota, A; Shibata, M; Shimokata, T; Takeuchi, D; Tsunoda, N | 1 |
| Gai, YH; Hou, H; Luan, XD; Mu, Q; Wan, Y; Wang, QT; Zhao, KH | 1 |
| Davoudi, MA; Rasoul-Amini, S; Varshosaz, J | 1 |
| Bernard-Marty, C; Dalenc, F; de Lafontan, B; Dulguerova, P; Guerrero, D; Guyonnaud, J; Levasseur, N; Levecq, JM; Massabeau, C; Ranc Royo, AL; Ribet, V; Rossi, AB; Salas, S; Sarda, C; Sibaud, V | 1 |
| Abbasi, A; Dinarvand, R; Jeddi-Tehrani, M; Rezaei, M; Varshochian, R | 1 |
| Ali, AA; Chavarri-Guerra, Y; de Lima Lopes, G; Diaby, V; Ezendu, K; Soto-Perez-de-Celis, E; Williams, KJ | 1 |
| Lamichhane, S; Shah, RK | 1 |
| Aarts, MJ; de Boer, M; Dercksen, MW; Jacobs, EM; Mandigers, CM; Peer, N; Peters, FP; Smilde, TJ; Stouthard, JM; Tjan-Heijnen, VCG; Tol, J; van de Wouw, AJ; van der Rijt, CCD; van der Velden, AW; van Warmerdam, LJ; Vriens, BE | 1 |
| Nakamura, S; Okuyama, H; Sasaki, T; Sasaki, Y; Sato, H; Sato, VH; Shimizu, H; Sugiyama, E; Tagawa, N; Tajima, M | 1 |
| DeLuca, AN; Esserman, LJ; Melisko, ME; Rice, BA; Rugo, HS; Ver Hoeve, ES | 1 |
| Arun, B; Babiera, GV; Basen-Engquist, K; Chaoul, A; Cohen, L; Engle, R; Hall, MH; Harrison, CA; Li, Y; Milbury, K; Perkins, GH; Shih, YT; Spelman, A; Valero, V; Wangyal, T; Wei, Q | 1 |
| Azavedo, E; Bendahl, PO; Bergh, J; Bjöhle, J; Fernö, M; Hatschek, T; Hedenfalk, I; Hellström, M; Kimbung, S; Lekberg, T; Loman, N; Markholm, I; Paquet, E; Saracco, A; Veerla, S; von Wachenfeldt, A | 1 |
| Guan, J; Guo, W; He, Z; Lin, B; Luo, C; Sun, B; Sun, J; Sun, M; Wang, Y; Zhang, D; Zhang, H; Zhang, S | 1 |
| Bandos, H; Brufsky, AM; Fehrenbacher, L; Ganz, PA; Julian, TB; Margolese, RG; McCarron, EC; Melnikow, J; Rivera, DR; Sturtz, K; Swain, SM; Wade, JL | 1 |
| Bianchi, GV; Bonfantini, F; Cosentino, V; De Santis, MC; Di Cosimo, S; Di Salvo, F; Fiorentino, A; Gennaro, M; Lozza, L; Pignoli, E; Riboldi, VM; Sant, M; Valdagni, R | 1 |
| Chan, ALF; Leung, HWC; Leung, JH; Muo, CH | 1 |
| Asano, Y; Goto, W; Hatano, T; Hirakawa, K; Kashiwagi, S; Motomura, H; Ohira, M; Ohsawa, M; Takada, K; Takahashi, K; Takashima, T; Tomita, S | 1 |
| Gao, S; Gao, Y; Gong, C; Gu, F; Hu, C; Qiang, L; Xia, Q; Yao, C; Zhang, L | 1 |
| Chen, D; Huang, H; Lu, Y; Yang, H | 1 |
| Freedman, RA; Gross, CP; Haddad, TC; Jemal, A; Keegan, THM; Leal, AD; Loprinzi, CL; Mougalian, SS; Mutter, RW; Neuman, HB; Ruddy, KJ; Sangaralingham, L; Shah, N; Van Houten, H | 1 |
| Joensuu, H; Lindman, H | 1 |
| Altundag, K | 1 |
| Boggiani, D; Musolino, A; Palli, D; Pellegrino, B; Tommasi, C | 1 |
| Blackwell, K; Gascon, P; Gattu, S; Harbeck, N; Krendyukov, A; Li, Y | 1 |
| Chan, ALF; Leung, HWC; Leung, JH | 1 |
| Choi, MR; Clare, SE; Goodman, AM; Halas, NJ; Henderson, L; Neumann, O; Nørregaard, K | 1 |
| Beattie, MS; Fung, A; Heeson, S; Im, YH; Knott, A; Miles, D; Swain, SM; Yoo, B | 1 |
| Beurskens, CHG; Bos, WCAM; Hidding, JT; Nijhuis-van der Sanden, MWG; van der Wees, PJ; van Laarhoven, HWM | 1 |
| Hanaoka, T; Ishizone, S; Ito, K; Maeno, K; Oba, T | 1 |
| Alcácera, MA; Andrés, R; Frutos Pérez-Surio, A; Puértolas, I; Salvador, MDT | 1 |
| Loi, S; Luen, SJ | 1 |
| Chiu, L; Chiu, N; Chow, E; Chow, R; DeAngelis, C; Drost, L; Ganesh, V; Lao, N; Lee, J; Wan, BA; Zhang, L | 1 |
| Afenjar, K; Beckmann, MW; Boileau, JF; Campone, M; Fresco, R; Harbeck, N; Helms, HJ; Huang, CS; Hurvitz, SA; Jung, KH; Lin, YG; Martin, M; Slamon, D; Sparano, J; Stroyakovskiy, D; Symmans, WF; Thompson, AM; Valero, V; Wildiers, H; Xu, J | 1 |
| Eguchi, S; Hayashida, N; Kanetaka, K; Kobayashi, K; Kuba, S; Morita, M; Sakimura, C; Takatsuki, M; Yamanouchi, K | 1 |
| Chen, W; Hung, MC; Lin, X; Wei, F; Xie, X; Zhou, BP | 1 |
| Kamal, MM; Nazzal, S | 1 |
| Aviñó, V; Bayo, J; Jiménez, F; Toscano, F | 1 |
| Alonso-González, C; Cos, S; González, A; González-González, A; Martínez-Campa, C; Menéndez-Menéndez, J | 1 |
| Bharti, R; Das, AK; Dey, G; Mandal, M; Sen, R | 1 |
| Chavez-MacGregor, M; Giordano, SH; Niu, J; Rosenstock, AS; Wolff, AC; Zhao, H | 1 |
| Chen, J; Huan, Y; Huang, M; Jia, Q; Ming, Y; Wang, B; Wang, J; Wang, L; Wang, T; Yao, Q; Zhang, J; Zhou, X | 1 |
| Gwin, WR; Hobeika, A; Lyerly, HK; Morse, MA; Qiao, G; Ren, J; Song, Q; Wang, X; Zhou, X | 1 |
| Endo, K; Kuriyama, A | 1 |
| Gerber, NK; Perez, CA; Tam, M; Vega, RM; Wu, SP | 1 |
| De Grève, J; Decoster, L; Fontaine, C; Schallier, D; Vanacker, L | 1 |
| Arpino, G; Bilancia, D; Bonotto, M; Bruzzese, D; Buono, G; Caputo, R; Cianniello, D; Ciccarese, M; De Laurentiis, M; De Placido, S; Fabi, A; Giuliano, M; Locci, M; Lorusso, V; Michelotti, A; Puglisi, F; Riccardi, F; Schettini, F; Veneziani, BM; Von Arx, C | 1 |
| Bektasoglu, HK; Erdogan, EB; Ersoy, YE; Gucin, Z; Guzel, M; Kadioglu, H; Malya, FU; Yildiz, S; Yucel, S | 1 |
| Chen, Y; Gao, J; Huang, J; Liu, J; Lu, Y; Sun, D; Sun, Z; Tao, C; Wang, D; Xu, H; Yu, F; Yu, Y; Zhang, G; Zhang, H; Zhong, Y; Zhou, G; Zou, H | 1 |
| Ding, Y; Gao, M; Li, L; Li, Z; Liu, K; Tian, Y; Wang, C; Wang, Y; Xu, Y; Zhang, J | 1 |
| Albain, KS; Crew, KD; Fehrenbacher, L; Fisch, MJ; Greenlee, H; Hershman, DL; Lew, DL; Lynn Henry, N; Minasian, LM; Moinpour, CM; Till, C; Unger, JM; Wade, JL; Wong, SF | 1 |
| Abe, T; Chijimatsu, H; Furuya, K; Hayashi, H; Kondo, J; Kubo, H; Maeda, Y; Nagano, H; Nagashima, Y; Somura, H; Takemoto, N; Yahara, N; Yamamoto, S | 1 |
| Adamo, V; Franchina, T; Mastroeni, G; Ricciardi, GRR; Russo, A; Santacaterina, A; Schifano, S | 1 |
| Ahn, JH; Bello, M; Bondarenko, I; Chatterjee, S; Dvorkin, M; Im, SA; Lim, J; Moiseyenko, V; Nowecki, Z; Pivot, X; Sarosiek, T; Semiglazov, V; Shparyk, Y; Song, S; Trishkina, E; Vinnyk, Y; Wojtukiewicz, MZ | 1 |
| Enteshari, S; Hashemi-Beni, B; Hassanzadeh, F; Minaiyan, M; Mirsafaei, R; Varshosaz, J | 1 |
| Belum, VR; Blinder, VS; Goldfarb, SB; Gucalp, A; Kamboj, M; Lacouture, ME; Virgen, CA | 1 |
| Ahn, JH; Bello, M; Bondarenko, I; Chatterjee, S; Dvorkin, M; Im, SA; Lee, Y; Lim, J; Moiseyenko, V; Nowecki, Z; Pivot, X; Sarosiek, T; Semiglazov, V; Shparyk, Y; Trishkina, E; Wojtukiewicz, MZ | 1 |
| Bu, W; Cao, J; Chen, X; Chen, Y; Dobrolecki, LE; Feng, XH; Gong, Y; Han, L; Hartig, SM; Hu, DZ; Jiang, Y; Kaipparettu, BA; Lewis, MT; Li, F; Li, M; Lin, X; Liu, X; Lu, Y; Lv, X; Patterson, JB; Putluri, N; Rosen, JM; Shen, H; Shi, Q; Sicheri, F; Sun, Z; Talukdar, M; Tang, Q; Wang, X; Wang, Y; Xiang, Y; Xu, L; Ying, H; Yuan, B; Zeng, Q; Zhao, N | 1 |
| Fukahori, M; Ito, Y; Kanematsu, K; Nakayama, M; Saitou, H; Suematsu, Y; Takahashi, M; Wakabayashi, K; Yamagishi, S | 1 |
| Ameye, L; Anderson, M; Campbell, I; Crown, J; de Azambuja, E; Di Leo, A; Francis, PA; Gelber, RD; Gnant, M; Goldhirsch, A; Gutiérez, J; Habib, JG; Joseph, DJ; Lluch, A; Nordenskjöld, B; Paesmans, M; Piccart-Gebhart, M; Zeidan, YH | 1 |
| Cheah, SH; Dean, M; Ditsiou, A; Gagliano, T; Giamas, G; Lee, SC; Lit, LC; O'Hanlon, T; Roslani, AC; Shah, K; Simon, T; Stebbing, J; Szabó, KS; Wang, T; Wendler, F | 1 |
| Blohmer, JU; Eggemann, H; Fasching, PA; Fehm, T; Gerber, B; Hanusch, C; Hauschild, M; Huober, J; Jackisch, C; Kunz, G; Loibl, S; Nekljudova, V; Rezai, M; Schem, C; Solbach, C; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Bergere, M; Berjaud, C; Germain, M; Levy, L; Meyre, ME; Mpambani, F; Paolini, M; Pottier, A; Poul, L | 1 |
| Ahiwale, R; Bothiraja, C; Mahadik, K; Pawar, A; Poudel, I | 1 |
| Beckmann, MW; de Gregorio, N; Fasching, PA; Fehm, T; Friedl, TWP; Harbeck, N; Jäger, B; Janni, W; Jückstock, J; Mahner, S; Mohrmann, S; Mutschler, NS; Rack, B; Salmen, J; Schochter, F; Scholz, C; Weissenbacher, T; Widschwendter, P; Ziegler, C; Zwingers, T | 1 |
| Hayakawa, A; Hirano, T; Kiyomi, A; Onda, K; Sugiura, M; Sugiyama, K; Takagi, N; Tanaka, S; Uematsu, N; Yuan, BO; Zhao, Y | 1 |
| Asano, Y; Fujita, H; Goto, W; Hirakawa, K; Kashiwagi, S; Morisaki, T; Ohira, M; Ohsawa, M; Takada, K; Takashima, T | 1 |
| Brunton, T; Evans, A; Henderson, SA; Jordan, LB; Muhammad Gowdh, N; Purdie, CA; Thompson, AM; Vinnicombe, S | 1 |
| Dora, CP; Gupta, RC; Jain, S; Katiyar, SS; Kumar Agrawal, A; Kushwah, V; Lamprou, DA | 1 |
| Agrawal, AK; Gupta, RC; Jain, S; Katiyar, SS; Kushwah, V | 1 |
| Ayon, NJ; Jaiswal, A; Murowchick, J; Ngo, AN; Thomas, D; Youan, BC | 1 |
| Arava, S; Gogia, A; Kumar, R; Kumar, S; Tripathi, M | 1 |
| Alcalde-Castro, J; Chávarri-Guerra, Y; León-Rodríguez, E; Orozco-Topete, R; Reyes-Gutiérrez, E; Soto-Perez-de-Celis, E | 1 |
| Guan, J; Li, M; Liu, D; Wang, Y; Yang, B; Yang, R; Yu, J; Zhang, D; Zhang, H; Zhang, S; Zhang, T | 1 |
| Auvinen, P; Canney, P; Fraser, J; Granstam-Björneklett, H; Halonen, P; Harvey, VJ; Huovinen, R; Huttunen, T; Joensuu, H; Johansson, O; Kellokumpu-Lehtinen, PL; Lindman, H; Lundgren, L; Neven, P; Nyandoto, P; Ritchie, D; Sailas, L; Tanner, M; Turpeenniemi-Hujanen, T; Utriainen, M; Villman, KK; Wildiers, H; Yachnin, J | 1 |
| Turki, T; Wang, JTL; Wei, Z | 1 |
| Arving, C; Fjällskog, ML; Hellerstedt-Börjesson, S; Nordin, K; Peterson, M; Rissanen, R | 1 |
| Bouquet, F; Brunel, JM; Ciccolini, J; Correard, F; Fanciullino, R; Giacometti, S; Lacarelle, B; Maccario, H; Mas, E; Orneto, C; Rodallec, A; Savina, A | 1 |
| Abdel-Rahman, O | 1 |
| Kai, M; Kubo, M; Kurata, K; Mori, H; Nakamura, M; Yamada, M | 1 |
| Harris, AR; Munson, JM; Perez, MJ | 1 |
| Dalenc, F; Roché, H; Sarradin, V; Sibaud, V; Tournier, E | 1 |
| Azim, HA; Kassem, L; Lasheen, S | 1 |
| He, Z; Kan, Q; Liu, Y; Luo, C; Sun, B; Sun, J; Wang, Y; Wei, W; Yang, J; Yang, W; Zhao, D | 1 |
| Aghebati-Maleki, L; Atyabi, F; Jadidi-Niaragh, F; Jafari, R; Majidi Zolbanin, N; Majidi, J; Rafatpanah, H; Shanehbandi, D; Soltani Zangbar, MS; Yousefi, M | 1 |
| Alshaker, H; Low, CMR; Monteil, D; Pchejetski, D; Srivats, S; Wang, Q | 1 |
| Carr, A; Coté, D; Cremona, M; Crown, J; Eustace, A; Fay, J; Furney, S; Hennessy, B; Kay, E; Kennedy, S; Madden, S; Milewska, M; Toomey, S | 1 |
| Hayashi, N; Kitani, A; Kuwayama, T; Nakamura, S; Okuyama, H; Sato, T; Takano, T; Tsugawa, K; Yamauchi, H | 1 |
| Bahceci, A; Yildirim, N | 1 |
| Cristofanilli, M; DiNatale, A; Fatatis, A; Kaur, R; Meucci, O; Qian, C; Shen, F; Worrede-Mahdi, A; Zhang, Q | 1 |
| Kachare, N; Thomas, J; Warrier, A | 1 |
| Akata, D; Aktoz, F; Gültekin, M; Yalcin, AC; Yüzdemir, HS | 1 |
| Huma, ZE; Hussain, I; Hussain, SZ; Jahan, S; Javed, I; Nadhman, A; Rehman, M; Saeed, H; Sarwar, HS; Shahnaz, G; Sohail, MF | 1 |
| Bergh, J; Hatschek, T; Hellström, M; Sim, S; Xie, H | 1 |
| Enteshari, S; Hashemi-Beni, B; Hassanzadeh, F; Minaiyan, M; Sadeghian-Rizi, S; Varshosaz, J | 1 |
| Fan, D; Liu, Y | 1 |
| Clemons, M; Dudani, S; Fergusson, D; Fernandes, R; Gyawali, B; Hutton, B; Ibrahim, MFK; Majeed, H; Mazzarello, S; Perdrizet, K; Shorr, R; Stober, C; Vandermeer, L | 1 |
| Chavez-MacGregor, M; Giordano, SH; Kehl, KL; Niu, J | 1 |
| Huang, Q; Jiang, Y; Li, Q; Li, S; Liu, J; Wei, W; Yang, H | 1 |
| Cao, Y; Cheng, L; Guo, J; Liu, H; Liu, M; Liu, P; Peng, Y; Tong, F; Wang, S; Xie, F; Yang, H; Zhou, B; Zhou, L | 1 |
| Bao, Y; Chai, J; Chen, X; Gao, H; Liu, H; Shi, S; Yu, K; Zou, L | 1 |
| Cheng, G; Lanza-Jacoby, S | 1 |
| Agrawal, P; Bharti, S; Koch, B; Kumar Mehata, A; Kumari, L; Muthu, MS; Singh, P; Singh, S; Viswanadh, MK | 1 |
| Benítez, J; Caronia, D; de la Torre-Montero, JC; García-Sáenz, JÁ; González-Neira, A; Martin, M; Moreno, F; Moreno, LT; Pita, G; Ruiz-Pinto, S | 1 |
| Chen, H; Chen, L; Li, H; Li, Q; Qi, H; Shao, J; Shi, X; Ye, T; Zhang, L; Zhong, M | 1 |
| Aksoy, S; Aktas, BY; Alacacioglu, A; Aliyev, A; Artac, M; Basaran, G; Beypinar, I; Bilen, E; Bilici, A; Cabuk, D; Cetin, B; Cicin, I; Cil, T; Degirmencioglu, S; Demir, A; Demir, H; Demirci, U; Er, O; Erdur, E; Eren, T; Erturk, I; Esin, E; Evrensel, T; Gumusay, O; Haksoyler, V; Harputluoglu, H; Imamoglu, I; Kaplan, MA; Karaagac, M; Karadurmus, N; Kocer, M; Korkmaz, T; Kostek, O; Oksuzoglu, B; Olgun, P; Oyan, B; Ozdemir, O; Paydas, S; Pilanci, KN; Sakalar, T; Sakin, A; Seker, M; Sumbul, AT; Tanrikulu, E; Urun, Y; Yetisir, E; Yildirim, N; Yilmaz, H; Yumuk, PF | 1 |
| Albrecht, TL; Beebe-Dimmer, JL; Greenwald, MK; Ruterbusch, JJ; Schwartz, AG; Simon, MS | 1 |
| Bengala, C; Bisagni, G; Brandes, AA; Cagossi, K; Gianni, L; Gori, S; Iannacone, C; Montemurro, F; Morandi, P; Stell, A; Zamagni, C; Zambetti, M | 1 |
| Ardavanis, A; Dede, M; Drizou, M; Kapiris, M; Kokkali, S; Magou, E; Nasi, D; Ntokou, A; Prevezanou, M; Stefanou, D; Tripodaki, ES; Zylis, D | 1 |
| Desale, JP; Jain, S; Katiyar, SS; Kushwah, V; Swami, R | 1 |
| Asleh, K; Balslev, E; Burugu, S; Ejlertsen, B; Gao, D; Jensen, MB; Laenkholm, AV; Lyck Carstensen, S; Nielsen, DL; Nielsen, TO; Tykjaer Jørgensen, CL; Won, JR | 1 |
| Kalantzis, ED; Scorilas, A; Vassilacopoulou, D | 1 |
| Chai, JW; Chen, VC; Lin, TY; Weng, JC; Yeh, DC | 1 |
| Bouquet, F; Carré, M; Ciccolini, J; Fanciullino, R; Giacometti, S; Lacarelle, B; Pourroy, B; Rodallec, A; Savina, A; Sicard, G | 1 |
| Chaudhari, N; Clemons, TD; Hubbard, A; Iyer, KS; Singh, R; Sorolla, A | 1 |
| Dukhanin, AS; Dukhanina, EA; Georgieva, SG; Portseva, TN | 1 |
| Chang, F; Jiang, W; Qin, X; Wang, Z | 1 |
| Bruzzone, M; Caparica, R; Ceppi, M; de Azambuja, E; Lambertini, M; Poggio, F | 1 |
| Cserni, G; Zombori, T | 1 |
| Chen, Y; Cheng, A; Deng, Y; Jiang, J; Kang, H; Li, H; Li, Y; Liu, J; Su, F; Wang, S; Xie, H; Yu, S; Zhang, C; Zhang, GJ; Zheng, M | 1 |
| Guo, Z; Hu, B; Jiang, X; Li, H; Su, X; Zhang, X | 1 |
| Abou-El-Naga, AM; El-Sherbiny, IM; Mousa, SA; Mutawa, G | 1 |
| Brünner, N; Dong, Z; Gao, Q; Huang, P; Li, F; Li, L; Luo, S; Stenvang, J; Wu, S; You, Y | 1 |
| Cai, R; Chen, S; Fan, Y; Guan, X; Hu, S; Huang, J; Li, C; Li, Q; Luo, Y; Ma, F; Sun, X; Wang, J; Wu, S; Xu, B; Zhang, P | 1 |
| Bu, JH; Bu, QA; Cui, T; You, FP; Yuan, QZ | 1 |
| Kayal, S; Priyadarshini, R; Raj, GM; Ramesh, A; Shewade, DG | 1 |
| Kato, H; Kawai, Y; Kitamura, M; Mori, T; Sakai, S; Shimada, K; Shimizu, T; Tani, M; Tatsumi, M; Tomida, K; Umeda, T | 1 |
| Ben-Batalla, I; Bokemeyer, C; Cubas-Cordova, M; Denkert, C; Fasching, PA; Fehm, T; Gensch, V; Holms, F; Janning, M; Just, M; Karn, T; Kittel, K; Krabisch, P; Kühn, T; Loges, S; Loibl, S; Müller, V; Overkamp, F; Pantel, K; Rack, B; Rezai, M; Schem, C; Schnappauf, B; Tesch, H; Untch, M; Vettorazzi, E; von Minckwitz, G; Zu Eulenburg, C | 1 |
| Aradi, I; Bondarenko, I; Grecea, D; Horvat-Karajz, K; Illes, A; Kahan, Z; Perjesi, L; Smakal, M; Tjulandin, S | 1 |
| Agapito, G; Altomare, E; Arbitrio, M; Arpino, G; Cannataro, M; Caracciolo, D; Di Martino, MT; Fabiani, F; Galeano, T; Grillone, F; Iuliano, E; Santini, D; Scionti, F; Staropoli, N; Tagliaferri, P; Tassone, P | 1 |
| Goodwin, A; O'Connell, DL; Wilcken, N; Willson, ML; Zaheed, M | 1 |
| Allen, RJ; Bishop, RT; de Ridder, D; Idris, AI; Lefley, DV; Marino, S; Ottewell, PD; Sims, AH; Wang, N | 1 |
| He, W; Li, L; Li, Z; Liu, T; Ren, Y; Wang, J; Yan, M; Zhang, Y | 1 |
| Banke, A; Cold, S; Dahl, JS; Ewertz, M; Fosbøl, EL; Gislason, GH; Jensen, MB; Møller, JE; Poulsen, MK; Schou, M; Videbæk, L | 1 |
| Baek, S; Fasching, P; Foerster, F; Gerber, B; Grischke, EM; Hartmann, S; Klare, P; Marmé, F; Mavratzas, A; Moebus, V; Schmidt, M; Schneeweiss, A; Solomayer, E; Strumberg, D; Windemuth-Kieselbach, C | 1 |
| Hersi, F; Noreddin, AM; Nunes, ACF; Omar, HA; Tolba, MF | 1 |
| Beith, J; De Boer, RH; Redfern, A; Truman, M; White, M; Woodward, N; Young, J | 1 |
| Feng, T; Li, P; Peng, L; Qin, S; Wan, J; Yuan, P; Zhang, L; Zhao, T | 1 |
| Ingle, JN; Liu, M; Qin, S; Shen, K; Wang, G; Wang, L; Weinshilboum, RM; Zayas, J | 1 |
| Cheng, M; Qi, Y; Shi, J; Song, Z; Wang, M; Wang, X; Zhang, L | 1 |
| Babu, PV; Chitkara, D; Khurana, RK; Kumar, V; Raza, K; Sharma, S; Singh, B; Thotakura, N | 1 |
| Chitkara, D; Italiya, K; Kothari, IR; Mazumdar, S; Mittal, A; Sharma, S | 1 |
| Fries, H; Hitzschke, M; Lordick, F | 1 |
| Furuya, Y | 1 |
| Gao, J; Liu, H; Lu, M; Si, C; Xu, M; Yao, Q; Zhang, S; Zhong, W; Zhou, L | 1 |
| do Brasil Costa, VI; Jorge, RV; Nobre, FF; Paula, DP | 1 |
| De Grève, J; Decoster, L; Fontaine, C; Joris, S; Schallier, D; Vanacker, L | 1 |
| Anders, CK; Basch, E; Carey, LA; Choi, SK; Deal, AM; Dees, EC; Jolly, TA; Karuturi, MS; Kimmick, GG; Lee, JT; Muss, HB; Nyrop, KA; Reeder-Hayes, KE; Reeve, BB; Reinbolt, RE; Shachar, SS; Speca, JC; Wood, WA | 1 |
| Alshreef, A; Chalkidou, K; Culyer, AJ; Dawkins, B; Dixon, S; Edoka, I; MacQuilkan, K; Meads, D; Riddin, J; Ruiz, F; Taylor, M; Ward, S | 1 |
| Gao, B; Jiang, L; Jiang, X; Li, Y; Luo, D; Tang, Y; Wang, C; Yu, F; Zou, J | 1 |
| Cao, M; Dong, C; Liu, L; Pizzo, D; Ren, X; Ruan, X; Shen, M; Wang, SE; Wu, X; Yan, W; Yang, L | 1 |
| Ahmaidi, S; Al-Haddabi, B; Doutrellot, PL; Gmada, N; Hiraoui, M; Mezlini, A | 1 |
| Borley, A; Dolan, G; Hanna, L; Roberts, R; Williams, EM | 1 |
| Bronich, TK; Cohen, SM; Hyun, MA; Liu, T; Romanova, S; Singh, RK; Wang, S; Zhang, C | 1 |
| Afenjar, K; Boileau, JF; Boulet, T; Campone, M; Fasching, PA; Harbeck, N; Huang, CS; Hurvitz, SA; Jung, KH; Lopez-Valverde, V; Martin, M; Slamon, D; Song, C; Sparano, JA; Spera, G; Stroyakovskiy, D; Symmans, WF; Thompson, AM; Trask, P; Valero, V; Wildiers, H | 1 |
| Fei, W; Fu, T; Gu, X; Han, T; Hou, Y; Li, N; Liu, Y; Yang, J | 1 |
| Beith, J; Boyle, FM; Chen, TYT; Currow, DC; Della-Fiorentina, SA; Johnston, A; Lin, E; Moylan, EJ; Tervonen, HE | 1 |
| Arioka, H; Chishima, T; Doi, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Kosaka, Y; Kuranami, M; Mogaki, M; Morita, S; Narui, K; Nawata, S; Niikura, N; Oba, MS; Ogata, H; Ota, T; Saito, Y; Sasaki, T; Sengoku, N; Shimizu, D; Suto, A; Suzuki, Y; Tanabe, M; Tokuda, Y; Tsugawa, K; Yamada, A | 1 |
| Field, CJ; Goruk, S; Mazurak, V; Newell, M; Postovit, L | 1 |
| Ochiya, T; Prieto-Vila, M; Sasaki, H; Shimomura, I; Takahashi, RU; Usuba, W; Yamamoto, Y | 1 |
| Calleja-Cervantes, ME; Collado-Sole, A; Diaz-Lagares, A; Dobrolecki, LE; Eroles, P; Esteller, M; Gómez, A; Gómez-Miragaya, J; González-Suárez, E; Lewis, MT; Morán, S; Paré, L; Prat, A; Serra, V | 1 |
| Aho, S; Alitalo, K; Hämäläinen, M; Jukkola, A; Karihtala, P; Kellokumpu-Lehtinen, PL; Korhonen, EA; Lahdenperä, O; Leppänen, VM; Luukkaala, T; Moilanen, E; Tanner, M; Tiainen, L; Vihinen, P | 1 |
| Alp, D; Benovic, JL; Jacinto, AZ; Lagman, J; Lee, CS; Peng, N; Sayegh, P; So, CH; Sok, V; Sulon, SM | 1 |
| Akbarzadeh, M; Bazzaz, R; Ghanbarzadeh, S; Ghorbani, M; Hajipour, H; Khiavy, HA; Kooti, W; Maroufi, NF; Mazrakhondi, SAM; Pirouzpanah, SM; Ramezani, F; Sabzichi, M; Vahedian, V | 1 |
| Feng, SS; Mi, Y; Zhao, J | 1 |
| Chen, E; Christensen, JG; Fang, DD; John-Baptiste, A; Lira, ME; Painter, C; Yan, Z; Zhang, CC; Zhang, Q; Zong, Q | 1 |
| Arnold, T; Bachleitner-Hofmann, T; Bartsch, R; Baumann, S; Bergmann, M; Burghuber, C; Gnant, M; Michlmayr, A; Oehler, R; Pluschnig, U; Steger, G | 1 |
| Chan, A; Cortés, J; de Haas, SL; Delmar, PR; Dirix, LY; Miles, DW; Pivot, X; Provencher, L; Romieu, G; Scherer, SJ; Tomczak, P | 1 |
| Budman, DR; Calabro, A; Lesser, M; Rosen, L | 1 |
| Chen, Y; Cui, X; Hu, H; Jiao, Y; Li, S; Lin, L; Lv, X; Song, E; Wang, M; Yao, H; Yu, F | 1 |
| Feng, SS; Muthu, MS; Raju, A | 1 |
| Hahn, SY; Han, BK; Im, YH; Kim, RB; Ko, ES; Ko, EY; Lee, JE; Lee, SK; Nam, SJ; Park, YH; Shin, JH | 1 |
| Gonzalez-Angulo, AM; Hernandez-Aya, LF | 1 |
| Bayet-Robert, M; Morvan, D | 1 |
| Shim, KN; Yoon, SY | 1 |
| Amadori, D; Baselga, J; Benyunes, MC; Clark, E; Cortés, J; Ewer, MS; Knott, A; Miles, D; Ross, G; Swain, SM | 1 |
| Gao, F; Luo, J; Sun, X; Sun, Z; Wang, H; Zhang, Y; Zhao, X; Zhong, B | 1 |
| Dirix, LY; Dirix, M; Huget, P; Rutten, A | 1 |
| Batten, K; Cornelius, C; Fasciani, G; Lum, L; Shay, JW; Singel, SM; Wright, WE | 1 |
| Deslandes, A; Lazar, V; Massard, C; Mery-Mignard, D; Ozoux, ML; Soria, JC; Tolcher, AW | 1 |
| Han, W; Im, SA; Moon, HG; Moon, WK; Noh, DY; Park, IA; Park, SJ; Shin, HC | 1 |
| Coleman, RE; Cross, SS; Evans, A; Freeman, JV; Hatton, MQ; Holen, I; Ingram, CE; Jolley, IJ; Mori, S; Syddall, SP; Wilson, C; Winter, MC | 1 |
| A'hern, R; Barrett-Lee, PJ; Bartlett, JM; Bliss, JM; Cameron, DA; Dowsett, M; Ellis, IO; Ellis, P; Johnston, S; Mallon, EA; Piper, T | 1 |
| Boy, D; Bruzzi, P; Ceccarelli, M; Cognetti, F; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Kazeem, G; La Torre, I; Mansutti, M; Marchi, P; Merlo, DF; Venturini, M | 1 |
| Angspatt, A; Sriussadaporn, S | 1 |
| Gomez-Fernandez, C; Hurley, J; Larrieu, R; Leone, JP; Pegram, MD; Reis, IM; Rodgers, SE; Wright, J | 1 |
| Hertz, DL; Krens, SD; McLeod, HL | 1 |
| Allen, P; Buchholz, TA; Buzdar, AU; Gonzalez-Angulo, AM; Hortobagyi, GN; Hunt, KK; Kim, MM; Kuerer, HM; Litton, JK; Meric-Bernstam, F; Mittendorf, EA; Woodward, WA | 1 |
| Henry-Tillman, RS; Hutchins, LF; Klimberg, VS; Korourian, S; Makhoul, I; Siegel, ER; Westbrook, KC | 1 |
| Bhar, P; Gradishar, WJ; Iglesias, J; O'Shaughnessy, J | 1 |
| Abramson, VG; Beckermann, KE; Iams, W; Mayer, IA; Neff, AT | 1 |
| Andre, F; Chan, A; Chan, S; Gianni, L; Greil, R; Lichinitser, M; Lipatov, O; Mansutti, M; Mariani, P; Moore, N; Pallaud, C; Pivot, X; Prot, S; Romieu, GH; Semiglazov, V; Serrano, SV; Wardley, A | 1 |
| Seidman, AD | 2 |
| Meden, H | 1 |
| Koroleva, IA; Mochalova, AS | 3 |
| Baselga, J; Benyunes, MC; Campone, M; Ciruelos, E; Clark, E; Cortés, J; Ferrero, JM; Kim, SB; Knott, A; Ro, J; Ross, G; Schneeweiss, A; Semiglazov, V; Swain, SM | 1 |
| Benhabbour, SR; Feng, L; Mumper, RJ | 1 |
| Asselain, B; Bieche, I; Cizkova, M; de Cremoux, P; Dujaric, ME; Lehmann-Che, J; Marty, M; Pierga, JY; Scott, V; Spyratos, F; Tembo, O | 1 |
| Ayadi, M; Boussen, H; Chraiet, N; Gligorov, J; Krimi, S; Labidi, S; Lagha, A | 1 |
| Ballardini, P; Borghi, A; Corazza, M; Minghetti, S; Virgili, A | 1 |
| Hatanaka, KC; Hatanaka, Y; Hosoda, M; Matsuno, Y; Taguchi, K; Takakuwa, E; Yamamoto, M; Yamashita, H; Yoshioka, T | 1 |
| Chan, A; de Boer, RH; Gajdatsy, A; Su, C | 1 |
| Baumann, K; Belau, A; Darb-Esfahani, S; Denkert, C; Dietel, M; Eidtmann, H; Grasshoff, ST; Hoffmann, G; Holzhausen, HJ; Kronenwett, R; Loibl, S; Mehta, K; Sinn, BV; Tesch, H; Thommsen, C; von Minckwitz, G | 1 |
| Antoine, M; Avenin, D; Beerblock, K; Bernaudin, JF; Fajac, A; Gligorov, J; Lévy, E; Lévy, P; Lokiec, F; Lotz, JP; Rezai, K; Saintigny, P; Selle, F | 1 |
| Booser, DJ; Eckmann, K; Esparza-Guerra, L; Green, MC; Hortobagyi, GN; Kawedia, J; Madden, TL; Michaud, LB; Rivera, E; Valero, V | 1 |
| Hong, DS; Im, YH; Kang, SY; Kim, HY; Kwon, HC; Lee, HJ; Lee, S; Park, IH; Park, JH; Park, KH; Park, S; Park, YH; Seo, JH; Shin, SH; Sohn, JH | 1 |
| Chen, CS; Chiou, HY; Hung, CS; Pan, CK; Tai, CJ; Wu, CH | 1 |
| D'Auria, G; Fabbri, MA; Frittelli, P; Massari, A; Moscetti, L; Natoli, G; Nelli, F; Ruggeri, EM | 1 |
| Berger, M; Layman, R; Lustberg, M; Mrozek, E; Olson, E; Poi, MJ; Ramaswamy, B; Shapiro, CL; Wesolowski, R | 1 |
| Chen, J; Huan, Y; Li, D; Wang, J; Wang, L; Wang, T; Yao, Q; Yu, M; Zhang, J; Zhou, X | 1 |
| Biagioni, C; Biganzoli, L; Cavaciocchi, D; Di Leo, A; Pestrin, M; Sanna, G; Turner, N; Zafarana, E | 1 |
| Chiarotto, JA; Dranitsaris, G | 1 |
| Belbaraka, R; Elomrani, A; Ismaili, N; Khouchani, M; Tahri, A | 1 |
| He, XM; Xiang, H; Yang, HJ; Yu, Y; Zong, XY | 1 |
| Chou, H; Mekata, E; Nagasawa, Y; Shimizu, T; Sonoda, H; Tani, T | 1 |
| Bono, P; Claes, B; Fumagalli, D; Joensuu, H; Kataja, V; Kellokumpu-Lehtinen, PL; Lambrechts, D; Loi, S; Michiels, S; Piccart, MJ; Sotiriou, C | 1 |
| Chun, B; Li, CX; Niu, ZH; Wang, Y; Wu, L | 1 |
| Awada, Z; Bazarbachi, A; El-Saghir, NS; Haider, S; Salem, Z; Shamseddine, A; Taher, A; Tfayli, A; Zgheib, NK | 1 |
| Antunes, L; Burikhanov, R; de Bessa-Garcia, SA; Nagai, MA; Pavanelli, AC; Pereira, MC; Rangnekar, VM | 1 |
| Abbate, A; Biondi-Zoccai, G; Cavarretta, E; De Marco, E; Di Persio, S; Frati, G; Loperfido, F; Lotrionte, M; Mezzaroma, E; Palazzoni, G | 1 |
| Crawford, J; Dale, DC; Lyman, GH; Tomita, D; Whittaker, S | 1 |
| Gach, JE; Khan, M; Poole, CJ; Taibjee, SM | 1 |
| Au, HJ; Bée, V; Chan, A; Crown, J; Eiermann, W; Ferrero, JM; Fornander, T; Glaspy, J; Lalla, D; Liu, MC; Mackey, J; Martin, M; Miller, DP; Pawlicki, M; Pienkowski, T; Pintér, T; Robert, NJ; Santana, MJ; Sehdev, S; Slamon, DJ | 1 |
| Huang, L; Liu, T; Mei, L; Ouyang, C; Tao, W; Wang, Z; Xiong, Q; Zeng, X | 1 |
| Bilban, M; Dressler, AC; Fink-Retter, A; Gschwantler, D; Helmy, S; Klinglmüller, F; Pfeiler, G; Sartori, C; Singer, CF; Staudigl, C; Stratmann, R | 1 |
| Aarts, MJ; Borm, GF; de Boer, M; de Vries, B; Smilde, TJ; Tjan-Heijnen, VC; van Gastel, SM; van Spronsen, DJ; van Warmerdam, LJ; Vriens, BE; Wals, J | 1 |
| Chen, Y; Huang, J; Liu, J; Lu, Y; Sun, D; Sun, Z; Wang, D; Wang, X; Yu, Y; Zhang, G; Zhang, H; Zhong, Y; Zhou, G; Zou, H | 1 |
| Kneip, B | 1 |
| Baselga, J; Clark, E; Cortés, J; Im, SA; Im, YH; Knott, A; Pivot, X; Ross, G; Swain, SM | 1 |
| Chalvatzis, N; Dimitrakos, S; Hytiroglou, P; Manthou, ME; Tzamalis, A | 1 |
| Burris, HA; Crown, J; DeSilvio, M; Diéras, V; Espie, M; Kennedy, MJ; Koch, KM; Kothari, D; Lau, MR; Marty, M; Tresca, P | 1 |
| Besson, P; Bon, E; Bougnoux, P; Chamouton, J; Chevalier, S; Goupille, C; Mahéo, K; Roger, S; Wannous, R | 1 |
| Cladés, T; de la Hoya, M; Del Prado, N; Díaz-Rubio, E; Furió, V; García-Sáenz, JA; Martín, M; Pelayo, A; Perou, CM; Prat, A; Román, JM; Romero, A | 1 |
| Ernsting, MJ; Foltz, WD; Holwell, N; Li, SD; Murakami, M; Undzys, E | 1 |
| Gustafson, DL; Hudachek, SF | 1 |
| Atkins, JN; Azar, CA; Biggs, DD; Brufsky, AM; Costantino, JP; Donnellan, PP; Fehrenbacher, L; Geyer, CE; Levine, EA; Mamounas, EP; Northfelt, DW; Paik, S; Polikoff, JA; Provencher, L; Rastogi, P; Robidoux, A; Swain, SM; Tang, G; Wolmark, N; Zapas, JL | 1 |
| Coussy, F; Cuvier, C; de Roquancourt, A; Espié, M; Giacchetti, S; Groheux, D; Hatt, M; Hindié, E; Marty, M; Vercellino, L | 1 |
| DeMichele, A; Farrar, JT; Hennessy, S; Mao, JJ; Sammel, MD; Speck, RM; Stineman, MG | 1 |
| Bias, P; Bondarenko, I; Buchner, A; Elsaesser, R; Gladkov, OA | 1 |
| Hai, T; Kang, H; Rong, G; Sun, H; Wang, Y | 1 |
| Ahlgren, J; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Saarni, O; Tanner, M; Villman, K | 1 |
| Baselga, J; Brewster, M; Cortés, J; Garg, A; Grincuka, E; Hauschild, M; Kudaba, I; Lum, BL; Marier, JF; Masuda, N; McNally, V; Nijem, I; Patel, T; Ross, G; Swain, SM; Trinh, MM; Visich, J | 1 |
| McCormack, PL | 1 |
| Chen, Z; Li, W; Xu, J; Zhao, J; Zhong, S | 1 |
| Brewster, M; Carrothers, TJ; Clark, E; Cortés, J; Garg, A; Knott, A; Li, J; Lum, B; Marier, JF; Visich, J | 1 |
| Allison, MAK; Asmar, L; Brooks, BD; Collea, R; Crockett, MW; Favret, AM; Gore, I; Holmes, FA; Jones, SE; Lindquist, DL; O'Shaughnessy, J; Paul, D; Portillo, RM; Robert, NJ; Sedlacek, S; Steinberg, MS; Stokoe, C; Vukelja, SJ; Wang, Y | 1 |
| Hanaoka, M; Iwatani, T; Kawabata, H; Miura, D; Takano, T | 1 |
| Armesilla, AL; Brown, S; Darling, JL; Jiang, W; Kannappan, V; Kumar, IS; Liu, P; Tang, JZ; Tawari, PE; Wang, W | 1 |
| Dillon, PM; Greer, KE; Marchetti, MA; Noland, MM | 1 |
| Fang, P; Ji, TF; Liu, H; Shi, WW; Yang, B; Yang, JL; Zhu, YY | 1 |
| Al-Sakaff, N; Bell, R; Chang, J; Feng, FY; Heinzmann, D; Jassem, J; Láng, I; Lopez, RI; Semiglazov, V | 1 |
| Delaloge, S; Dunant, A; Garbay, JR; Kane, A; Leymarie, N; Mazouni, C; Naveau, A; Rimareix, F; Sarfati, B | 1 |
| Dionysopoulos, D; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Kotoula, V; Kourea, HP; Koutras, AK; Papadimitriou, C; Papadopoulou, K; Pectasides, D; Samantas, E; Skarlos, DV; Zagouri, F | 1 |
| Bassini, A; Bertola, M; Del Conte, A; Foltran, L; Gion, M; Lorenzon, M; Micheli, E; Saracchini, S; Sulfaro, S; Tuccia, F; Tumolo, S | 1 |
| Li, WJ; Tang, JH; Wu, YJ; Xu, JJ; Xu, WD; Zhao, JH; Zhong, SL | 1 |
| Abe, H; Kawai, Y; Kubota, Y; Mori, T; Tani, T; Tomida, K; Umeda, T | 2 |
| Boukovinas, I; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Malamos, N; Mavroudis, D; Papakotoulas, P; Politaki, E; Polyzos, A; Tryfonidis, K; Xenidis, N | 1 |
| Blum, JL; Glück, S; Hu, S; McKenna, EF; O'Shaughnessy, J; Odom, D; Russell, C | 1 |
| Aogi, K; Bando, H; Chow, LW; Fakhrejahani, E; Hisamatsu, K; Ito, Y; Iwata, H; Kamigaki, S; Kashiwaba, M; Kuroi, K; Masuda, N; Morimoto, T; Nakamura, S; Nakayama, T; Ohno, S; Sasano, H; Sato, N; Takahashi, F; Toi, M; Ueno, T; Yamamoto, Y; Yamashita, H; Yoshida, N | 1 |
| Candon, D; Crown, J; Healy, J | 1 |
| Amadori, D; Baselga, J; Clark, E; Knott, A; Miles, D; Ross, G; Semiglazov, V; Sunpaweravong, P; Swain, SM | 1 |
| Eckhoff, L; Ejlertsen, B; Ewertz, M; Jensen, MB; Knoop, AS | 1 |
| Boulaiz, H; Marchal, JA; Ortega-Vinuesa, JL; Peula-García, JM; Sánchez-Moreno, P | 1 |
| Chen, Y; Huang, J; Liu, J; Lu, Y; Sun, D; Sun, Z; Wang, D; Yu, Y; Zhang, G; Zhang, H; Zhong, Y; Zhou, G | 1 |
| Bruining, A; Doll, PK; Gilhuijs, KG; Linn, SC; Lips, EH; Loo, CE; Mandjes, IA; Rigter, LS; Rodenhuis, S; Sonke, GS; van Werkhoven, E; Vrancken Peeters, MJ; Warnars, HA; Wesseling, J | 1 |
| Chaigneau, L; Chelly, J; Fiteni, F; Limat, S; Meneveau, N; Monnot, T; Montcuquet, P; Nerich, V; Perrin, S; Pivot, X; Villanueva, C; Voidey, A | 1 |
| Li, Z; Yang, J; Zhang, F | 1 |
| Gupta, S; Yadav, S | 1 |
| Balslev, E; Bjerre, KD; Ejlertsen, B; Jørgensen, CL; Nielsen, DL; Nielsen, KV | 1 |
| Beijnen, JH; Helgason, HH; Huitema, AD; Koolen, SL; Kruijtzer, CM; Malingre, MM; Schellens, JH; Schot, ME; Smit, WM; Werkhoven, Ev | 1 |
| Badarinath, S; Burris, H; Childs, BH; Daniel, BR; Drosick, DR; Hart, L; Murphy, P; Waterhouse, D; Whorf, R; Yardley, DA | 1 |
| Bauerfeind, I; Blohmer, JU; Costa, SD; Denkert, C; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kümmel, S; Loibl, S; Mehta, K; Paepke, S; Rezai, M; Schneeweiss, A; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Ahmad, A; Ahmad, I; Gopichand, M; Kumar, V; Paithankar, M; Prasad, K; Rajappa, SJ; Rane, RC; Sharma, M; Sheikh, S; Srivastav, SP; Taran, R | 1 |
| Cao, Y; Chen, X; Chen, Y; Li, X; Ni, D; Shen, K; Tang, J; Wei, Z; Wu, K; Xie, X; Ye, G; Zhang, C; Zheng, H | 1 |
| Böttcher, J; Engelken, FJ; Fallenberg, EM; Hamm, B; Maurer, MH; Pfeil, A; Renz, DM; Streitparth, F; Zahm, DM | 1 |
| Bulut, G; Calka, O; Ozkol, HU | 1 |
| Chung, HC; Kim, EK; Kim, JH; Kim, MJ; Kim, SI; Koo, JS; Lee, S; Moon, YW; Park, BW; Park, S; Sohn, J | 1 |
| Champagne, C; Gaillot-Petit, N; Guilbert, P; Lamberth, F; Looten-Vieren, L; Nguyen, TD | 1 |
| Bonnetain, F; Dalban, C; Ecarnot, F; Fumoleau, P; Ghiringhelli, F; Ladoire, S; Levy, C; Martin, AL; Roché, H; Spielmann, M | 1 |
| Alberici, G; Bastid, J; Bensussan, A; Bonnefoy, N; Cochaud, S; Curé, H; Eliaou, JF; Garbar, C; Giustiniani, J; Laprevotte, E; Mascaux, C; Savoye, AM; Thomas, C | 1 |
| Cantin, G; Côté, I; Desbiens, C; Doyle, C; Hogue, JC; Leblond, AF; Lemieux, J; Poirier, B; Poirier, E; Provencher, L | 1 |
| Chaker, M; Clatot, F; Gouérant, S; Lauridant, G; Leheurteur, M; Modzelewski, R; Rigal, O; Veyret, C | 1 |
| Abdi, E; Bonaventura, A; Craft, P; de Souza, P; Hill, A; Hovey, E; Lloyd, A; Marx, G; Michele, A; Parente, P; Rapke, T | 1 |
| Li, ZM; Liang, D; Lv, F; You, W; Yu, Y; Zhang, B | 1 |
| Saggar, JK; Tannock, IF | 1 |
| Akiyama, F; Iwata, H; Kuroi, K; Kurosumi, M; Masuda, N; Nakamura, S; Ohno, S; Sato, N; Toi, M; Tsuda, H | 1 |
| Chen, J; Chow, LW; Liu, Q; Loo, WT; Ng, EL; Wang, M; Yip, MC | 1 |
| Burkard, ME; Dietrich, L; Donohue, S; Goggins, T; Hegeman, R; Kim, K; Mansky, P; Njiaju, UO; Qamar, R; Shah, V; Stella, A; Tevaarwerk, AJ; Traynor, AM; Wisinski, KB | 1 |
| da Silva, PR; de Almeida, AM; Gozzo, Tde O; Moysés, AM | 1 |
| Bartsch, R; Dubsky, P; Fesl, C; Fitzal, F; Gampenrieder, SP; Gnant, M; Greil, R; Hartmann, BL; Hubalek, M; Jakesz, R; Lang, A; Melbinger, E; Mlineritsch, B; Muss, C; Petzer, AL; Ressler, S; Rudas, M; Singer, CF; Steger, GG; Stoeger, H; Zielinski, CC | 1 |
| Barlow, WE; Dammann, K; Gralow, JR; Hortobagyi, GN; Lew, D; Livingston, RB; Rinn, KJ; Somlo, G; Vogel, SJ; Wong, L | 1 |
| Balslev, E; Bjerre, KD; Ejlertsen, B; Jørgensen, CL; Liu, S; Nielsen, DL; Nielsen, TO; Wallden, B | 1 |
| Abdi, E; Badger, HD; Boyle, F; Bull, J; Chirgwin, J; Forbes, JF; Francis, PA; Gebski, V; Kannourakis, G; Leong, E; Lindsay, DF; McCarthy, N; Reaby, L; Simpson, A; Veillard, AS; Wilcken, N; Zannino, D; Zdenkowski, N | 1 |
| Zhou, X | 1 |
| Aoyagi, H; Hasegawa, K; Kaneko, J; Maejima, S; Matsui, T; Yoshida, T | 1 |
| Habiro, T; Hatate, K; Hayashi, K; Oshida, S; Sengoku, N | 1 |
| Akiyoshi, T; Fujii, T; Fujisawa, T; Hirakata, T; Horikoshi, H; Iijima, M; Kinoshita, T; Kuwano, H; Miyamoto, T; Oya, N; Yanagita, Y | 1 |
| Yaqub, F | 1 |
| Bahng, A; Black, A; Britten, CD; Christofk, HR; Crabtree, MJ; Dubinett, SM; Garon, EB; Hong, CS; Hosmer, W; Kabbinavar, F; Kamranpour, N; Michelakis, ED; Patel, C; Pitts, S; Slamon, DJ; von Euw, E | 1 |
| Amini, M; Atyabi, F; Dinarvand, R; Ghahremani, MH; Goodarzi, N; Nateghian, N; Ostad, SN; Shabani Ravari, N | 1 |
| Brindley, DN; Chen, X; Hajar, A; Li, S; Parissenti, AM; Vo, T; Wang, H; Wang, Z | 1 |
| Alba, E; Albanell, J; Barnadas, A; Burgués, O; Caballero, R; Calvo, L; Cámara, MC; Carrasco, E; de la Haba, J; Lluch, A; Porras, I; Ramos, M; Rojo, F; Sánchez-Rovira, P; Tibau, A | 1 |
| Chen, ML; Li, K; Zhang, J; Zhu, ZL | 1 |
| A'hern, RP; Barrett-Lee, P; Bartlett, JM; Bliss, JM; Dowsett, M; Ellis, IO; Ellis, P; Gillett, C; Hanby, A; Irshad, S; Johnston, S; Pinder, SE; Tutt, A | 1 |
| Dorval, T; Lantz, O; Louis, D; Milder, M; Péguillet, I; Piperno-Neumann, S; Scholl, SM; Vincent-Salomon, A | 1 |
| Carroll, JP; Cheng, ME; Fay, M; Martin, JH; Nguyen, L; Pillay, PS; Protani, MM; Saleem, M; Walpole, E | 1 |
| Ernsting, MJ; Hoang, B; Li, SD; Murakami, M; Roy, A; Undzys, E | 1 |
| Farrah, JJ; Moloney, TP; Oliveira, N; Rallah-Baker, K; Woodward, N; Xu, W | 1 |
| Badarinath, S; Childs, BH; Keaton, MR; Schwartzberg, LS | 1 |
| Eskridge, C; Kmiec, EB; Niamat, RA; Samuel, S; Sims-Mourtada, J | 1 |
| Dhakal, I; Griffin, RJ; Hutchins, LF; Jamshidi-Parsian, A; Kadlubar, S; Klimberg, S; Lee, J; Makhoul, I; Raj, V; Siegel, E | 1 |
| Itoh, F; Maeda, I; Miyoshi, Y; Ohta, T; Oikawa, R; Tsuchiya, K; Tsugawa, K; Watanabe, Y; Wu, W | 1 |
| Charehbili, A; Dercksen, M; Hamdy, NA; Heijns, JB; Kessels, L; Kroep, JR; Liefers, GJ; Maartense, E; Meershoek-Klein Kranenbarg, E; Nortier, JW; Pepels, MJ; Putter, H; Smit, VT; van de Velde, CJ; van de Ven, S; van Laarhoven, HW; van Leeuwen-Stok, AE; van Warmerdam, LJ; Vriens, B; Wasser, MN | 1 |
| Ali, Z; Malik, Z; Misra, V; Mullard, AP; O'Reilly, SM; Sumra, P | 1 |
| Agrahari, V; Murowchick, JB; Youan, BB; Youm, I | 1 |
| Hayashi, N; Kajiura, Y; Matsuda, N; Nakamura, S; Ohde, S; Suzuki, K; Tsunoda, H; Yagata, H; Yamauchi, H; Yoshida, A | 1 |
| Chen, WX; Hu, Q; Ji, H; Lv, MM; Ma, TF; Tang, JH; Zhang, JY; Zhao, JH; Zhong, SL | 1 |
| Chia, VM; Langeberg, WJ; Morrow, PK; Page, JH; Siozon, CC | 1 |
| Charles-Edwards, G; Ganeshan, B; Glendenning, J; Goh, V; Harries, M; Mansi, J; Parikh, J; Selmi, M; Tutt, A; Verma, H | 1 |
| Amini, M; Atyabi, F; Dinarvand, R; Kamalinia, G; Khoshayand, MR; Ostad, SN; Rouhani, H; Tavassolian, F; Tehrani, MR | 1 |
| Baselga, J; Cortés, J; Im, YH; Lee, LF; Miles, D; Quah, C; Swain, SM | 1 |
| Ng, CH; Rozita, AM; Taib, NA; Tiong, V; Yip, CH | 1 |
| Bazzil, JD; Caruso, AN; Murowchick, JB; Otto, JW; Youan, BB; Youm, I | 1 |
| Charalambous, E; Dimopoulos, MA; Dionysopoulos, D; Fountzilas, G; Kotoula, V; Koutras, A; Kouvatseas, G; Papandreou, CN; Papazisis, K; Pectasides, D; Pentheroudakis, G; Samantas, E; Zagouri, F | 1 |
| Chan, S; Seidman, AD; Wang, J; Xu, B; Xu, C; Zhu, C | 1 |
| Arun, B; Cohen, L; Lam, CY; Ratcliff, CG; Valero, V | 1 |
| Ahn, JH; Chung, HC; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, JH; Kim, SB; Park, HS; Ro, J; Song, HS; Yoo, C | 2 |
| Deo, SV; Gogia, A; Mohanti, BK; Raina, V; Sharma, DN; Shukla, NK | 1 |
| Cho, N; Han, W; Im, SA; Lee, KH; Li, M; Moon, WK; Noh, DY; Park, IA | 1 |
| Blohmer, JU; Eggemann, H; Eidtmann, H; Fasching, P; Gerber, B; Hanusch, C; Hauschild, M; Huober, J; Jackisch, C; Kittel, K; Kunz, G; Loibl, S; Nekljudova, V; Rezai, M; Schrader, I; Solbach, C; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Alamgeer, M; Fox, J; Ganju, V; Harris, M; Hart, S; Kumar, B; Prodanovic, Z; Schneider-Kolsky, ME; Stuckey, J; Watkins, DN; White, M | 1 |
| Al-Ani, A; Bolln, C; Hodnett, R; Ramsingh, J | 1 |
| Barni, S; Blasi, L; Cinieri, S; Colucci, G; De Vita, F; Fedele, P; Filippelli, G; Gebbia, N; Giotta, F; Lorusso, V; Maiello, E; Orlando, L; Pappagallo, GL; Pisconti, S; Riccardi, F; Verderame, F | 1 |
| Chandarlapaty, S; Crews, JR; Davidson, NE; Esteva, FJ; Giordano, SH; Gonzalez-Angulo, AM; Kirshner, JJ; Krop, I; Levinson, J; Lin, NU; Modi, S; Patt, DA; Perez, EA; Perlmutter, J; Ramakrishna, N; Temin, S; Winer, EP | 1 |
| Chan, MS; Chen, SF; Chow, LW; Felizola, SJ; Ishida, T; Nemoto, N; Ohuchi, N; Sasano, H; Tamaki, K; Wang, L | 1 |
| Ah Lee, S; Gwe Ahn, S; Jeong, J; Min Lee, H; Woo Lee, H | 1 |
| Augustin, D; Böhmer, S; Du Bois, A; Erber, R; Gluz, O; Harbeck, N; Hartmann, A; Hoffmann, G; Huober, J; Jänicke, F; Kates, RE; Kiechle, M; Kreienberg, R; Kreipe, HH; Kuhn, W; Lisboa, B; Möbus, V; Mohrmann, S; Moustafa, Z; Nitz, U; Sattler, D; Scholz, M; Thomssen, C; Wallwiener, D; Weiss, E | 1 |
| Andergassen, U; Beckmann, MW; Fasching, PA; Fehm, T; Friedl, TW; Friese, K; Hepp, P; Janni, W; Jückstock, J; Lichtenegger, W; Lorenz, R; Pantel, K; Rack, B; Schindlbeck, C; Schneeweiss, A; Tesch, H; Zwingers, T | 1 |
| Chen, L; Luo, F; Qian, Z; Tan, L; Wang, Y; Wei, Y; Zhao, Q | 1 |
| Blakely, T; Kvizhinadze, G; Rivalland, G; Webber-Foster, R | 1 |
| Cserni, G; Csörgő, E; Kelemen, G; Kővári, B; Lázár, P; Nyári, T; Rusz, O; Vörös, A | 1 |
| Guan, Y; Liu, J; Liu, S; Liu, X; Niu, Y; Wang, L; Wang, Y; Zhang, W | 1 |
| Barcenas, CH; Buchholz, TA; Elting, LS; Giordano, SH; Hortobagyi, GN; Niu, J; Smith, BD; Zhang, N; Zhang, Y | 1 |
| Baselga, J; Chan, V; Clark, E; Im, SA; Im, YH; Knott, A; Miles, D; Ross, G; Swain, SM | 1 |
| Balslev, E; Bartels, A; Bjerre, C; Bjerre, KD; Brünner, N; Ejlertsen, B; Jørgensen, CL; Nielsen, DL | 1 |
| Chen, W; Gao, Z; Huang, W; Jin, M; Li, Y; Shao, S; Xia, G; Yang, F; Zhang, S | 1 |
| Amler, LC; Gianni, L; Guardino, E; Hurvitz, SA; Mundt, KE; Ng, V; Perez, EA | 1 |
| Carothers, S; Layman, R; Lustberg, MB; Macrae, ER; Mrozek, E; Pan, X; Puhalla, S; Ramaswamy, B; Shapiro, CL; Wesolowski, R; Zhao, M | 1 |
| Ding, C; Jia, L; Li, W; Li, Y; You, W; Zhai, B; Zhang, B; Zhi, H | 1 |
| Asthana, S; Chaurasia, M; Chourasia, MK; Meher, JG; Pawar, VK; Verma, P | 1 |
| Coşkun, HŞ; Mutlu, H | 1 |
| Duan, L; Fang, L; Long, X; Qu, H | 1 |
| Cai, KQ; Domanitskaya, N; Egleston, B; Foster, K; Hopper-Borge, E; Jacobs, J; Mahdaviyeh, Y; Malofeeva, E; Paulose, C; Peiffer, E; Wangari-Talbot, J; Zhou, Y | 1 |
| Azarenko, O; Jordan, MA; Mah, J; Smiyun, G; Wilson, L | 1 |
| Balslev, E; Cold, S; Nielsen, DL; Tange, UB; Tuxen, MK | 1 |
| Assi, H; Boyle, L; Murray, J; Rayson, D | 1 |
| Belli, P; Bufi, E; D' Agostino, GR; De Santis, MC; Diletto, B; Franceschini, G; Mulé, A; Nardone, L; Sapino, A; Terribile, D; Valentini, V | 1 |
| Borgen, E; Gilje, B; Naume, B; Nordgård, O; Smaaland, R; Synnestvedt, M; Tjensvoll, K | 1 |
| Li, J; Li, X; Liu, H; Liu, M; Wang, J; Xu, J; Yang, H; Zhang, Y | 1 |
| Bonetti, F; Bria, E; Brunelli, M; Caliolo, C; Carbognin, L; Furlanetto, J; Manfrin, E; Massari, F; Nortilli, R; Pedron, S; Pellini, F; Pollini, GP; Scarpa, A; Sperduti, I; Tortora, G | 1 |
| Conant, EF; Da, X; Davatzikos, C; DeMichele, A; Englander, S; Gaonkar, B; Hsieh, MK; Kontos, D; Ou, Y; Rosen, M; Weinstein, SP | 1 |
| Guo, X; Jiao, S; Jing, F; Li, J; Linghu, R; Liu, M; Yang, J; Zhu, Y | 1 |
| Chen, L; Chen, WX; Hu, Q; Lv, MM; Ma, TF; Tang, JH; Zhang, J; Zhao, JH; Zhong, SL; Zhu, XY | 1 |
| DiMaio, MA; Erdrich, J; Kastenberg, ZJ; Longacre, TA; Rhoads, KF | 1 |
| Cao, J; Huang, XE; Wang, L | 1 |
| Ghanbari, P; Mohseni, M; Rashidi, MR; Saei, AA; Samadi, N; Sharifi, S; Tabasinezhad, M; Yousefi, B | 1 |
| Abe, H; Kawai, Y; Kubota, Y; Mori, T; Tani, T; Umeda, T; Yamazaki, K | 1 |
| Ah-See, ML; Beresford, MJ; Collins, DJ; Gogbashian, A; Li, SP; Makris, A; Padhani, AR; Stirling, J; Taylor, NJ; Woolf, DK | 1 |
| Bagust, A; Beale, S; Dickson, R; Dundar, Y; Dwan, K; Fleeman, N; Proudlove, C | 1 |
| Jeon, WH; Jeung, HJ; Kim, DK; Kim, GC; Park, SI; Sim, YJ | 1 |
| Charehbili, A; Kroep, JR; Liefers, GJ; Meershoek-Klein Kranenbarg, WM; Nortier, JW; Putter, H; Smit, VT; van de Velde, CJ; van Leeuwen-Stok, AE; Wasser, MN | 1 |
| Boirie, Y; Chadeyras, JB; Coudert, B; Durando, X; Gadea, E; Kwiatkowski, F; Merlin, C; Morio, B; Paulon, R; Thivat, E | 1 |
| Dieudonné, AS; Hatse, S; Lambrechts, D; Neven, P; Paridaens, R; Peeters, M; Pettengell, R; Pfeil, AM; Schwenkglenks, M; Szucs, TD; van Dam, P; Vulsteke, C; Wildiers, H | 1 |
| Abi Gerges, D; Buyse, M; Fung, H; Gelmon, KA; Gorbunova, V; Hegg, R; Ibrahim, A; Konecny, GE; Krasnozhon, D; Lipatov, O; Mackey, JR; Manikhas, A; Martin, M; McCarthy, N; Ramos-Vazquez, M; Semiglazov, V; Simms, L; Thireau, F; Verma, S; Webster, M | 1 |
| Bayraktar, S; de Snoo, F; Glück, S; Royce, M; Stork-Sloots, L | 1 |
| Choi, MK; Han, W; Kim, DJ; Kim, GS; Kim, J; Lee, GH; Lee, KM; Lee, SK; Lee, WY; Park, NW | 1 |
| Ali Sanli, U; Bicakli, DH; Cakar, B; Degirmenci, M; Durusoy, R; Karaca, B; Tunali, D; Uslu, R; Varol, U | 1 |
| Adachi, S; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Narui, K; Sasaki, T; Satake, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A | 1 |
| Bias, P; Buchner, A; Elsässer, R | 1 |
| Arnold, KM; Davis, J; Flynn, D; Opdenaker, LM; Sims-Mourtada, J | 1 |
| Alba, E; Bines, J; Cortes, P; Costa, R; de Ducla, S; Doval, D; Freudensprung, U; Gligorov, J; Gupta, V; Mustacchi, G; Pierga, JY; Srock, S | 1 |
| Chen, H; Huang, L; Liang, X; Liu, Z; Mei, L; Tao, W; Xiao, X; Yang, Y; Zeng, X; Zhang, X | 1 |
| Angelucci, D; Barba, M; Bartucci, M; Dattilo, R; De Maria, R; Di Benedetto, A; Di Lauro, L; Gamucci, T; Maugeri-Saccà, M; Mottolese, M; Natoli, C; Pagliuca, A; Pizzuti, L; Ramieri, MT; Sergi, D; Sperati, F; Terrenato, I; Vici, P | 1 |
| Amit, L; Ben-Aharon, I; Bonilla, L; Ciuraru, NB; Goldvaser, H; Granot, T; Hendler, D; Neiman, V; Rizel, S; Stemmer, SM; Sulkes, A; Yerushalmi, R; Zer, A | 1 |
| Nahta, R; O'Regan, RM; Paplomata, E | 1 |
| Hoelen, W; Hugenholtz-Wamsteker, W; Meeus, M; Nijs, J; Robbeson, C | 1 |
| Bendigtsen Schirmer, C; Borgen, E; Falk, RS; Kersten, C; Mjaaland, I; Naume, B; Risberg, T; Rypdal, MC; Sommer, HH; Synnestvedt, M; Sætersdal, AB; Vindi, L; Weyde, K; Wiedswang, G; Wist, EA | 1 |
| Parsons, LM; Trotter, MJ; Tsang, RY; Wong, NY | 1 |
| Bi, X; Cong, W; Dai, Z; Ge, Y; Han, J; Li, Y; Ma, D; Yuan, Q | 1 |
| Bergmann, TK; Eckhoff, L; Ewertz, M; Feddersen, S; Knoop, AS | 1 |
| Agelaki, S; Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Mavroudis, D; Vamvakas, L; Vardakis, N | 1 |
| Athanasiadis, A; Boukovinas, I; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, C; Makrantonakis, P; Malamos, N; Mavroudis, D; Polyzos, A; Saloustros, E; Ziras, N | 1 |
| Ham, HS; Han, W; Im, SA; Jang, IJ; Keam, B; Kim, HJ; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Noh, DY; Oh, DY; Park, IA | 1 |
| Han, DY; Jiang, DQ; Nie, HG; Song, ZG; Sun, T | 1 |
| Florendo, J; Higgins, B; Jones, G; Kano, J; Leung, M; Marr-Del Monte, T; Menon, T; Myers, R | 1 |
| Arakawa, A; Harada-Shoji, N; Himuro, T; Hino, O; Horimoto, Y; Igari, F; Mamat, O; Saito, M; Sonoue, H; Tanabe, M; Tokuda, E; Yoshida, Y | 1 |
| Amarillo, I; Fisher, SI; Rashidi, A | 1 |
| Brufsky, A | 1 |
| Briscoe, K; Jain, A; Linsell, J | 1 |
| Arnould, L; Bachelot, T; Berriolo-Riedinger, A; Bougnoux, P; Coeffic, D; Coudert, B; Coudert, M; Dupré, PF; Ferrero, JM; Gabelle, P; Giard, S; Hernandez, J; Kerbrat, P; Kerrou, K; Mouret-Reynier, MA; Paintaud, G; Petit, T; Pierga, JY; Prevost, JB; Thibault, G | 1 |
| Bodmer, A; Bonnefoi, H; Brain, E; Cameron, D; Chakiba, C; Jacot, W; Jerusalem, G; Matos, E; Messina, CG; Moldovan, C; Petit, T; Quenel-Tueux, N; Saghatchian, M; Slaets, L; Tredan, O; Venat-Bouvet, L; Vuylsteke, P; Zaman, K | 1 |
| Feng, SS; Kutty, RV; Luo, Z; Muthu, MS; Xie, J | 1 |
| Fu, L; Gu, F; Guo, X; Li, H; Li, S; Li, X; Liu, F; Zhai, L; Zhang, X | 1 |
| Barni, S; Botti, G; Colantuoni, G; D'Aiuto, M; Daniele, B; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Di Maio, M; Di Rella, F; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Iodice, G; Labonia, V; Landi, G; Lauria, R; Montanino, A; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, E; Signoriello, S; Tinessa, V | 1 |
| Hirakawa, K; Kashiwagi, S; Kawajiri, H; Noda, S; Onoda, N; Takashima, T | 1 |
| Aliño, SF; Bosó, V; de la Cueva, H; Herrero, MJ; Marqués, MR; Megias, JE; Montalar, J; Palomar, L; Poveda, JL; Rojas, L; Santaballa, A | 1 |
| Kang, RY; Kim, HS; Kim, KS; Lee, BK; Lee, JY; Lee, SH; Lee, YJ; Suh, SY; Yoo, KE | 1 |
| Aktas, B; Aydogdu, M; Feisel-Schwickardi, G; Höffkes, HG; Illmer, T; Janni, W; Loibl, S; Lübbe, K; Lück, HJ; Maass, N; Mehta, K; Nekljudova, V; Neunhöffer, T; Ober, A; Park-Simon, TW; Reinisch, M; Schumacher, C; Tomé, O; von Minckwitz, G; Wagner, H | 1 |
| Eckhoff, L; Ewertz, M; Jensen, MB; Knoop, A | 1 |
| Chica Marchal, A; De Andrés Bautista, M; Ferris Villanueva, E; García Simón, MS; Guerrero Bautista, R; Pérez Cañadas, P | 1 |
| Clemens, MR; Crown, J; Gartner, E; Gladkov, OA; Jie, F; Keating, A; Steinberg, J; Vladimirov, V | 1 |
| Chen, L; Chen, W; Mao, Cf; Sun, DW; Tang, JH; Wu, JZ; Zhang, Hd; Zhang, J; Zhao, JH; Zhong, SL | 1 |
| Cao, C; Dong, WL; Tian, Y; Wang, XF; Yang, L; Zhang, XY; Zhang, ZQ; Zheng, LY | 1 |
| Gilbar, P; McPherson, I; Sorour, N | 1 |
| Belling, KC; Brünner, N; Ditzel, HJ; Do, KN; Fogh, L; Gupta, R; Hansen, SN; Moreira, J; Schrohl, AS; Stenvang, J; Thomsen, MB; Vistesen, M; Wang, J; Westergaard, D; Yang, H | 1 |
| Adinolfi, MI; Bafile, A; Bruera, G; Cannita, K; Ciccozzi, A; Cocciolone, V; Ficorella, C; Mancini, M; Pelliccione, M; Penco, M; Ricevuto, E; Romano, S | 1 |
| Dent, S; Earle, C; Eisen, A; Enright, K; Ghannam, M; Grunfeld, E; Kaizer, L; Krzyzanowska, MK; Moineddin, R; Trudeau, M; Yun, L | 1 |
| Abrial, C; Chollet, P; Cure, H; DuBray-Longeras, P; Eymard, JC; Garbar, C; Kwiatkowski, F; Lebouedec, G; Mouret-Reynier, MA; Penault-Llorca, F; Savoye, AM; Vanpraagh, I; Wang-Lopez, Q | 1 |
| Abdal-Kader, YS; Abdalmassih, MK; Azim, HA; Ibrahim, NY; Malek, RA; Mousa, MM | 1 |
| Gu, X; Jia, S; Wei, W; Zhang, WH | 1 |
| Bria, E; Brunelli, M; Carbognin, L; Giannarelli, D; Nortilli, R; Pellini, F; Pollini, GP; Sperduti, I; Tortora, G; Vicentini, C | 1 |
| Banala, VT; Gupta, GK; Mishra, PR; Pawar, VK; Shukla, R; Singh, SK; Tripathi, P; Verma, A | 1 |
| Feng, X; Jin, X; Liang, Y; Sun, L; Tang, X; Zhang, R | 1 |
| Baselga, J; Benyunes, MC; Campone, M; Ciruelos, E; Clark, E; Cortés, J; Ferrero, JM; Heeson, S; Kim, SB; Ro, J; Ross, G; Schneeweiss, A; Semiglazov, V; Swain, SM | 1 |
| Chan, KK; Lee, EK; Trudeau, ME; Wong, WW | 1 |
| Ito, Y; Masuda, N; Nakamura, S; Shimazaki, R; Tamura, K; Tokuda, Y | 1 |
| Demir, N; Erin, N; Kale, Ş; Köksoy, S; Korcum, AF; Tanrıöver, G | 1 |
| Bao, JL; Pan, YH; Shan, M; Wang, C; Xu, M; Zhao, LM | 1 |
| Adar, L; Avisar, N; Barash, S; Bock, J; Müller, U; Pukac, L; Shen, D | 1 |
| Aksoy, S; Altundag, K; Berk, V; Karaca, H; Ozdemir, N; Ozkan, M; Ozturk, B; Sendur, MA; Yazici, O; Yazilitas, D; Zengin, N | 1 |
| Chuang, E; Cigler, T; Fiederlein, B; Isseroff, D; Moore, A; Schneider, S; Vahdat, L | 1 |
| Kostopoulos, A; Koutsilieris, M; Papageorgiou, E; Sivolapenko, G | 1 |
| Chen, L; Ding, B; Gao, J; Han, Y; Jin, G; Liu, C; Liu, X; Ma, G; Tian, X; Xuan, S | 1 |
| Chen, H; Deng, Q; Du, N; Guo, L; Guo, N; Hu, C; Hu, Y; Liu, D; Liu, Y; Shi, M; Wang, T; Yang, Z; Yu, M | 1 |
| Alexopoulou, Z; Aravantinos, G; Bafaloukos, D; Bobos, M; Chrisafi, S; Efstratiou, I; Fountzilas, G; Kosmidis, P; Kotoula, V; Kourea, HP; Koutras, A; Papakostas, P; Papaspirou, I; Pectasides, D; Scopa, CD; Skarlos, DV; Varthalitis, I; Zagouri, F | 1 |
| Qiu, WS; Sun, LB; Yao, RY; Yao, YS; Yue, L; Zhang, Q; Zhou, F; Zhuang, LK | 1 |
| Jiang, Z; Li, C; Wang, L; Xia, J; Zhang, W | 1 |
| Maejima, A; Tamura, K | 1 |
| Arnould, L; Boidot, R; Burillier, L; Cadouot, M; Chevrier, S; Coudert, B; Fumoleau, P; Lizard-Nacol, S; Schmitt, E; Végran, F | 1 |
| Enzsoly, A; Kammerer, K; Nemeth, J; Schneider, M | 1 |
| Bergh, J; Foukakis, T; Giorgetti, C; Hedayati, E; Jacobsson, H; Lindström, LS; Lövrot, J; Sandqvist, P; Xie, H | 1 |
| Bansal, R; Hennink, WE; Hu, Q; Prakash, J; Rijcken, CJ; Storm, G | 1 |
| Dank, M; Györke, T; Kajáry, K; Kulka, J; Lengyel, Z; Molnár, BÁ; Szentmártoni, G; Tőkés, AM; Tőkés, T; Torgyík, L | 1 |
| Behnke, ML; Caldas, C; Campbell, DA; Cheng, CK; Chernoff, J; Chin, SF; Dehdashti, S; Duron, SG; Ellis, IO; Forrest, WF; Friedman, LS; Gierke, S; Green, AR; Haverty, PM; Hoeflich, KP; Huang, W; Jubb, AM; Koeppen, H; McKew, JC; O'Brien, T; Ong, CC; Pitt, C; Rakha, EA; Rudolph, J; Sagolla, M; Schmidt, M; Shen, M; Strickland, L; Yang, N; Zheng, W; Zhou, W | 1 |
| Dai, XL; Feng, YZ; Han, ZB; Liu, YF; Qiu, J; Yang, YT | 1 |
| Abbasi, AZ; Amini, MA; Cai, P; Foltz, WD; Gordijo, CR; He, C; Prasad, P; Rauth, AM; Wu, XY | 1 |
| Ahmed, R; Chatterjee, S; Mukhopadhyay, S; Pilaka, VK; Shrimali, RK | 1 |
| Andre, F; Arnould, L; Beuzeboc, P; Coeffic, D; Ferrero, JM; Lortholary, A; Spano, JP | 1 |
| Atmaca, H; Bozkurt, E; Degirmenci, M; Karabulut, B; Karaca, B; Ozveren, A; Sanli, UA; Uslu, R | 1 |
| Amir, E; Clemons, M; Daigle, K; Eggert, L; Gregario, N; Hutton, B; Ibrahim, MF; Jacobs, C; Joy, A; Mazzarello, S; Smith, S | 1 |
| Boukovinas, I; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Malamos, N; Mavroudis, D; Papakotoulas, P; Saloustros, E; Ziras, N | 1 |
| Adar, L; Avisar, N; Barash, S; Bias, P; Bondarenko, IN; Gladkov, O; Moiseyenko, V; Shparyk, Y | 1 |
| Abraham, J; Ahmad, R; Bartlett, J; Blenkinsop, C; Caldas, C; Cameron, DA; Chan, S; Dunn, JA; Earl, HM; Gounaris, I; Grybowicz, L; Hayward, L; Hickish, T; Hiller, L; Houston, S; Hughes-Davies, L; McAdam, K; Provenzano, E; Rea, D; Thomas, J; Vallier, AL | 1 |
| Bellersen, L; Bulten, BF; de Geus-Oei, LF; Joosten, LA; Kapusta, L; Mandigers, CM; Mavinkurve-Groothuis, AM; van Boxtel, W; van Laarhoven, HW | 1 |
| Hasebe, T; Hirokawa, E; Kuji, I; Matsuura, K; Osaki, A; Saeki, T; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S; Yamane, T | 1 |
| Arora, S; Arora, SK; Bharadwaj, LM; Kaur, H; Kaur, I; Kumar, R; Rayat, CS; Srivastava, J | 1 |
| Chen, K; Duan, WM; Gong, FR; Gui, Q; Li, DM; Li, W; Lian, L; Liu, L; Shen, M; Tao, M; Wang, WJ; Wu, MY; Xu, MD; Zhu, J | 1 |
| Bias, P; Bondarenko, IM; Buchner, A | 1 |
| Blum, JL; Brooks, R; Brownstein, C; Hoersch, S; Holmes, FA; Jones, S; Koeppen, H; Krekow, L; Lackner, MR; Lindquist, D; McIntyre, K; O'Shaughnessy, J; Paul, D; Pippen, J; Rivera, R; Sedlacek, S; Stokoe, C; Vukelja, S; Xiao, Y | 1 |
| De Brabander, JK; Gellert, G; Krauth, M; Meyer, CJ; Miller, JH; Northcote, PT; Shay, JW; Wick, MJ | 1 |
| Anastasov, N; Atkinson, MJ; Hadian, K; Höfig, I; Kelm, JM; Lichtenberg, J; Radulović, V; Rothenaigner, I; Salomon, M; Ströbel, S; Thirion, C | 1 |
| Kodaira, M; Minoura, K; Miyazaki, H; Mori, M; Ochiya, T; Ono, M; Takahashi, RU; Takeshita, F; Tamura, K; Yamamoto, Y | 1 |
| Abdel-Aziz, NM; Abozeed, WN; Alsaleh, K; Alzahrani, A; Elbiomy, MA; Elsamany, S; Farooq, MU; Rasmy, A; Rawah, E | 1 |
| Ameye, L; Anderson, M; Azim, HA; Barnadas, A; Cortes-Funes, H; Crown, J; de Azambuja, E; Di Leo, A; Francis, PA; Gnant, M; Goldhirsch, A; Gutiérez, J; Lluch, A; Mastropasqua, MG; Nordenskjöld, B; Piccart, M; Quinaux, E; Sonnenblick, A | 1 |
| Davidson, NE; Ligibel, JA; Martino, S; Perez, EA; Saphner, T; Sledge, GW; Sparano, JA; Wolff, AC; Wood, WC; Zhao, F | 1 |
| Rayson, D; Skedgel, C; Younis, T | 1 |
| Bias, P; Buchner, A; Elsässer, R; Gladkov, OA; Müller, U | 1 |
| Cai, R; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Atyabi, F; Dinarvand, R; Esfandyari-Manesh, M; Irani, S; Kordezangeneh, M; Mirfakhraie, R | 1 |
| Antolín-Novoa, S; Antón, A; Blanco-Campanario, E; de la Cruz-Merino, L; Galán-Brotons, A; Gallegos-Sancho, MI; Murías-Rosales, A; Peláez, I; Pérez-Carrión, R | 1 |
| André, R; Brito, M; Esteves, S; Isidoro, M; Moreira, A | 1 |
| Nishimura, H; Senda, N; Shiozaki, T; Tsuyuki, S; Yamaguchi, A | 1 |
| Aydiner, A; Cabioglu, N; Deniz, M; Erturk, K; Karanlik, H; Kilic, B; Onder, S; Ozgur, I; Sen, F; Yavuz, E | 1 |
| Chen, Z; Ding, Q; Guo, G; Li, Z; Luo, F; Qian, Z; Shi, S; Yang, Y | 1 |
| Karpińska, A; Kładny, J; Safranow, K; Sulżyc-Bielicka, V | 1 |
| Cai, SQ; Chen, XB; Dou, TT; Man, XY; Min, M; Yang, JQ; Zheng, M | 1 |
| Imanishi, S; Koyama, H; Matsui, C | 1 |
| Amini, M; Atyabi, F; Dinarvand, R; Goodarzi, N; Khorramizadeh, MR; Nateghian, N | 1 |
| Bocaccio, F; Chanat, C; Cojean-Zelek, I; Delbaldo, C; Denis, J; Le Guyader, N | 1 |
| Adams, PT; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Liu, Q; Mamounas, EP; Margolese, RG; Mehta, RS; Paik, S; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Du, XJ; Li, HJ; Liu, WW; Luo, YL; Shen, S; Sun, CY; Sun, R; Wang, J; Wang, JL; Yang, JX; Yang, XZ; Ye, XD; Zhu, YH | 1 |
| Tang, JH; Yao, YF; Zhang, HD; Zhang, J; Zhao, JH; Zhong, SL | 1 |
| Choi, DH; Huh, SJ; Keum, KC; Kim, KH; Kim, YB; Noh, JM; Park, W; Suh, CO | 1 |
| Arlen, PM; Donahue, RN; Farsaci, B; Folio, LR; Grenga, I; Gulley, JL; Heery, CR; Ibrahim, NK; Jochems, C; Koenig, K; Madan, RA; Marté, JL; McMahon, S; Mohebtash, M; Murray, JL; Schlom, J; Steinberg, SM | 1 |
| Gao, D; Jiang, Q; Li, H; Liu, J; Luo, H; Luo, X; Tang, W; Yang, Z; Zhang, C; Zhang, X | 1 |
| Cao, HX; Chen, W; Ji, H; Jiang, LH; Li, J; Ma, R; Mao, L; Sun, DW; Tang, JH; Wang, J; Wu, JZ; Wu, Y; Zhang, HD; Zhang, J | 1 |
| Bhat, R; Chen, H; Do, T; Medhekar, R; Niravath, P; Trivedi, MV | 1 |
| Chang, DT; Dudley, SA; Durkee, BY; Gibbs, IC; Goldhaber-Fiebert, JD; Horst, KC; King, MT; Pollom, EL; Qian, Y; Shaffer, JL | 1 |
| Golovin, YI; Klyachko, NL; Korenkov, VV; Kuznetsova, NR; Markvicheva, EA; Privalova, AM; Uglanova, SV; Vodovozova, EL | 1 |
| Agrawal, AK; Jain, S; Kushwah, V; Spandana, G; Thanki, K | 1 |
| Pankowska-Supryn, M; Roszkowska-Śliż, B; Roszkowski-Śliż, K; Załęska, M | 1 |
| Castro-Lopes, JM; Dias, T; Fontes, F; Fragoso, M; Lunet, N; Pereira, S; Sonin, T | 1 |
| De Iuliis, F; Giantulli, S; Giuffrida, A; Milana, B; Rubinacci, G; Salerno, G; Scarpa, S; Silvestri, I; Taglieri, L; Terella, F | 1 |
| Bellersen, L; Bulten, BF; de Geus-Oei, LF; Kapusta, L; Mavinkurve-Groothuis, AM; Oyen, WJ; Sabaté-Llobera, A; van Laarhoven, HW; Verberne, HJ | 1 |
| Bu, XB; Wang, J; Wang, T; Wang, ZG; Yang, L; Yin, GY | 1 |
| Alvarez, RH; Barcenas, CH; Fujii, T; Kogawa, T; Le Du, F; Shen, Y; Ueno, NT; Valero, V; Xiao, L | 1 |
| Crocamo, S; Delbue, D; Gomes, AR; Khongkow, P; Lam, EW; Magalhães, LM; Maia, RC; Mencalha, AL; Nestal de Moraes, G; Robaina, MC; Silva, KL; Zona, S | 1 |
| Brito, M; Cardoso, C; Miguel, I; Moreira, A; Sousa, M; Winckler, P | 1 |
| Adrover, E; Andrés, R; Baena-Cañada, JM; Ballesteros, AI; Barnadas, A; Calvo, L; Carrasco, EM; Casas, M; de la Haba-Rodríguez, J; Del Barco Berron, S; del Carmen Cámara, M; González, S; Jara, C; Lluch, A; López-Vega, JM; Margelí Vila, M; Martín, M; Martínez de Dueñas, E; Martínez-Jáñez, N; Mendiola Fernández, C; Muñoz-Mateu, M; Plazaola, A; Ramos, M; Ribelles, N; Rodríguez, CA; Rodríguez-Lescure, Á; Ruiz Borrego, M; Ruiz Simón, A; Sánchez-Rovira, P; Santaballa, A | 1 |
| Fox, MJ; Gibbs, P; Pickles, MD | 1 |
| Hao, X; Li, C; Su, W; Zhang, J; Zhang, S | 1 |
| Kumagai, K; Miyaki, T; Nakamura, R; Okubo, Y; Tsujimura, H; Yamamoto, N | 1 |
| Chen, Y; Han, C; Jiao, S; Li, J; Linghu, R; Si, W; Yang, B; Yang, J; You, J; Zhang, X; Zhu, Y | 1 |
| Chen, S; Li, M; Liu, W; Wang, Y; Wei, Y; Ye, M; Yu, S; Zhang, H; Zhang, J; Zhang, Y | 1 |
| Bora, HK; Chaurasia, M; Chourasia, MK; Gupta, A; Gupta, S; Meher, JG; Pawar, VK; Sharma, K; Singh, P; Singh, Y | 1 |
| Cyriac, SL; Dhanraj, KM; Dubashi, B; Gollapalli, S; Kayal, S | 1 |
| Cai, YQ; Chen, WX; Li, J; Mao, L; Tang, JH; Yu, DD; Zhao, JH; Zhong, SL; Zhou, JW | 1 |
| A L-Abdulkarim, H; A L-Tweigeri, T; Abulkhair, O; Ajarim, D; Alawadi, S; AlSayed, A; Ashour, W; Ibrahim, M; Jaafar, H; Khalid, H | 1 |
| Ahomadegbe, JC; Alsafadi, S; André, F; Bessoltane, N; Salomé-Desnoulez, S; Tourpin, S; Vassal, G | 1 |
| Cho, S; Ham, HS; Han, SW; Han, W; Im, SA; Keam, B; Kim, H; Kim, TY; Lee, KH; Min, A; Noh, DY; Oh, DY; Park, IA; Ryu, HS; Yang, Y; Youk, J | 1 |
| Afonso, N; Alves, C; Andrade, S; Batel-Marques, F; Cardoso, F; Costa, L; Mendes, D; Passos-Coelho, JL | 1 |
| Chen, J; Hu, AP; Shen, P; Yang, L; Yu, SF; Zhang, XC; Zhu, HQ | 1 |
| Cho, S; Choi, YJ; Han, J; Min, JJ; Nguyen, VD; Park, IK; Park, JO; Park, S; Park, SH; Uthaman, S; Zheng, S | 1 |
| Balsari, A; Bianchi, GV; Di Modica, M; Generali, D; Mariani, G; Oliviero, B; Regondi, V; Sfondrini, L; Tagliabue, E; Triulzi, T; Varchetta, S | 1 |
| Dong, N; Lyerly, HK; Ren, J; Song, Q; Wang, X; Yang, H; Yu, J; Zhou, X | 1 |
| Beijnen, JH; Hendrikx, JJ; Huitema, AD; Rottenberg, S; Schellens, JH; Yu, H | 1 |
| Hara, F; Hozumi, Y; Imoto, S; Matsubara, N; Mukai, H; Nishimura, R; Ohashi, Y; Park, Y; Sagara, Y; Saito, T; Shimozuma, K; Takano, T; Takashima, T; Toyama, T; Tsurutani, J; Watanabe, T | 1 |
| Adili, A; Esfehani, A; Jafarpour-Sadegh, F; Mesgari, M; Montazeri, V; Pirouzpanah, S; Rashidi, MR | 1 |
| Buhari, SA; Chng, WJ; Hartman, M; Iau, P; Lee, SC; Loh, M; Miao, H; Sapari, NS; Soong, R; Tan, SH | 1 |
| Dong, T; Dong, Y; Guo, M; Herman, JG; van Engeland, M; Zhang, M; Zhong, G | 1 |
| Feng, B; Guo, C; Li, Y; Wang, D; Wang, T; Xu, Z; Yin, Q; Yu, H; Zhang, J; Zhang, Z | 1 |
| Adar, L; Avisar, N; Barash, S; Bondarenko, IN; Gladkov, O; Moiseyenko, V; Shparyk, Y | 1 |
| Chen, Z; Jia, X; Wang, L; Wang, M; Wang, S; Wang, Z; Wu, M; Xu, Z; Zhang, J | 1 |
| Byun, H; Im, KH; Jeon, P; Kim, B; Kim, JH; Kim, K; Lee, JH | 1 |
| Darb-Esfahani, S; Denkert, C; Eidtmann, H; Fasching, PA; Furlanetto, J; Hartmann, A; Huober, J; Jackisch, C; Klimowicz, A; Lederer, B; Loibl, S; Mehta, K; Pfitzner, B; Tiemann, K; Untch, M; von Minckwitz, G | 1 |
| Hou, L; Huang, H; Zhang, H; Zhang, Y; Zhang, Z; Zhu, X | 1 |
| Bergh, J; Betsholtz, C; Foukakis, T; Genové, G; He, L; Landberg, G; Lindström, LS; Östman, A; Tobin, NP; Wennmalm, K | 1 |
| Bi, J; Cao, B; Chen, L; Dai, H; Deng, Y; Hu, J; Jia, L; Jiang, H; Li, W; Meng, C; Nan, K; Shen, K; Shen, P; Shi, J; Song, Y; Sun, Q; Sun, Y; Tang, L; Tian, F; Tong, Z; Wang, S; Wu, G; Wu, Q; Wu, Y; Xie, X; Xu, B; Yu, J; Yuan, Z; Yue, S; Zhang, B; Zhang, Q; Zhang, Y; Zhuang, W | 1 |
| Aluzaite, K; Brünner, N; Damsgaard, B; Do, KN; Foekens, J; Fogh, L; Gajjar, M; Hamerlik, P; Hansen, SN; Jandu, H; Knudsen, BR; Martens, J; Moreira, J; Nielsen, SL; Noer, JB; Pommier, Y; Proszek, J; Schrohl, AS; Smid, M; Stenvang, J; Stougaard, M; Thrane, SW | 1 |
| Bousquet, G; Hamdan, D; Janin, A; Jourdan, N; Leboeuf, C; Pereira, C; Verneuil, L | 1 |
| Blanc, C; Bougnoux, P; Chauvin, L; Chevalier, S; Domingo, I; Goupille, C; Guimaraes, C; Mahéo, K; Pinault, M | 1 |
| Barsoum, IB; Black, M; Cotechini, T; Craig, AW; Graham, CH; Koti, M; Macdonald-Goodfellow, SK; Petroff, M; Siemens, DR; Truesdell, P | 1 |
| Bayo, J; Prieto, B; Rivera, F | 1 |
| Fujita, Y; Fujiwara, I; Fukuda, K; Goto, M; Hamaoka, A; Imai, A; Imanishi, S; Kadotani, Y; Kawakami, S; Konishi, E; Kotani, T; Koyama, H; Matsuda, T; Mizuta, N; Morita, M; Nakatsukasa, K; Okamoto, A; Oouchi, Y; Sakaguchi, K; Soushi, M; Taguchi, T; Yamada, K; Yanagisawa, A | 1 |
| Burman, R; Gill, MS; Pawar, H; Singh, C; Surapaneni, SK; Suresh, S; Tikoo, K | 1 |
| Li, X; Liu, L; Zhang, J | 1 |
| Hou, MF; Kim, SB; Nguyen Ba, D; Sayeed, A; Shah, MA; Shen, ZZ; Villalon, AH | 1 |
| Hanai, A; Ishiguro, H; Itohara, K; Masuda, S; Matsubara, K; Motohashi, H; Onoue, H; Tanaka, A; Yano, I | 1 |
| Copson, B; Hayes, T; McLean, C; Pratap, U | 1 |
| Chen, X; Lv, M; Shen, H; Tang, J; Wang, D; Yang, S; Zhang, X; Zhao, J; Zhong, S | 1 |
| Guo, B; Lannér, C; Masilamani, T; Mispel-Beyer, K; Narendrula, R; Parissenti, AM; Pritzker, K; Pritzker, LB; Wang, X | 1 |
| Ba, DN; Chao, TY; Hou, MF; Kim, SB; Sayeed, A; Shah, MA; Shen, ZZ; Thuan, TV; Villalon, AH; Yau, TK | 1 |
| Bensfia, S; Buyse, M; Chan, A; Crown, J; Drevot, P; Eiermann, W; Hitier, S; Houé, V; Lindsay, M; Mackey, JR; Martin, M; Pieńkowski, T; Press, MF; Provencher, L; Sadeghi, S; Saleh, M; Sauter, G; Sehdev, S; Semiglazov, V | 1 |
| Berg, AL; Carraway, KL; Curiel, DA; Hatakeyama, J; Leon, LJ; Rowson-Hodel, AR; Sweeney, C; VanderVorst, K; Wald, JH | 1 |
| Barbolosi, D; Ciccolini, J; Freyer, G; Iliadis, A; Meille, C | 1 |
| Angulo, Mdel M; Calvo, L; Cámara, MC; Carañana, V; Carrasco, E; Casas, MI; Dalmau, E; Fernández-Morales, LA; Garcia-Mace, AI; García-Saenz, JA; González, A; González-Farré, X; Jara-Sánchez, C; Llombart-Cussac, A; Morales, S; Moreno, F; Murillo, L; Ramos, M | 1 |
| Barbolosi, D; Freyer, G; Guitton, J; Hénin, E; Iliadis, A; Meille, C; You, B | 1 |
| He, W; Luan, Y; Song, A; Zhang, H; Zhang, P; Zhao, D | 1 |
| Augustin, D; Erber, R; Gluz, O; Harbeck, N; Hartmann, A; Hoffmann, G; Huober, J; Jänicke, F; Kates, RE; Kiechle, M; Kreipe, HH; Kuhn, W; Liedtke, C; Möbus, V; Mohrmann, S; Nitz, U; Pelz, E; Peyro-Saint-Paul, H; Thomssen, C; Wallwiener, D | 1 |
| Annecke, K; Augustin, D; Friedl, TW; Harbeck, N; Huober, J; Janni, W; Jueckstock, J; Kiechle, M; Rack, B; Scholz, C; Wischnik, A; Zwingers, T | 1 |
| Autret, A; Bachelot, T; Barthelemy, P; Bertucci, F; Bidard, FC; Bonnefoi, H; Bonneterre, J; Charafe-Jauffret, E; Dalenc, F; Deblock, M; Eymard, JC; Fekih, M; Ferrero, JM; Hardy-Bessard, AC; Kerbrat, P; Lemonnier, J; Lerebours, F; Levy, C; Lortholary, A; Mouret-Reynier, MA; Petit, T; Pierga, JY; Romieu, G; Soulie, P; Viens, P | 1 |
| Ahn, JH; Baek, SK; Chae, YS; Choi, IS; Choi, YJ; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, JH; Kim, SB; Kim, SH; Kim, TY; Lee, KS; Lee, S; Park, IH; Park, S; Park, YH; Sohn, JH | 1 |
| Chen, L; Chen, X; Ma, T; Tang, J; Wu, Y; Xu, Y; Yang, S; Yu, D; Zhang, X; Zhao, J; Zhao, Y; Zhong, S | 1 |
| Don, LF; Long, JP; Wan, F; Zhang, F; Zhou, J | 1 |
| Albanell, J; Campone, M; Chang, JC; de Haas, SL; Dewar, JA; Fumoleau, P; Garcia-Saenz, JA; Limentani, SA; Martin, M; Patre, M; Strasak, A; Xu, J | 1 |
| Eichler, M; Fink, V; Forstbauer, H; Friedl, TW; Harbeck, N; Härtl, K; Huober, J; Janni, W; Kiechle, M; Rack, B; Scholz, C; Schwentner, L; Singer, S; Weissenbacher, T; Wischnik, A | 1 |
| Gu, X; Han, SJ; Qian, SY; Xue, JQ; Zhang, WH | 1 |
| Al-Haddabi, I; Al-Khanbashi, M; Al-Moundhri, MS; Al-Riyami, M; Alajmi, AM; Caramuta, S; Lui, WO | 1 |
| DI, LJ; Jiang, HF; Li, HP; Liang, X; Lin, XL; Shao, B; Song, GH; Wan, FL; Wang, CY; Wang, LN; Yan, Y; You, MN; Yuan, YH | 1 |
| Blancafort, P; Evans, CW; Ho, D; Iyer, KS; Ormonde, CF; Rashwan, R; Singh, R; Sorolla, A; Wang, E | 1 |
| Lederer, B; Miquel-Cases, A; Retèl, VP; Steuten, LM; van Harten, WH; von Minckwitz, G | 1 |
| Baishya, R; Bharadwaj, R; Das, MK; Dash, S; Hazarika, H; Loying, P; Sahu, BP | 1 |
| Bian, Y; He, X; Hu, S; Li, J; Miao, H; Partridge, SC; Qiu, B; Ren, J; Yu, Y | 1 |
| Cerri, A; Gualandri, L; Mapelli, ET; Menni, S | 1 |
| Amodio, A; Anzà, M; Barba, M; Botti, C; Carpano, S; Catenaro, T; Di Benedetto, A; Di Filippo, S; Di Lauro, L; Giannarelli, D; Giordano, A; Marchetti, P; Maugeri-Saccà, M; Mottolese, M; Natoli, C; Perracchio, L; Pizzuti, L; Sanguineti, G; Sergi, D; Tomao, F; Vici, P | 1 |
| Chen, K; Chen, Y; Gong, C; Nie, Y; Qu, S; Song, E; Su, F; Xiao, X | 1 |
| Auvinen, P; Eidt, S; Heikkilä, P; Isola, J; Joensuu, H; Jyrkkiö, S; Kellokumpu-Lehtinen, PL; Laible, M; Lakis, S; Sahin, U; Schlombs, K; Sihto, H; Turpeenniemi-Hujanen, T; Weber, S; Wirtz, RM | 1 |
| Datta, D; Dave, KM; Gayen, JR; Gupta, AP; Mitra, K; Riyazuddin, M; Singh, A; Syed, AA; Valicherla, GR | 1 |
| Pugliano, L; Ryan, C; Tsoi, D; White, M; Woodward, N | 1 |
| Dehkordi, AJ; Setayesh, S; Varshosaz, J | 1 |
| Gligorov, J; Khalil, A; Lotz, JP; Richard, S; Selle, F; Soares, DG | 1 |
| Cheon, GJ; Chung, JK; Kang, KW; Kim, EE; Kim, YI; Lee, DS; Moon, WK; Paeng, JC; Yoon, HJ | 1 |
| Cui, S; Hu, X; Liao, N; Liu, D; Luo, R; Sun, Q; Wang, X; Xu, B; Yu, S; Zhang, Q; Zheng, H | 1 |
| Bolund, L; Brünner, N; Ditzel, HJ; Ehlers, NS; Gupta, R; Hansen, SN; Hou, Y; Liu, D; Moreira, J; Nielsen, RL; Schrohl, AS; Stenvang, J; Thomsen, MB; Wang, G; Wang, J; Xu, X; Yang, H; Zhang, X; Zhu, S | 1 |
| Kawara, H; Kawashima, Y; Noguchi, Y; Shimizu, Y; Tamura, Y; Tokuyama, Y; Uchiyama, K | 1 |
| Abraham, J; Budd, GT; Calhoun, B; Fanning, A; Grobmyer, SR; Mishra, P; Montero, AJ; Moore, H; Raska, P; Stewart, R; Tiwari, SR; Valente, S | 1 |
| Chaudhari, AMW; Loprinzi, CL; Lustberg, MB; Monfort, SM; Pan, X; Patrick, R; Singaravelu, J | 1 |
| Du, H; Liu, M; Zhai, G | 1 |
| Atyabi, F; Atyabi, SM; Dinarvand, M; Dinarvand, R; Irani, S; Mirfakhraie, R; Mirzaie, ZH; Varshochian, R | 1 |
| Bai, Z; Gao, Y; Ge, Z; Ma, X; Qu, X; Wang, T; Wang, Z; Yang, Y; Yuan, Z; Zhang, H; Zhang, Z | 1 |
| Choi, HG; Choi, JY; Gupta, B; Kim, JO; Ku, SK; Poudel, BK; Ramasamy, T; Thapa, RK; Yong, CS; Youn, YS | 1 |
| Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kodaira, M; Koizumi, F; Komori, O; Nakatochi, M; Okuma, HS; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Bisson, JN; Dvorkin-Gheva, A; Giacomelli, AO; Girgis-Gabardo, A; Gwynne, WD; Hallett, RM; Hassell, JA; Jensen, JE | 1 |
| Bergh, J; Hatschek, T; Saracco, A; Szabó, BK; Tánczos, E | 1 |
| Afzal, SM; Dinesh, T; Kishan, V; Shareef, MZ | 1 |
| André, R; Brito, M; Correia, L; Costa, L; Fernandes, J; Filipe, P; Gouveia, J; Metzger-Filho, O; Miranda, A; Moreira, A; Palha, A; Passos-Coelho, JL; R Ferreira, A; Ribeiro, J; Rodrigues, V; U Lin, N; Vaz-Luís, I | 1 |
| Dawoud, R; Faqeer, NA; Hanoun, E; Mashni, O; Nazer, L; Rumman, A | 1 |
| Chang, M; Guan, Y; Lin, G; Lu, S; Shao, W; Wei, T; Zhang, F; Zuo, T | 1 |
| Denkert, C; Eiermann, W; Furlanetto, J; Lederer, B; Loibl, S; Marmé, F; Möbus, V; Nekljudova, V; Reimer, T; Reinisch, M; Schmatloch, S; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Weber, K | 1 |
| Athanasiadis, A; Boukovinas, I; Georgoulias, V; Kakolyris, S; Katsaounis, P; Kentepozidis, N; Malamos, N; Matikas, A; Mavroudis, D; Papakotoulas, P; Saloustros, E; Ziras, N | 1 |
| Bernardo, PS; Buarque, CD; Costa, PR; Delbue, D; Lam, EW; Lemos, LG; Maia, RC; Nestal de Moraes, G; Vasconcelos, Fda C | 1 |
| Andre, V; Enas, N; Gueorguieva, I; Ribba, B; Tate, SC | 1 |
| Li, W; Peng, J; Qian, Z; Qu, Y; Shi, K; Tan, L; Wei, X; Wu, J | 1 |
| Capelan, M; Lote, H; Mohammed, K; Papadimitraki, E; Redana, S; Ring, A; Sharp, A | 1 |
| Belaaloui, G; Jiang, ZZ; Khaled, M; Zhang, LY; Zhu, X | 1 |
| Asselain, B; Bertheau, P; Bieche, I; de Cremoux, P; Guinebretière, JM; Hamy, AS; Lehmann-Che, J; Marty, M; Matthieu, MC; Scott, V; Sigal-Zafrani, B; Spyratos, F; Tembo, O | 1 |
| Aogi, K; Dalal, R; Gao, L; Ibrahim, A; Iwata, H; Masuda, N; Sasaki, Y; Xu, Y; Yoshikawa, R | 1 |
| Hamaoka, A; Konishi, E; Matsuda, T; Taguchi, T | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Fasching, P; Fehm, T; Friedl, TW; Hecker, N; Hepp, P; Jäger, B; Janni, W; Lorenz, R; Rack, B; Schneeweiss, A; Trapp, E | 1 |
| Afqir, S; Brahmi, SA; Youssef, S; Ziani, FZ | 1 |
| Dagher, NM; Yaghan, RJ | 1 |
| Acheson, AK; Agiro, A; Barron, JJ; Lyman, GH; Ma, Q; Malin, JL; Patt, DA; Rosenberg, A; Schilsky, RL; Wu, SJ | 1 |
| Arnaout, A; Clemons, M; Fergusson, D; Hilton, J; Hutton, B; Joy, AA; Mazzarello, S; Robinson, A; Vandermeer, L | 1 |
| Gao, JJ; Pohlmann, PR; Swain, SM; Tan, M | 1 |
| Ling, R; Lv, YG; Xu, X; Yan, CY; Yi, J | 1 |
| Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G | 1 |
| Baron, P; Beatty, J; Beitsch, P; de Snoo, FA; Dul, CL; Lee, LA; Mislowsky, A; Murray, M; Nash, C; Pellicane, JV; Rotkis, M; Stork-Sloots, L; Whitworth, P | 1 |
| Büdi, L; Erfán, J; Győrfy, K; Hitre, E; Horváth, Z; Kahán, Z; Kocsis, J; Kószó, R; Landherr, L; Máhr, K; Pajkos, G; Pápai, Z; Sántha, D | 1 |
| Doihara, H; Hamada, A; Hinotsu, S; Hirata, T; Iwamoto, T; Matsuoka, J; Mizoo, T; Motoki, T; Nogami, T; Shien, T; Tabata, M; Taira, N; Tamura, T | 1 |
| Clemons, M; Dudani, S; Fergusson, D; Fernandes, R; Hutton, B; Ibrahim, MF; Majeed, H; Mazzarello, S; Perdrizet, K; Shorr, R; Stober, C; Vandermeer, L | 1 |
| Abeyakoon, O; Bedair, R; Gilbert, FJ; Gill, AB; Graves, MJ; Griffiths, JR; Manavaki, R; McLean, MA; Patterson, AJ; Priest, AN | 1 |
| Gao, B; Guo, LJ; Hao, S; Jiang, Y; Luo, DL; Tian, WG; Zhang, S; Zhang, XH | 1 |
| Kang, Y; Li, J; Ma, Y; Ren, W; Zang, L; Zhang, S | 1 |
| Anderson, H; Bengtsson, NO; Bergh, J; Brandberg, Y; Carlsson, L; Egle, D; Fornander, T; Foukakis, T; Gnant, M; Greil, R; Hellström, M; Johansson, H; Karlsson, E; Loibl, S; Malmström, P; Mlineritsch, B; Möbus, V; Schmatloch, S; Singer, CF; Steger, G; Untch, M; von Minckwitz, G; Wallberg, B | 1 |
| Elalami, I; Ichou, M | 1 |
| Adams, PT; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Kidwell, KM; Mamounas, EP; Margolese, RG; Mehta, RS; Paik, S; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA; Zoon, CK | 1 |
| Batista de Carvalho, AL; Costa, FM; Diniz, C; Marques, MP; Medeiros, PS; Ribeiro, VP; Sousa, JB | 1 |
| Augustin, D; Eichler, M; Ettl, J; Fink, V; Harbeck, N; Janni, W; Kiechle, M; Leinert, E; Rack, B; Schwentner, L; Singer, S; Weissenbacher, T; Wischnik, A | 1 |
| Chen, D; Ding, L; Li, J; Luo, LJ; Ma, R; Tang, JH; Wang, DD; Wu, JZ; Yang, F; Yang, SJ; Zhang, L | 1 |
| Abesamis-Tiambeng, ML; Akewanlop, C; Baczkowski, M; Baramidze, K; Barve, A; Bondarenko, I; Hernandez-Bronchud, M; Herson, J; Kothekar, M; Loganathan, S; Mamillapalli, G; Manikhas, A; Mukhametshina, G; Nemsadze, G; Parra, JD; Pennella, E; Ray, S; Rugo, HS; Sharma, R; Sriuranpong, V; Vynnychenko, I; Waller, CF; Yanez Ruiz, EP; Yuan, J | 1 |
| Baselga, J; Clark, E; Eng-Wong, J; Fox, S; Kiermaier, A; Loi, S; Luen, SJ; Michiels, S; Salgado, R; Savas, P; Swain, SM | 1 |
| Hu, Q; Kirk, TB; Ma, D; Tang, Q; Wu, J; Xu, J; Xu, Z; Xue, W; Zhang, Y | 1 |
| Guo, Y; He, W; Li, Z; Luan, Y; Yang, S; Zhao, D | 1 |
| Chen, W; Gu, H; Li, D; Li, X; Ren, J; Shu, Y; Wang, D; Zhu, W | 1 |
| Bueno, C; Del Monte-Millan, M; Echavarria, I; García-Saenz, JA; Granja, M; Jerez, Y; Lobo, M; Lopez-Tarruella, S; Marquez-Rodas, I; Martín, M; Moreno, F; Peinado, P; Sotelo, M; Torres, G | 1 |
| Bassa, P; Capdevila, L; Garcia, JR; Pérez, C; Ramos, F; Valenti, V | 1 |
| Allaoui, M; Elm'hadi, C; Errihani, H; Ichou, M; Khmamouche, MR; Mahtat, E; Messaoudi, N; Oukabli, M; Tanz, R; Toreis, M | 1 |
| Benyunes, MC; Garg, A; Jin, JY; Li, H; Lum, BL; McNally, V; Nijem, I; Quartino, AL; Viganò, L; Wada, DR | 1 |
| Abdelhay, ESFW; Assumpção, PP; Burbano, RR; de Souza, MC; Demachki, S; Leal, MF; Moreira-Nunes, CA; Pereira, CBL; Smith, MC; Tanaka, AMDS | 1 |
| Aichberger, KJ; Doleschal, B; Petzer, A | 1 |
| Al-Awar, RS; Aman, AM; Ganesh, AN; Logie, J; Shoichet, MS | 1 |
| Amler, LC; Bianchi, GV; Bianchini, G; Dowsett, M; Eng-Wong, J; Gianni, L; Im, YH; Kiermaier, A; Kirk, S; Liu, MC; Pienkowski, T; Szado, T; Tseng, LM; Valagussa, P; Zabaglo, L | 1 |
| Aguirresarobe-Gil de San Vicente, M; Aresti, S; Cabriada-Nuno, JL; de Miguel, E; Hidalgo-Blanco, A | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Camara, O; de Gregorio, N; Decker, T; Fasching, PA; Fehm, TN; Friedl, TWP; Heinrich, G; Jaeger, B; Janni, W; Mahner, S; Ober, A; Pantel, K; Rack, BK; Schneeweiss, A; Schochter, F; Schramm, A; Trapp, E | 1 |
| Chung, HC; Gho, SG; Kim, GM; Kim, SI; Paik, S; Park, HS; Park, S; Sohn, J | 1 |
| de Boer, M; Dercksen, MW; Joore, MA; Lobbezoo, DJA; Peters, FPJ; Peters, NAJB; Ramaekers, BLT; Smilde, TJ; Tjan-Heijnen, VCG; van de Wouw, AJ; van den Berkmortel, F; van Kampen, RJW; van Riel, JMG | 1 |
| Bou-Dargham, MJ; Liu, JS; Lively, T; Lung, PY; Sang, QA; Sheffield, C; Tan, W; Yu, K; Zhang, J | 1 |
| Cruz E Melo, N; de Bessa Garcia, SA; Nagai, MA; Pavanelli, AC | 1 |
| Dang, Z; Du, J; Feng, J; Hu, K; Liu, H; Tu, L; Wang, L; Zhou, Y | 1 |
| Bagante, F; Connolly, R; Pawlik, TM; Spolverato, G; Vitale, A | 1 |
| Wang, H; Wang, R; Wang, Z | 1 |
| Ahn, JH; Chung, HC; Im, SA; Im, YH; Jung, KH; Kim, J; Kim, SB; Lee, KS; Park, HS; Ro, J; Sohn, BS; Song, HS | 1 |
| Castro, M; Corvacho, E; Costa, JG; Fernandes, AS; Guerreiro, PS; Miranda, JP; Oliveira, NG; Saraiva, N | 1 |
| Han, HS; Kang, HS; Kim, SW; Lee, DH; Lee, ES; Lee, H; Lee, KS; Nam, BH; Ro, J; Seo, JA | 1 |
| Andre, F; Broglio, K; Hortobagyi, GN; Mackey, JR; Martin, M; Penault-Llorca, F; Pusztai, L; Roche, H | 1 |
| Blackwell, K; Bullock, K | 1 |
| Bachelot, T; Blay, JY; Dufresne, A | 1 |
| Andersson, M; Azambuja, E; Balil, A; Crown, JP; Dolci, S; Francis, P; Gelber, RD; Gnant, M; Gutierrez, J; Láng, I; Nordenskjöld, B; Pestalozzi, BC; Piccart-Gebhart, M; Quinaux, E; Viale, G | 1 |
| Korski, K; Lamperska, K; Mackiewicz, A; Wysocki, PJ; Zaluski, J | 1 |
| Baselga, J; Prat, A | 1 |
| Hino, M; Homma, K; Sano, M; Sato, N | 1 |
| Abdullah, S; Doliny, P; Gautam, U; Gluck, S; Hurley, J; Lobo, C; Lopes, G; Morgenzstern, D; Reis, I; Santos, E; Silva, O; Slingerland, J; Welsh, C | 1 |
| Strother, RM; Sweeney, C | 1 |
| Bernard-Marty, C; Bissery, MC; Cardoso, F; Di Leo, A; Dumontet, C; Durbecq, V; Galmarini, CM; Gancberg, D; Larsimont, D; Paesmans, M; Piccart, MJ; Treilleux, I | 1 |
| Ishiguro, H; Kanao, S; Kato, H; Mikami, Y; Takada, M; Takeuchi, M; Toi, M; Ueno, T; Yamashiro, H; Yamauchi, C; Yoshibayashi, H; Yoshikawa, K | 1 |
| Kami, M; Komatsu, T; Tsubokura, M | 1 |
| Aksoy, S; Altundag, K; Dizdar, O | 1 |
| Davidson, NE; Goldstein, LJ; Martino, S; O'Neill, A; Perez, EA; Shulman, LN; Sparano, JA | 1 |
| Fujii, K; Fukutomi, T; Hara, K; Mouri, Y; Nakano, S; Nakaoka, T; Yamada, S; Yorozuya, K; Yoshida, M | 1 |
| Chan, J; Ip, EJ; Lee-Ma, A; Troxell, LS | 1 |
| Honma, K; Iwao-Koizumi, K; Kato, K; Nagahara, S; Nishio, K; Ochiya, T; Takeshita, F; Yamamoto, Y; Yoshida, T | 1 |
| Blasinska-Morawiec, M; Brandely, M; Campone, M; Douville, I; Koralewski, P; Pouget, JC; Tekiela, A | 1 |
| Hamada, Y; Horikoshi, N; Ichinose, I; Ikeda, T; Ishikawa, E; Kobayashi, S; Mitsuyama, S; Tamura, K | 1 |
| Choi, IK; Kim, AR; Kim, JS; Kim, YH; Koo, BH; Lee, JB; Oh, SC; Park, KH; Seo, JH; Shin, SW; Sung, HJ | 1 |
| Toi, M | 1 |
| Braun, M; Deertz, H; Deuss, B; Illiger, HJ; Janssen, J; Küchler, T; Meier, CR; Oeney, HT; Rotermund, S; Steder, M | 1 |
| Guo, QS; Liu, ZF; Song, SP; Wang, MY; Wu, N; Yang, XG; Zhang, XQ | 1 |
| Modrusan, Z; Nguyen, D; Steinberg, SM; Swain, SM; Wu, TD; Yang, SX | 1 |
| Jiang, WQ; Lin, XB; Liu, DG; Teng, XY; Zhong, JT; Zhou, NN | 1 |
| Georgoulias, V; Mavroudis, D; Saloustros, E | 1 |
| Eskiocak, U; Gunduz, U; Iseri, OD; Kars, MD; Sakin, V | 1 |
| Harris, P; Hartwell, D; Loveman, E; Takeda, A; Welch, K | 1 |
| Botti, C; Corsetti, S; Di Lauro, L; Fattoruso, SI; Foggi, P; Giannarelli, D; Giotta, F; Lopez, M; Mottolese, M; Sergi, D; Vici, P; Viola, G | 1 |
| Dafni, U; Fountzilas, G; Fragkoulidi, A; Fragoulakis, V; Galani, E; Grimani, I; Maniadakis, N | 1 |
| Agostara, B; Belfiglio, M; Bertetto, O; Bruzzi, P; Cascinu, S; Cognetti, F; Conte, P; Crinó, L; D'Amico, R; Di Leo, A; Frassoldati, A; Guarneri, V; Molino, A; Pronzato, P | 1 |
| Ebetino, FH; Lowik, CW; Papapoulos, SE; van Beek, ER; van Wijngaarden, J | 1 |
| Azzouz, F; Borges-Gonzales, S; Desta, Z; Flockhart, DA; Jason, RD; Li, L; McLeod, HL; Nguyen, A; Shen, C; Skaar, T; Sweeney, CJ; Yu, M | 1 |
| Côté, GB; Hembruff, SL; Laberge, ML; Parissenti, AM; Reed, K; Villeneuve, DJ | 1 |
| Glück, S; McKenna, EF; Royce, M | 1 |
| Castadot, P; Chargari, C; Di Leo, A; Magné, N; Philippson, C; Van Houtte, P | 1 |
| del Giglio, A; Eniu, A; Ganea-Motan, D; Lubenau, H; Topuzov, E | 1 |
| Calvo, L; Cruz, JJ; García-Mata, J; García-Palomo, A; Mel, R; Ramos, M | 1 |
| Cottrell, W; Dranitsaris, G; Hopkins, S; Spirovski, B | 1 |
| Booser, DJ; Brewster, AM; Buchholz, TA; Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Hunt, KK; Lipsanen, C; Madden, TL; Moulder, SL; Symmans, WF; Valero, V; Yuan, L; Zwiebel, J | 1 |
| Ding, G; Fu, Q; Ren, H; Su, FX; Wang, N; Wang, YJ; Wu, Q; Yang, JQ; Ye, ZB; Zhang, J; Zhou, LZ | 1 |
| Ciccarese, M; Lorusso, V | 1 |
| Bayo, J; Bernabé, R; Fernández, A; Fernández-Freire, A; Fuentes, J; Lomas, M; Moreno, A; Rodríguez, A; Ruiz, M; Salvador, J | 1 |
| Leonard, RC; Morishita, M | 1 |
| Antón, A; Calvo, L; Fernández, L; Lao, J; Muñoz, M; Ruiz, A; Sancho, F; Seguí, MA | 1 |
| Haid, A; Konstantiniuk, P; Kugler, F; Pöstlberger, S; Reitsamer, R; Roka, S; Tausch, C | 1 |
| Elling, D; Heinrich, G; Kittel, K; Klare, P; Kreienberg, R; Krocker, J; Kümmel, S; Lichtenegger, W; Schmid, P; Sommer, H; Steck, T | 1 |
| Dygai, AM; Gol'dberg, VE; Khrichkova, TY; Matyash, MG; Miroshnichenko, LA; Popova, NO; Shatalova, VA; Simolina, EI; Vysotckaya, VV; Zhdanov, VV | 1 |
| Chia, S; Dent, S; Eisenhauer, EA; Ellard, S; Ellis, PM; Gelmon, K; Powers, J; Seymour, L; Vandenberg, T; Walsh, W | 1 |
| Hasegawa, T; Hirata, K; Nakamura, Y; Okazaki, M; Sasaki, A; Suzuki, Y; Tsunoda, T; Yoshimoto, M; Zembutsu, H | 1 |
| Cobb, P; Houts, AC; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Clynes, M; Corkery, B; Crown, J; O'Donovan, N | 1 |
| Alanko, T; Asola, R; Bono, P; Joensuu, H; Jyrkkiö, S; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Turpeenniemi-Hujanen, T | 1 |
| Brosa-Riestra, M; Martín-Jiménez, M; Rodríguez-Lescure, A; Ruiz-Borrego, M; Seguí-Palmer, MA | 1 |
| Adrover, E; Andreu, X; Bernet, L; Castellá, E; Cuevas, JM; Fortes, JL; G Estevez, L; Margel, M; Peiró, G; Segui, MA | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Kalbakis, K; Kalykaki, A; Mavroudis, D; Vamvakas, L | 1 |
| Shao, ZY; Zhang, JD | 1 |
| Zhang, B | 1 |
| Dong, GL; Hao, CF; He, LH; Li, SF; Shi, YH; Tong, ZS; Wang, C; Wang, X | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Chang, E; Cho, H; Gwak, G; Han, S; Kim, J; Lee, J; Park, K; Park, S; Yang, KH | 1 |
| Bahadoran, P; Birtwisle-Peyrottes, I; Bondiau, PY; Chamorey, E; Chapellier, C; Courdi, A; Ferrero, JM; Lallement, M; Quielle-Roussel, C | 1 |
| Gianni, L; Valagussa, P | 1 |
| Asmar, L; Blum, JL; Boehm, KA; Bordelon, JH; Holmes, FA; Hyman, WJ; Jones, S; Kirby, RL; Mackey, D; McIntyre, KJ; Mennel, RG; Meyer, WG; Muss, H; O'Shaughnessy, J; Pippen, JE; Richards, DA; Riedel, S; Sandbach, J; Savin, MA; Vukelja, SJ | 1 |
| Cheang, MC; Dumontet, C; Hanson, J; Hugh, J; Krajewska, M; Mackey, J; Magherini, E; Martin, M; Nielsen, TO; Perou, CM; Reed, J; Rupin, M; Treilleux, I; Vogel, C | 1 |
| Bares, R; Dittmann, H; Dohmen, BM; Fersis, N; Jusufoska, A; Kehlbach, R; Machulla, HJ; Pritzkow, M; Smyczek-Gargya, B; Vonthein, R | 1 |
| Matard, B; Pinquier, L; Prevezas, C; Reygagne, P | 1 |
| Duarte, M; García-Sancho, L; Gil-López, JM; Trébol, J | 1 |
| Leighl, N; Lwin, Z | 1 |
| Burgess, LJ; Demetriou, GS; Jordaan, JP; Moodley, SD; Nosworthy, AL; Raats, J; Ruff, P; Vorobiof, DA; Werner, ID | 1 |
| Mayor, S | 3 |
| Greil, R; Menzel, C; Mlineritsch, B; Moik, M; Namberger, K; Reitsamer, R; Ressler, S; Stoll, M | 1 |
| Andoh, J; Aogi, K; Ikeda, T; Katsumata, N; Masuda, N; Minami, H; Sano, M; Shibata, T; Tabei, T; Takashima, S; Watanabe, T | 1 |
| Antón, A; Carrasco, E; Chan, S; Delozier, T; du Bois, A; Frimodt-Moller, B; Fumoleau, P; Harrison, M; Huober, J; Jones, A; Kreienberg, R; Llombart, A; Lluch, A; Mayordomo, JI; Romieu, G; Schneeweiss, A; Tubiana-Hulin, M; Vaury, AT | 1 |
| Dubé, P; Dumitra, S; Leblanc, G; Leclerc, Y; Sideris, L | 1 |
| Burris, HA; Farley, CP; Greco, FA; Hainsworth, JD; Infante, JR; Spigel, DR; Webb, C; Yardley, DA | 1 |
| Clemons, M; Dent, R; Dranitsaris, G; Enright, K; Flynn, C; Fralick, M; Kassam, F; Kumar, R; Myers, J | 1 |
| Astras, G; Hickish, T; Hickish, TF; Kerr, D; Penfold, S; Purandare, L; Thomas, P | 1 |
| Lu, W; Wang, J; Yang, Y; Zhang, Q; Zhang, X | 1 |
| Hou, LA; Hou, MF; Lin, CY; Ma, H; Tsai, LY; Tsai, SM; Wu, SH | 1 |
| Goh, BC; Iau, P; Lee, SC; Lim, SE; Lim, YW; McLeod, H; Sukri, N; Tan, P; Tan, SH; Xu, X; Yap, HL; Yeo, WL | 1 |
| Dalrymple, SL; Dannals, RF; Davidson, NE; Frost, JJ; Huang, Y; Isaacs, JT; Madar, I; Ravert, H | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Espinosa Arranz, E; Gil, JM; Guallar, JL; Méndez, M; Perulero, N; Tusquets, I | 1 |
| André, F; Antoine, M; Asselain, B; Baranzelli, MC; Bibeau, F; Denoux, Y; Jacquemier, J; Lacroix-Triki, M; Lagarde, N; Martin, AL; Penault-Llorca, F; Roché, H; Sagan, C; Verriele, V | 1 |
| Ishitobi, M; Kohama, K; Masuda, H; Masuda, N; Nakamori, S; Ogawa, M; Tanaka, T; Todaka, K; Tsujinaka, T; Ueno, H; Yamamura, J | 1 |
| Aogi, K; Mimae, T; Nishimura, R; Ohsumi, S; Taira, N; Takabatake, D; Takashima, S | 1 |
| Bahadoran, P; Birtwisle-Peyrottes, I; Bondiau, PY; Chamorey, E; Chapellier, C; Courdi, A; Ferrero, JM; Lallement, M; Quielle-Roussel, C; Thariat, J | 1 |
| Blot, E; Clatot, F; Guillemet, C; Laberge-Le-Couteulx, S; Philippin-Lauridant, G; Rigal, O | 1 |
| Bally, M; Daynard, T; Dedhar, S; Dragowska, W; Edwards, L; Fang, K; Gelmon, K; Kalra, J; Sutherland, BW; Warburton, C; Waterhouse, D | 1 |
| Abdul-Karim, F; Baar, J; Chen, H; Dowlati, A; Dumadag, L; Fu, P; Hartman, P; Hohler, E; Jesberger, J; Leeming, R; Lyons, J; McCrae, K; Overmoyer, B; Remick, SC; Shenk, R; Silverman, P; Wasman, J; Ziats, N | 1 |
| Dos Santos, ML; Gimenes, KP; Nagai, MA; Silva, WA | 1 |
| Elson, P; Peereboom, D; Thomas Budd, G; Weiss, P; Wesolowski, R | 1 |
| Ahmad, A; Ali, S; Banerjee, S; Kong, D; Rahman, KM; Sakr, WA; Wang, Z | 1 |
| Brandi, M; Colucci, G; Corsetti, S; DI Lauro, L; Fattoruso, SI; Foggi, P; Gebbia, V; Giannarelli, D; Giotta, F; Lopez, M; Lorusso, V; Sergi, D; Vici, P; Viola, G; Vitucci, C | 1 |
| Martin, M | 1 |
| Barrett-Lee, P; Bartlett, JM; Bliss, JM; Bloomfield, D; Cameron, D; Canney, P; Coleman, R; Dowsett, M; Earl, H; Ellis, I; Ellis, P; Hall, E; Hopwood, P; Johnson, L; Johnston, S; O'Reilly, S; Peckitt, C; Poole, C; Smith, I; Twelves, C; Verrill, M; Wardley, A; Yarnold, J | 1 |
| Kabashima, R; Nakamura, M; Sawada, Y; Sugita, K; Tokura, Y | 1 |
| Berry, H; Dodwell, DJ; Gillibrand, A; Kumar, S; Perren, TJ; Velikova, G; Waters, SH | 1 |
| Hashimoto, Y; Iizuka, H; Ishida-Yamamoto, A; Kajita, S; Nakamura, S; Takagi, A; Takahashi, H | 1 |
| Fujii, T; Inoue, Y; Matsubayashi, RN; Momosaki, S; Sawada, Y; Shirouzu, K; Takahashi, H; Toh, U; Uesugi, N; Yokoyama, G | 1 |
| Bhar, P; Cheporov, S; Clawson, A; Gradishar, WJ; Krasnojon, D; Makhson, AN; Manikhas, GM | 1 |
| Boidot, R; Coudert, B; Fumoleau, P; Lizard-Nacol, S; Soubeyrand, MS; Vegran, F | 1 |
| Chen, YQ; Jin, YC; Kong, QL; Li, J; Li, R; Li, XR; Ma, B; Wang, JD; Zhang, YJ; Zheng, YQ | 1 |
| Aogi, K; Doihara, H; Hara, F; Kiyoto, S; Ohsumi, S; Sien, T; Taira, N; Takabatake, D; Takashima, S | 1 |
| Coleman, R; Dranitsaris, G; Gradishar, W | 1 |
| Boytim, M; Dhillon, N; Dorr, R; Hersh, E; Hong, D; Kurzrock, R; La Paglia, A; Moulder, S; Naing, A; Ng, C; Tse, S; Wheler, J | 1 |
| Belvin, M; Eastham-Anderson, J; Friedman, LS; Gunter, B; Haverty, PM; Hoeflich, KP; Lee-Hoeflich, ST; Lewin-Koh, N; Murray, LJ; Sliwkowski, MX; Truong, T; Yao, E; Zhou, W | 1 |
| Barthomeuf, C; Bayet-Robert, M; Chollet, P; Morvan, D | 1 |
| Ajarim, DS; Al-Malik, OA; Al-Tweigeri, TA; Alsayed, AA; Alshabanah, MO; El-Husseiny, GA; Elkum, NB; Ezzat, AA; Fatani, DM; Rahal, MM; Tulbah, AM | 1 |
| Aramendía, JM; Arbea, L; Aristu, J; De la Cruz, S; Espinós, J; Fernández-Hidalgo, O; Martínez-Monge, R; Moreno, M; Nieto, Y; Pina, L; Regueira, FM; Santisteban, M; Sola, J; Zornoza, G | 1 |
| Arpaci, F; Gündüz, U; Işeri, OD; Kars, MD | 1 |
| Alfonso, PG; Cañón, EP; Carrión, JB; Manga, GP; Pereira, RQ; Peron, YI; Plaza, MI; Shahi, PK; Ureña, MM; Val, RG | 1 |
| Addeo, R; Capasso, E; Caraglia, M; Cennamo, G; Del Prete, S; Faiola, V; Guarrasi, R; Montella, L | 1 |
| Bachelot, T; Cretin, J; de la Fouchardière, C; Goubely, Y; Hardy-Bessard, AC; Largillier, R; Orfeuvre, H; Paraiso, D; Pujade-Lauraine, E; Slama, B | 1 |
| Chilcott, J; Lloyd Jones, M; Wilkinson, A | 1 |
| Sivaramamoorthy, C; Tattersall, MH; Thientosapol, ES | 1 |
| Ataseven, B; Kaufmann, M; Kozian, D; Marmé, F; Rom, J; Scharf, A; Schlehe, B; Schneeweiss, A; Schuetz, F; Sievert, M; Sohn, C; von Minckwitz, G | 1 |
| Agarwal, A; Boire, A; Covic, L; Kuliopulos, A; Nguyen, N; O'Callaghan, K; Tu, P; Yang, E | 1 |
| Anderson, DM; Bernath, AM; Gamini, SS; Hillman, DW; Niedringhaus, R; Northfelt, DW; Palmieri, F; Perez, EA; Salim, M; Stella, PJ; Tan, WW | 1 |
| García-Donas Jiménez, J; Jara Sánchez, C; Olier Gárate, C; Peñalver Párraga, J | 1 |
| Bathen, TF; Bofin, AM; Goa, PE; Gribbestad, IS; Huuse, EM; Jensen, LR; Lundgren, S; Pedersen, TB | 1 |
| Beuselinck, B; Dirix, L; Kains, JP; Paridaens, R; Wildiers, H; Wynendaele, W | 1 |
| Haj, R; Higgins, B; Leung, MG; Myers, J; Myers, R; Rajagopal, S; Soong, D | 1 |
| Gordian, E; Ramachandran, K; Singal, R | 1 |
| Panasci, LC | 1 |
| Akiyama, F; Domoto, K; Horii, R; Ito, Y; Iwase, T; Matsuura, M; Miyagi, Y; Ogiya, A; Osako, T; Takahashi, S | 1 |
| Balashova, OI; Bogdanova, NV; Bondarenko, IN; Chatikhine, VA; Makhson, AN; Manikhas, GM; Oliynychenko, GP; Rackoff, WR; Semiglazov, VF; Sparano, JA; Tjulandin, SA; Xiu, L; Yuan, Z; Zhuang, SH | 1 |
| Ando, M; Eguchi, K; Fujiwara, Y; Hozumi, Y; Inoue, K; Masuda, N; Miura, S; Mizutani, M; Nakagami, K; Noguchi, S; Ohashi, Y; Saito, M; Sano, M; Shinkai, T; Tsukamoto, F; Watanabe, T | 1 |
| Fung, AS; Tannock, IF; Wu, L | 1 |
| Chang, HR; Chung, DU; Faull, KF; He, J; Saxton, RE; Shen, D; Whitelegge, JP | 1 |
| Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Makatsoris, T; Papadimitriou, CA; Papakostas, P; Zagouri, F | 1 |
| Arima, N; Hayashi, M; Nishimura, R; Okumura, Y; Osako, T | 1 |
| Andersson, M; Crown, JP; de Azambuja, E; Demol, J; Dewar, J; Di Leo, A; Francis, P; Gelber, RD; Giuliani, R; Gutiérez, J; Jakesz, R; Lluch, A; McCaskill-Stevens, W; Nordenskjöld, B; Olsen, S; Piccart-Gebhart, M; Quinaux, E; Santoro, A; Vicente, M; Vila, MM | 1 |
| Bernard, R; Braun, M; Harbeck, N; Ihbe-Heffinger, A; Jacobs, VR; Kuhn, W; Nitz, U; Sattler, D; Wagenpfeil, S | 1 |
| Bertucci, F; Charafe-Jauffret, E; Deblock, M; Esterni, B; Extra, JM; Gilabert, M; Gonçalves, A; Houvenaeghel, G; Jacquemier, J; Tarpin, C; Viens, P | 1 |
| Cardoso, F; Senkus-Konefka, E | 1 |
| Bergh, J; Castany, R; Liljegren, A | 1 |
| Abe, M; Doiguchi, M; Hasuo, T; Miyamoto, Y; Sakamoto, F; Tanigawa, T | 1 |
| Arnould, L; Boidot, R; Causeret, S; Coudert, B; Dembélé, D; Fraise, J; Fumoleau, P; Garnier, J; Lizard-Nacol, S; Végran, F | 1 |
| Blohmer, JU; Budczies, J; Darb-Esfahani, S; Denkert, C; Dietel, M; du Bois, A; Gerber, B; Jackisch, C; Kaufmann, M; Komor, M; Loibl, S; Müller, BM; Noske, A; Richter, K; Roller, M; Schlüns, K; von Minckwitz, G; Weichert, W | 1 |
| Bartsch, R; Brodowicz, T; Gerges, DA; Inbar, M; Pawlega, J; Spanik, S; Timcheva, C; Tomova, A; Tzekova, V; Wiltschke, C; Zielinski, CC | 1 |
| Aránega, A; Boulaiz, H; Caba, O; Melguizo, C; Ortiz, R; Prados, J; Rama, AR; Ramos, JL; Segura, A; Vélez, C | 1 |
| Chapman, JA; Clemons, MP; Dent, R; Fitzgerald, B; Guo, B; Han, L; Jong, R; Kahn, HJ; O'Brien, P; Parissenti, AM; Pritchard, KI; Shepherd, LE; Trudeau, ME | 1 |
| Characiejus, D; Fokas, V; Juodzbaliene, E; Juozaityte, E; Kregzdyte, R; Liutkauskiene, S; Sveikata, A | 1 |
| Jung, SY; Kang, HS; Kim, EA; Kim, SK; Kim, SW; Ko, KL; Kwon, Y; Lee, KS; Lee, S; Lee, SJ; Min, SY; Nam, BH; Park, C; Park, IH; Ro, J; Shin, KH | 1 |
| Cipriano, R; De, S; Jackson, MW; Stark, GR | 1 |
| Benedict, A; Cameron, DA; Corson, H; Jones, SE | 1 |
| Chongqing, T; Gannong, C; Jianhe, L; Junhua, C; Karnon, J; Liubao, P; Wei, C; Xia, L; Xiaomin, W | 1 |
| Bansal, P; Lalos, AT; Rishikesh, R | 1 |
| Buhari, SA; Chng, WJ; Chuah, B; Goh, BC; Guo, J; Iau, P; Lee, SC; Lim, SE; Lim, YW; McLeod, HL; Sukri, N; Tan, P; Watson, M; Wong, CI; Xu, X; Yap, HL | 1 |
| Alanko, T; Asola, R; Bono, P; Hahka-Kemppinen, M; Huuhtanen, R; Joensuu, H; Kellokumpu-Lehtinen, P; Kokko, R; Leinonen, M; Pyrhönen, S; Sailas, L; Sunela, K; Turpeenniemi-Hujanen, T; Utriainen, M; Wigren, T | 1 |
| Brown, I; Kastl, L; Schofield, AC | 3 |
| Anami, S; Fujii, C; Kitada, N; Kondoh, M; Minegaki, T; Morita, S; Nishino, M; Takara, K; Watari, M; Yasuda, J | 1 |
| Siau, K; Varughese, M | 1 |
| Bidard, FC; Brain, E; de Cremoux, P; Delaloge, S; Giachetti, S; Marty, M; Mathiot, C; Pierga, JY | 1 |
| Codacci-Pisanelli, G; Peccatori, FA; Spinelli, GP | 1 |
| Hayashida, T; Ikeda, T; Jinno, H; Kitagawa, Y; Mukai, M; Sakata, M; Takahashi, M | 1 |
| Puglisi, F | 1 |
| Alanko, T; Asola, R; Auvinen, P; Bono, P; Helle, L; Huusko, M; Ingalsuo, S; Isola, J; Joensuu, H; Jyrkkiö, S; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, H; Leinonen, M; Möykkynen, K; Pajunen, M; Salminen, T; Turpeenniemi-Hujanen, T; Utriainen, T | 1 |
| Altomare, V; Bertoldo, F; Ferraro, E; Galluzzo, S; Lippi, C; Santini, D; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Dentchev, T; Dueck, AC; Fitch, TR; Geeraerts, LH; Graham, DL; Gross, HM; Hillman, DW; Kahanic, SP; Le-Lindqwister, NA; Liu, H; Palmieri, FM; Patel, TA; Perez, EA | 1 |
| Abrial, C; Barthomeuf, C; Bayet-Robert, M; Chollet, P; Durando, X; Gachon, F; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Planchat, E | 1 |
| Brites, MM; Figueiredo, A; Frutuoso, C; Saleiro, S; Santiago, F | 1 |
| Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Hemminki, A; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Lahtela, SL; Lehtiö, K; Leinonen, M; Lindman, H; Nilsson, G; Nuortio, L; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K | 1 |
| Ardavanis, A; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Ziras, N | 1 |
| Bourgeois, H; Campone, M; Canon, JL; Coudert, B; Delozier, T; Extra, JM; Hardy-Bessard, AC; Kerbrat, P; Kramar, A; Lortholary, A; Machiels, JP; Maerevoet, M; Martin, AL; Orfeuvre, H; Penault-Llorca, F; Piot, G; Roché, H; Romieu, G; Serin, D; Spielmann, M | 1 |
| Rolston, KV | 1 |
| Barada, WM; Bazarbachi, AA; Otrock, ZK; Saab, JF; Sawaya, RA | 1 |
| Canbay, E; Igci, A; Kecer, M; Mudun, A; Muslumanoglu, ME; Ozcinar, B; Ozmen, V; Tunaci, M; Tuzlali, S; Unal, ES | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Mainwaring, M; Markus, T; Spigel, DR; Waterhouse, DM; Webb, CD; Yardley, DA | 1 |
| Barton, J; Burris, HA; Clark, BL; Greco, FA; Hainsworth, JD; Montes, I; Shipley, D; Spigel, DR; Thompson, D; Vazquez, E; Yardley, DA | 1 |
| Gelmon, K; Mackey, J; Martin, M; McCarthy, N; Pinter, T; Rupin, M; Youssoufian, H | 1 |
| Bristianou, M; Georgiou, C; Kamposioras, K; Karathanasi, I; Mauri, D; Polyzos, NP; Tsali, L; Valachis, A | 1 |
| Andrulis, M; Aulmann, S; Penzel, R; Schirmacher, P; Sinn, HP; Waldburger, N | 1 |
| Chao, TY; Huang, TC | 1 |
| Budryk, M; Byrski, T; Dent, R; Gronwald, J; Grzybowska, E; Huzarski, T; Lubinski, J; Mierzwa, T; Narod, S; Siolek, M; Stawicka, M; Szwiec, M; Wisniowski, R | 1 |
| Ikeda, T; Minamoto, K | 1 |
| Camphausen, K; Hunter, K; Korde, LA; Lebowitz, PF; Lukes, L; Lusa, L; McShane, L; Parker, JS; Swain, SM; Zujewski, JA | 1 |
| Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH | 1 |
| Balser, S; Einmahl, S; Fuhr, U; Gascon, P; Kinzig-Schippers, M; Makhson, A; Muenzberg, M; Sörgel, F | 1 |
| Gao, HY; Zhang, XL; Zheng, L | 1 |
| Fumoleau, P; Le Corroller Soriano, AG; Marino, P; Martin, AL; Protière, C; Roché, H; Siani, C; Spielmann, M; Viens, P | 1 |
| Barton, C; Button, P; de Fátima Dias Gaui, M; Hersberger, V; Jassem, J; Morales-Vasquez, F; Pivot, X; Reyes, DO; Torres, AA; Wardley, AM; Zetina, LM | 1 |
| Alcorn, J; Chen, L; Ling, B; Ma, B; Yang, J | 1 |
| Bibeau, F; Bleuse, JP; Colombo, PE; Gourgou-Bourgade, S; Gutowski, M; Jacot, W; Kramar, A; Romieu, G | 1 |
| Alvarez, RH; Booser, DJ; Cristofanilli, M; Gonzalez-Angulo, AM; Guerra, L; Hortobagyi, GN; Kau, SW; Sahin, AA; Strom, EA; Valero, V | 1 |
| Fujii, H; Fujisawa, T; Inoue, K; Kurosumi, M; Saeki, T; Sato, N; Tabei, T; Takei, H; Yamamoto, N; Yanagita, Y | 1 |
| Blohmer, JU; Friese, K; Hilfrich, J; Kleine-Tebbe, A; Koelbl, H; Kuemmel, S; Lichtenegger, W; Morack, G; Schmid, P; Sommer, H; Wischnewsky, MB | 1 |
| Hillner, BE; Smith, TJ | 1 |
| Aglietta, M; Beano, A; Donadio, M; Jacomuzzi, ME; Martinello, R; Montemurro, F; Nolè, F; Redana, S; Sapino, A; Viale, G | 1 |
| Li, T; Liu, YH; Qin, XQ; Wang, YH; Ye, JM; Yin, HF; Zhang, H | 1 |
| Aitini, E; Baconnet, B; Barbato, A; Bighin, C; Colucci, G; Crinò, L; Del Mastro, L; Garrone, O; Mansutti, M; Marini, G; Olmeo, N; Paccagnella, A; Puglisi, F; Venturini, M | 1 |
| Gabizon, A; Grenader, T | 1 |
| Amankwa, L; Bally, MB; Ciufolini, MA; Crawford, J; Cullis, PR; Harasym, N; Heller, L; Masin, D; Maurer, N; Srinivasulu, M; Waterhouse, D; Webb, M; Winters, G; Wong, M; Zhigaltsev, IV | 1 |
| Asakawa, H; Fukuda, M; Iwase, H; Koike, A; Koizumi, H; Ohta, T; Takahashi, M; Wu, W | 1 |
| Chan, A; Coyuco, JC; Fu, WH; Ng, R; Shih, V; Tan, SH | 1 |
| Bergougnoux, L; Bidard, FC; de Cremoux, P; Degeorges, A; Delva, R; Etienne-Grimaldi, MC; Mathiot, C; Milano, G; Pierga, JY; Pivot, X; Veyret, C | 1 |
| Chishima, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kawachi, K; Morita, S; Nozawa, A; Ota, I; Sasaki, T; Shimada, H; Shimizu, D; Tanabe, M | 1 |
| Bauerfeind, I; Blohmer, JU; Dan Costa, S; du Bois, A; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kühn, T; Loibl, S; Mehta, K; Rezai, M; Tesch, H; Thomssen, C; Untch, M; von Minckwitz, G | 2 |
| Kanzaki, M; Maeda, M; Matsumoto, K; Miyoshi, S; Takano, Y; Teshima, S; Wakita, T; Yoshinouchi, S | 1 |
| Maehara, Y; Matsuda, H; Nagata, S; Ueda, N; Yoshida, Y | 1 |
| Biganzoli, L; Conte, P; Diéras, V; Glaspy, J; Guarneri, V; Miles, D; Robert, N; Smith, I; Taran, T; Thomssen, C | 1 |
| Antonini, N; Linn, SC; Loo, CE; Oldenburg, HS; Rodenhuis, S; Russell, NS; Rutgers, EJ; Straver, ME; Vrancken Peeters, MT; Wesseling, J | 1 |
| Ardavanis, A; Arnogiannaki, N; Doufexis, D; Kountourakis, P; Maliou, S; Missitzis, I; Pissakas, G; Sotiropoulou, A; Zobolas, V | 1 |
| Gündüz, U; Işeri, OD; Kars, MD | 2 |
| Feng, SS; Liu, Y; Pan, J | 1 |
| Eidtmann, H; Fehm, T; Hilfrich, J; Holms, F; Huober, J; Komor, M; Loibl, S; Müller, V; Pantel, K; Rau, T; Riethdorf, S; Roller, M; Schrader, I; Tesch, H; Untch, M; von Minckwitz, G; Zhang, L | 1 |
| Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Shimizu, T; Tanaka, M; Tani, T; Umeda, T | 1 |
| Andre, F; Berrada, N; Broglio, K; Chan, S; Hortobagyi, GN; Mackey, JR; Nabholtz, JM; Pusztai, L | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K | 1 |
| Buhari, SA; Chan, CW; Chuah, BYS; Cordero, MT; Goh, BC; Iau, P; Lee, SC; Lim, SE; Lim, YW; Soo, R; Sukri, NB; Tan, SH; Wang, LZ | 1 |
| Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T | 1 |
| Imai, T; Iwata, H; Ohashi, Y; Sasaki, E; Sato, Y; Sawaki, M; Toyama, T; Wada, M; Yatabe, Y | 1 |
| Groshen, S; Lee, AS; Lee, E; Nichols, P; Spicer, D | 1 |
| Bertheau, P; Brain, E; Delaloge, S; Espié, M; Guinebretière, JM; Marty, M; Mathieu, MC; Pierga, JY; Savignoni, A; Sigal-Zafrani, B; Spielmann, M | 1 |
| Iwatani, T; Kawabata, H; Makuuchi, R; Miura, D; Nakazawa, H; Suzuki, N | 1 |
| Amano, S; Hino, N; Ikawa, K; Ikushima, Y; Kawakita, N; Matsuoka, H; Mikami, C; Miyake, H; Miyoshi, T; Mori, R; Ogata, Y; Okubo, A; Sounaka, Y; Tsuyuguchi, M; Wada, D; Yamasaki, S | 1 |
| Dickson, NR; Foust, JT; Grapski, R; Hainsworth, JD; Hendricks, LK; Peacock, NW; Scott, WL; Vázquez, ER; White, MB; Yardley, DA | 1 |
| Chan, A; Chlistalla, A; Cortés, J; Delozier, T; Dirix, LY; Harbeck, N; Miles, DW; Pivot, X; Provencher, L; Puglisi, F; Romieu, G; Schneeweiss, A; Sohn, JH; Steger, GG; Tomczak, P; Wardley, AM | 1 |
| Berriolo-Riedinger, A; Brunotte, F; Cochet, A; Couturier, O; Girault, S; Rousseau, C | 1 |
| Atkins, JN; Costantino, JP; Erban, JK; Fehrenbacher, L; Ganz, PA; Geyer, CE; Jeong, JH; Land, SR; Livingston, RB; Mamounas, EP; Pajon, ER; Perez, EA; Polikoff, J; Rastogi, P; Swain, SM; Vogel, VG; Wolmark, N | 1 |
| Ellis, M | 1 |
| Niculescu-Duvaz, I | 1 |
| Akay, BN; Akyol, A; Buyukcelik, A; Unlu, E | 1 |
| Chen, L; Dai, JC; Ling, LJ; Liu, XA; Ma, JJ; Tao, AD; Wang, S; Yin, H; Zha, XM; Zhou, WB | 1 |
| Allison, MA; Chang, HR; Chung, DU; Elashoff, R; Glaspy, J; Gornbein, J; Kass, FC | 1 |
| Cameron, DA; Coleman, RE; Crown, J; Earl, HM; Evans, TR; Gallagher, CJ; Highley, M; Jones, AL; Leonard, RC; Lipscombe, J; Mansi, JL; Perren, T; Quigley, M; Yellowlees, A | 1 |
| Fox, J; Ganju, V; Hart, S; Hofman, M; Midolo, P; Schneider-Kolsky, ME; Stuckey, J | 1 |
| Dumontet, C; Krajewska, M; Lafanechère, L; Mackey, JR; Martin, M; Reed, JC; Rupin, M; Treilleux, I | 1 |
| Roy, V; Vishnu, P | 1 |
| Cheng, YC; Devata, S; Singh, V | 1 |
| Alfaro, J; Antolín, S; Antón, A; Calvo, L; Cámara, MC; Camps, J; Carrasco, E; Lao, J; Miguel, A; Muñoz, M; Plazaola, A; Ruiz, A; Sánchez, P; Santaballa, A; Seguí, MA | 1 |
| Avenin, D; Beerblock, K; Bernaudin, JF; Fajac, A; Gligorov, J; Hugonin, S; Lévy, E; Lévy, P; Lokiec, F; Rezai, K; Saintigny, P; Selle, F | 1 |
| Baricordi, OR; Ferlini, A; Indelli, M; Lelli, G; Rimessi, P; Rizzo, R; Spaggiari, F | 1 |
| Jang, SJ; Kang, YS; Kim, SW; Lee, UH; Park, HS | 1 |
| Jotoku, H; Taguchi, K; Tamura, M; Watanabe, K; Yamamoto, M | 1 |
| Araque Arroyo, P; Calleja Hernández, MA; Cancela Díez, B; Fernández Feijóo, MA; Hernández Magdalena, J; Ubago Pérez, R | 1 |
| Fotiou, S; Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Algros, MP; Bazan, F; Chaigneau, L; Llombart-Cussac, A; Maisonnette-Escot, Y; Montcuquet, P; Pivot, X; Sautiere, JL; Thiery-Vuillemin, A; Villanueva, C | 1 |
| Belau, A; Darb-Esfahani, S; Denkert, C; Hauschild, M; Högel, B; Huober, J; Khandan, F; Loibl, S; Mehta, K; Tesch, H; Thomssen, C; von Minckwitz, G; Weiss, E; Zahm, DM | 1 |
| Chen, DR; Chen, ST; Hsieh, CM; Huang, CS; Kuo, SH; Lu, YS; Tseng, LM; Wang, HC; Yeh, DC; Yeh, HT | 1 |
| Allen, HJ; Applebaum, SH; Chan, D; Glaspy, J; Hagenstad, C; Hu, EH; Hurvitz, SA; Kabbinavar, F; Lin, LS; Moroose, RL; Patel, G; Ryba, N; Slamon, DJ; Wang, H | 1 |
| Amant, F; Christiaens, MR; Debrock, G; Neven, P; Paridaens, R; Renard, V; Smeets, A; Squifflet, P; Van Eenoo, L; van Limbergen, E; Weltens, C; Wildiers, H; Wynendaele, W | 1 |
| Barnadas, A | 1 |
| Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mekata, E; Mori, T; Tanaka, M; Tani, T; Umeda, T | 1 |
| Ambrosetti, D; Bourcier, C; Durivault, J; Guyot, M; Hannoun-Levi, JM; Ortholan, C; Pagès, G; Safe, S | 1 |
| Bauknecht, T; Bottini, A; Kennedy, L; Manikhas, AG; Mansouri, K; Marmé, F; Ruiz, A; Schneeweiss, A; Sinn, HP; Wolf, M | 1 |
| Hilli, J; Jyrkkiö, S; Laine, K; Pyrhönen, S; Sailas, L | 1 |
| Abbruzzese, A; Caraglia, M; Maglio, G; Marra, M; Ostacolo, L; Quaglia, F; Ungaro, F; Zappavigna, S | 1 |
| Andreasson, I; Boér, K; Láng, I; Llombart-Cussac, A; Murray, E; Pover, GM; Sanders, N; Vivanco, GL | 1 |
| Anido, U; Areses, C; Bernárdez, B; Calvo, M; Candamio, S; Cueva, JF; Curiel, T; Gallardo, E; García, J; Gayoso, L; Javier Barón, F; Jesús Lamas, M; León, L; López, R; Vázquez, F; Vidal, Y | 1 |
| Li, J; Li, XR; Liu, M; Ma, B; Song, X; Wang, JD; Zhang, YJ; Zheng, YQ | 2 |
| Ah-See, ML; Beresford, MJ; Collins, DJ; d'Arcy, JA; Li, SP; Makris, A; Padhani, AR; Stirling, JJ; Taylor, NJ | 1 |
| Allmaier, G; Bachleitner-Hofmann, T; Bartsch, R; Baumann, S; Bergmann, M; Burghuber, C; Gnant, M; Graf, A; Greil, R; Marchetti-Deschmann, M; Michlmayr, A; Oehler, R; Pluschnig, U; Rech-Weichselbraun, I; Steger, G | 1 |
| Jeong, JH; Jung, SY; Kang, HS; Kim, EA; Kim, SW; Ko, KL; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J | 1 |
| Alberto, M; Alessandro, C; Artioli, G; Borgato, L; Bozza, F; Cappetta, A; Davide, P; Fernando, B; Giorgio, Z; Grazia, A; Lucia, B; Marchet, A; Mocellin, S; Pastorelli, D; Simone, M; Stefania, Z; Zavagno, G; Zovato, S | 1 |
| Casado, MÁ; Cortés, J; Frías, C; Oyagüez, I; Seguí, MÁ | 1 |
| Hirai, Y; Kiyoi, M; Miyasaka, M; Naito, K; Nakamura, R; Okamura, Y; Oura, S; Yoshimasu, T | 1 |
| Akbulut, H; Demirkazık, A; Icli, F; Onur, H; Senler, FÇ; Yalcin, B | 1 |
| Andrade, JM; Carrara, HH; Macchetti, AH; Marana, HR; Mouro, LR; Pimentel, FF; Tiezzi, DG; Zola, FE | 1 |
| Ahmad Kiadaliri, A; Bastani, P | 1 |
| Bai, YX; Cheng, Y; Jiang, ZF; Jiao, SC; Li, X; Liu, DQ; Liu, JW; Liu, WC; Ren, J; Sun, Q; Tang, LL; Wang, HQ; Wang, Y; Wang, YS; Wei, Y; Xiao, JX; Xie, XD; Zhang, SH | 1 |
| Grosse-Onnebrink, E; Harbeck, N; Hoopmann, M; Kates, R; Mallmann, P; Stoff-Khalili, M; Thomas, A; Warm, M | 1 |
| Fink, M | 1 |
| Bertucci, F; Marino, P; Martin, AL; Roche, H; Seror, V; Siani, C; Viens, P | 1 |
| Ansari, RH; Brufsky, A; Cavalheiro, J; Chen, SC; De La Cruz Vargas, JA; Fein, LE; Gill, JF; Hart, LL; Kim, SB; Obasaju, CK; Orlando, M; Russell, CA; Schwartzberg, LS; Seidman, AD; Stein, RS; Stewart, JF; Tai, DF; Zhao, L | 1 |
| Al Zaman, A; Fraser, J; Steele, N; Yule, A | 1 |
| Buyse, M; Crown, J; Eiermann, W; Forbes, J; Fumoleau, P; Jagiello-Gruszfeld, A; Mackey, JR; Martin, M; Mrsic-Krmpotic, Z; Pegram, MD; Pienkowski, T; Press, MF; Riva, A; Roche, H; Rolski, J; Sauter, G; Slamon, DJ; Taupin, H; Valero, V; von Minckwitz, G | 1 |
| Adrover, E; Alba, E; Almenar, S; Antón, A; Aranda, I; Arcusa, A; Barnadas, A; Calvo, L; Florián, J; Grosse, R; Isla, D; Jara, C; Li, J; Llorca, C; Lluch, A; López García-Asenjo, JA; López Vega, JM; Martín, M; Martinez del Prado, P; Mel, JR; Munarriz, B; Muñoz, M; Peiró, G; Ramos, M; Rios, MJ; Rodríguez-Lescure, A; Ruiz Borrego, M; Ruiz, A; Sáez, A; Seguí, MA; Zaluski, J | 1 |
| Cui, L; Huang, XE; Jiang, Y; Tang, JH; Xiang, J; Yan, PW | 1 |
| Arteaga, C; Chakrabarty, A; Chamness, GC; Chang, JC; Dave, B; Gutierrez, MC; Hilsenbeck, SG; Huang, J; Migliaccio, I; Narasanna, A; Osborne, CK; Rimawi, M; Schiff, R; Wong, H; Wu, MF | 1 |
| Aftimos, P; Chahine, G; Farhat, FS; Ghosn, M; Haddad, N; Hanna, C; Kattan, JG; Nasr, F | 1 |
| Baselga, J; Swain, SM | 1 |
| Andersson, M; Bergh, J; Bjerre, K; Enevoldsen, K; Jensen, AB; Karlsson, P; Langkjer, ST; Lidbrink, E; Møller, S; Sørensen, PG; Tange, UB; Wist, E | 1 |
| Pal, SK; Sartor, O; Twardowski, P | 1 |
| Ahmad, A; Ali, AS; Ali, S; Rahman, KM; Raz, A; Sakr, WA; Sethi, S; Wang, Z | 1 |
| Hao, XS; Hou, Y; Li, LF; Liu, XM; Qian, ZZ; Qiu, LH; Wang, HQ; Xie, CH; Zhang, HL; Zhou, SY | 1 |
| Nagykálnai, T | 1 |
| Bengtsson, NO; Bergh, J; Carlsson, L; Edlund, P; Hellstrøm, M; Karlsson, P; Lidbrink, E; Linderholm, B; Lindman, H; Malmström, P; Margolin, S; Pettersson Skøld, D; Søderberg, M; Villman, K | 1 |
| Carboni, JM; Chan, BT; Chang, JC; Creighton, CJ; Gottardis, MM; Hilsenbeck, SG; Huang, F; Lee, AV; Lewis, MT; Litzenburger, BC; Rimawi, MF; Tsimelzon, A; Wang, T | 1 |
| Baumann, I; Darb-Esfahani, S; Denkert, C; Grasshoff, ST; Heinrich, G; Hoffmann, G; Kronenwett, R; Loibl, S; Müller, BM; Noske, A; Roller, M; Steffen, J; Ulmer, HU; von Minckwitz, G; von Toerne, C; Wirtz, R | 1 |
| Cheng, JP; Jia, J; Lu, YL; Ren, J; Wang, XY; Yan, Y; Yuan, YH | 1 |
| Aoyagi, H; Hamada, S; Hasegawa, K; Kaneko, J; Katsuta, E; Maejima, S; Ohkubo, T; Saguchi, M; Someno, Y; Takahata, T | 1 |
| Garantziotis, S | 1 |
| Beekman, CA; Buckle, T; Rottenberg, S; Valdés Olmos, RA; van Leeuwen, AC; van Leeuwen, FW; Verheij, M | 1 |
| Creemers, GJ; de Graaf, H; de Munck, L; Erjavec, Z; Schröder, CP; Smit, WM; Stouthard, JM; Vader, W; van Bochove, A; van Deijk, G; Westermann, AM; Willemse, PH | 1 |
| Hillemanns, P; Kramer, F; Park-Simon, TW; Rinnau, F; Schippert, C | 1 |
| Bessette, B; Fermeaux, V; Giraud, S; Lautrette, C; Loum, E | 1 |
| Fong, D; Gastl, G; Gostner, JM; Hermann, M; Krobitsch, S; Lehne, F; Martowicz, A; Spizzo, G; Wrulich, OA; Zitt, M | 1 |
| Bates, M; Bono, P; Huang, W; Isola, J; Joensuu, H; Jyrkkiö, S; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lie, Y; Paquet, A; Sperinde, J; Turpeenniemi-Hujanen, T; Weidler, J | 1 |
| Cheng, LQ; Li, J; Li, XR; Liu, L; Liu, M; Song, X; Wang, JD; Zhang, AL; Zhang, YJ; Zheng, YQ | 1 |
| Kajiura, Y; Yagata, H; Yamauchi, H | 1 |
| Atkins, JN; Cecchini, RS; Costantino, JP; Erban, JK; Fehrenbacher, L; Ganz, PA; Geyer, CE; Land, SR; Livingston, RB; Mamounas, EP; Pajon, ER; Perez, EA; Polikoff, JA; Swain, SM; Vogel, VG; Wolmark, N | 1 |
| Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E; Thomas, R | 1 |
| Ballestrero, A; Bergaglio, M; Bertolotti, F; Brema, F; Canobbio, L; Cinzia, N; Folco, U; Mencoboni, M; Murialdo, R; Parodi, M; Pastorino, G; Simoni, C; Vaira, F | 1 |
| Baker, SD; Connolly, RM; Davidson, NE; Donehower, MG; Emens, LA; Fetting, JH; Garrett-Mayer, E; Jeter, SC; Rudek, MA; Stearns, V; Wolff, AC; Wright, LA; Zhao, M | 1 |
| Halim, A; Wahba, H | 1 |
| Bando, H; Iwata, H; Kashiwaba, M; Mizuno, T; Murakami, S; Nakayama, T; Ohashi, Y; Sawaki, M; Taira, N; Tokudome, N; Uemura, Y; Yamamoto, Y | 1 |
| Abenhardt, W; Artmann, A; Gröll de Rivera, I; Harbeck, N; Heinemann, V; Kiechle, M; Meerpohl, HG; Rauthe, G; Sommer, H; Stemmler, HJ; Vehling Kaiser, U | 2 |
| Anantha, M; Bally, MB; Kalra, J; Masin, D; Osooly, M; Strut, D; Warburton, C; Waterhouse, D; Yan, H; Yang, YJ | 1 |
| Bang, YJ; Han, SW; Han, W; Heo, DS; Im, SA; Keam, B; Kim, DW; Kim, JH; Kim, TY; Lee, KH; Lee, SH; Noh, DY; Oh, DY; Park, IA | 1 |
| Avisar, E; Glück, S; McKenna, EF; Perou, CM; Ross, JS; Royce, M; Wu, L | 1 |
| Candeloro, G; Desideri, G; Necozione, S; Piazze, J; Rea, S; Recchia, CO; Recchia, F | 1 |
| del Valle, ML; Sanz, A | 1 |
| Venniyoor, A | 1 |
| Kishi, S; Matsumoto, A; Morise, M; Suzuki, H; Suzuki, T; Takeshita, T; Tsutsui, A; Yoneyama, K | 1 |
| Kim, SI; Koo, JS; Park, BW; Park, HS; Park, SH; Sohn, J | 1 |
| Biganzoli, L; Bogdanova, N; Chen, Z; Cheng, Y; Chmielowska, E; Crivellari, D; Dalenc, F; Delva, R; Di Vincenzo, E; Espié, M; Hamm, C; Jiang, Z; Just, M; Lichinitser, M; Semiglazov, V; Shen, Z; Smith, I; Vinholes, J; Vivanco, GL | 1 |
| Bluemke, DA; Gabrielson, E; Jacobs, MA; Jeter, S; Ouwerkerk, R; Stearns, V; Wahl, R; Warzecha, H; Wolff, AC | 1 |
| Caldés, T; Casado, A; Cheang, MC; de la Torre, J; Diaz-Rubio, E; Furio, V; García-Saenz, JA; He, X; López García-Asenjo, JA; Lopez-Tarruella, S; Martin, M; Oliva, B; Perou, CM; Puente, J; Román, JM; Romero, A; Vidart, JA | 1 |
| Bruno, R; Claret, L; Frances, N; Iliadis, A | 1 |
| Bebek, G; Budd, GT; De, S; Downs-Kelly, E; Eng, C; Orloff, MS; Stark, GR; Tan, MH; Wesolowski, R | 1 |
| Amoroso, D; Camerini, A; Cavazzana, A; De Luca, F; Donati, S; Martini, L; Puccetti, C; Siclari, O; Tartarelli, G; Valsuani, C; Viacava, P | 1 |
| Agresti, B; Bertocci, S; Bianchi, S; Biti, G; Cassani, S; Cataliotti, L; de Luca Cardillo, C; Franzese, C; Livi, L; Meattini, I; Nori, J; Sanchez, L; Scotti, V | 1 |
| Corrado, G; di Stefano, A; Ferrandina, G; Lucidi, A; Margaritora, S; Piraino, A; Salutari, V; Scambia, G | 1 |
| Augustin, D; Hanf, V; Harbeck, N; Jaenicke, F; Kantelhardt, EJ; Martin, PM; Meisner, C; Paepke, D; Schmidt, M; Schmitt, M; Sweep, F; Thomssen, C; Vetter, M; Veyret, C; von Minckwitz, G | 1 |
| Plummer, RS; Shea, CR | 1 |
| Blohmer, JU; Budczies, J; Darb-Esfahani, S; Denkert, C; Dietel, M; du Bois, A; Eidtmann, H; Fend, F; Gerber, B; Hanusch, C; Hilfrich, J; Hoffmann, G; Huober, J; Khandan, F; Loibl, S; Mehta, K; Müller, BM; von Minckwitz, G; Weiss, E; Zahm, DM | 1 |
| Ishiguro, H; Kanao, S; Mikami, Y; Sugie, T; Takada, M; Takuwa, H; Toi, M; Ueno, T | 1 |
| Amano, S; Enomoto, K; Matsuo, S; Sakurai, K; Shiono, M | 1 |
| Bair, AH; Bycott, P; Chan, S; Joy, AA; Kim, S; Liau, KF; Lluch, A; Rosbrook, B; Rugo, HS; Soulieres, D; Stopeck, AT; Verma, S | 1 |
| Schneider, BP; Sledge, GW | 1 |
| Choi, SY; Choi, Y; Chung, IY; Kang, E; Kim, EJ; Kim, IA; Kim, JH; Kim, SW; Kim, YJ; Lee, HE; Park, SY; Ryu, HS | 1 |
| Berdah, JF; Campone, M; Coeffic, D; Facchini, T; Falandry, C; Freyer, G; Hilaire, Pde S; Jacquin, JP; Peron, J; Terret, C | 1 |
| Bontenbal, M; Bos, MM; Braun, HJ; Creemers, GJ; Erdkamp, FL; Hamberg, P; Klijn, JG; Loosveld, OJ; Muller, EW; Portielje, JE; Pruijt, JF; Schmitz, PI; Seynaeve, C; Smit, WM; Stouthard, JM; van Deijk, GA; van der Stelt-Frissen, IN | 1 |
| Bagot, M; Cosnes, A; Duong, TA; Gantzer, A; Ortonne, N; Regnier, S; Wolkenstein, P | 1 |
| Ducros, C; Montana, M; Rathelot, P; Terme, T; Vanelle, P; Verhaeghe, P | 1 |
| Aloysius, MM; Baria, K; Beer, J; Clarke, DJ; Cowley, G; El-Sheemy, M; Eremin, JM; Eremin, O; Jibril, JA; Kamal, M; Samphao, S; Thorpe, GW; Valerio, D; Vassanasiri, W; Walker, LG; Walker, MB; Wiseman, J | 1 |
| Chen, HD; Geng, L; Ji, YZ; Qu, HM; Wei, HC; Xiao, T; Zhou, HB | 1 |
| Eastwood, A; Epstein, D; Fox, D; Rodgers, M; Soares, M; Yang, H | 1 |
| Cheng, JY; Chiang, CL; Chou, HY; Hsiung, LC; Huang, YH; Jong, DS; Kuo, CT; Lee, H; Lin, CH; Wang, CH; Wo, AM; Wu, V | 1 |
| Kawaguchi, H; Koga, C; Nakamura, Y; Nishimura, S; Ohno, S; Tanaka, K; Yamaguchi, H; Yoshiyama, T | 1 |
| Buzdar, AU; Cheporov, S; Digumarti, R; Goedhals, L; Gotovkin, E; Hoersch, S; Hu, X; Miles, DW; O'Shaughnessy, J; Rittweger, K; Semiglazov, V; Tjulandin, S; Xu, B | 1 |
| Furukawa, H; Inokuchi, M; Kawashima, H; Kitamura, S | 1 |
| Amadori, D; Baconnet, B; Barbato, A; Barone, C; Bordonaro, R; Comella, G; Gasparini, G; Gattuso, D; Gebbia, V; Milandri, C; Nanni, O; Salvagni, S; Saracchini, S; Serra, P | 1 |
| Clemens, MR; Darb-Esfahani, S; Denkert, C; Diebold, K; Dietrich, K; Eidtmann, H; Hanusch, C; Henschen, S; Hoffmann, G; Holms, F; Huober, J; Just, M; Loibl, S; Schrader, I; Solbach, C; Tesch, H; Tiemann, K; Untch, M; von Minckwitz, G | 1 |
| Andrieu, JM; Bats, AS; Eme, D; Hofmann, H; Huchon, C; Le Frere-Belda, MA; Lecuru, F; Levy, E; Medioni, J; Oudard, S | 1 |
| Buyse, ME; Dy, PA; Geyer, CE; Jacobs, SA; Liepman, MK; Mamounas, EP; Melnik, MK; Pajon, ER; Piette, F; Posada, JG; Rastogi, P; Robidoux, A; Swain, SM; Wolmark, N | 1 |
| Collie-Duguid, ES; Heys, SD; Miller, ID; Smyth, E; Stewart, KN; Sweeney, K | 1 |
| Aogi, K; Ishiguro, H; Iwata, H; Kawaguchi, K; Kuroi, K; Masuda, N; Morita, S; Nakamura, S; Ohno, S; Toi, M | 1 |
| Bang, YJ; Han, SW; Han, W; Heo, DS; Im, SA; Keam, B; Kim, DW; Kim, JH; Kim, TY; Lee, SH; Nam, BH; Noh, DY; Oh, DY; Park, IA; Park, S | 1 |
| Akiyama, F; Iwata, H; Kuroi, K; Kurosumi, M; Masuda, N; Nakamura, S; Ohashi, Y; Sato, N; Toi, M; Tsuda, H; Yamamoto, N | 1 |
| Danno, K; Imaoka, S; Inatome, J; Kagara, N; Kagawa, K; Kanoh, T; Kim, C; Kimura, Y; Monden, T; Nakamura, H; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Watanabe, A | 1 |
| Agostini, C; Bachelot, T; Bajard, A; Boisseau, M; Coeffic, D; Dramais, D; Ferri-Dessens, RM; Guastalla, JP; Kaphan, R; Oprea, C; Perol, D; Provencal, J; Ray-Coquard, I | 1 |
| Brodowicz, T; Csörgo, E; Kahán, Z; Kaizer, L; Lázár, G; Nikolényi, A; Ormándi, K; Sükösd, F; Thurzó, L; Uhercsák, G; Vörös, A | 1 |
| Barrett-Lee, P; Bliss, J; Bloomfield, D; Cameron, D; Campbell, HE; Dunn, J; Earl, H; Ellis, P; Epstein, D; Gray, AM; Griffin, S; Harris, AL; Hiller, L; Hopwood, P; Johnson, L; Manca, A; Poole, C; Sculpher, MJ; Yarnold, J | 1 |
| Apetoh, L; Arnould, L; Coudert, B; Fumoleau, P; Ghiringhelli, F; Ladoire, S; Martin, F; Mignot, G; Rébé, C | 1 |
| Benedetti, G; Chang, HT; Ciruelos, E; Duenne, AA; Miles, DW; Passos-Coelho, JL; Pivot, X; Schneeweiss, A; Thomssen, C; Verma, S; von Moos, R | 1 |
| Breslin, K; Deb, S; Feleppa, F; Fox, SB; Generali, D; Huang, DC; Lee, L; Lim, E; Lindeman, GJ; Oakes, SR; Ritchie, ME; Smyth, GK; Strasser, A; Takano, E; Vaillant, F; Visvader, JE; Ward, T | 1 |
| Bliss, JM; Coleman, RE; Coombes, RC; Cooper, D; den Boer, MO; Erdkamp, F; Espie, M; Hupperets, P; Kilburn, LS; Marty, M; Reise, JA; Thomas, MW; Tres, A; Tubiana-Mathieu, N; Wals, J; Wardley, A; Wilkinson, K | 1 |
| Gitsch, G; Jäger, M; Klar, M; Orlowsk-Volk, M; Pils, D; Stickeler, E; Tempfer, CB; Watermann, D; Zeillinger, R; Zur Hausen, A | 1 |
| Casado, MA; Ginés, J; Grau, M; Martorell, C; Monroy, M; Sabater, E | 1 |
| Bertucci, F; Birnbaum, D; Borg, JP; Finetti, P; Gonçalves, A; Kadra, G; Toiron, Y; Viens, P | 1 |
| Gao, F; Luo, J; Sun, X; Sun, Z; Wang, H; Zhao, X; Zhong, B | 1 |
| Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N | 1 |
| Advani, PP; Kossoff, EB; Levine, EG; Ngamphaiboon, N; O'Connor, TL | 1 |
| Eckhoff, L; Knoop, A; Moeller, S; Nielsen, M | 1 |
| Albain, KS; Barlow, WE; Flaherty, LE; Gralow, JR; Hortobagyi, GN; Kash, JJ; Lew, DL; Livingston, RB; Royce, ME | 1 |
| Kubota, N; Shimoda, K | 1 |
| Astruc, D; François, A; Laroche, A; Pinaud, N; Robert, J; Ruiz, J; Salmon, L | 1 |
| Alles, JU; Ataseven, B; Darb-Esfahani, S; Denkert, C; du Bois, A; Fissler-Eckhoff, A; Gerber, B; Kulmer, U; Loibl, S; Mehta, K; Müller, BM; Roller, M; Schwabe, M; von Minckwitz, G | 1 |
| Aapro, M; Bhar, P; Gradishar, W; Tjulandin, S | 1 |
| Blum, JL; Hennessy, BT; Leonard, R; O'Shaughnessy, J | 1 |
| Hatake, K; Hosonaga, M; Ito, Y; Iwase, T; Takahashi, S; Tokudome, N | 1 |
| Almanza, C; Alvarez, E; Antolín, S; Calvo, L; de Paz, L; García-Mata, J; García-Palomo, A; González, A; Mel, R; Ramos, M | 1 |
| Cortes, J; Roché, H | 1 |
| Appia, F; Baquero, MT; Bassi, KA; Camp, RL; Gustavson, MD; Harris, LN; Lostritto, K; Molinaro, AM; Rimm, DL | 1 |
| Buyse, M; Chan, A; Crown, J; Drevot, P; Eiermann, W; Lindsay, MA; Mackey, JR; Martin, M; Pienkowski, T; Press, M; Provencher, L; Riva, A; Sadeghi, S; Saleh, M; Sauter, G; Sehdev, S; Semiglazov, V; Taupin, H | 1 |
| Goto, M; Imai, A; Konishi, E; Mizuta, M; Mizuta, N; Morita, M; Nishiyama, A; Sakaguchi, K; Taguchi, T; Umeda, Y | 1 |
| Cals, L; Curtit, E; Dohollou, N; Facchini, T; Gligorov, J; Grangé, V; Jaubert, D; Levy, E; Lortholary, A; Maille, N; Nouyrigat, P; Pivot, X | 1 |
| Amini, M; Atyabi, F; Dinarvand, R; Emami, S; Koopaei, MN; Ostad, SN; Rabbani, H | 1 |
| Chen, H; Huang, L; Liu, K; Liu, R; Mei, L; Song, X; Zeng, X; Zheng, Y | 1 |
| Tweardy, DJ; Weatherhead, JE | 1 |
| Abe, M; Esaki, T; Fukazawa, M; Hayashi, T; Ikesue, H; Ohno, S; Oishi, R; Tomizawa, T | 1 |
| Bayraktar, S; Buzdar, AU; Gonzalez-Angulo, AM; Hortobagyi, GN; Kuerer, HM; Lei, X; Melhem-Bertrandt, A; Meric-Bernstam, F; Sahin, AA; Valero, V | 1 |
| Altevogt, P; Benner, A; Biakhov, MY; Bottini, A; Bretz, N; Burwinkel, B; Friedrichs, K; Hug, S; Keller, S; Khailenko, VA; Kristiansen, G; Lichter, P; Manikhas, GM; Marmé, F; Moldenhauer, G; Ruiz, A; Rupp, AK; Rupp, C; Sánchez-Rovira, P; Santoro, A; Schneeweiss, A; Segui, MA; Sinn, P; Sohn, C; Villena, C; Walter, A; Wang, X; Werft, W | 1 |
| Brandi, M; Colucci, G; Di Benedetto, A; Di Lauro, L; Filippelli, G; Foggi, P; Gebbia, N; Giannarelli, D; Giotta, F; Lopez, M; Massidda, B; Mottolese, M; Schittulli, F; Vici, P | 1 |
| Abair, T; O'Shaughnessy, J | 1 |
| Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I | 1 |
| Booser, D; Brewster, A; Cristofanilli, M; Ensor, J; Giordano, SH; Gladish, G; Gonzalez-Angulo, AM; Hortobagyi, GN; Moore, J; Moulder, S; Murray, JL; Rivera, E; Tran, HT | 1 |
| Duan, H; Song, S; Sun, J; Wu, Z; Xu, Y | 1 |
| Baba, Y; Kim, SJ; Kishi, K; Nakayama, T; Naoi, Y; Noguchi, S; Shimazu, K; Tamaki, Y; Tanei, T; Tominaga, N; Tsunashima, R | 1 |
| Basile, FG; Creamer, S | 1 |
| Aravantinos, G; Bafaloukos, D; Bournakis, E; Dimopoulos, AM; Fountzilas, G; Fountzilas, H; Kalofonos, HP; Kalogeras, KT; Korantzis, I; Kosmidis, P; Kotoula, V; Koutras, A; Papakostas, P; Papaxoinis, G; Pectasides, D; Skarlos, D; Varthalitis, I | 1 |
| Aboagye, EO; Ahmad, R; Al-Nahhas, A; Challapalli, A; Contractor, KB; Coombes, RC; Jacob, J; Kenny, LM; Rosso, L; Sharma, R; Stebbing, J; Turkheimer, F | 1 |
| Abdeen, G; Kamona, A; Massarweh, S; Sapp, C; Wilson, B | 1 |
| Chung, C; Frankel, P; Gu, L; Hurria, A; Kane, SE; Koczywas, M; Lau, SK; Leong, L; Luu, T; Martel, CL; McNamara, M; Morgan, R; Ruel, C; Russell, CA; Somlo, G | 1 |
| Andre, F; Bertucci, F; Birnbaum, D; Boher, JM; Campone, M; Charafe-Jauffret, E; Esterni, B; Finetti, P; Jacquemier, J; Kerbrat, P; Martin, AL; Penault-Llorca, F; Roche, H; Serin, D; Viens, P | 1 |
| Freeman, S; Jenkins, P; Scaife, J | 1 |
| Fukuoka, Y; Horii, R; Kato, T; Kosaka, N; Minoura, K; Ochiya, T; Takahashi, RU; Takeshita, F; Taya, T; Yamamoto, Y; Yoshioka, Y | 1 |
| Caldés, T; de la Hoya, M; de la Torre, J; Diaz-Rubio, E; Furio, V; García-Sáenz, JA; Martín, M; Moreno, A; Oliva, B; Román, JM; Romero, A | 1 |
| Friberg, LE; Hansson, EK | 1 |
| Di Mauro, M; Ficorella, C; Fratini, S; Mancini, M; Penco, M; Procaccini, V; Ricevuto, E; Romano, S; Stifano, G | 1 |
| Chae, SW; Choi, JM; Choi, SJ; Cui, JX; Jadhav, VB; Jun, YJ; Kim, IS; Lee, HJ; Min, JH; Sohn, YS | 1 |
| Dees, EC | 1 |
| Andersson, M; Bjerre, KD; Cold, S; Jakobsen, EH; Jørgensen, CL; Kamby, C; Møller, S; Nielsen, DL; Stenbygaard, L; Sørensen, PG | 1 |
| Fukushima, M; Ishiguro, H; Niimi, M; Sugie, T; Takashima, S; Takeuchi, M; Toi, M; Ueno, T; Yamamoto, T; Yamashiro, H; Yanagihara, K; Yano, I; Yoshimura, K | 1 |
| Hu, D; Li, MQ; Su, J; Xu, H | 1 |
| Belfiglio, M; Fanizza, C; Ficorella, C; Iacobelli, S; Natoli, C; Tinari, N | 1 |
| Deng, Z; Du, WW; Fang, L; Jeyapalan, Z; Seth, A; Shan, SW; Yang, BB; Yang, BL; Yee, AJ; Zhang, Y | 1 |
| Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K | 1 |
| García-Estevez, L; Gil, M; Ramos, M; Sánchez-Rovira, P; Servitja, S; Tusquets, I; Vázquez-Estevez, S; Velasco, A; Virizuela, JA | 1 |
| Chuttani, K; Mishra, AK; Misra, A; Naik, S; Patel, D | 1 |
| Agarwal, V; Cawkwell, L; Drew, PJ; ELFadl, D; Fox, JN; Garimella, V; Hodgkinson, VC; Kneeshaw, PJ; Lind, MJ; Long, ED; Mahapatra, TK; McManus, PL; Russell, C | 1 |
| Ayala de la Peña, F; Chaves Benito, A; Garcia Garcia, T; Garcia-Martinez, E; Gonzalez Billalabeitia, E; Vicente Conesa, MA; Vicente Garcia, V | 1 |
| Bazan, F; Cals, L; Chaigneau, L; Chaumard, N; Dobi, E; Fagnoni, P; Limat, S; Nerich, V; Pivot, X; Villanueva, C | 1 |
| Characiejus, D; Juozaitytė, E; Liutkauskienė, S; Šeštakauskas, K; Sveikata, A; Tamošaitytė, L | 1 |
| Alba, E; García-Tapiador, A; González-Sánchez, LA; Jiménez, B; Medina, L; Navarro, V; Romero-García, G; Sánchez-Muñoz, A | 1 |
| Bandyopadhyay, D; Basu, S; Ghosh, SK; Ghoshal, L | 1 |
| Avisar, E; Deutsch, YE; Diaz-Montero, CM; Garret-Mayer, E; Glück, S; Hurley, J; Jorda, M; Koniaris, LG; Montero, AJ; Pegram, MD; Rumboldt, T; Schuhwerk, K; Seo, P; Silva, O; Slingerland, J; Welsh, C; Yasir, S | 1 |
| Gradishar, WJ | 7 |
| Baselga, J; Benyunes, MC; Clark, E; Cortés, J; Hegg, R; Im, SA; Im, YH; Kim, SB; Knott, A; Pedrini, JL; Pienkowski, T; Roman, L; Ross, G; Swain, SM | 1 |
| Bianchi, G; de la Haba-Rodriguez, J; Gianni, L; Im, SA; Im, YH; Liu, MC; Lluch, A; Morandi, P; Pedrini, JL; Pienkowski, T; Poirier, B; Ratnayake, J; Roman, L; Ross, G; Semiglazov, V; Srimuninnimit, V; Staroslawska, E; Szado, T; Tseng, LM; Valagussa, P | 1 |
| Akiyama, F; Ando, M; Aogi, K; Fujiwara, Y; Ino, H; Iwata, H; Kasai, H; Kurosumi, M; Masuda, N; Nakamura, S; Takeuchi, M; Tokuda, Y; Tsuda, H; Yamamoto, N | 1 |
| Beisswanger, E; Buyko, E; Hahn, U | 1 |
| Bauknecht, T; Benhadji, KA; Davidson, N; Gümüş, M; Soldatenkova, V | 1 |
| Harbeck, N | 1 |
| Feng, SS; Liu, Y | 1 |
| Bollag, DT; Caralt, M; Cortés, J; Cortes-Funes, H; Delaloge, S; Miles, DW; Pierga, JY; Pritchard, KI | 1 |
| Gao, F; Sun, X; Sun, Z; Wang, H; Zhang, YH; Zhong, B | 1 |
| Bordeleau, L; Kim, S; Seki, J; Sridhar, S; Tannock, I | 1 |
| Armstrong, SR; Guo, B; Hembruff, SL; Kalatskaya, I; Lanner, C; Parissenti, AM; Reed, K; Sprowl, JA; Stein, L; Tam, A | 1 |
| Barg, FK; DeMichele, A; Farrar, JT; Hennessy, S; Mao, JJ; Speck, RM; Stineman, MG | 2 |
| Burshtein, ES; Dygai, AM; Gol'dberg, VE; Khrichkova, TY; Minakova, MY; Popova, NO; Shatalova, VA; Zhdanov, VV | 1 |
| Kolbin, AS; Zagorodnikova, KA | 1 |
| Bessonov, AA; Dashian, GA; Kolar'kova, VV; Paltuev, RM; Pen'kov, KD; Remizov, AS; Semiglazov, VF; Semiglazov, VV; Semiglazova, TIu; Vasil'ev, AG | 1 |
| Bozhok, AA; Donskikh, RV; Matsko, DE; Semiglazov, VV; Semiglazova, TIu | 1 |
| Besova, NS | 1 |
| Chapelle, C; Ellis, P; Jacquin, JP; Janni, W; Jones, S; Laporte, S; Magné, N; Martín, M; Mavroudis, D | 1 |
| Ahn, JH; Ahn, SH; Jung, KH; Kim, KP; Kim, SB; Lee, JS; Yoon, DH | 1 |
| Furuya, T; Hirowatari, H; Ito, K; Izawa, H; Karasawa, K; Mitsuhashi, N; Ozawa, S; Saito, M; Suzuki, T | 1 |
| Gou, JX; Gu, PF; He, HB; Meng, LK; Qi, N; Sui, BW; Sun, F; Tang, X; Wang, XJ; Xu, H; Zhang, Y | 1 |
| Adams, PT; Atkins, JN; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Mamounas, EP; Margolese, RG; Mehta, RS; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Ancoli-Israel, S; Dimsdale, JE; Fiorentino, L; Liu, L; Mills, PJ; Natarajan, L; Parker, BA; Rissling, M; Sadler, GR | 1 |
| Jin, F; Li, B; Li, Y; Lv, M; Mao, X; Yao, F | 1 |
| Feng, SS; Kulkarni, SA; Muthu, MS; Raju, A | 1 |
| Bang, YJ; Cho, N; Chung, JK; Han, SW; Han, W; Im, SA; Kang, KW; Keam, B; Kim, JH; Kim, TY; Koh, Y; Moon, WK; Noh, DY; Oh, DY; Park, IA | 1 |
| Mahmood, A; Rahman, A | 1 |
| Booser, DJ; Brewster, AM; Broglio, K; Buzdar, AU; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Kelly, CM; Thomas, ES; Valero, V; Walters, RS | 1 |
| Bergh, J; Bischoff, J; Bondarenko, IM; Chan, A; Cortes, J; Delaloge, S; Giorgetti, C; Greil, R; Huang, X; Kern, KA; Lichinitser, MR; Liljegren, A; Lortholary, A; Makhson, AN; Voytko, NL | 1 |
| Arai, T; Kamigaki, S; Matsuura, M; Oshiro, C | 1 |
| Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH | 1 |
| Awada, A; Bergh, J; Cardoso, F; Gianni, L; Giorgetti, C; Huang, X; Kern, KA; Liljegren, A; Mariani, G; Verkh, L; Viganò, L | 1 |
| Guli, KZ; Guo, L; Hu, X; Li, X; Li, Y; Liu, W; Ma, Y; Wen, SJ; Yang, SE; Zhao, B | 1 |
| Barron, R; Edelsberg, J; Kartashov, A; Lyman, G; Weycker, D | 1 |
| Georgoulias, V; Kalbakis, K; Karachaliou, N; Kouroussis, Ch; Mavroudis, D; Papakotoulas, P; Poppis, E; Tryfonidis, K; Vardakis, N | 1 |
| Chang, KJ; Chang, TW; Chen, DR; Lin, C; Wang, HC | 1 |
| Baeuerle, PA; Eiermann, W; Göppel, G; Hanusch, CA; Lang, A; Marschner, N; Oruzio, D; Rüttinger, D; Schlimok, G; Schmidt, M; Schuler, M; Sebastian, M; Steger, GG; Wolf, A; Wolf, C | 1 |
| Imholz, ALT; Laddach, N; Lips, EH; Mulder, L; Oonk, AMM; Rodenhuis, S; Savola, SP; Smits, MM; van Rijn, C; Wesseling, J | 1 |
| Anderson, J; Barham, T; Chan, A; Hastrich, DJ; Ingram, D; Joseph, D; Latham, B; Redfern, A; Thomson, J; VAN DER Schaaf, A; Willsher, PC | 1 |
| Han, HS; Jung, S; Kang, HS; Kim, SW; Lee, H; Lee, KS; Lee, S; Park, IH; Ro, J | 1 |
| Aogi, K; Arioka, H; Inoue, K; Ito, Y; Iwata, H; Saeki, T; Sato, Y; Takatsuka, Y; Toi, M; Tokuda, Y | 1 |
| Loibl, S; Massey Skatulla, L; Müller, T; Schauf, B | 1 |
| Borst, P; de Hoon, B; de Ronde, J; Gillet, JP; Gottesman, MM; Gribnau, J; Jaspers, JE; Jonkers, J; Jonkers, M; Kersbergen, A; Linn, SC; Lodén, M; Pajic, M; Rottenberg, S; Schouten, PC; Sol, W; van der Burg, E; Vollebergh, MA; Wesseling, J; Wessels, L; Zander, SA | 1 |
| Becker-Putsche, M; Bocklitz, T; Hartmann, K; Niendorf, A; Pachmann, K; Popp, J; Rösch, P | 1 |
| Chawla, A; Hunt, KK; Mittendorf, EA | 1 |
| Liu, J; Liu, Y; Ma, Y; Zhang, J; Zhang, S; Zhang, X; Zhu, Y | 1 |
| Che, L; Di, L; Dong, N; Jia, J; Jiang, H; Ren, J; Song, G; Wang, C; Wang, X; Wang, Z; Yu, J; Zheng, X; Zhou, X; Zhu, B | 1 |
| Di, L; Dong, N; Liang, X; Lyerly, HK; Ren, J; Song, G; Wang, X; Wang, Z; Yan, Y; Yang, H; Yu, J; Zheng, X; Zhou, X; Zhu, Y | 1 |
| Kuranami, M; Ohashi, Y; Ohno, S; Ohsumi, S; Shimozuma, K; Suemasu, K; Takeuchi, A; Watanabe, T | 1 |
| Chen, CM; Chen, S; Shao, ZM; Yu, KD; Zhou, RJ | 1 |
| Bleuzen, A; Bougnoux, P; Chevalier, S; Goupille, C; Mahéo, K; Richard, S; Serrière, S; Tranquart, F; Vibet, S | 1 |
| Boulaamane, L; Boutayeb, S; Errihani, H | 1 |
| Akışık, E; Çamlıca, H; Dalay, N; Eralp, Y; İğci, A; Keskin, S; Müslümanoğlu, M; Özmen, V; Saip, P; Topuz, E; Tunacı, M; Tuzlalı, S; Yılmaz, S | 1 |
| Anderson, R; Balkrishnan, R; Camacho, F; Kamal, AH; Kimmick, G; Wei, W | 1 |
| Gao, Y; Hu, YJ; Meng, XL; Su, D; Wang, L; Xie, SN; Yang, HJ | 1 |
| Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Tani, T; Umeda, T | 1 |
| Berger, AM; Farr, L; Fischer, P; Geary, CR; Hertzog, M | 1 |
| Chen, H; Chen, WJ; Sun, HY; Wu, LL; Yuan, SF; Zhang, W; Zheng, WE; Zhu, LJ | 1 |
| Cao, Y; Ge, QD; Liu, P; Lv, N; Tang, J; Wang, X; Wei, WD; Xiao, XS; Xie, XM; Xie, ZM | 1 |
| Dong, Z; Fauzee, NJ; Juan, P; Li, QG; Lu, X; Mandarry, MT; Wang, T; Wang, YL | 1 |
| Bonnefoi, H; Brouste, V; Debled, M; Donamaria, C; Durand, M; MacGrogan, G; Madranges, N; Mauriac, L; Toulmonde, M | 1 |
| Brufsky, AM; Jankowitz, RC | 1 |
| Azambuja, ED; Buyse, M; Crown, J; Dell'orto, P; Dolci, MS; Falagan-Lotsch, P; Fernández-Cuesta, L; Francis, PA; Hainaut, P; Larsimont, D; Leo, AD; Oakman, C; Olivier, M; Piccart-Gebhart, M; Quinaux, E; Smoth, KS; Viale, G | 1 |
| Bastani, P; Kiadaliri, AA | 1 |
| Bleuse, JP; Chapelle, A; Jacot, W; Lamy, PJ; Pouderoux, S; Romieu, G; Thezenas, S | 1 |
| Bessis, D; Dereure, O; Frouin, E; Guillot, B; Jacot, W; Kluger, N; Poujol, S; Rigau, V; Romieu, G | 1 |
| Cho, KR; Gil, EY; Jeong, H; Jo, UH; Kim, A; Kim, YH; Koh, I; Lee, ES; Park, KH; Seo, JH; Whang, YM; Woo, OH | 1 |
| Anan, K; Arime, I; Chijiiwa, K; Fujii, T; Hara, S; Imamura, S; Inoue, H; Ishikawa, E; Mitsuyama, S; Nishimura, R; Ohchi, T; Ohkido, M; Ohno, S; Oikawa, T; Shimada, K; Tamura, K; Tanaka, M; Taniguchi, H; Yano, H | 1 |
| Aranishi, T; Hausheer, FH; Katsumata, N; Kuranami, M; Kuroi, K; Makino, H; Morita, S; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takeuchi, A; Watanabe, T | 1 |
| Bender, E | 1 |
| Belmont, LD; Belvin, M; Berry, L; Friedman, LS; Guan, J; Koeppen, H; Lee, LB; Prior, WW; Sampath, D; Wallin, JJ | 1 |
| Shen, H; Sun, X; Sun, Z; Wang, H; Zhang, Y; Zhong, B | 1 |
| Bertucci, F; Birnbaum, D; Cabaud, O; Cervera, N; Charafe-Jauffret, E; Finetti, P; Ginestier, C; Guille, A; Josselin, E; Larderet, G; Monville, F; Sebti, S; Viens, P; Wicinski, J | 1 |
| Aránega, A; Boulaiz, H; Ortega-Vinuesa, JL; Peula-García, JM; Sánchez-Moreno, P | 1 |
| Asselain, B; Audhuy, B; Beauduin, M; Campone, M; Canon, JL; Coudert, B; Eymard, JC; Jerusalem, G; Lévy, C; Machiels, JP; Martin, AL; Orfeuvre, H; Pénault-Llorca, F; Petit, T; Piot, G; Roché, H; Romieu, G; Serin, D; Spielmann, M; Veyret, C | 1 |
| Baselga, J; Bombonati, A; Rafferty, EA; Smith, BL | 1 |
| Dalenc, F; Filleron, T; Fumoleau, P; Kerbrat, P; Kramar, A; Martin, AL; Roché, H; Spielmann, M | 1 |
| Czepas, J; Gwozdzinski, K; Koceva-Chyla, A; Piasecka-Zelga, J; Pieniazek, A; Tabaczar, S | 1 |
| Coulon Sfairi, MA; Dalenc, F; Delva, R; Espié, M; Hardy-Bessard, AC; Kockler, L; Lortholary, A; Monnier, A; Pavlyuk, M; Pierga, JY; Pivot, X; Serin, D; Veyret, C | 1 |
| Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N | 1 |
| Dong, Z; Fauzee, NJ; Li, QG; Mandarry, MT; Pan, J; Wang, T; Wang, YL; Xu, L | 1 |
| Alba, E; Albanell, J; Arcusa Lanza, A; Bermejo, B; Calvo, L; Carrasco, E; Chacon, JI; De la Haba, JR; Lluch, A; Lopez Garcia-Asenjo, JA; Plazaola, A; Sanchez-Rovira, P | 1 |
| Andersen, KG; Eckhoff, L; Gärtner, R; Jensen, MB; Kehlet, H; Kroman, N | 1 |
| Ahmed, M | 1 |
| Dixon, JM; Symmans, WF; Verrill, M; Wilson, V | 1 |
| Abe, H; Cho, H; Kawai, Y; Kubota, Y; Mori, T; Tani, T; Umeda, T | 1 |
| Dong, DW; Qi, XR; Tong, SW; Xiang, B | 1 |
| Bhar, P; Cheporov, S; Clawson, A; Gradishar, WJ; Iglesias, J; Krasnojon, D; Makhson, AN; Manikhas, GM; McGuire, JR | 1 |
| Bramati, A; Farina, G; Girelli, S; La Verde, N; Mihali, D; Moretti, A; Piva, S; Sburlati, P | 1 |
| Bian, L; Cao, Y; Huang, H; Jiang, Z; Song, S; Wang, T; Wu, S; Zhang, S | 1 |
| de Vos, FY; van Laarhoven, HM | 1 |
| Lacjakova, K; Laputkova, G; Slaba, E; Trebunova, M; Verebova, A | 1 |
| Belli, P; Bonatesta, A; Bonomo, L; Bufi, E; Costantini, M; De Santis, MC; Di Matteo, M; Mulé, A; Nardone, L; Rinaldi, P; Terribile, D | 1 |
| Crown, J; Gullo, G; Santoro, A; Sclafani, F; Zuradelli, M | 1 |
| Akiyama, F; Aogi, K; Ikeda, T; Kashiwaba, M; Kuroi, K; Kurosumi, M; Masuda, N; Miyakoda, K; Nakamura, S; Nishimura, R; Ohno, S; Rai, Y; Saeki, T; Sato, N | 1 |
| Anan, K; Hara, S; Imamura, S; Ishikawa, E; Itoyanagi, N; Kamada, Y; Kato, M; Kudaka, M; Matsuo, F; Mitsuyama, S; Nishimura, R; Okido, M; Rai, Y; Shirouzu, M; Takamatsu, Y; Tamura, K; Watanabe, R | 1 |
| Bazan, F; Chaigneau, L; Compagnat, F; Dobi, E; Limat, S; Nerich, V; Perrin, S; Pivot, X; Villanueva, C; Voidey, A | 1 |
| Hao, Y; Liang, X; Liu, N; Ma, M; Wang, L; Yin, Z; Zhang, X | 1 |
| Allred, JB; Apsey, H; Mattar, B; Nikcevich, D; Northfelt, DW; Perez, EA; Pockaj, BA; Roy, V | 1 |
| Chen, C; Di, GH; Fei, F; Liu, GY; Lu, JS; Shao, ZM; Wu, J; Xue, J | 1 |
| Adewoye, AH; Chan, A; De Boer, RH; Kaufman, PA; Koczwara, B; Kotasek, D; Mainwaring, P; Melara, R; Sikorski, R; White, S; Ye, Y | 1 |
| Bhat, A; Cardonick, E; Gilmandyar, D; Somer, R | 1 |
| Chang, JC; Dave, B; Dobrolecki, LE; Hilsenbeck, SG; Landis, MD; Lewis, MT; Liu, D; Tweardy, DJ; Westbrook, TF; Wu, MF; Zhang, X | 1 |
| Heys, SD; McKenzie, EJ; Miller, ID; Rees, AJ; Sellar, G; Stewart, KN; Wong, SY | 1 |
| Barnett, F; Stewart, J; Turner, N; White, S | 1 |
| Bang, YJ; Han, HS; Han, SW; Han, W; Im, SA; Jeon, YK; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Noh, DY; Oh, DY; Park, IA | 1 |
| Bergman, BC; Eckel, RH; Gijón, MA; Hitz, CA; Jacobsen, BM; Schlaepfer, IR | 1 |
| Aksoy, S; Altundag, K; Sendur, MA | 1 |
| Hao, J; Liu, GY; Wang, DH; Xu, YF; Yu, J; Yuan, BB | 1 |
| Fan, Y; Li, Q; Ma, F; Wang, JY; Wang, WM; Xu, BH; Yuan, P; Zhang, P | 1 |
| Ando-Tanabe, N; Iwamitsu, Y; Kuranami, M; Miyaoka, H; Nakatani, Y; Okazaki, S; Watanabe, M; Yamamoto, K; Yasuda, H | 1 |
| Frances, N; Iliadis, A; Marouani, H; Mercier, C; Woloch, C | 1 |
| Braun, M; Feller, AM; Fersching, DM; Gabka, CJ; Hamann, U; Heinemann, V; Holdenrieder, S; Nagel, D; Salat, C; Siegele, B; Steinkohl, O; Stoetzer, OJ | 1 |
| Andersen, RF; Brandslund, I; Jakobsen, A; Jakobsen, EH; Maae, E; Steffensen, KD; Sørensen, FB | 1 |
| Bartlett, J; Bogaerts, J; Bonnefoi, H; Cameron, D; Debled, M; Fiche, M; Fournier, M; Koch, KM; Marreaud, S; Nobahar, M; Pierga, JY; Zaman, K; Zimmer, A | 1 |
| Alifrangis, C; Coombes, RC; Emson, M; Mackie, D; Palmieri, C; Shipway, D; Tat, T; Watson, V | 1 |
| Belardelli, F; Borghi, P; Buoncervello, M; Gabriele, L; Romagnoli, G; Spadaro, F; Toschi, E | 1 |
| Aldrighetti, D; Amadori, D; Bouko, Y; Canon, JL; Cardoso, F; Dirix, L; Giorgetti, C; Kern, KA; Machiels, JP; Usari, T; Verkh, L | 1 |
| Bell, R; Khasraw, M | 1 |
| Anderson, SJ; Bear, HD; Dignam, JJ; Geyer, CE; Julian, TB; Mamounas, EP; Taghian, A; Wickerham, DL; Wolmark, N | 1 |
| Abahssain, H; Aitelhaj, M; Bensouda, Y; Errihani, H; Khannoussi, B; Khoyaali, S; Mrabti, H; Naciri, S; Rais, F; Rais, G; Raissouni, S | 1 |
| Carroll, C; Gajiwala, K; Gallo, J; Gao, Y; Han, G; Jiang, I; Kraynov, E; Li, G; Li, K; Lippincott, J; Peng, Q; Qiu, M; Rymer, I; Sofia, S; Stone, D; Thibault, S; Wei, P; Yang, J; Zachwieja, J | 1 |
| Christodoulou, C; Dionysopoulos, D; Fountzilas, G; Kalogeras, KT; Korantzis, I; Kotoula, V; Koutras, A; Linardou, H; Papakostas, P; Papaxoinis, G; Pectasides, D; Samantas, E; Soupos, N | 1 |
| Cao, X; Xue, J; Zhao, B | 1 |
| Papachristopoulou, G; Scorilas, A; Talieri, M | 1 |
| Caldés, T; de la Hoya, M; Díaz-Rubio, E; Fuentes-Ferrer, M; Furió, V; García-Sáenz, JA; López Garcia-Asenjo, JA; Martín, M; Moreno, A; Román, JM; Romero, A | 1 |
| Date, M; Fujiwara-Honjo, N; Haba, R; Hashimoto, S; Houchi, H; Kontani, K; Kuroda, N; Kushida, Y; Murazawa, C; Norimura, S; Ohtani, M; Tanaka, H; Yamauchi, A; Yokomise, H | 1 |
| Blot, E; Bonneterre, J; Desauw, C; Fournier, C; Hornez, L; Kramar, A; Peyrat, JP; Révillion, F | 1 |
| Jonkers, J; Rottenberg, S | 1 |
| Chavez-Macgregor, M; Chen, H; Do, KA; Gonzalez-Angulo, AM; Hortobagyi, GN; Liu, S; Meric-Bernstam, F; Mills, GB; Sahin, A | 1 |
| Che, L; Di, L; Jiang, H; Liang, X; Lu, Y; Lyerly, HK; Ren, J; Shao, B; Wang, X; Wang, Z; Yan, Y; Yang, H; Yu, J; Zhang, J; Zhou, X; Zhu, Y | 1 |
| Alvarez, R; Aribi, A; Chan, KT; Doan, NB; Gery, S; Ho, Q; Koeffler, HP; Lee, DH; Lee, K; Said, JW; Thoennissen, GB; Thoennissen, NH; Toh, M | 1 |
| Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB | 1 |
| Bustam, AZ; Ng, CH; Phua, CE; Saad, M; Taib, NA; Teh, YC; Yip, CH; Yusof, MM | 1 |
| Olson, EM; Reardon, J; Smith, MB | 1 |
| Grant, AD; Marwick, TH; Negishi, T; Plana, JC; Popović, ZB; Thavendiranathan, P | 1 |
| de Ronde, JJ; Kerkhoven, R; Lips, EH; Mulder, L; Nieuwland, M; Rodenhuis, S; Sonke, GS; Vincent, AD; Vrancken Peeters, MJ; Wesseling, J; Wessels, LF | 1 |
| Hayashida, T; Hirose, S; Ikeda, T; Jinno, H; Kitagawa, Y; Matsuda, S; Takahashi, M | 1 |
| Annuar, MA; Ho, GF; Jabir, RS; Munisamy, M; Naidu, R; Stanslas, J | 1 |
| He, AN; Lin, F; Min, DL; Qi, WX; Shen, Z; Sun, YJ; Tang, LN; Yao, Y | 1 |
| Chen, CS; Chiou, HY; Chiou, JF; Hsu, CH; Hung, CS; Kuo, LJ; Tai, CJ; Wei, PL; Wu, CH | 1 |
| Børretzen, A; Eikesdal, HP; Gravdal, K; Holmaas, G; Storaas, E | 1 |
| Bassi, K; Childs, BH; Coleman, R; Colwell, B; Fornander, T; Glaspy, J; Guastalla, JP; Hainsworth, J; Houé, V; Hugh, JC; Juhos, E; Laing, K; Lindsay, MA; Mackey, JR; Martin, M; Modiano, MR; Pienkowski, T; Pinter, T; Price, C; Provencher, L; Rodríguez-Lescure, A; Rolski, J; Rupin, M; Sami, A; Vinholes, J; Vogel, C; Walde, D; Wardley, A; Whitlock, P; Wilson, V | 1 |
| Balsamo, T; Barbano, R; Castelvetere, M; Coco, M; Fazio, VM; Fontana, A; la Torre, A; Maiello, E; Marangi, GF; Murgo, R; Muscarella, LA; Parrella, P; Pasculli, B; Pellegrini, F; Poeta, ML; Valori, VM | 1 |
| Borgen, E; Kersten, C; Mjaaland, I; Naume, B; Nesland, JM; Risberg, T; Schirmer, C; Synnestvedt, M; Vindi, L; Weyde, K; Wiedswang, G; Wist, E | 1 |
| Fersching, DM; Holdenrieder, S; Lehner, J; Nagel, D; Stötzer, OJ | 1 |
| Akazawa, N; Ebuchi, M; Maruyama, M; Maruyama, S; Murakata, A; Ono, S; Sakoma, T; Satoh, E; Sugano, N; Suzuki, K; Tanami, H; Uehira, D; Yonekura, K | 1 |
| Kakimoto, M; Kawashima, H; Koshiishi, H; Miyamoto, H; Okamura, T | 1 |
| Jiang, ZF; Ma, Y; Meng, XY; Song, ST; Sun, B; Wang, T; Wu, SK; Zhang, SH | 1 |
| Andersson, M; Buyse, M; Crown, J; De Azambuja, E; Dell'orto, P; Di Leo, A; Francis, PA; Gelber, RD; Gutiérrez, J; Harvey, V; Jakesz, R; Larsimont, D; Margeli Vila, M; Nordenskjöld, B; Oakman, C; Piccart-Gebhart, M; Punzalan, L; Quinaux, E; Steinberg, I; Thürlimann, B; Viale, G | 1 |
| Cho, KW; Choi, C; Choi, SH; Choi, Y; Eun, SJ; Kim, HJ; Kim, HS; Lee, KM; Moon, WK; Noh, DY; Whangbo, TK; Woo, J; Yi, YJ | 1 |
| Chan, EK; Come, C; Evan, GI; Joensuu, H; Junttila, MR; Kähäri, VM; Kellokumpu-Lehtinen, PL; Khanna, A; Laine, A; Marine, JC; Niemelä, M; Rosenfeldt, MT; Ryan, KM; Sansom, OJ; Sihto, H; Westermarck, J; Zwolinska, A | 1 |
| Chen, LH; Lin, Y; Shao, N; Wang, SM; Ye, RY | 1 |
| Anter, AH; Hamed, RH; Sakr, H; Yossef, T | 1 |
| Chumsri, S; Zimrin, A | 1 |
| Agelaki, S; Apostolaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kalykaki, A; Mavroudis, D; Perraki, M; Vardakis, N; Xenidis, N; Xyrafas, A | 1 |
| Chen, J; Huan, Y; Jia, Q; Jiang, W; Wang, L; Wei, M; Xu, J; Zheng, M | 1 |
| Gabram, SG; Harichand-Herdt, S; Kim, S; Liu, Y; O'Regan, RM; Rizzo, M; Styblo, TM; Wood, WC; Zelnak, AB | 1 |
| Chang, JC; Dobrolecki, LE; Dontu, G; Froehlich, AM; Griffith, KA; Hayes, DF; Krop, I; Landis, MD; Layman, RM; Lewis, MT; Paranilam, J; Paskett, LA; Schott, AF; Wicha, MS; Wong, H | 1 |
| Crown, JP; de Azambuja, E; Di Leo, A; Francis, P; Hitre, E; Loi, S; Michiels, S; Piccart, MJ; Piette, F; Quinaux, E; Rouas, G; Salgado, R; Sirtaine, N; Sotiriou, C; Van Eenoo, F; Viale, G | 1 |
| Aogi, K | 1 |
| Liu, S; Qiu, W; Wang, X; Wang, Z; Xiang, J; Yue, L; Zhou, F | 1 |
| Che, L; Di, L; Jia, J; Jiang, H; Liang, X; Lyerly, HK; Ren, J; Song, G; Wan, F; Wang, X; Yan, Y; Yu, J; Zhang, J; Zhou, X; Zhu, Y | 1 |
| Farsaci, B; Ferrone, S; Gameiro, SR; Garnett, CT; Hodge, JW; Palena, C; Tsang, KY | 1 |
| Ahn, MH; Han, SW; Jang, YH; Kim, HM; Kim, SY; Kim, Z; Lee, EJ; Lee, J; Lee, MH; Lim, C; Park, JH; Rho, J | 1 |
| Ardizzoni, A; Bisagni, G; Boni, C; De Matteis, A; Gamucci, T; Gnoni, R; Gori, S; Moretti, G; Musolino, A; Nuzzo, F; Panebianco, M; Passalacqua, R | 1 |
| Ahn, JS; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, HR; Kim, SB; Kim, SI; Lee, KH; Lee, S; Park, KH; Sohn, JH | 1 |
| Bianchi, GV; Chu, YW; Dirix, L; Guardino, E; Hurvitz, SA; Kocsis, J; Lu, J; Ng, V; Perez, EA; Song, C; Tong, B; Vinholes, J | 1 |
| Chow, LW; Glück, S; Im, SA; Lee, MH; Ng, TY; Toi, M; Tung, SY; Yip, AY | 1 |
| Antón, A; Aranda, E; Dalmau, E; de la Haba-Rodríguez, J; Fernández, M; Jaén, A; Llombart, A; Lomas, M; Morales, S; Porras, I; Sánchez, A; Sánchez-Rovira, P; Seguí, MA | 1 |
| Aigner, J; Jäger, D; Lorenzo Bermejo, J; Marmé, F; Schneeweiss, A; Sinn, P; Sohn, C | 1 |
| Esteva, FJ | 1 |
| Hortobagyi, GN | 4 |
| Valero, V | 3 |
| Brassard, M; Budman, DR; Cohen, G; Dhami, M; George, T; Glaspy, J; Hackett, J; Holmes, FA; Jones, SE; Liang, BC; Meza, L; O'Shaughnessy, J; Richards, D; Savin, M; Vukelja, S; Yang, BB | 1 |
| Ligibel, JA; Winer, EP | 1 |
| Perez, EA; Qu, G | 1 |
| Hara, A; Harada, T; Iwamoto, S; Izumi, N; Matsubara, C; Satake, K; Tsunematsu, I | 1 |
| Budman, DR; Calabro, A | 1 |
| Baron, R; Binder, A; Hilpert, F; Pfisterer, J; Schattschneider, J; Wasner, G | 1 |
| Hortobagyi, GN; Kris, MG | 1 |
| Lindsay, MA; Nabholtz, JM; Reese, DM; Riva, A | 2 |
| Chan, AT; Chiu, SK; Ho, WM; Johnson, PJ; Kwan, WH; Lam, KC; Leung, TW; Mo, FK; Mok, TS; Tse, KK; Yeo, W | 1 |
| Friedrichs, K; Hölzel, F; Jänicke, F | 1 |
| Adjei, AA; Baron, AT; Geeraerts, L; Hatfield, AK; Ingle, JN; Kugler, JW; Kuross, SA; Lafky, JM; Maihle, N; Michalak, JC; Perez, EA; Suman, VJ | 1 |
| Antonopoulos, MJ; Gregoriou, A; Kosmas, C; Malamos, NA; Rokana, S; Stamataki, M; Tsavaris, NB; Vartholomeou, M | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Matsuo, K; Tsuda, H; Watanabe, T | 1 |
| Goker, E; Karabulut, B; Omay, SB; Sanli, UA; Saydam, G; Sezgin, C; Uslu, R | 1 |
| Ahmadi, MA; Esmaeli, B; Hutto, T; Jackson, DM; Newman, RA; Rivera, E; Valero, V | 1 |
| Aruga, E; Karasawa, K; Kimura, T; Kohno, M; Maebayashi, K; Mitsuhashi, N; Muramatsu, H; Nasu, S; Saitou, M; Seki, K; Suzuki, K; Ueda, M; Umeda, M | 1 |
| Aida, Y; Chishima, Y; Kitajima, A; Noro, M; Okamoto, H; Satou, Y; Takano, S | 1 |
| Street, JC; Taguchi, T | 1 |
| Twelves, CJ; Wright, TL | 1 |
| Ansari, R; Einhorn, LH; Fata, F; McClean, JW; Miller, KD; Porcu, P; Sledge, GW; Soule, SE; Zon, R | 1 |
| Accurso, V; Agostara, B; Failla, G; Fanelli, M; Ferraù, F; Gasparini, G; Leonardi, V; Massidda, B; Morabito, A; Palmeri, S; Tamburo De Bella, M; Vaglica, M; Valenza, R | 1 |
| Asola, R; Ekholm, E; Hinkka, S; Korpela, J; Mali, P; Pyrhönen, S; Salminen, E; Varjo, P; Varpula, M | 1 |
| Bleiweiss, I; Gurry, R; Lehrer, D; Paciucci, PA; Raptis, G; Weltz, C | 1 |
| Breidenbach, M; König, E; Kurbacher, C; Mallmann, P; Schwonzen, M | 1 |
| Azli, N; Bisset, D; Kaye, SB; Ramazeilles, C; Riva, A; Roché, H; Terret, C; Twelves, CJ; Vasey, PA; Vernillet, L | 1 |
| Brugarolas, A; Calvo, E; Cortes, J; Fernández-Hidalgo, O; Martínez-Monge, R; Perez-Calvo, J; Rodríguez, J; Santisteban, M | 1 |
| Hahn, PF; Halpern, EF; Jhaveri, KS; Prasad, SR; Saini, S; Sumner, JE | 1 |
| Benezery, K; Lagrange, JL; Magné, N; Namer, M; Otto, J | 1 |
| Krempien, R; Piroth, MD; Wannenmacher, M; Zierhut, D | 1 |
| Bachmann, N; Barberi-Heyob, M; Merlin, JL | 1 |
| Blohmer, JU; Caputo, A; Costa, SD; Eidtmann, H; Gademann, G; Gerber, B; Hilfrich, J; Jackisch, C; Kaufmann, M; Lampe, D; Merkle, E; Raab, G; Schütte, M; Tulusan, AH; von Minckwitz, G | 1 |
| Cantin, J; Chang, J; Guevin, R; Lindsay, MA; Mackey, J; Nabholtz, JM; Patel, R; Reese, D; Riva, A; Tkaczuk, K; Vodvarka, P | 1 |
| O'Shaughnessy, J | 2 |
| Di Leo, A | 1 |
| Eremin, O; Heys, SD; Hutcheon, AW; Miller, ID; Ogston, KN; Payne, S; Sarkar, TK; Smith, I; Walker, LG | 1 |
| Davidson, NE | 1 |
| Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H | 1 |
| Budman, DR | 1 |
| Besse, B; Spano, JP | 1 |
| André, T; Culine, S; Epaud, C; Gligorov, J | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Miles, D; Seidman, AD; von Minckwitz, G | 1 |
| Eich, D; Eich, HT; Krieg, T; Scharffetter-Kochanek, K; Tantcheva-Poor, I | 1 |
| Abali, H; Celik, I | 1 |
| Mokbel, K; Singh-Ranger, G | 1 |
| Crawford, J | 1 |
| Baselga, J; Clemens, MR; Galid, A; Gascon, P; Green, MD; Guillem, V; Koelbl, H; Lalisang, RI; Liang, BC; Piccart, MJ; Renwick, J; Samonigg, H; Siena, S; Zani, V | 1 |
| Perez, EA | 2 |
| Bando, H; Kuroi, K; Saji, S; Toi, M | 1 |
| Hudis, C | 1 |
| Anderson, SJ; Brown, A; Desai, AM; Kardinal, CG; Lembersky, BC; Mamounas, EP; Scholnik, AP; Smith, RE | 1 |
| Bernard-Marty, C; Bissery, MC; Cardoso, F; Di Leo, A; Dumontet, C; Fellous, A; Gancberg, D; Larsimont, D; Paesmans, M; Piccart, MJ; Treilleux, I | 1 |
| Conte, PF; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Ricci, S; Rondini, M; Salvadori, B | 1 |
| Camerlo, J; Catalin, J; Ciccolini, J; Genre, D; Giovanini, M; Gonçalves, A; Gravis, G; Maraninchi, D; Viens, P; Viret, F | 1 |
| Antila, K; Ekholm, E; Korpela, J; Salminen, E; Syvänen, K; Varjo, P; Varpula, M | 1 |
| Antman, K; Brafman, L; Fine, R; Nelsen, C; Petrylak, DP; Shriberg, L; Talbot, S; Tiersten, AD; Troxel, A; Vahdat, L | 1 |
| Hofer, S; Hunziker, S; Ludwig, CU; Tornillo, L | 1 |
| Aihara, T; Hiraki, S; Horikoshi, N; Inaji, H; Itoh, K; Katsumata, N; Noguchi, S; Sasaki, Y; Sonoo, H; Tabei, T; Takatsuka, Y; Watanabe, T | 1 |
| Antón, A; Cuevas, JM; Estévez, LG; Florián, J; Fortes, J; Herrero, A; Lobo, F; López-Vega, JM; Velasco, A | 1 |
| Chinchilli, V; Engle, L; Lipton, A; Santala, SM; Witters, LM | 1 |
| Aglietta, M; Alabiso, O; Capaldi, A; Choa, G; Donadio, M; Faggiuolo, R; Minischetti, M; Montemurro, F; Salomone, A; Sperti, E; Vietti-Ramus, G | 1 |
| Azli, N; Boudraa, Y; Cocquyt, V; Georgoulias, V; Hausmaninger, H; Paridaens, R; Ramazeilles, C; Samonnig, H; Van Aelst, F; Wildiers, J; Willemse, P; Zielinski, C | 1 |
| Bighin, C; Colozza, MA; Contu, A; Del Mastro, L; Durando, A; Garrone, O; Genta, F; Lambiase, A; Stevani, I; Venturini, M | 1 |
| Alba, E; Antón, A; Florián, J; Godes, MJ; Llanos, M; López-Vega, JM; Menéndez, M; Pelegri, A; Pérez-Carrión, R; Ribelles, N | 1 |
| Borsellino, N; Colombo, A; Ferrera, P; Gebbia, V; Marrazzo, A; Mauceri, G; Musso, M; Porretto, F; Testa, A; Tirrito, ML | 1 |
| Fukushima, M; Ono, Y; Sawada, M | 1 |
| Filipits, M; Jakesz, R; Pirker, R; Pohl, G; Rudas, M; Steger, GG; Stranzl, T; Taucher, S | 1 |
| Baick, CH; Chiou, JY; Fruehauf, JP; Mehta, RS; Nalcioglu, O; Su, MY; Wang, J; Yu, H | 1 |
| Chaikin, P; Durrleman, S | 1 |
| Haidara, K; Mamer, O; Nikolakakis, A; Sauriol, F; Zamir, LO | 1 |
| Buchholz, TA; Davis, DW; Hess, KR; McConkey, DJ; Sahin, AA; Valero, V | 1 |
| Emi, M; Inoue, H; Kim, R; Tanabe, K; Toge, T; Uchida, Y | 1 |
| Glasmacher, A; Gorschlüter, M; Kleinschmidt, R; Mey, U; Schmidt-Wolf, IG; Ziske, C | 1 |
| Glaspy, J; Green, MD; Hackett, J; Holmes, FA; Kubista, E; Neumann, T | 1 |
| Hortobagyi, GN; Valero, V | 1 |
| Azli, N; Campos, D; Chan, S; Falkson, C; Kennedy, I; Krzakowski, M; Leonard, R; Martin, M; Murawsky, M; Nabholtz, JM; Pienkowski, T; Pinter, T; Pouillart, P; Riva, A; Szanto, J; Vorobiof, D; Zaluski, J | 1 |
| Aperis, G; Barbounis, V; Demiri, M; Drufakou, S; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M | 1 |
| Madhere, SM; Sultan, MR | 1 |
| Chan, SY; Sundar, S | 1 |
| Haritoglou, C; Mueller, AJ | 1 |
| Teitelbaum, BA; Tresley, DJ | 1 |
| Doughman, DJ; Skolnick, CA | 1 |
| Agelaki, S; Alexopoulos, A; Androulakis, N; Ardavanis, A; Bozionelou, V; Georgoulias, V; Kandylis, C; Kouroussis, Ch; Malamos, N; Mavroudis, D; Stavrinidis, E | 1 |
| Heinemann, V | 2 |
| Gregoriou, A; Kosmas, C; Malamos, N; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N | 1 |
| Fountzilas, G; Gogas, H | 1 |
| Li, WL; Qin, YK; Yao, Q; Zhu, SW | 1 |
| Arizcun, A; Cruz, JJ; del Barco, E; Diz, P; Fonseca, E; García-Palomo, A; Gómez-Bernal, A; López, Y; Martín, G; Pujol, E; Rodríguez, C; Sánchez, P | 1 |
| Fumoleau, P | 3 |
| Hatake, K; Sugimoto, Y; Takahashi, S | 1 |
| Enomoto, K; Fukuda, M; Haga, S; Iino, Y; Ikeda, T; Shimizu, T; Taguchi, T | 1 |
| O'Shaughnessy, JA | 1 |
| Besson, D; Bougnoux, P; Bourgeois, H; Delozier, T; Gamelin, E; Lortholary, A; Lotz, V; Monnier, A; Riffaud, JCh; Tubiana-Mathieu, N | 1 |
| Ilersich, AL; Verma, S | 1 |
| Achard, JL; Amat, S; Body, G; Bougnoux, P; Chollet, P; Curé, H; Dauplat, J; Fétissof, F; Kwiatkowski, F; Penault-Llorca, F | 1 |
| Ballot, J; Crown, J; McDonnell, D | 1 |
| Chang, TW; Chen, GY; Chen, WC | 1 |
| Archibald, H; Hutcheon, A; Macduff, C; Mackenzie, T; Melville, L | 1 |
| Almanza, C; Amenedo, M; Gamazo, JL; Gómez-Martín, C; González-Ageitos, A; González-Quintas, A; Losada, G; Ramos, M; Romero, C; Togores, P | 1 |
| Elsdon, M; Farrugia, D; Guglani, S; Owen, JR; Parmar, M | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, ML; Malmström, P; Mouridsen, H; Ottoson, S; Pluzanska, A; Sjöström, J; Tennvall, L; Valvere, V | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Marchionatti, S; Pedani, F; Recalenda, V; Tagini, V | 2 |
| Booser, DJ; Cristofanilli, M; David, CL; Esparza-Guerra, LT; Hortobagyi, GN; Ibrahim, N; Murray, JL; Patel, S; Rahman, Z; Trent, JC; Valero, V; Vernillet, L | 1 |
| Nabholtz, JM | 3 |
| Crown, J; Pegram, M | 1 |
| Heys, SD; Hutcheon, AW; Sarkar, TK | 1 |
| Piccart, M | 3 |
| Bear, HD; Goble, S | 1 |
| Ahmadi, MA; Burnstine, MA; Esmaeli, B; Prieto, VG | 1 |
| Adinin, RB; Ahmadi, MA; Arbuckle, R; Coats, C; Esmaeli, B; Faustina, M; Hidaji, L; Rivera, E; Tu, SM; Valero, V | 1 |
| Mio, H | 1 |
| Crispino, J; Fraterrigo, T; Green, J; Lipton, A; Witters, LM | 1 |
| Brenton, JD; Caldas, C | 1 |
| Allred, DC; Chamness, GC; Chang, JC; Elledge, R; Gutierrez, MC; Hilsenbeck, SG; Mohsin, S; O'Connell, P; Osborne, CK; Tsimelzon, A; Wooten, EC | 1 |
| Egawa, C; Hasegawa, S; Ishitobi, M; Miyoshi, Y; Monden, M; Noguchi, S; Taguchi, T; Tamaki, Y | 1 |
| Haga, S; Hanyu, N; Karasawa, K; Katsui, K; Kimura, T; Kohno, M; Maebayashi, K; Mitsuhashi, N; Muramatsu, H; Nasu, S; Seki, K; Takahashi, I | 1 |
| Bernard-Marty, C; Cardoso, F; Piccart, MJ | 1 |
| Campone, M; Fumoleau, P; Merlin, JL | 1 |
| Goodger, NM; Pogrel, MA; Wang, J | 1 |
| Boér, K; Juhos, E; Láng, I; Pintér, T; Szántó, J | 1 |
| Bouffette, P; Llory, JF; Nabholtz, JM; Vannetzel, JM | 1 |
| Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fra, J; González de Sande, L; Lacave, AJ; Modollel, A; Muñiz, I; Palacio, I; Sala, M; Vieitez, JM | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Lapenta, L; Thomas, R; Vallone, P | 1 |
| Barbounis, V; Demiri, M; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M | 1 |
| Almanza, C; Ballesteros, P; Belón, J; Casal, J; Castellanos, J; Frau, A; Galán, A; Lizón, J; Llorca, C; Lorenzo, A; Machengs, I; Méndez, M; Morales, S; Moreno-Nogueira, JA; Oltra, A; Ramos, M | 1 |
| Anderson, S; Bear, HD; Brown, A; Fisher, B; Mamounas, EP; Margolese, R; Smith, R; Soran, A; Theoret, H; Wickerham, DL; Wolmark, N | 1 |
| Von Minckwitz, G | 3 |
| Atadja, P; Bali, P; Bhalla, K; Donapaty, S; Fuino, L; Guo, F; Wang, HG; Wittmann, S; Yamaguchi, H | 1 |
| Bissery, MC; Dykes, DJ; Kraus, LA; Samuel, SK; Schmid, SM; Waud, WR | 1 |
| Bachelot, T; Bendahmane, B; Combe, M; De Ybarlucea, LR; Dieras, V; Fumoleau, P; Ganem, G; Lotz, V; Misset, JL; Tubiana-Hulin, M; Vannetzel, JM | 1 |
| Hamada, K; Ito, S; Kubota, K; Mikami, H; Nakagawa, A; Okada, T; Tagaya, N | 1 |
| Vetter, C | 1 |
| Kawaguchi, Y; Saji, S; Sugiyama, Y | 1 |
| Green, MD; Hackett, JR; Holmes, FA; Meza, LA; Neumann, TA | 1 |
| Horiguchi, J; Iijima, K; Iino, Y; Koibuchi, Y; Morishita, Y; Ninomiya, J; Takata, D; Yokoe, T; Yoshida, M; Yoshida, T | 1 |
| Fitzpatrick, FA; Wheeler, R | 1 |
| Antón, A; Colomer, R; Corral, M; Hornedo, J; Lluch, A; Massuti, B | 1 |
| Ramaswamy, B; Shapiro, CL | 1 |
| Cardoso, F; Piccart, MJ | 1 |
| Alexopoulos, A; Ardavanis, A; Georganta, C; Gerasimidis, G; Kandilis, K; Karamouzis, MV; Karydas, I; Rigatos, G; Stavrakakis, J; Stavrinides, H; Tryfonopoulos, D | 1 |
| Bachleitner, T; Dubsky, P; Fitzal, F; Gnant, M; Jakesz, R; Kandioler, D; Mader, RM; Mittlböck, M; Roka, S; Rudas, M; Sporn, E; Steger, GG; Taucher, S; Wenzel, C | 1 |
| Allred, DC; Chang, JC; Elledge, RM; Granchi, T; Gutierrez, MC; Hilsenbeck, SG; Kalidas, M; Lucci, A; Mohsin, S; Scott, BG; Van Pelt, AE | 1 |
| Andreola, G; Crucitta, E; D'Aprile, M; De Lena, M; Locopo, N; Lorusso, V; Marini, L; Silvestris, N | 1 |
| Wang, Q; Wieder, R | 1 |
| Akashi-Tanaka, S; Ando, M; Fukutomi, T; Hasegawa, T; Iwamoto, E; Katsumata, N; Miyakawa, K; Sato, N; Watanabe, T | 1 |
| Hawkins, N; Jones, L; Richardson, G; Riemsma, R; Westwood, M; Wright, K | 1 |
| Abrams, KR; Cooper, NJ; Sutton, AJ; Turner, D; Wailoo, A | 1 |
| Azli, N; Buzzi, F; Capri, G; Cresta, S; Cuna, GR; Frevola, L; Gianni, L; Grasselli, G; Jirillo, A; Lelli, G; Mansutti, M; Martoni, A; Murawsky, M; Sguotti, C; Tarenzi, E; Terzoli, E | 1 |
| Colomer, R; Lupu, R; Menendez, JA | 2 |
| Fujii, H; Ichihara, F; Inoue, S; Kono, K; Kunitomo, K; Matsumoto, Y; Ooi, A | 1 |
| Blum, KA; Edgerton, S; Goldstein, LJ; Gradishar, WJ; Johnson, DH; Merkel, DE; Murrey, D; Nicholson, BP; Shyr, Y; Sledge, GW; Tedesco, KL; Thor, AD | 1 |
| Hopkins, U; Malik, U; Manalo, JM; Negassa, A; Novik, Y; Raff, JP; Rajdev, L; Sarta, C; Sparano, JA | 1 |
| Aglietta, M; Alabiso, O; Capaldi, A; Choa, G; Donadio, M; Durando, A; Faggiuolo, R; Minischetti, M; Montemurro, F; Vietti-Ramus, G | 1 |
| Appia, F; Basser, R; Cebon, J; Chipman, M; Davis, ID; Green, M; Grigg, A; Mansfield, R; Mitchell, PL | 1 |
| Armeanu, S; Fersis, N; Friedrich, M; Gagulic, E; Pantic, L; Relakis, K; Smyczek-Gargya, B; Wallwiener, D | 1 |
| D'hondt, R; Dumez, H; Paridaens, R; Pauwelyn, K; Thomas, J; Van Oosterom, AT; Wildiers, H | 1 |
| El Saghir, NS; Otrock, ZK | 1 |
| Bergh, J; Linderholm, B | 1 |
| Julka, PK; Mukhopadhyay, P; Rath, GK; Sharma, DN | 1 |
| Hurtubise, A; Momparler, RL | 1 |
| Bonsignori, M; Marcucci, F; Massacesi, C; Mazzanti, P; Pilone, A; Rocchi, MB | 1 |
| Aebersold, DM; Altermatt, HJ; Berclaz, G; Djonov, V; Greiner, RH; Gruber, G; Hlushchuk, R | 1 |
| Haider, S; Shahab, N | 1 |
| Colomer, R; Lupu, R; Menendez, JA; Ropero, S | 1 |
| Paridaens, R; Wildiers, H | 1 |
| Sledge, GW | 1 |
| Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ | 1 |
| Blitz, S; Crown, J; Eiermann, W; Fumoleau, P; Lindsay, MA; Northfelt, DW; Patel, R; Pegram, MD; Pienkowski, T; Press, MF; Quan, E; Reese, D; Riva, A; Slamon, DJ; Smylie, M; Toppmeyer, D | 1 |
| Bando, H; Funata, N; Horiguchi, S; Kataoka, A; Muta, M; Ohno, S; Saji, S; Takada, M; Toi, M; Ueno, T | 1 |
| Bradley, C; Crawford, SM; Dent, J; Dodwell, D; Humphreys, AC; Joffe, JK; Perren, TJ; Rodwell, S | 1 |
| Huang, ZQ; Li, HX; Wan, SG; Wang, JL | 1 |
| Alexopoulos, A; Ardavanis, A; Georganta, C; Kandilis, K; Karamouzis, MV; Rigatos, G; Stavrakakis, J; Stavrinides, H | 1 |
| Estévez, LG; Gradishar, WJ | 1 |
| Crown, J; O'Leary, M; Ooi, WS | 1 |
| Blomqvist, C; Joensuu, H; Klaar, S; Madsen, EL; Nittby, LT; Poikonen, P; Sigurdsson, H; Sjöström, J | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinkski, CC | 1 |
| Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, N; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y | 1 |
| Ghersi, D; Hamilton, A; Nowak, AK; Stockler, MR; Wilcken, NR | 1 |
| Im, MM; Ostruszka, L; Robinson, BW; Shewach, DS | 1 |
| Brandi, M; Colucci, G; Gebbia, N; Giotta, F; Lopez, M; Schittulli, F; Valerio, MR; Vici, P | 1 |
| Alexopoulos, A; Karamouzis, MV; Rigatos, G | 1 |
| Antón, A; Arcusa, A; Bayo, JL; Calvo, L; Carrasco, E; Florián, J; Martn-Richard, M; Mayordomo, JI; Pelegrí, A; Vázquez, S; Virizuela, J | 1 |
| Calvo, I; Casado, V; Daz, M; Dómine, M; Estévez, LG; Jaén, A; León, A; Lobo, F; Miró, C; Rubio, G; Sánchez-Rovira, P | 1 |
| Yardley, DA | 1 |
| Becht, C; Bleuse, JP; Culine, S; Cupissol, D; Fabbro, M; Gourgou, S; Guillemare, C; Lotz, V; Romieu, G | 1 |
| Adrover, E; Alba, E; Amenedo, M; Balil, A; Barnadas, A; Casado, A; Fernández-Aramburo, A; Jara, C; Martín, M; Ramos, M; Sánchez-Rovira, P | 1 |
| Broglio, KR; Buzdar, AU; Esteva, FJ; Gonzalez-Angulo, AM; Hortobagyi, GN; Krishnamurthy, S; Pusztai, L; Yamamura, Y | 1 |
| Möbus, V; Moisidis, C | 1 |
| Baena, JM; Burrilo, MA; Garcia, MJ; Illarramendi, J; Lorenzo, A; Machengs, I; Mayordomo, JI; Milla, A; Modolell, A; Morales, S; Sanz, J; Tres, A; Yubero, A | 1 |
| Acharya, MR; Baker, SD; Figg, WD; Sparreboom, A; Verweij, J | 1 |
| Baker, SD; Enting, RH; Loos, WJ; Sparreboom, A; ten Tije, AJ; van der Meulen, H; Verweij, J; Zhao, M | 1 |
| Bickler, PE; Paige, M | 1 |
| Bouker, KB; Chen, H; Figueira, M; Frankel, SR; Hayes, DF; Ling, Y; Lippman, M; Marshall, J; Yang, D | 1 |
| Diéras, V; Girre, V; Laurence, V; Pierga, JY; Piperno-Neumann, S; Pouillart, P | 1 |
| Baldi, PL; Calista, F; Cannita, K; Cianci, G; DE Galitiis, F; DI Rocco, ZC; Ficorella, C; Marchetti, P; Morelli, MF; Natoli, C; Porzio, G; Ricevuto, E; Tinari, N | 1 |
| Berman, A; Brahim, JS; Chow, C; Figg, WD; Parr, AL; Sparreboom, A; Steinberg, SM; Swain, SM; Tan, AR; Yang, X; Zhai, S | 1 |
| Karabulut, B; Oktem, G; Omay, SB; Sanli, UA; Selvi, N; Sezgin, C; Uslu, R; Yurtseven, ME | 1 |
| Habeshaw, T; Miles, DW; Papazisis, KT | 1 |
| Belón, J; Borrega, P; Casas, A; Checa, T; de la Puente, M; Espinosa, E; González Barón, M; Illarramendi, JA; Janáriz, J; Lizón, J; Machengs, I; Madroñal, C; Mel, JR; Morales, S; Moreno, JA | 1 |
| Brown, I; Heys, SD; Hutcheon, AW; McDonald, SL; Moir, SE; Schofield, AC; Shalli, K | 1 |
| Albanell, J; Antón, A; Barnadas, A; Baselga, J; Climent, MA; Estaun, N; Garcia-Conde, J; Guillem, V; Laurent, C; Lluch, A; Losa, I; Mayordomo, JI; Tabernero, J; Tisaire, JL; Vermorken, JB | 1 |
| Julian, TB; Malay, MB; Patel, JA; Patel, NA; Piper, G | 1 |
| Hall, A; Miles, DW; Twelves, CJ | 1 |
| Anderson, SJ; Brown, A; Lembersky, BC; Mamounas, E; Smith, RE | 1 |
| España, L; Gu, B; Méndez, O; Sierra, A; Torregrosa, A | 1 |
| Currie, VE; D'Andrea, GM; Dang, CT; Dickler, MN; Fornier, M; Hudis, CA; Hurria, A; Lake, D; Moynahan, ME; Norton, L; Panageas, KS; Robson, ME; Seidman, AD; Theodoulou, M | 1 |
| Nortier, JW | 1 |
| Buzdar, AU; Hortobagyi, GN; Ibrahim, NK; Li, Z; Mante Menchu, RP; Theriault, R; Valero, V; Wang, M; Wathen, JK | 1 |
| Bendahmane, B; Bonneterre, J; Bonneterre, ME; Bougnoux, P; Culine, S; Delozier, T; Dieras, V; Dohoulou, N; Mayer, F; Tubiana-Hulin, M | 1 |
| Hashimoto, K; Higami, T; Itakura, M; Koike, M; Nio, Y; Yano, S | 1 |
| Friese, K; Janni, JW; Klanner, E; Rack, B; Sommer, H | 1 |
| Heys, SD; Hutcheon, AW; Sarkar, T | 2 |
| Bodrogi, I; Cardoso, F; Chan, S; Crown, J; Desmedt, C; Di Leo, A; Durbecq, V; Friedrichs, K; Korec, S; Larsimont, D; Leroy, JY; Lesperance, B; Murray, E; Paesmans, M; Perren, TJ; Piccart, M; Pinter, T; Rouas, G; Simmonds, P; Sotiriou, C; Van Belle, S; Walpole, E | 1 |
| Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U | 1 |
| Mills, J; Mortimer, NJ | 1 |
| Berman, A; Chow, CK; Danforth, D; Eng-Wong, J; Lebowitz, PF; Liu, E; Merino, MJ; Swain, SM; Venzon, D; Zia, F; Zujewski, J | 1 |
| Ayoub, JP; Cervantes, G; Liu, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, JA; Van Hazel, G; Vukelja, S | 1 |
| Au, HJ; Bodnar, DM; Joy, AA; Koski, SL; Mackey, JR; Scarfe, AG; Smith, SW; Smylie, MG; Soulieres, D; Tonkin, KS | 1 |
| Bastert, G; Beldermann, F; Hamerla, R; Huober, J; Krauss, K; Rudlowski, C; Schneeweiss, A; Sinn, HP; Solomayer, E; von Fournier, D; Wallwiener, D | 1 |
| Arbion, F; Body, G; Brunereau, L; Chapiron, C; Denis, F; Desbiez-Bourcier, AV | 1 |
| Aiba, K; Hagino, T; Hirano, A; Kawase, K; Kobayashi, M; Kobayashi, T; Okawa, Y; Shioya, H; Sugiyama, K; Uno, S; Usui, N; Yoshida, K | 1 |
| Saeki, T; Takashima, S | 1 |
| Enomoto, T; Handa, K; Hayashi, K; Kuranami, M; Sengoku, N; Watanabe, M | 1 |
| Cals, L; Juin, P; Nouyrigat, P; Pedinelli, FJ; Valenza, B | 1 |
| Androulakis, N; Christophilakis, Ch; Georgoulias, V; Kalbakis, K; Kouroussis, Ch; Malamos, N; Mavroudis, D; Milaki, G; Polyzos, A; Varthalitis, I | 1 |
| Chen, LM; Ding, Y; Fu, LW; Gu, LQ; Liang, YJ; Shi, Z; Wang, XW; Yang, XP | 1 |
| Aapro, M; Bodrogi, I; Chan, S; Cocquyt, V; Crown, J; Di Leo, A; Durbecq, V; Friedrichs, K; Isola, J; Korec, S; Larsimont, D; Leroy, JY; Lesperance, B; Murray, E; Paesmans, M; Piccart, MJ; Pinter, T; Simmonds, P; Von Minckwitz, G; Walpole, E | 1 |
| Castellana, MA; De Sio, L; Fanelli, M; Ferraù, F; Gasparini, G; Gattuso, D; Lo Vullo, S; Lorusso, V; Mariani, L; Morabito, A; Priolo, D; Sarmiento, R; Stani, SC; Vitale, S | 1 |
| Doliny, P; Gomez-Fernandez, C; Hurley, J; Lee, YJ; Powell, J; Reis, I | 1 |
| Anderson, CM; Barrett, B; Dorr, VJ; Lyss, AP; Malhotra, V; Perry, MC; Reynolds, M; Westgate, S | 1 |
| Akçay, S; Eyüboglu, FO; Karacan, O; Ozyilkan, O | 1 |
| El-Sheemy, M; Eremin, J; Eremin, O; Griffiths, PA; Marshall, C | 1 |
| Asaga, T; Fukuda, M; Fukuma, E; Hamaguchi, Y; Inaba, M; Ishida, K; Ishikawa, T; Ishiyama, A; Katayama, K; Shimada, H; Shimizu, S; Suda, T; Tokuda, Y | 1 |
| Besova, NS; Gorbunova, VA | 1 |
| Blohmer, JU; Dieing, A; Eggemann, H; Elling, D; Heilmann, V; Krocker, J; Michniewicz, K; Possinger, K; Schmid, P; Schulz, CO; Sezer, O | 1 |
| Arizcun, A; Cruz, JJ; Fonseca, E; Gómez-Bernal, A; Martín, G; Martín, T; Olaverri, A; Rodríguez, CA; Sánchez, P | 1 |
| Akazawa, K; Inoue, T; Kamigaki, S; Kim, SJ; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Ueda, S; Yanagisawa, T | 1 |
| Hamada, K; Kakihara, Y; Kubota, K; Sawada, T; Tagaya, N | 1 |
| Nortier, JW; Rodenburg, CJ; Slee, PH; van Bochove, A | 1 |
| Casorzo, L; Montemurro, F; Redana, S; Risio, M | 1 |
| Caduff, R; Pestalozzi, B; Varga, Z | 1 |
| Babu, KG; Bapsy, PP; Girish, MH; Prabhash, K; Ravi, S | 1 |
| Kim, SJ; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y | 1 |
| Ando, A; Iwao-Koizumi, K; Kato, K; Kim, SJ; Maeda, E; Matoba, R; Miyoshi, Y; Noguchi, S; Ueno, N | 1 |
| Domchek, SM; Fox, K; Hwang, WT; Schwartz, J | 1 |
| Bastert, G; Hamerla, R; Huober, J; Lichter, P; Schneeweiss, A; Wallwiener, D | 1 |
| Allred, DC; Chamness, GC; Chang, JC; Elledge, R; Gutierrez, MC; Hilsenbeck, SG; Kalidas, M; Lewis, MT; Mohsin, S; O'Connell, P; Osborne, CK; Tham, YL; Tsimelzon, A; Wong, H; Wooten, EC | 1 |
| Barajas-Figueroa, LJ; Carroll, RR; Neumann, TA; Schwartzberg, LS; Tjulandin, SA; Vogel, CL; Wiens, BL; Wojtukiewicz, MZ | 1 |
| Castells, M; Feldweg, AM; Lee, CW; Matulonis, UA | 1 |
| Bang, SM; Cho, EK; Lee, JH; Lee, YD; Park, SH; Shin, DB | 1 |
| Griffith, KA; Kleer, CG; Pu, RT; Schott, AF; Sturtz, DE | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| DeZarraga, F; Doliny, P; Gomez, C; Hurley, J; Powell, J; Reis, I; Silva, O; Velez, P; Welsh, C | 1 |
| Esmaeli, B | 1 |
| Ando, M; Fujiwara, Y; Katsumata, N; Kouno, T; Matsumoto, K; Shimizu, C; Takeuchi, M; Tokunaga, S; Uno, H; Yamanaka, Y; Yonemori, K | 1 |
| Abdellatif, M; Chandra, R; Korah, R; Najmi, S; Wieder, R | 1 |
| Apostolikas, N; Barbounis, V; Chrissohoou, M; Demiri, M; Efremidis, AP; Koumakis, G; Panopoulos, C; Vassilomanolakis, M | 1 |
| Ando, J; Asaga, T; Fujii, H; Kimura, M; Kurosumi, M; Sano, M; Tabei, T; Yamamoto, N | 1 |
| Bokemeyer, C; Lipp, HP | 1 |
| Abenhardt, W; Brudler, O; Deutsch, G; Dorn, B; Heinemann, V; Jackisch, C; Kentenich, C; Leinung, S; Mair, W; Malekmohammadi, M; Papke, J; Stamp, J; Stauch, M; Stemmler, J; Vehling-Kaiser, U | 1 |
| Blotta, S; Costanzo, F; D'Andrea, E; Eramo, OP; Masciari, S; Migale, L; Montagna, M; Palmieri, C; Quaresima, B; Tagliaferri, P; Tassone, P; Venuta, S | 1 |
| Fossella, F; Hortobagyi, G; Montero, A; Valero, V | 1 |
| Chisholm, GB; Cruz, AB; Kahlenberg, MS; Learn, PA; McNutt, M; Pollock, BH; Rousseau, DL; Sharkey, FE; Yeh, IT | 1 |
| Blohmer, JU; Caputo, A; Costa, SD; du Bois, A; Eidtmann, H; Gerber, B; Hilfrich, J; Jackisch, C; Kaufmann, M; Lampe, D; Merkle, E; Raab, G; Schütte, M; von Minckwitz, G | 1 |
| Anderson, S; Bear, HD; Brown, A; Caldwell, CB; Fisher, B; Julian, T; Mamounas, EP; Mikkelson, WM; Miller, B; Robidoux, A; Smith, R; Soran, A; Sovan, A; Stauffer, JS; Theoret, H; Walker, AP; Wickerham, DL; Wolmark, N | 1 |
| Berman, AW; Brufsky, A; Fojo, T; Lee, JJ; Low, JA; Mannan, N; Poruchynsky, MS; Steinberg, SM; Swain, SM; Wedam, SB; Yang, SX | 1 |
| Allen, J; Hade, EM; Mrózek, E; Rhoades, CA; Shapiro, CL | 1 |
| Hamel, K; Hamolsky, D; Melisko, M; Topp, KS; Wampler, MA | 1 |
| Akiyama, F; Hisamatsu, K; Iwata, H; Kaise, H; Kuroi, K; Kurosumi, M; Kusama, M; Masuda, N; Nakamura, S; Ohno, S; Sato, Y; Shin, E; Takatsuka, Y; Toi, M; Tsuda, H; Yamazaki, K | 1 |
| Cameron, DA; Coleman, RE; Crown, J; Earl, H; Evans, TR; Foster, E; Gallagher, CJ; Highley, M; Hutcheon, AW; Jones, AL; Leonard, RC; Mansi, JL; Perren, T; Quigley, M; Yellowlees, A | 1 |
| Haites, NE; Heys, SD; Hutcheon, AW; McDonald, SL; Moir, SE; Schofield, AC; Stevenson, DA | 1 |
| Kosmas, Ch; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdaridis, D; Xynotroulas, J | 1 |
| Hornberger, J; Jamieson, C; Jones, S; Maraninchi, D; Martín, M; McKendrick, J; Miles, D; O'Shaughnessy, J; Twelves, C; Verma, S | 1 |
| Hughes, BG; Stuart-Harris, R | 1 |
| Bosquet, A; Grandjean, M; Grasland, A; Rist, S; Vinceneux, P | 1 |
| Bourstyn, E; Cuvier, C; de Roquancourt, A; Espié, M; Giacchetti, S; Hocini, H | 1 |
| Magné, N; Milano, G | 1 |
| Bennett, M; Huang, X; Thorpe, PE | 1 |
| Bachelot, T; Brain, EG; Combe, M; Extra, JM; Eymard, JC; Fourme, E; Graic, Y; Kirscher, S; Noguès, C; Rouëssé, J; Serin, D | 1 |
| Erban, J; Gradishar, WJ; Jahanzeb, M; Limentani, SA; Olsen, SR; Swain, SM; Tsai, KT; Wedam, SB | 1 |
| Bosch, CA; Hannemann, J; Loo, C; Oosterkamp, HM; Rodenhuis, S; Rutgers, EJ; van de Vijver, MJ; Velds, A; Wessels, LF | 1 |
| Filatova, LV; Gershanovich, ML; Semiglazova, TIu | 1 |
| Engels, FK; Verweij, J | 1 |
| Antón, A; Chan, S; Cognetti, F; Conte, P; Extra, JM; Green, M; Grimes, D; Kennedy, J; Lluch, A; Maraninchi, D; Marty, M; Mauriac, L; Mayne, K; O'Byrne, K; Snyder, R; Tubiana-Hulin, M; Ward, C | 1 |
| Fujii, K; Fujino, S; Higashide, S; Hori, T; Inamoto, T; Kan, N; Lee, CJ; Maruhashi, K; Mise, K; Mitsumori, M; Nishimura, S; Okamoto, M; Okamura, T; Sawai, S; Takemoto, Y; Yamauchi, A | 1 |
| Carboni, R; Caristi, N; Chiofalo, G; La Torre, F; Mafodda, A; Maisano, R; Mare, M; Picciotto, M | 1 |
| Gasparini, G; Longo, R; Morabito, A; Torino, F | 1 |
| Accurso, A; Cancello, G; Caputo, F; De Laurentiis, M; De Placido, S; Esposito, A; Giordano, A; Giuliano, M; Malorni, L; Montagna, E; Pennacchio, R; Silvestro, L; Zinno, L | 1 |
| Al-Tweigeri, T; Blitz, S; Chap, L; Coleman, R; Colwell, B; Fornander, T; Guastalla, JP; Guevin, R; Hainsworth, J; Howell, A; Hugh, J; Jacobs, P; Juhos, E; Loret, C; Mackey, J; Martin, M; Modiano, M; Murawsky, M; Pawlicki, M; Pienkowski, T; Pinter, T; Prady, C; Provencher, L; Riva, A; Rodriguez-Lescure, A; Rupin, M; Tang, SC; Tomiak, E; Vinholes, J; Vogel, C; Walde, D; Weaver, C | 1 |
| Blomqvist, C; Larsson, R; Nygren, P; Villman, K | 1 |
| Fruehauf, JP; Jakowatz, JG; Kong, KM | 1 |
| Battelli, N; Boccetti, T; Bonsignori, M; Marcucci, F; Massacesi, C; Pilone, A; Rocchi, MB | 1 |
| Brown, I; Heys, SD; Schofield, AC; Shalli, K | 1 |
| Alexopoulos, A; Apostolikas, N; Ardavanis, A; Karamouzis, MV; Papadopoulou, A; Rigatos, G | 1 |
| Chang, EL; Tu, AH | 1 |
| Badve, S; Campbell, RA; Kumar, S; Mehrotra, S; Murry, DJ; Nakshatri, H; Roman, Y; Sadaria, MR; Sheridan, C; Shortle, NH; Sweeney, CJ | 1 |
| Gligorov, J; Nabholtz, JM | 3 |
| Bartz, B; Carson, PL; Fowlkes, JB; Gordon, SP; Johnson, TD; LeCarpentier, GL; Pai, D; Roubidoux, MA; Schott, AF | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Longhi, S; Munzone, E; Nolè, F; Pagani, O; Ruggeri, M; Sessa, C; Thürlimann, B | 1 |
| Carlson, RW; Gradishar, WJ; Jovanovic, B; Khan, S; Malik, U; Morrow, M; O'Regan, RM; Sparano, JA; Staradub, V; Von Roenn, JH | 1 |
| Engels, FK; Mathot, RA; Sparreboom, A; Verweij, J | 1 |
| Bang, YJ; Ham, HS; Hong, YS; Im, SA; Im, YH; Kim, KW; Kim, SB; Kim, TY; Kim, WK; Lee, J; Lee, KE; Lee, KH; Lee, MA; Lee, MH; Lee, NS; Lee, SN; Park, HS; Park, YH; Seo, JH; Song, HS | 1 |
| Barni, S; Bria, E; Carlini, P; Cognetti, F; Cuppone, F; Ferretti, G; Frontini, L; Garufi, C; Milella, M; Nisticò, C; Terzoli, E; Vanni, B | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; D'Aniello, R; De Rosa, V; Di Bonito, M; Frasci, G; Giordano, R; Lapenta, L; Thomas, R; Vallone, P | 1 |
| Cajozzo, M; Comella, G; Condemi, G; Danova, M; De Cataldis, G; Farris, A; Ferraù, F; Filippelli, G; Iannitto, E; Leonardi, V; Macaluso, MC; Mangiameli, A; Massidda, B; Misino, A; Palmeri, L; Palmeri, S; Spada, S; Vaglica, M | 1 |
| Dieing, A; Eggemann, H; Elling, D; Flath, B; Hauptmann, S; Heilmann, V; Jehn, C; Krocker, J; Kümmel, S; Lehenbauer-Dehm, S; Michniewicz, K; Possinger, K; Schmid, P; Schulz, CO; Wischnewsky, MB | 1 |
| Bourbouloux, E; Campone, M; Fumoleau, P; Kerbrat, P; Roché, H | 1 |
| Broglio, KR; Buzdar, AU; Cristofanilli, M; Hanrahan, EO; Hortobagyi, GN; Kau, SW; Rivera, E; Theriault, RL; Valero, V; Yin, G | 1 |
| Chen, J; Ehrlichova, M; Gut, I; Kovar, J; Kuznetsova, LV; Ojima, I; Pepe, A; Truksa, J; Vaclavikova, R | 1 |
| Ahmed, F; Ali, S; Kucuk, O; Li, Y; Philip, PA; Sarkar, FH | 1 |
| Blohmer, JU; Elling, D; Heinrich, G; Kohls, A; Kümmel, S; Lichtenegger, W; Paepke, S; Schwarz, M; Thomas, A; Wetzel, A | 1 |
| Alliot, C | 1 |
| Ahn, JH; Kang, YK; Kim, SB; Kun Kim, W; Lee, JS; Sohn, HJ | 1 |
| Hitzl, W; Peintinger, F; Prokop, E; Reitsamer, R | 1 |
| Budd, GT; Erban, J; Hutchins, L; Jones, SE; Laufman, L; Lower, E; Mennel, R; Meyers, ML; Olsen, S; Overmoyer, B; Pritchard, KI; Ravdin, PM; Richards, D; Sundaram, S; Urba, WJ | 1 |
| Addo, FK; Cole, JT; Fitch, TR; Flynn, PJ; Ingle, JN; Mailliard, JA; Perez, EA; Suman, VJ; Veeder, MH; Walsh, DJ | 1 |
| Borgia, F; Guarneri, C; Guarneri, F; Vaccaro, M | 1 |
| Androulakis, N; Georgoulias, V; Kalykaki, A; Kentepozidis, N; Kouroussis, Ch; Saridaki, Z; Spiridonakou, S; Vamvakas, L; Xiropoulou, E | 1 |
| Booser, D; Esparza-Guerra, L; Hortobagyi, G; Montero, A; Murray, J; Rosales, M; Valero, V | 1 |
| Ahluwalia, MS; Daw, HA | 1 |
| Noronha, V | 1 |
| Balasis, M; Bali, P; Bhalla, K; Fiskus, W; Pranpat, M; Richon, V; Rocha, K; Swaby, R; Wang, HG; Yamaguchi, H | 1 |
| Baker, LH; Griffith, KA; Hayes, DF; Helvie, MA; Hunt, KA; Kleer, CG; Murray, S; Newman, LA; Paramagul, C; Pierce, LJ; Roubidoux, MA; Schott, AF | 1 |
| Hahn, M; Lauschner, I; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; von Fournier, D | 1 |
| Allen, J; Burak, W; Farrar, W; Hauger, M; Kendra, K; Orlowski, RZ; Povoski, SP; Ramaswamy, B; Rhoades, C; Shapiro, CL; Somasundaram, S; Yee, L; Young, D | 1 |
| Erkisi, M; Kara, IO; Sahin, B | 1 |
| Disilvestro, P; Dizon, DS; Gordinier, ME; Granai, CO; Legare, RD; Miller, J; Moore, R; Pires, L; Rojan, A; Schwartz, J | 1 |
| Giatromanolaki, A; Koukourakis, MI; Liberis, V; Manavis, J; Simopoulos, C; Sivridis, E | 1 |
| Le Pen, C; Maurel, F; Priol, G | 1 |
| Arzumanov, AS; Bozhok, AA; Ivanova, OA; Kletcel', AE; Semiglazov, VF; Semiglazov, VV | 1 |
| Gillies, RJ; Gray, H; Morse, DL; Payne, CM | 1 |
| Senior, K | 1 |
| G Oumlker, E; Rodenhuis, S | 1 |
| Eniu, A; Palmieri, FM; Perez, EA | 1 |
| Alexopoulos, A; Ardavanis, A; Karamouzis, M; Orfanos, G; Rigatos, G; Scorilas, A; Tryfonopoulos, D | 1 |
| Allred, DC; Chamness, GC; Chang, JC; Elledge, RM; Gomez, LF; Gutierrez, MC; Hilsenbeck, SG; Mohsin, S; Osborne, CK; Tham, YL; Weiss, H | 1 |
| Ambrózay, E; Boross, G; Gyánti, R; Hajnal, L; Lorincz, M; Maráz, R; Markó, L; Svébis, M; Szucs, M; Vizhányó, R | 1 |
| Crown, J; Mackey, J; Martin, M; Vogel, C | 1 |
| Douek, M; Tobias, J | 1 |
| Ellis, PA; Ring, AE | 1 |
| Bighin, C; Cappuzzo, F; Del Mastro, L; Durando, A; Lambiase, A; Monfardini, S; Nicoletto, O; Olmeo, N; Puglisi, F; Venturini, M | 1 |
| Fenton, C; Lyseng-Williamson, KA | 1 |
| Amano, S; Enomoto, K; Kashio, M; Kitajima, A; Matsuo, S; Negishi, N; Sakamoto, A; Sakurai, K; Suzuki, M; Tani, M | 1 |
| Doggrell, SA | 1 |
| Kato, K; Kim, SJ; Miyoshi, Y; Nakamura, H; Noguchi, S; Taguchi, T; Tamaki, Y; Yodoi, J | 1 |
| Arnould, L; Causeret, S; Chollet, P; Coudert, BP; Feutray, S; Fumoleau, P; Garnier, J; Mery-Mignard, D; Misset, JL; Moluçon, C; Moreau, L; Tubiana, N; Vanlemmens, L; Weber, B | 1 |
| Cooper, BW; Overmoyer, BA; Parry, MP; Pham, HT; Radivoyevitch, T; Samuels, JR; Shenk, RR; Silverman, P | 1 |
| Jida, M; Kubo, M; Maeda, H; Miyatani, K; Mizuta, M; Shirakawa, K; Sogabe, O; Udaka, T; Yamane, M | 1 |
| Fumoleau, P; Levy, C | 1 |
| Antón, A; Arcusa, A; Bayo, JL; Calvo, L; Carrasco, E; Florián, J; Martín-Richard, M; Mayordomo, JI; Pelegrí, A; Vásquez, S; Virizuela, J | 1 |
| Beam, CA; Bowman, T; Cantor, A; Cox, C; Diaz, N; Eweis, I; Garcia, R; Gritsko, T; Jove, R; Lee, JH; Livingston, S; Minton, S; Muro-Cacho, CA; Seijo, E; Sullivan, D; Wloch, M | 1 |
| Fujimura, M; Inoue, K; Isobe, K; Komagata, H; Sakai, H; Shirai, T; Tabei, T; Yoneda, S | 1 |
| Arnould, L; Benoit, L; Bertheau, P; Bonnetain, F; Cabaret, V; Coudert, B; Fermeaux, V; Garnier, J; Gelly, M; Jeannin, JF; Migeon, C; Penault-Llorca, F | 1 |
| Baltas, D; Filipowicz, I; Hoffmann, G; Kolotas, C; Kontova, M; Kuner, RP; Kurek, R; Martin, T; Pollow, B; Roddiger, SJ; Rogge, B; Zamboglou, N | 1 |
| Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N | 1 |
| Canney, P; Evans, V; Fraser, G; Gray, M; Kazmi, A; Kerr, J; Mano, MS | 1 |
| Asproudis, I; Gorezis, S; Peschos, D; Psilas, K; Stefaniotou, M | 1 |
| Dohden, K; Hattori, M; Hayashi, H; Hosokawa, O; Kaizaki, Y; Kiya, T; Morishita, M; Morita, M; Ohta, K | 1 |
| Akamatsu, H; Imazu, Y; Koshida, Y; Motegi, K; Murayama, T; Ohyama, R; Toeda, H; Toriumi, F; Yoneyama, K | 2 |
| Alanko, T; Asola, R; Bono, P; Elomaa, I; Flander, M; Helle, L; Hemminki, A; Ingalsuo, S; Isola, J; Jääskeläinen, AS; Joensuu, H; Johansson, K; Jyrkkiö, S; Kaleva-Kerola, J; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Pajunen, M; Rauhala, M; Salminen, T; Tarkkanen, M; Turpeenniemi-Hujanen, T; Utriainen, T | 1 |
| Dang, CT | 1 |
| Muss, HB; Perez, E | 1 |
| Akiyama, F; Hisamatsu, K; Iwata, H; Kaise, H; Kuroi, K; Kurozumi, M; Kusama, M; Masuda, N; Nakamura, S; Ohnoa, S; Sato, Y; Shin, E; Takatsuka, Y; Toi, M; Tsuda, H; Yamazaki, K | 1 |
| Clemons, M; Gainford, MC | 1 |
| Ford, HE; Hall, M; Harries, M; Johnston, SR; Makris, A; Miles, DW; Miller, L; Smith, IE; Yap, YS | 1 |
| Cheung, PS; Epstein, RJ; Leung, TW | 1 |
| Doliny, P; Gomez-Fernandez, C; Hurley, J; Pauletti, G; Pegram, MD; Powell, JE; Reis, I; Silva, O; Slamon, DJ; Velez, P | 1 |
| Brufsky, AM; Erban, JK; Jahanzeb, M; Lewis, D; Limentani, SA | 2 |
| Asmar, L; Ilegbodu, D; Khandelwal, P; O'Shaughnessy, JA; Pluenneke, R; Sternberg, J | 1 |
| Aramendía, JM; Fernández-Hidalgo, O; García-Manero, M; López, G; Nieto, Y; Santisteban, M | 1 |
| Anderson, S; Bear, HD; Brown, AM; Fisher, B; Geyer, CE; Kahlenberg, MS; Mamounas, EP; Margolese, R; Paik, S; Robidoux, A; Smith, RE; Soran, A; Wickerham, DL; Wolmark, N | 1 |
| Benner, A; Brors, B; Eils, R; Hahn, M; Kramer, H; Lichter, P; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; Tews, B; Thuerigen, O; Toedt, G; Warnat, P | 1 |
| Botti, G; Chiodini, P; D'Aiuto, G; De Maio, E; de Matteis, A; Di Maio, M; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Normanno, N; Nuzzo, F; Pacilio, C; Perrone, F; Rossi, E | 1 |
| Aumiller, J | 1 |
| Aldaz Pastor, A; Aramendia Beitia, JM; Arrobas Velilla, J; Giraldez Deiró, J; Zufía López, L | 1 |
| Bardia, A; Goetz, MP; Loprinzi, CL | 1 |
| Bria, E; Carlini, P; Ciccarese, M; Cognetti, F; Cuppone, F; Giannarelli, D; Milella, M; Natoli, G; Nistico, C; Terzoli, E | 1 |
| Li, LS; Song, HF; Song, ST; Sun, JZ; Zhao, H; Zhu, JH | 1 |
| Desai, K; Einstein, M; Fields, A; Goel, S; Goldberg, G; Macapinlac, M; Mani, S; Martin, R; Volterra, F; Wadler, S; Wong, B | 1 |
| Bianco, AR; Caputo, F; Catalano, G; Ciardiello, F; Colantuoni, G; De Laurentiis, M; De Placido, S; De Vita, F; Diadema, MR; Gridelli, C; Orditura, M; Palmieri, G; Tortora, G; Troiani, T | 1 |
| Fukushima, M; Ikeda, T; Kitajima, M; Kubota, T; Ohmiya, H; Suto, A; Takeshita, T | 1 |
| Puhalla, S; Ramaswamy, B | 1 |
| Allen, J; Chen, HX; Dodley, A; Eckhardt, SG; Elias, AD; Hauger, M; Kelbick, NT; Kendra, K; Morrow, M; Ramaswamy, B; Rhoades, C; Shapiro, CL | 1 |
| Chang, ES; Han, S; Kang, SS; Kim, JR; Kim, SB; Lim, SH; Noh, WC; Paik, NS; Park, HS | 1 |
| Ando, J; Asaga, T; Fujii, H; Inoue, K; Kimura, M; Kurosumi, M; Sano, M; Sato, N; Tabei, T; Yamamoto, N | 1 |
| Chow, LW; Yip, AY | 1 |
| To, H | 1 |
| Agostara, B; Gebbia, V; Laudani, A; Leonardi, V; Pepe, A; Savio, G; Scianna, C | 1 |
| Clavarezza, M; Del Mastro, L; Venturini, M | 1 |
| Dang, C; Hudis, C | 2 |
| Adrover, E; Antón, A; Arcusa, A; Calvo, L; del Prado, PM; Fernandez-Chacón, C; Grosse, R; Iglesias, L; Isla, D; Lluch, A; López-Vega, JM; Martín, M; Mel, JR; Muñoz, M; Ramos, M; Rodríguez-Lescure, A; Roset, M; Ruiz, A; Seguí, MA; Zaluski, J | 1 |
| Schaerlig, E | 1 |
| Fujiuchi, N; Okubo, K; Saeki, T; Takeuchi, H | 1 |
| Saito, Y; Suzuki, Y; Tokuda, Y | 1 |
| Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K | 1 |
| Stevenson, B; Tan, TH; Yip, D | 1 |
| Crom, D; Moore, K | 1 |
| Smith, IE | 1 |
| Allen, J; Hauger, M; Kendra, K; Merriman, N; Moore, T; Mrozek, E; Nadella, P; Ramaswamy, B; Rhoades, CA; Shapiro, CL; Villalona-Calero, M; Watson, H; Young, D | 1 |
| Burton, GV; Lewis, D; Potluri, V | 1 |
| Arlen, PM; Gulley, JL; Pazdur, M; Rauckhorst, M; Skarupa, L | 1 |
| Noguchi, S | 1 |
| Amadori, D; Cecconetto, L | 1 |
| Kato, K; Noguchi, S; Ooe, A | 1 |
| Cao, Z; Jiang, BH; Karna, P; Peng, XH; Yang, L; Zhou, M | 1 |
| Arun, B; Booser, DJ; Broglio, K; Cristofanilli, M; Guerra, L; Hortobagyi, GN; Krishnamurthy, S; Menander, K; Valero, V; Van Wart Hood, J | 1 |
| Adinin, R; Amin, S; Arbuckle, R; Banay, R; Do, KA; Esmaeli, B; Rivera, E; Valero, V | 1 |
| Berman, A; Cox, MC; Denduluri, N; Figg, WD; Lee, J; Low, J; Permenter, MG; Petros, WP; Price, DK; Sparreboom, A; Swain, SM; Walshe, J | 1 |
| Bauernhofer, T; Dandachi, N; Holub, R; Samonigg, H; Schippinger, W | 1 |
| Arai, H; Fukuda, Y; Kagawa, N; Komekami, Y; Matsugu, Y; Nakahara, H; Sasada, T; Tanaka, T; Yamashita, M | 1 |
| Cecere, F; Cuello, M; Felip, E; Reguart, N; Rosell, R; Santarpia, M; Taron, M | 1 |
| Ando, M; Katsumata, N; Mizuno, T; Mukai, H; Shimizu, C; Watanabe, T | 1 |
| Amat, S; Chollet, P; Coudert, B; Curé, H; Dauplat, J; Delva, R; Leduc, B; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F | 1 |
| Curiel, DT; Dent, P; Fisher, PB; Gilfor, D; Grant, S; Hagan, MP; Hanna, D; Hawkins, W; Park, MA; Yacoub, A | 1 |
| Barak-Wigler, N; Bexon, AS; Chan-Navarro, CA; Gorbounova, V; Harker, WG; Leonard, R; Maraninchi, D; McKendrick, JJ; O'Shaughnessy, J; Twelves, C; Vukelja, S | 1 |
| James, J; Miller, KD; Murry, DJ; Sidor, C; Sledge, GW; Storniolo, AM; Treston, AM | 1 |
| Blohmer, JU; Dan Costa, S; du Bois, A; Eidtmann, H; Gerber, B; Hilfrich, J; Jackisch, C; Kaufmann, M; Loibl, S; Petrich, S; Raab, G; von Minckwitz, G | 1 |
| Barrett-Lee, P; Grieve, R; Houston, S; Howell, A; Johnston, S; Leonard, R; Malinovszky, K; O'Reilly, S; Verrill, M; Wardley, A | 1 |
| Ahr, A; Gätje, R; Holtrich, U; Karn, T; Kaufmann, M; Kissler, S; Kourtis, K; Loibl, S; Munnes, M; Rody, A; Ruckhäberle, E; Solbach, C; von Minckwitz, G | 1 |
| Bashir, T; Budman, DR; Mandelblat, J | 1 |
| Abrams, J; Biernat, L; Bouwman, D; Flaherty, L; LoRusso, P; Philip, PA; Simon, M; Stephens, D; Thatai, LC; Vereeke, K; Vishnubhotla, P | 1 |
| Cold, S; Groult, V; Harvey, V; Jakobsen, E; Mouridsen, H; Murawsky, M; Robinson, BA; Semiglazov, V; Voznyi, E | 1 |
| Ando, J; Asaga, T; Fujii, H; Honma, K; Inoue, K; Kimura, M; Kurosumi, M; Sano, M; Sato, N; Suemasu, K; Tabei, T; Takei, H; Yamamoto, N; Yanagita, Y | 1 |
| Angellier, E; Berdah, JF; Buyse, M; Fabbro, M; Greget, S; Herait, P; Jehl, V; Laplaige, P; Piedbois, P; Priou, F; Serin, D; Teissier, E; Valenza, B | 1 |
| Burla, ML; Dauphine, CE; Gonzalez, KD; Isaac, NM; Kaufmann, P; Rosing, D; Vargas, HI; Vargas, MP | 1 |
| Altorjai, G; Bartsch, R; Gnant, M; Haid, A; Hussian, D; Jakesz, R; Lang, A; Pluschnig, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Baker, SD; Caravelli, J; Cutchall, K; D'Andrea, G; Fleming, MT; Gomez, J; Hudis, C; Hurria, A; Kelly, WK; Kris, MG; Miller, VA; Norton, L; Panageas, K; Scher, HI; Yeung, H | 1 |
| Alexandrescu, DT; Vaillant, J; Wiernik, PH | 1 |
| Berton-Rigaud, D; Bourbouloux, E; Bouriel, C; Bridji, B; Campion, L; Campone, M; Chatal, JF; Clouet, M; Delecroix, V; Devillers, A; Doutriaux, I; Ferrer, L; Garin, E; Kerbrat, P; Resche, I; Ricaud, M; Rouquette, S; Rousseau, C; Sagan, C | 1 |
| Amboldi, N; Ciomei, M; Croci, V; Giavarini, R; Pesenti, E; Stellari, F | 1 |
| Blanc-Fournier, C; Chasle, J; Guedin, P; Lacroix, J | 1 |
| Hernández-Vargas, H; Moreno-Bueno, G; Palacios, J | 2 |
| Hata, Y; Taguchi, K; Takahashi, H; Takahashi, M; Tamura, M; Todo, S; Watanabe, K | 1 |
| Asselain, B; Bonneterre, J; Campone, M; Canon, JL; Delozier, T; Eichler, F; Ferrero, JM; Fumoleau, P; Genève, J; Goudier, MJ; Kerbrat, P; Martin, AL; Monnier, A; Roché, H; Serin, D; Soulié, P; Spielmann, M; Symann, M; Viens, P; Vindevoghel, A | 1 |
| Arslan, M; Demiray, M; Ercan, I; Evrensel, T; Gokgoz, S; Manavoglu, O; Saraydaroglu, O; Ulukaya, EE | 1 |
| Ates, U; Bilir, A; Oktem, G; Omay, SB; Selvi, N; Uysal, A; Vatansever, S; Yurtseven, ME | 1 |
| Anthony, SP; Asmar, L; Blum, JL; Boehm, KA; Bordelon, JH; Holmes, FA; Hyman, WJ; Jones, SE; Khandelwal, P; Kirby, R; McIntyre, KJ; Mennel, RG; Meyer, WG; Negron, AG; O'Shaughnessy, JA; Pippen, JE; Richards, DA; Sandbach, J; Savin, MA; Vukelja, S | 1 |
| Coombes, RC; Fayaz, A; Heller, W; Lowdell, C; Mazhar, D; Palmieri, C; Phillips, R; Shousha, S; Sinnett, HD; Ward, R | 1 |
| Abrial, C; Achard, JL; Chollet, P; Cure, H; Durando, X; Ferrière, JP; Gimbergues, P; Leheurteur, M; Mouret-Reynier, MA; Van Praagh, I | 1 |
| Feng, SQ; Jiang, ZF; Liu, F; Song, ST; Sun, JZ; Zhang, SH | 1 |
| Gao, YJ; Guan, XQ; Li, EX; Liu, JW; Nan, KJ; Sheng, LJ; Song, SP; Sun, Y; Wang, DL; Wang, XW; Wang, ZP; Wang, ZX; Yu, XJ; Zhang, MH; Zhang, XR | 1 |
| Wang, JY; Xu, BH; Yuan, P; Zhao, LM | 1 |
| Abdel-Khalek, Z; Bitar, N; Charafeddine, M; Chehal, A; Dandashi, A; Dheiny, M; El-Saghir, NS; Jalloul, R; Khalifeh, MJ; Otrock, ZK; Shamseddine, AI; Wehbeh, M; Yassine, HR | 1 |
| Feng, FY; Guan, ZZ; Guo, Y; Hu, XH; Liu, DG; Peng, RJ; Tang, GD; Xiong, JP; Zhao, HY | 1 |
| Amathieu, R; Dhonneur, G; Fessenmeyer, C; Tual, L | 1 |
| Chang, HK; Chen, JS; Liaw, CC; Lin, YC; Wang, HM; Yang, TS | 1 |
| Iwama, T; Karasawa, K; Kato, K; Sato, S; Sato, T; Takahashi, T; Tsunozaki, H | 1 |
| Suzuki, M | 1 |
| Ando, M; Matsuyama, Y; Ooi, Y; Rai, Y; Sagara, Y; Takahama, T; Tamada, S; Tsuchimochi, S | 1 |
| Marsh, S; McLeod, HL | 1 |
| Day, S; Galons, JP; Gillies, RJ; Jennings, DL; Morse, DL; Payne, CM; Xia, G | 1 |
| Ayla, S; Bilir, A; Goksel, G; Oktem, G; Saydam, G; Uysal, A; Yavasoglu, A | 1 |
| Miyoshi, Y; Morimoto, K; Noguchi, S; Taguchi, T; Takahashi, Y; Tamaki, Y | 1 |
| Christodoulou, C; Economopoulos, T; Efstratiou, I; Fountzilas, G; Gogas, H; Papadimitriou, C; Papakostas, P; Pectasides, D; Skarlos, D; Timotheadou, E | 1 |
| Andrade, JM; Marana, HR; Ribeiro-Silva, A; Tiezzi, DG; Tiezzi, MG; Zola, FE | 1 |
| Cho, JY; Lew, W; Roh, MR | 1 |
| Tilstone, C | 1 |
| Akehi, S; Gangi, J; Honda, K; Kurokawa, T; Masuda, J; Nomoto, M; Okada, K; Sagawa, T; Soga, H; Tashiro, H; Watanabe, R; Watanabe, Y; Yasuoka, Y | 1 |
| Endo, K; Fujii, K; Ikeda, T; Mashino, K; Ninomiya, M; Sakata, H; Shibahara, K; Tashiro, H | 1 |
| Angelucci, D; Carella, C; Cianchetti, E; De Tursi, M; Ficorella, C; Grassadonia, A; Grossi, S; Iacobelli, S; Natoli, C; Ricevuto, E; Rispoli, AI; Tinari, N; Zilli, M | 1 |
| Aapro, M; Cardoso, F; Chan, S; Desmedt, C; Di Leo, A; Durbecq, V; Isola, J; Larsimont, D; Paesmans, M; Perren, T; Piccart, MJ; Sotiriou, C; Tanner, M | 1 |
| Gassiamis, A; Karabelis, A; Kosmas, C; Malamos, N; Mylonakis, N; Polyzos, A; Tsakonas, G; Tsavaris, N | 1 |
| Jiang, DQ; Li, S; Long, F; Xu, H; Zhang, B; Zhang, Q; Zhao, L | 1 |
| Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM | 1 |
| Gaetje, R; Holtrich, U; Karn, T; Kaufmann, M; Kissler, S; Loibl, S; Minckwitz, GV; Munnes, M; Rody, A; Ruckhäberle, E; Solbach, C | 1 |
| Alvarez, L; Baehner, FL; Baker, J; Chamness, GC; Chang, JC; Clark-Langone, K; Gray, T; Gutierrez, MC; Hackett, JR; Hilsenbeck, SG; Jeong, J; Liu, ML; Makris, A; Mohsin, S; Osborne, CK; Sexton, K; Shak, S | 1 |
| Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A | 1 |
| Budryk, M; Byrski, T; Gronwald, J; Grzybowska, E; Huzarski, T; Lubinski, J; Mierzwa, T; Narod, SA; Siolek, M; Stawicka, M; Szwiec, M; Wiśniowski, R | 1 |
| Ahn, JS; Cho, EY; Choi, YL; Han, BK; Im, YH; Kim, HJ; Kim, JH; Ko, YH; Lee, J; Lee, SH; Lim, HY; Nam, SJ; Park, YS; Yang, JH | 1 |
| Bauknecht, T; Goerke, K; Guerrero, A; Hahn, M; Lauschner, I; Lichter, P; Manikhas, AG; Mansouri, K; Marmé, F; Ruiz, A; Sánchez-Rovira, P; Schneeweiss, A; Seguí, MA; Sinn, HP; Sohn, C; Wacker, J; Wolf, M | 1 |
| Galid, A; Gnant, M; Greil, R; Haid, A; Jakesz, R; Klug, E; Kubista, E; Kwasny, W; Lang, A; Luschin-Ebengreuth, G; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Singer, CF; Steger, GG; Tausch, C; Wenzel, C | 1 |
| Arnould, L; Bleuse, JP; Campone, M; Chollet, P; Coeffic, D; Coudert, BP; Gligorov, J; Largillier, R; Martin, X; Namer, M; Priou, F; Serin, D; Trillet-Lenoir, V; Vasseur, B; Weber, B | 1 |
| Awada, A; De Porre, P; de Valeriola, D; Gil, T; Lalami, Y; Piccart-Gebhart, MJ; Zhang, S | 1 |
| Calvo, I; Carrasco, E; Casado, V; Casillas, M; Díaz, M; Dómine, M; Estévez, LG; Jaén, A; León, A; Lobo, F; Miró, C; Rubio, G; San Antonio, B; Sánchez-Rovira, P | 1 |
| Dent, S; Messersmith, H; Trudeau, M | 1 |
| Caputo, A; Hilfrich, J; Kaufmann, M; Müller, C; Raab, G; Schumacher, M; Schütte, M; von Minckwitz, G | 1 |
| Andersson, E; Aulitzky, WE; Cai, F; Havelka, AM; Linder, S; Muerdter, TE; Olofsson, MH; Pan, Y; Schwarz, S; Shoshan, MC; Sonnenberg, M; Toi, M; Ueno, T; van der Kuip, H; Xu, R | 1 |
| Cescon, TP; Dennison, SK; Geyer, CE; Jacobs, SA; Raymond, JM; Seeger, J; Swain, SM; Wilson, JW; Wolmark, N | 1 |
| Fujiwara, Y; Ono, M | 1 |
| Blasinska-Morawiec, M; Bonneterre, J; Campone, M; Chatelut, E; Deporte-Fety, R; Douville, I; Ecochard, L; Koralewski, P; Leger, F; Longerey, B | 1 |
| Hess, D; Köberle, D; Korte, W; Seeholzer, N; Thürlimann, B | 1 |
| Ewer, MS; O'Shaughnessy, JA | 1 |
| Gassiamis, A; Karabelis, A; Kosmas, C; Malamos, N; Mylonakis, N; Polyzos, A; Skopelitis, H; Tsakonas, G; Tsavaris, N | 1 |
| Assayag, F; Auger, N; de Cremoux, P; De Pinieux, G; de Plater, L; Degeorges, A; Delattre, O; Diéras, V; Guyader, C; Judde, JG; Marangoni, E; Poupon, MF; Rebucci, M; Sastre-Garau, X; Sigal-Zafrani, B; Tran-Perennou, C; Vincent-Salomon, A | 1 |
| Agostini, C; Bachelot, T; Cassier, PA; Chabaud, S; Cure, H; Guastalla, JP; Jacquin, JP; Martin, C; Orfeuvre, H; Peaud, PY; Pérol, D; Salles, B; Tigaud, JD; Trillet-Lenoir, V | 1 |
| Diehl, KM; Griffith, KA; Hayes, DF; Hayman, JA; Helvie, MA; Layman, RM; Newman, LA; Pierce, LJ; Roubidoux, MA; Sabel, MS; Schott, AF; Smerage, JB; Thomas, DG | 1 |
| Baur, M; Coombes, RC; Diéras, V; Dittrich, C; Hatschek, T; Hudec, M; Klink-Alakl, M; Murawsky, M; Tubiana-Hulin, M; van Oosterom, AT | 1 |
| Chung, KW; Kang, HS; Kim, EA; Kim, SK; Kim, SW; Kwon, HS; Kwon, Y; Lee, ES; Lee, KS; Nam, BH; Ro, J; Shin, KH | 1 |
| Day, S; Gillies, RJ; Howison, C; Job, C; Morse, DL; Murthi, S; Raghunand, N; Sadarangani, P | 1 |
| Bergström, M; Blomqvist, C; Carlsson, J; Josephsson, R; Långström, B; Monazzam, A | 1 |
| Choe, KJ; Choi, HY; Choi, SH; Han, WS; Kim, HA; Kim, HK; Moon, BI; Oh, SY; Park, HK; Sung, SH; Yom, CK; Yoon, EJ | 1 |
| Sekar, R; Stone, PR | 1 |
| Bagchi, S | 1 |
| Chang, SY; Chang, WS; Kang, CY; Kim, YJ; Kim, YS; Ko, HJ; Ko, SY; Sakaguchi, S | 1 |
| Altorjai, G; Bartsch, R; Gnant, M; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Miyaguni, T; Murayama, S; Nishimaki, T | 1 |
| Masuda, N | 1 |
| Lebrun-Vignes, B; Vignes, S | 1 |
| Chahine, G; Farhat, F; Gasmi, J; Ghosn, M; Kattan, J; Moukadem, W; Nasr, F; Younes, F | 1 |
| Furlow, B | 1 |
| Xu, BH | 1 |
| Guan, JH; Huan, HY; Mao, F; Sun, Q; Zhou, YD | 1 |
| Akazawa, K; Arai, T; Kim, SJ; Maruyama, N; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y | 1 |
| Twelves, C | 1 |
| Harbeck, N; Kates, R; Mallmann, P; Nawroth, F; Ohlinger, R; Pantke, E; Thomas, A; Valter, M; Warm, M | 1 |
| Ahn, JS; Choe, YH; Choi, N; Choi, YL; Han, BK; Im, YH; Kim, HJ; Kim, JH; Ko, YH; Lee, J; Nam, SJ; Park, YS; Yang, JH | 1 |
| Horwitz, SB; Wiesen, KM; Xia, S; Yang, CP | 1 |
| Fan, L; Goh, BC; Guo, JY; Hor, SY; Lee, HS; Lee, SC; Lim, RC; Lim, YW; Tan, T; Wang, LZ; Wong, CI | 1 |
| Ferrario, C; Panasci, LC | 1 |
| Akiyama, F; Hisamatsu, K; Iwata, H; Kaise, H; Kashiwaba, M; Kuroi, K; Kurosumi, M; Kusama, M; Masuda, N; Nakamura, S; Ohashi, Y; Ohno, S; Sato, Y; Takatsuka, Y; Toi, M; Tsuda, H; Yamazaki, K | 1 |
| Andreu, J; Cortés, J; Martínez, P; Montero, MA; Prat, A; Serrano, C | 1 |
| Chang, HK; Chen, JS; Lin, YC; Shen, WC; Wang, HM | 1 |
| Fite, A; Goua, M; Heys, SD; Hutcheon, AW; Schofield, AC; Wahle, KW | 1 |
| Davis, S; Hind, D; Rees, A; Simpson, E; Ward, S; Wilkinson, A | 1 |
| Chow, LW; Loo, WT; Sasano, H | 1 |
| Aiba, K; Hatake, K; Hosoyama, H; Ito, Y; Katayama, K; Minowa, S; Mitsuhashi, J; Nishi, S; Noguchi, K; Oh-hara, Y; Shibata, H; Sugimoto, Y; Suzuki, R; Takahashi, S; Tsukahara, S | 1 |
| Appel, M; Boissonnade, MM; Deyme, M; Henni-Silhadi, W; Le Cerf, D; Picton, L; Rosilio, V | 1 |
| Rayson, D; Sellon, M; Skedgel, C; Younis, T | 1 |
| Lambert-Falls, R; Modugno, S | 1 |
| Berveiller, P; Goffinet, F; Goldwasser, F; Mir, O; Pons, G; Ropert, S; Treluyer, JM | 1 |
| Egawa, C; Kim, SJ; Kurebayashi, J; Kurosumi, M; Masuda, N; Matsuura, N; Miyoshi, Y; Noguchi, S; Okishiro, M; Taguchi, T; Takahashi, M; Tamaki, Y; Tokunaga, E; Ueda, S; Yanagisawa, T | 1 |
| Barduagni, M; Belli, F; D'Ottavio, AM; Gamucci, T; Magnolfi, E; Meliffi, L; Moscetti, L; Sperduti, I; Vaccaro, A | 1 |
| Ferguson, T; Ghersi, D; Nowak, AK; Vagg, R; Wilcken, N | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Han, W; Heo, DS; Im, SA; Keam, B; Kim, DW; Kim, HJ; Kim, JH; Kim, TY; Lee, SH; Moon, WK; Noh, DY; Oh, DY; Park, IA | 1 |
| Radaideh, SM; Sledge, GW | 1 |
| Debled, M; Donamaria, C; Durand, M; Floquet, A; Houédé, N; Madranges, N; Mauriac, L | 1 |
| Boire, JY; Fajac, A; Levy, P; Xhemo, E | 1 |
| de Lemos, ML; Ellard, S; Hu, F; Kuik, K; Olivotto, IA; Speers, CH; Taylor, SC; Vu, T | 1 |
| Cubo, T; Delgado Y P Menéndez, M; López, A; Padilla, D; Villarejo, P | 1 |
| Acharya, CR; André, S; Becette, V; Bergh, J; Blot, E; Bonnefoi, H; Cameron, D; Campone, M; Delorenzi, M; Farmer, P; Iggo, RD; Jassem, J; Mauriac, L; Mukherjee, S; Nevins, JR; Petit, T; Potti, A; Rouanet, P; Tubiana-Hulin, M | 1 |
| Cinieri, S; La Torre, I; Lorusso, V; Numico, G; Orlando, L; Pezzella, G; Silvestris, N | 1 |
| O'Brien, ME | 1 |
| Bleiweiss, IJ; Raptis, G | 1 |
| Goh, BC; Holford, NH; Hor, SY; Lee, HS; Lee, SC; Lim, RC; Tan, T; Tham, LS; Wang, L | 1 |
| Barrett-Lee, P; Bliss, JM; Ellis, P; Johnson, L | 1 |
| Cao, Y; Ma, D; Meng, L; Song, X; Tao, W; Wang, S; Wang, W; Weng, D; Xing, H; Xu, G; Zhou, J | 1 |
| Colozza, M; D'Aiuto, G; De Maio, E; de Matteis, A; De Placido, S; Di Rella, F; Gallo, C; Gori, S; Gravina, A; Labonia, V; Landi, G; Lauria, R; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E; Signoriello, G; Thomas, R | 1 |
| Bianco, AR; Cancello, G; Criscitiello, C; D'Agostino, D; De Laurentiis, M; De Placido, S; Esposito, A; Forestieri, V; Giordano, A; Giuliano, M; Lauria, R; Limite, G; Montagna, E; Montanino, A; Pennacchio, R; Silvestro, L | 1 |
| Chen, G; Lu, Y; Ma, D; Meng, L; Tao, W; Wang, S; Weng, D; Xing, H; Yang, X; Zhu, T | 1 |
| Abraul, E; Belo, J; Campos, O; de Oliveira, C; Frutuoso, C; Gervásio, H; Henriques, I; Pazos, I; Pego, A | 1 |
| Andersson, M; Balil, A; Bendahmane, B; Buyse, M; Castiglione-Gertsch, M; Crown, J; Di Leo, A; Dolci, S; Francis, P; Gelber, RD; Goldhirsch, A; Gutiérrez, J; Jakesz, R; Jamin, S; Lang, I; Nordenskjöld, B; Piccart-Gebhart, M; van Hazel, G; Vorobiof, D | 1 |
| Collingridge, D | 1 |
| Chatelut, E; Dalenc, F; Delord, JP; Lochon, I; Nguyen, L; Pinguet, F; Poublanc, M; Roche, H | 1 |
| Ando, M; Katsumata, N; Mukai, H; Shimizu, C; Watanabe, T | 1 |
| Hansch, C; Verma, RP | 1 |
| Lamb, S; Tallon, B | 1 |
| Clynes, M; Liang, Y; Martinez, VG; O'Connor, R | 1 |
| Marino, P | 1 |
| Baselga, J; De Rosa, F; Fettner, S; Jones, R; Rakhit, A; Trigo, JM; Twelves, C; Wright, T | 1 |
| Anderson, SJ; Bear, HD; Dakhil, SR; Geyer, CE; Hoehn, JL; Kahlenberg, MS; King, KM; Mamounas, EP; Margolese, RG; Paik, S; Pajon, ER; Rastogi, P; Robert, J; Robidoux, A; Tamkus, D; Vogel, VG; Wolmark, N; Wright, MJ | 1 |
| Chang, HK; Chen, MF; Chen, SC; Cheung, YC; Hsueh, S; Leung, WM; Lin, YC; Lo, YF; Shen, SC; Tsai, CS; Tsai, HP | 1 |
| Asselah, J; Cottu, PH; Diéras, V; Lae, M; Mignot, L; Pierga, JY; Sigal-Zafrani, B; Vincent-Salomon, A | 1 |
| Abraham, J; Alkhouri, N; Haut, MW; Swayampakula, AK | 1 |
| Kim, SJ; Noguchi, S | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Seki, K; Shibata, T; Shien, T; Shimizu, C | 1 |
| Berliere, M; Dalenc, F; Donnez, J; Kerger, J; Machiels, JP; Malingret, N; Piette, P; Roche, H; Symann, M; Vindevogel, A | 1 |
| Biegel, J; Cook, R; Kim, A; Schuster, S; Wainwright, L; Wasik, M | 1 |
| Ai, CZ; Dong, PP; Ge, GB; Liu, CX; Liu, Y; Yang, L; Zhang, YY | 1 |
| Adinin, RB; Arun, BK; Brewster, A; Broglio, KR; Esmaeli, B; Hortobagyi, GN; Mejia, JA; Rivera, E; Valero, V; Walters, RS; Yin, G | 1 |
| Cecchini, RS; Costantino, JP; Ganz, PA; Land, SR; Mamounas, EP; Ritter, MW; Swain, SM; Wolmark, N | 1 |
| Kendra, K; Knapp, M; Maher, JF; McVey, A; Merriman, NJ; Moore, TD; Mrozek, E; Ottman, S; Patel, T; Puhalla, S; Shapiro, CL; Thompson, ME; Young, D | 1 |
| Chaigneau, L; Demarchi, M; Lorgis, V; Maurina, T; Meaux-Ruault, N; N'guyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Villanueva, C | 1 |
| Fukushima, M; Garbo, CL; Ishiguro, H; Kitano, T; Toi, M; Ueno, T; Yanagihara, K; Yasuda, H; Yoshibayashi, H | 1 |
| Amant, F; Clement, P; Dirix, L; Neven, P; Paridaens, R; Prové, A; Skacel, T; Squifflet, P; Wildiers, H | 1 |
| Ardizzoni, A; Bisagni, G; Bortesi, B; Camisa, R; Capelletti, M; Laccabue, D; Missale, G; Musolino, A; Naldi, N; Neri, TM; Pezzuolo, D; Zerbini, A | 1 |
| Abe, S; Iyama, S; Kato, J; Murase, K; Niitsu, Y; Okamoto, K; Sagawa, T; Sato, T; Sato, Y; Takahashi, S; Takayama, T | 1 |
| Hachisuka, Y; Hatano, H; Johira, H; Kamei, Y; Kawata, N; Kimura, M; Miyata, N; Ohmori, K; Umeoka, T; Uomoto, M; Watanabe, R; Yunoki, S | 1 |
| Chen, YQ; Jin, YC; Li, J; Li, R; Li, XR; Liu, HY; Ma, B; Wang, JD; Zhang, YJ; Zheng, YQ | 1 |
| Blohmer, JU; Caputo, A; Costa, SD; Eidtmann, H; Hilfrich, J; Jackisch, C; Kaufmann, M; Loibl, S; Merkle, E; Raab, G; Sinn, HP; von Minckwitz, G | 1 |
| Akehurst, R; Booth, A; Kaltenthaler, E; Tappenden, P | 1 |
| Marty, M; Pivot, X | 1 |
| Gasanov, ISh; Generalov, MI; Polikarpov, AA; Tarazov, PG | 1 |
| Davidson, NE; Jones, V; Martino, S; Perez, EA; Saphner, T; Sledge, GW; Sparano, JA; Wang, M; Wolff, AC; Wood, WC | 1 |
| Chung, HC; Im, SA; Im, YH; Jee, YG; Kim, SB; Lee, SG; Ro, J; Seo, JH | 1 |
| Anderssona, M; Awadab, A; Barrett-Leec, P; Ellisd, P; Hupperetse, P; Jackischf, C; Kubistag, E; Lückh, HJ; Monnerati, C; Nitzj, U; Untchl, M | 1 |
| Andreetta, C; Cardellino, GG; Crivellari, D; Damante, G; Di Loreto, C; Lombardi, D; Magri, MD; Mansutti, M; Minisini, AM; Perin, T; Puglisi, F; Russo, S; Veronesi, A | 1 |
| Au, HJ; Chia, S; Fassbender, K; Golmohammadi, K; Jacobs, P; Verma, S; Younis, T | 1 |
| Altundag, K; Bulut, N; Sari, E | 1 |
| Ardavanis, A; Baziotis, N; Garoufali, A; Kountourakis, P; Kyriakou, F; Malliou, S; Mantzaris, I; Rigatos, G; Scorilas, A; Yiotis, I | 1 |
| Cai, Y; Hong, X; Hu, X; Li, J; Ou, Z; Shen, Z; Wang, Z; Yang, X; Zhao, X | 1 |
| Albanell, J; Awada, A; Baselga, J; Canney, PA; Cardoso, F; Dirix, LY; Gascon, P; Gil, T; Piccart, MJ | 1 |
| Amar, S; Perez, EA; Roy, V | 1 |
| Gopalan, G; Govindasamy, KM; Lee, HH; Zhu, Y | 1 |
| Eichbaum, M; Eiermann, W; Kaufmann, M; Marmé, F; Rom, J; Scharf, A; Schlehe, B; Schneeweiss, A; Schuetz, F; Sievert, M; Sinn, HP; Sohn, C; von Minckwitz, G | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Kosmidis, P; Koutras, A; Maniadakis, N; Matsiakou, F; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Skarlos, D | 1 |
| Hidaka, T; Horiuchi, A; Ishida, N; Kawachi, K; Nakagawa, H; Sato, K; Sugishita, H; Watanabe, Y; Yamamoto, Y; Yoshida, M; Yukumi, S | 1 |
| Abe, H; Higashide, S; Kato, M; Ogawa, H; Okino, T; Sako, H; Sano, H; Shimomatsuya, T; Suwa, H | 1 |
| Fu, JM; Li, H; Xie, JS; Zhou, J | 1 |
| Arima, N; Iwase, H; Kai, K; Miyayama, H; Nishimura, R; Yamamoto, Y | 1 |
| Anand, A | 1 |
| Eisenhauer, EA; Trudeau, M | 1 |
| Cortes, JE; Pazdur, R | 1 |
| Kaye, SB | 1 |
| Shparik, IV | 1 |
| Taguchi, T | 1 |
| Ravdin, PM; Valero, V | 1 |
| Azli, N; Bayssas, M; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Van Glabbeke, M | 1 |
| Amadori, D; Bajorko, P; De Paola, F; Flamigni, A; Frassineti, GL; Gasperi-Campani, A; Milandri, C; Zoli, W | 1 |
| Depenbrock, H; Hanauske, AR; Rastetter, J; Shirvani, D | 1 |
| Azli, N; Bayssas, M; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, I; Lentz, MA; Roche, H; Van Glabbeke, M | 1 |
| Angioli, R; Averette, HE; Koechli, O; Perras, JP; Sevin, BU; Untch, A; Untch, M | 1 |
| Abrams, JS; Friedman, M; Moore, TD | 1 |
| Chevalier, B; Clavel, M; Verweij, J | 1 |
| Alakl, M; Clavel, M; Franklin, H; Piccart, M; Prove, AM; Steward, W; ten Bokkel Huinink, WW; Tursz, T; Verweij, J; Wanders, J | 1 |
| Adachi, I; Hirata, K; Kitajima, M; Kunii, Y; Sano, M; Shimada, H; Suwa, T; Tabei, T; Taguchi, T; Tominaga, T | 1 |
| Gelmon, K | 1 |
| Abe, R; Enomoto, K; Fujita, M; Hamano, K; Hasegawa, K; Mori, S; Morishita, Y; Sasaki, Y; Tabei, T; Taguchi, T | 1 |
| Cohen, PR; Kavanagh, JJ; Kudelka, AP; Pazdur, R; Raber, MN | 1 |
| Eisenhauer, E | 1 |
| Bellet, RE; Bierman, WA; Burris, HA; Cook, G; Eisenberg, P; Genevois, E; Kane, M; Mortimer, J; Ravdin, PM | 1 |
| Bellet, RE; Buzdar, AU; Esparza, L; Fonseca, GA; Fraschini, G; Holmes, FA; Hortobagyi, GN; Theriault, RL; Valero, V; Walters, RS | 1 |
| Chou, TC; Otter, GM; Sirotnak, FM | 1 |
| Adachi, I; Aoyama, H; Horikoshi, N; Narabayashi, M; Taguchi, T; Takashima, S; Watanabe, T | 1 |
| Pronk, LC; Stoter, G; Verweij, J | 1 |
| Balmaceda, C; Baselga, J; Bruno, R; Crown, JP; Currie, V; Freilich, R; Gilewski, TA; Gollub, M; Hakes, TB; Hudis, CA; Lebwohl, DE; Norton, L; Raptis, G; Robles, M; Seidman, AD | 1 |
| Piccart, MJ | 2 |
| van Oosterom, AT | 1 |
| Trudeau, ME | 4 |
| Ravdin, PM | 6 |
| Burris, HA; Fields, S; Peacock, N | 1 |
| Capri, G; Fulfaro, F; Gianni, L; Tarenzi, E | 1 |
| Delorme, F; Eisenhauer, EA; Higgins, BP; Letendre, F; Lofters, WS; Muldal, AM; Norris, BD; Trudeau, ME; Vandenberg, TA | 1 |
| Guy, RK; Nicolaou, KC; Potier, P | 1 |
| Auguste, L; Baselga, J; Currie, V; Edelman, B; Fennelly, D; Francis, P; Gilewski, TA; Gollub, M; Hochhauser, D; Hudis, CA; Moynahan, ME; Norton, L; O'Donaghue, M; Salvaggio, R; Seidman, AD; Spriggs, D; Tong, W; Yao, TJ | 1 |
| Chan, S; Gardner, S; Winterbottom, L | 1 |
| Fulton, B; Spencer, CM | 1 |
| Bernacki, RJ; Ojima, I; Sharma, A; Straubinger, RM | 1 |
| Azli, N; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, I; Lentz, MA; Misset, JL; Murawsky, M; Pouillart, P; Riva, A; Roche, H | 1 |
| Azli, N; Bougon, N; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, Y; Maugard-Louboutin, C; Misset, JL; Riva, A; Roche, H | 1 |
| Bernacki, RJ; Bissery, MC; Bounaud, PY; Kuduk, SD; Michaud, E; Ojima, I; Pera, P; Slater, JC; Veith, JM; Vrignaud, P | 1 |
| Norton, L | 1 |
| Armand, JP | 1 |
| Khayat, D | 1 |
| Azli, N; Bourgeois, H; Dieras, V; Fumoleau, P; Misset, JL; Pouillart, P | 1 |
| Kennedy, MJ | 1 |
| Verlag, GT | 1 |
| Bernacki, RJ; Kuduk, SD; Ojima, I; Pera, P; Veith, JM | 1 |
| Davison, JD; Francis, PA; Ganju, V; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC | 1 |
| Rodenhuis, S; ten Bokkel Huinink, WW; Westermann, AM | 1 |
| Béhar, A; Brun, MD; Chauvin, FF; Feuilhade de Chauvin, F; Hille, D; Maurel, A; Oulid-Aissa, D; Pujade-Lauraine, E | 1 |
| Hortobágyi, G | 2 |
| Diéras, V | 3 |
| Delorme, F; Janowska, A; Mackey, J; Nabholtz, JM; Noel, D; Paterson, A; Riva, A; Smylie, M | 1 |
| Azli, N; Delecroix, V; Féty, R; Fumoleau, P; Perrocheau, G | 1 |
| Tsukagoshi, S | 1 |
| Pestalozzi, BC | 1 |
| André, J; Song, M; Vandenbossche, L; Vandeveire, A; Vanhooteghem, O; Vindevoghel, A | 1 |
| Antoine, EC; Auclerc, G; Khayat, D; Rixe, O; Weil, M | 1 |
| Di Leo, A; Piccart, MJ | 1 |
| Awada, A; Bontenbal, M; Coleman, R; Klijn, J; Mauriac, L; Nooij, M; Paridaens, R; Piccart, MJ; Selleslags, J; Van Glabbeke, M; Van Vreckem, A | 1 |
| Bombardelli, E; De Vincenzo, R; Distefano, M; Fattorossi, A; Ferlini, C; Gaggini, C; Mancuso, S; Ojima, I; Panici, PB; Riva, A; Scambia, G | 1 |
| de Vries, EG; Haaxma-Reiche, H; Hofstra, LS; van der Graaf, WT; Willemse, PH | 1 |
| Von Hoff, DD | 1 |
| Antoine, E; Khayat, D | 1 |
| D'Andrea, GM; Seidman, AD | 1 |
| Viens, P | 1 |
| Bonneterre, J; Launois, RJ; Reboul-Marty, JM | 1 |
| Chan, S | 1 |
| Aapro, MS; Alaki, M; Bezwoda, WR; Deschênes, L; Douma, J; Drbal, J; Melnychuk, D; Murawsky, M; Nabholtz, JM; Rapoport, B; Riva, A; Rosso, R; Thuerlimann, B; Trillet-Lenoir, V; Vandenberg, TA | 1 |
| al-Tweigeri, T; Au, D; Delorme, F; Mackey, JR; Nabholtz, JM; Noel, D; Paterson, AH; Riva, A; Sansregret, E; Smylie, M | 1 |
| Aapro, MS | 2 |
| Llombart-Cussac, A; Pivot, X; Spielmann, M | 1 |
| Bruno, R; Burris, HA; Chevallier, B; Fossella, FV; Fumoleau, P; Hille, D; Kaye, SB; Ravdin, PM; Rigas, JR; Riva, A; Seidman, AD; Sheiner, LB; ten Bokkel Huinnink, WW; Valero, V; van Oosterom, AT; Verweij, J; Vivier, N | 1 |
| Costa, SD; von Minckwitz, G | 1 |
| Nelson, NJ | 2 |
| Eisenhauer, EA; Vermorken, JB | 1 |
| Clemons, M; Howell, A; Jayson, G; Leahy, M; Ranson, M; Valle, J | 1 |
| Rubens, RD | 1 |
| Azli, N; Diéras, V; Fumoleau, P; Kalla, S; Misset, JL; Pouillart, P | 1 |
| Dubbelman, R; Hiemstra, A; Lustig, V; Rodenhuis, S; ten Bokkel Huinink, WW | 1 |
| Cottu, PH; Espié, M; Extra, JM; Marty, M | 1 |
| Muggia, F; O'Leary, J; Volm, M; Wasserheit, C | 1 |
| Bhalla, K; Harris, WB | 1 |
| Mamounas, EP | 1 |
| Kokawa, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G | 2 |
| Hortobagyi, GN; Hung, MC; Ibrahim, N; Jing, T; Liu, B; Price, JE; Singletary, SE; Sun, D; Yu, D | 1 |
| Eckhardt, S | 1 |
| Di Nunno, L; Herrington, JD; Rinehart, JJ | 1 |
| Eliel, MR; Nortier, JW; Rodenburg, CJ; Slee, PH | 1 |
| Eland, IA; Krommendijk, R; Otter, R; Stricker, BH | 1 |
| Bressolle, F; Grosse, PY; Pinguet, F | 1 |
| Adachi, I; Ando, M; Fujii, H; Igarashi, T; Itoh, K; Katsumata, N; Narabayashi, M; Ohtsu, T; Omuro, Y; Sasaki, Y; Taguchi, T; Tokue, Y; Wakita, H; Watanabe, T; Ying, DF | 1 |
| Bontenbal, M; de Wit, R; Klijn, JG; Seynaeve, C | 1 |
| Bissery, MC; Fellous, A; Martinez, C; Veitia, R | 1 |
| Arlet, P; Auvinet, M; Dahan, S; Dingremont, C; Juchet, H; Ollier, S | 1 |
| Tankanow, RM | 1 |
| Booser, DJ; Burris, HA; Earhart, RH; Erban, JK; Esparza-Guerra, L; Holmes, FA; Hortobagyi, GN; Jones, SE; Mennel, RG; Rahman, Z; Ravdin, PM; Schottstaedt, MW; Valero, V; Von Hoff, DD | 1 |
| Paridaens, R; Thomas, J; Van Oosterom, A; Van Vaerenbergh, W; Wildiers, J | 1 |
| Jackisch, C | 1 |
| Archer, CD; Coombes, RC; English, J; Khan, S; Lowdell, C; Sinnett, HD | 1 |
| Hilkens, PH; Pronk, LC; Stoter, G; van den Bent, MJ; van Putten, WL; Verweij, J | 1 |
| Cuvier, C; Espié, M; Gorins, A; Marty, M | 1 |
| Crown, J; Nabholtz, JM | 1 |
| Colombo, T; D'Incalci, M; Riva, A; Schüller, J; Zucchetti, M | 1 |
| Sparano, JA | 3 |
| Aapro, M | 1 |
| Crown, J | 5 |
| Mackey, J; Nabholtz, JM; Smylie, M; Tonkin, K | 1 |
| Pagani, O | 1 |
| Löffler, TM | 1 |
| Brown, RE; Hutton, J | 1 |
| Espie, M | 1 |
| de Boer-Dennert, M; Pronk, LC; Stoter, G; van Beurden, V; van Putten, WL; Verweij, J | 1 |
| Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J | 1 |
| Miller, KD; Sledge, GW | 1 |
| Barrett-Lee, PJ; Bizzari, JP; Eggleton, SP; Leonard, RC; O'Brien, ME | 1 |
| Agelaki, S; Alexopoulos, A; Apostolaki, F; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kalbakis, K; Kosmas, C; Kourousis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Samonis, G; Sarra, E; Vlachonicolis, J | 1 |
| Buckner, CD; Franco, C; Hazelton, B; Moore, M; Schwartzberg, LS; Smith, R; Van Amburg, A; Weaver, CH; White, L; Zhen, B | 1 |
| Lønning, PE | 1 |
| Berdeaux, G; Hurteloup, P | 1 |
| Bonneterre, J; Henry, B; Launois, R; Reboul-Marty, J | 1 |
| Janowska-Wieczorek, A; Mackey, J; Nabholtz, JM; Smylie, M; Tonkin, K | 1 |
| Agrawal, S; Bianco, AR; Caputo, R; Ciardiello, F; Mendelsohn, J; Pepe, S; Pomatico, G; Tortora, G | 1 |
| Culine, S | 1 |
| Aapro, M; Alakl, M; Bezwoda, WR; Deschênes, L; Douma, J; Drbal, J; Genot, JY; Hupperets, PS; Melnychuk, D; Molino, A; Murawsky, M; Nabholtz, JM; Nagykalnai, T; Nortier, JW; Pannuti, F; Rapoport, B; Richel, DJ; Rosso, R; Senn, HJ; Siedlecki, P; Skarlos, D; Tomiak, EM; Trillet-Lenoir, V; Vandenberg, TA; Wilking, N | 1 |
| Nabholtz, JM; Vogel, CL | 1 |
| Lamb, HM; Wiseman, LR | 1 |
| Azevedo, C; Braga Cruz, F; Correia, O; Pinto Ferreira, E; Polónia, J | 1 |
| Abe, R; Kimijima, I; Ohtake, T; Sagara, H; Tsuchiya, A; Watanabe, T | 1 |
| Asmar, L; Hortobagyi, GN; Pivot, X | 1 |
| Au, HJ; Au, R; Mackey, J; Morrish, D; Nabholtz, JM; Salter, E; Smylie, M; Tonkin, K | 1 |
| Kokawa, Y; Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tamaki, T; Tanino, H; Umemura, T; Yoshimura, G | 1 |
| Bauer, J; Borner, M; Buonadonna, A; Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Martinelli, G; Pagani, O; Riva, A; Sessa, C; Thürlimann, B; Zampino, G; Zimatore, M | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kouroussis, C; Malamos, N; Mavroudis, D; Panagos, G; Papadouris, S; Potamianou, A; Samonis, G; Sara, E; Xydakis, E | 1 |
| Aussel, JP; Azli, N; Beuzeboc, P; Bourgeois, H; Bozec, L; Cvitkovic, E; Dieras, V; Gruia, G; Jasmin, C; Kalla, S; Misset, JL; Pouillart, P; Riva, A | 1 |
| Burris, HA | 4 |
| Blohmer, JU; Costa, SD; Dresel, V; Eidtmann, H; Gademann, G; Hilfrich, J; Jackisch, C; Kaufmann, M; Merkle, E; Raab, G; von Minckwitz, G | 1 |
| Alexopoulos, A; Alexopoulos, CG; Efremidis, AP; Papacharalambous, A; Patila, E; Rigatos, G; Vassilomanolakis, M | 1 |
| Hamaguchi, Y; Hasegawa, S; Hisatomi, H; Ichikawa, Y; Ishikawa, T; Kamiyama, M; Momiyama, N; Narita, T; Shimada, H | 1 |
| Barbaroux, C; de Cremoux, P; Dieras, V; Liva, S; Magdelenat, H; Martin, EC; Pouillart, P; Sastre-Garau, X; Vincent-Salomon, A | 1 |
| Boissier, S; Clezardin, P; Delmas, PD; Magnetto, S | 1 |
| Aiba, K; Hanai, M; Horikoshi, N; Ito, Y; Osawa, H; Takahashi, S; Uno, S; Yamada, Y | 1 |
| Aoki, T; Kaise, H; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Nakayama, S; Yoneda, K | 1 |
| Aritake, N; Fukunaga, M; Gotoh, K; Hasegawa, S; Imamoto, H; Kan, K; Kim, Y; Maruyama, H; Oozato, H; Takatsuka, Y; Touno, T; Yamazaki, K | 1 |
| Hada, M; Hagiwara, J; Kamiya, K; Koshizuka, K; Muto, S; Nakagomi, H; Tada, Y; Takano, K | 1 |
| Loesch, DM; McCaskill-Stevens, W; Miller, KD; Monaco, F; Seshadri, R; Sisk, J; Sledge, GW | 1 |
| Dranitsaris, G; Leung, PP; Oza, AM; Puodziunas, A; Tannock, IF | 1 |
| Anibali-Charpiat, MF; Calluaud, L; Fabre-Guillevin, E; Ravaud, A; Tchen, N | 1 |
| Choy, H | 1 |
| Kadota, M; Masuda, N; Miyazaki, M; Monden, M; Ohue, M; Ooka, M; Sakita, I; Sekimoto, M; Tamaki, Y; Tomita, N | 1 |
| Harada, K; Konishi, T; Maeda, Y; Mori, N; Nishida, M; Oka, M; Somura, H; Takao, T; Tamesa, T; Tangoku, A | 1 |
| Kim, SJ; Maeura, Y; Matsunaga, S; Saito, M; Ueda, N | 1 |
| Bergman, M; Ekholm, E; Huhtala, S; Salminen, E | 1 |
| Angiolini, C; Bergaglio, M; Del Mastro, L; Esposito, M; Garrone, O; Lunardi, G; Rosso, R; Tolino, G; Vannozzi, MO; Venturini, M; Viale, M | 1 |
| Blohmer, JU; Costa, SD; Eiermann, W; Jackisch, C; Kaufmann, M; Tulusan, AH; von Minckwitz, G | 1 |
| Alakl, M; Bodrogi, I; Buzzi, F; Chan, S; Crown, J; Duarte, R; Friedrichs, K; Gil Gil, M; González Mancha, R; Korec, S; Murawsky, M; Murray, E; Noel, D; Pintér, T; Richardson, G; Riva, A; Ronzoni, M; Simmonds, P; Van Belle, S; von Minckwitz, G; Vorobiof, D; Walpole, E; Yelle, L | 1 |
| Hayashi, K; Kuroi, K; Nagai, S; Toi, M; Tominaga, T | 1 |
| Funahashi, H; Hayashi, H; Imai, T; Itoh, T; Kikumori, T; Mase, T; Oiwa, M; Sekiya, M; Shibata, A | 1 |
| Gnant, M; Jakesz, R; Locker, GJ; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
| Miller, M | 1 |
| Anderson, H; Bengtsson, NO; Bergh, J; Blomqvist, C; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Palm-Sjövall, M; Pluzanska, A; Sjöström, J; Valvere, V; Wist, E | 1 |
| Crown, JP | 2 |
| Le Cesne, A; Llombart, A; Rixe, O; Spielmann, M; Sverdlin, R; Zelek, L | 1 |
| Cortesi, E; Leone, G; Mancuso, S; Martelli, O; Perillo, A; Pierelli, L; Scambia, G | 1 |
| Lyerly, HK; Morse, MA; Vredenburgh, JJ | 1 |
| Alexandre, J; Bensmaïne, A; Bleuzen, P; Bonneterre, J; Chahine, A; Cvitkovic, E; Faivre, S; Guastalla, J; Mahjoubi, M; Marty, M; Misset, JL; Spielman, M; Sutherland, W; Viens, P | 1 |
| Doi, K; Inoue, K; Ishihara, A; Kimura, Y; Kudo, S; Ochiai, T; Ohchi, T; Sakae, T; Sakamoto, T; Takahashi, M | 1 |
| Beijnen, JH; Bult, A; Huizing, MT; Lustig, V; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ | 1 |
| Olszewski, W | 1 |
| Bergerat, JP; Bonneterre, J; Bourgeois, H; Chollet, P; Fumoleau, P; Guastalla, JP; Mahjoubi, M; Marty, M; Mauriac, L; Misset, JL; Namer, M; Roché, H; Spielman, M; Trandafir, L; Viens, P | 1 |
| Boehnke-Michaud, L; Buzdar, AU; Dubrow, RA; Hortobagyi, GN; Ibrahim, NK; Lynch, PM; Sahin, AA; Valero, V | 1 |
| Antonopoulos, M; Kosmas, C; Malamos, NA | 1 |
| Ajaikumar, BS; Cleveland, MG; Reganti, R | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; De Laurentiis, M; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Bunnell, CA; Burstein, HJ; Clarke, KD; Garber, JE; Manola, J; Matulonis, UA; Parker, LM; Scheib, R; Shulman, LN; Winer, EP; Younger, J | 1 |
| Aiba, K | 1 |
| Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yamamiti, N; Yoshimasu, T | 1 |
| Amsrud, T; Chen, V; Forler, PA; Menon, K; Phares, VG; Shih, C; Teicher, BA | 1 |
| de Matteis, A; Landi, G; Nuzzo, F; Perrone, F; Rossi, E | 1 |
| Bartholomeus, S; Crown, J; Di Leo, A; Dolci, S; Duffy, K; Larsimont, D; Nogaret, JM; O'Higgins, N; Paesmans, M; Piccart, MJ; Riva, A; Rowan, S | 1 |
| Ah-See, AK; Chilcott, F; Eremin, O; Gilbert, FJ; Heys, SD; Hutcheon, AW; Miller, ID; Payne, S; Sharp, PF; Smith, IC; Waikar, S; Welch, AE; Whitaker, T | 1 |
| Figgitt, DP; Wiseman, LR | 1 |
| Carpino, A; Cognetti, F; D'Ottavio, AM; Ferraresi, V; Giannarelli, D; Marsella, A; Milella, M; Nisticò, C; Papaldo, P; Terzoli, E; Thorel, MF; Vaccaro, A | 1 |
| Amano, G; Furuta, A; Harada, Y; Ikegaki, H; Kijima, G; Ohnuki, K; Ohuchi, N; Satomi, S; Yoshida, R | 1 |
| Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E | 1 |
| Crown, J; O'Leary, M | 1 |
| Au, HJ; Au, R; Mackey, J; Morrish, D; Nabholtz, JM; North, S; Salter, E; Smylie, M; Tonkin, K | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Elmo, M; Frasci, G; Lapenta, L; Petrillo, A; Thomas, R; Vallone, P | 1 |
| Brodowicz, T; Herscovici, V; Koestler, WJ; Steger, GG; Tomek, S; Vaclavik, I; Wiltschke, C; Zielinski, CC | 1 |
| Rajdev, L; Sparano, JA | 1 |
| Falkson, CI; O'Neill, A; Schaefer, PL; Sparano, JA; Wood, WC | 1 |
| Androulakis, N; Dimopoulos, MA; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kouroussis, C; Samonis, G; Souglakos, J; Voloudaki, A | 1 |
| Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G | 1 |
| Darwis, I; Muthalib, A; Prayogo, N | 1 |
| Beijnen, JH; Bo, M; Lustig, V; Mackay, M; Pronk, L; Schellens, JH; Ten Bokkel Huinink, WW; van Tinteren, H; Verweij, J | 1 |
| Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, M; Malmström, P; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Pluzanska, A; Sjödin, M; Sjöström, J | 1 |
| Budman, D; Kreis, W; Petrylak, D; Savarese, D | 1 |
| Coleman, RE; Eggleton, SP; Howell, A; Maling, SJ; Miles, DW | 1 |
| Aravantinos, G; Bafaloukos, D; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Nicolaides, C; Pavlidis, N; Samelis, G | 1 |
| Kunisue, H; Kurebayashi, J; Shimozuma, K; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, S; Yamamoto, Y | 1 |
| Amaya, H; Aotake, T; Chiba, Y; Fujii, H; Horiuchi, T; Shimomatsuya, T; Uchinami, M; Yokomachi, J | 1 |
| Fujii, H; Igarashi, T; Imoto, S; Ishizawa, K; Ito, K; Kubota, K; Minami, H; Saeki, T; Sasaki, Y; Takashima, S | 1 |
| Kubota, K | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Boguslawski, KV; Heikkilä, P; Malmström, P; Mjaaland, I; Ostenstadt, B; Räisänen-Sokolowski, A; Saksela, E; Sjöström, J; Valvere, V; Wist, E | 1 |
| Feenstra, J; Stricker, BH; Vermeer, RJ | 1 |
| Endo, T; Fujimoto, K; Haseyama, Y; Koike, T; Koizumi, K; Nishio, M; Sawada, K; Takashima, H; Yamamoto, S | 1 |
| Austin Seymour, MM; Bellon, JR; Ellis, GK; Gralow, JR; Lindsley, KL; Livingston, RB | 1 |
| Besenval, M; Boisdron-Celle, M; Delva, R; Gamelin, E; Lortholary, A; Maillard, P; Perard, D; Vernillet, L | 1 |
| Antonopoulos, M; Kosmas, C; Malamos, NA; Tsavaris, N | 1 |
| Chen, YZ; Fan, W; Fu, L; Johnson, KR; Zeng, S | 1 |
| Camidge, DR; Kunkler, IH | 1 |
| Fukuda, H; Fukuda, K; Kim, YH; Kitano, H; Kokufu, I; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wall, D; Wolf, M | 1 |
| Takatsuka, Y | 1 |
| Tashiro, H | 1 |
| Fujii, H | 1 |
| Naito, Y; Oura, S; Tanino, H | 1 |
| Ames, FC; Breslin, TM; Buzdar, AU; Cohen, L; Delpassand, ES; Feig, BW; Fleming, JB; Hortobagyi, GN; House, R; Hunt, KK; Kuerer, HM; Newman, LA; Ross, MI; Sahin, A; Singletary, SE | 1 |
| Naito, Y; Sakurai, T; Suzuma, T; Tamaki, T; Umemura, T; Yoshimura, G | 1 |
| Bauer, J; Borner, M; Crivellari, D; D'Incalci, M; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Zucchetti, M | 1 |
| Awada, A; Piccart, MJ | 1 |
| Fujii, H; Igarashi, T; Itoh, K; Kashimura, M; Minami, H; Ohashi, Y; Ohtsu, T; Onozawa, Y; Sasaki, Y; Wakita, H; Watanabe, Y | 1 |
| Asanuma, F; Kawamura, E; Suzuki, T; Yamada, T; Yamada, Y | 1 |
| Khan, KS; Kleijnen, J; Lister-Sharp, D; McDonagh, MS | 1 |
| Chang, HK; Chen, JS; Liaw, CC; Lin, YC; Wang, CH | 1 |
| Hortobagyi, G; Michaud, LB; Valero, V | 1 |
| Azama, T; Furukawa, J; Hashimoto, T; Katsumoto, Y; Nakaguchi, K; Okajima, S; Shingai, T; Sue, F; Takekuni, K; Yoshihara, W; Yukawa, M | 1 |
| Doi, K; Ishihara, A; Kudo, S; Ochiai, T; Ohchi, T; Sakae, T; Sakamoto, T; Takahashi, M | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Tsavaris, N; Ziras, N | 1 |
| Depisch, D; Haider, K; Kornek, G; Kwasny, W; Lang, F; Penz, M; Scheithauer, W; Ulrich-Pur, H; Valencak, J | 1 |
| Briasoulis, E; Constantopoulos, S; Froudarakis, M; Milionis, HJ; Pavlidis, N; Peponis, I | 1 |
| Brugarolas, A; Fernández-Hidalgo, O; Martín-Algarra, S; Pérez-Calvo, J; Salgado, E; Subirá, ML | 1 |
| Amodio, A; Belli, F; Botti, C; Conti, F; Di Lauro, L; Ferraironi, A; Foggi, P; Gionfra, T; Lopez, M; Morelli, MF; Vici, P | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Penz, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Fleming, DR; Goldsmith, GH; Goldsmith, J; Herzig, RH; Stevens, DA | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Matsuo, K; Miyakawa, K; Nakamura, T; Shimizu, C; Tsuda, H | 1 |
| Heilmann, M; Langer-Nitsche, C; Lück, HJ | 1 |
| Al-Tweigeri, T; Azli, N; Mackey, JR; Nabholtz, JM; Noël, DR; North, S; Paterson, A; Riva, A; Smylie, M; Tonkin, K | 1 |
| Adachi, I; Ando, M; Katsumata, N; Nagata, K; Narabayashi, M; Watanabe, T | 1 |
| Blach, M; Brodowicz, T; Budinsky, AC; Hojas, S; Ilsinger, P; Kubista, E; Locker, GJ; Maca, S; Pluschnig, U; Schmidinger, M; Seewann, L; Steger, GG; Wenzel, C; Zabernigg, A; Zielinski, CC | 1 |
| Esteva, FJ; Fornier, M; Seidman, AD | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Katsumata, N; Matsuo, K; Miyakawa, K; Nanasawa, T; Tsuda, H; Watanabe, T | 1 |
| Doihara, H; Hino, M; Ishibe, Y; Nagahiro, I; Ogasawara, Y; Sano, Y; Shimizu, N; Teramoto, A; Yoshitomi, S | 1 |
| Georgoulias, VA | 1 |
| Hara, A; Harada, T; Hashimoto, K; Izumi, N; Matsubara, C; Miyazaki, H; Satake, K; Tsunematsu, I | 1 |
| Kamata, S; Kiyosawa, Y; Kudo, T; Nakagawa, T; Ogawa, J; Onuki, M; Seto, T | 1 |
| Baron, R; Hilpert, F; Pfisterer, J; Wasner, G | 1 |
| Pegram, M; Slamon, D | 1 |
| Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T | 1 |
| Mileshkin, L; Prince, HM; Rischin, D; Zimet, A | 1 |
| Milla, L; Milla-Santos, A; Rallo, L; Solano, V | 1 |
| Kokawa, Y; Matsuyama, K; Naito, Y; Nakamura, T; Oura, S; Sakurai, T; Tanino, H; Yoshimasu, T | 1 |
| Bauer, J; Borner, M; Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Veronesi, A | 1 |
| Ardizzoia, A; Conti, A; Fumagalli, E; Gardani, G; Lissoni, P; Maestroni, GJ; Tancini, G; Vaghi, M | 1 |
| Miller, ID; Smith, IC | 1 |
| Pintér, T; Szántó, J | 1 |
| Pagani, O; Sessa, C | 1 |
| Baselga, J; Tabernero, JM | 1 |
| Tolcher, AW | 1 |
| al Raheb, K; Bemer, M; Muhizi, J; Platini, C; Steinbach, G; Tomassini, E | 1 |
| Fleming, GF; Grinblatt, DL; Laport, GG; Waggoner, S; Williams, SF; Zimmerman, TM | 1 |
| Prescott, LM | 1 |
| Aydiner, A; Karadeniz, A; Sakar, B; Tas, F; Tenekeci, N; Topuz, E | 1 |
| Ikeda, H; Koshiba, R | 1 |
| Bruno, R; Montay, G; Rhodes, GR; Veyrat-Follet, C; Vivier, N | 1 |
| Baldini, E; Bengala, C; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Salvadori, B | 1 |
| Egawa, C; Miyoshi, Y; Noguchi, S; Taguchi, T; Takamura, Y; Tamaki, Y | 1 |
| Hopkins, U; Malik, U; Rajdev, L; Sarta, C; Sparano, JA; Wolff, AC | 1 |
| Bojko, P; Borquez, D; Kasimir-Bauer, S; Mayer, S; Neumann, R; Seeber, S | 1 |
| Bando, H; Hayashi, K; Kuroi, K; Nagai, S; Tanaka, C; Toi, M | 1 |
| Haga, S; Hirano, A; Imamura, H; Kajiwara, T; Kimura, K; Kinoshita, J; Nagumo, H; Okabe, T; Shimizu, T; Utada, Y; Watanabe, O | 2 |
| Hamazoe, R; Komuro, I; Murata, Y; Shimoyama, M; Sumi, KI | 1 |
| Ambrosini, G; Antoine, EC; Azli, N; Benhammouda, A; Borg-Olivier, O; Chollet, P; Khayat, D; Mazen, MF; Monfardini, S; Ramazeilles, C; Riva, A; Sorio, R | 1 |
| Delozier, T; Fumoleau, P; Guastalla, JP; Kerbrat, P; Roché, H; Viens, P | 1 |
| Pawlicki, M; Rolski, J; Rysz, B; Utych, G; Wiczyńska, B; Zemełka, T | 1 |
| Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H | 1 |
| Donaldson, KL; Mixan, BJ; Siegall, CB; Trail, PA; Wahl, AF | 1 |
| Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T | 1 |
| Blohmer, JU; Costa, SD; Eidtmann, H; Eiermann, W; Gademann, G; Graf, E; Hilfrich, J; Jackisch, C; Kaufmann, M; Merkle, E; Raab, G; Tulusan, AH; von Minckwitz, G | 1 |
| Baker, M; Bradof, JE; Burris, HA; Erland, JB; Greco, FA; Grimaldi, M; Hainsworth, JD; Kalman, LA; Sullivan, T; Yardley, DA | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J | 1 |
| Bunnell, CA; Burstein, HJ; Winer, EP | 1 |
| Azli, N; Bissery, MC; Borg-Olivier, O; Campone, M; Delecroix, V; Deporte-Fety, R; Fumoleau, P; Louboutin, JP; Perrocheau, G; Riva, A; Vernillet, L | 1 |
| Hada, M; Koshizuka, K; Mouri, N; Muto, S; Nakagomi, H; Serizawa, M; Tada, Y; Takano, K | 1 |
| Berry, D; Cooper, BW; Goldberg, S; Gray, R; Jennis, A; Lazarus, HM; Pecora, AL; Preti, R; Stadtmauer, EA; Van Vliet, A; Winter, J | 1 |
| Holmes, FA; Rowinsky, EK | 1 |
| Dieras, V; Perez, E; Valero, V | 1 |
| Pagani, O; Trudeau, M | 1 |
| Fujii, H; Igarashi, T; Imoto, S; Ishizawa, K; Itoh, K; Minami, H; Saeki, T; Sasaki, Y; Shigeoka, Y | 1 |
| Andres, R; Bueso, P; Escudero, P; Filipovich, E; Isla, MD; Martí, JL; Mayordomo, JI; Murillo, L; Saenz, A; Tres, A | 1 |
| Bergaglio, M; Cognetti, F; Del Mastro, L; Donati, S; Frevola, L; Lionetto, R; Lunardi, G; Michelotti, A; Papaldo, P; Rosso, R; Sguotti, C; Venturini, M | 1 |
| Giesel, BU; Kutz, GG; Thiel, HJ | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Katsumata, N; Miyakawa, K; Takahashi, T; Tsuda, H; Watanabe, T | 1 |
| Suzuki, Y; Tokuda, Y | 1 |
| Ishikawa, T; Itasaka, H; Kume, K; Matsusaka, T; Ohshiro, T; Ohta, M; Sonoda, K; Tashiro, H; Yamamura, S | 1 |
| Akaike, H; Ashizawa, I; Chiba, S; Imamura, K; Mitui, T; Miyauchi, Y; Muto, S; Nakagomi, H; Nakazawa, M; Okuda, J; Takahashi, M | 1 |
| Schwetz, BA | 1 |
| Beuzeboc, P; Diéras, V; Laurence, V; Pierga, JY; Pouillart, P | 1 |
| Leyland-Jones, B; Smith, I | 1 |
| Carman, L; Colborn, D; Gutterman, L; Jones, J; Kuebler, JP; Larrimer, N; Laufman, LR; Moore, T; Patel, T; Pritchard, J; Roach, R; Segal, M; Spiridonidis, CH; Zangmeister, J | 1 |
| Ishitobi, M; Kikkawa, N; Shin, E | 1 |
| Honda, S; Kawaguchi, Y; Kimura, A; Kunieda, K; Matsui, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H | 1 |
| Kawano, R; Kuroki, S; Matsuo, K; Nagata, S; Ogawa, T; Onzuka, T; Shinohara, M; Sumitomo, K; Suzuki, H; Yamanaka, N; Yoshida, J | 1 |
| Ezumi, K; Furukawa, H; Ikeda, M; Imamura, H; Ishida, H; Kawasaki, T; Masuda, N; Masutani, S; Miya, A; Satomi, T; Shimizu, J; Tatsuta, M | 1 |
| Oka, M; Saito, K; Takano, N; Tangoku, A | 1 |
| Blohmer, JU; Caputo, A; Costa, SD; du Bois, A; Eidtmann, H; Gademann, G; Gerber, B; Graf, E; Hilfrich, J; Jackisch, C; Kaufmann, M; Lampe, D; Merkle, E; Raab, G; Schütte, M; Sinn, HP; Tulusan, AH; von Minckwitz, G | 1 |
| Bastert, G; Beldermann, F; Geberth, M; Goerner, R; Lenz, F; Schneeweiss, A; Solomayer, E | 1 |
| Kunisue, H; Kurebayashi, J; Kurosumi, M; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, S | 1 |
| Hiraga, K; Honda, O; Matsuo, K | 1 |
| Airoldi, M; Arpicco, S; Brusa, P; Bumma, C; Cattel, L; Recalenda, V; Tagini, V | 1 |
| Aiba, K; Hashimoto, D; Horikoshi, N; Irie, T; Ito, Y; Mizunuma, N; Nakane, M; Saotome, T; Sugiyama, K; Takahashi, S; Tanigawara, Y; Yoshida, N | 1 |
| Chino, Y; Ogata, M; Suzuki, Y; Tani, T; Ubukata, N; Yoshihara, K | 1 |
| Ishihama, H | 1 |
| Brown, RE; Burrell, A; Hutton, J | 1 |
| Ahmadi, MA; Esmaeli, B | 1 |
| Blum, JL; Buzdar, A; Dieras, V; Horton, J; Lo Russo, PM; Osterwalder, B; Rutman, O | 1 |
| Bischoff, J; Forstpointner, R; Geuenich, S; Gutschow, K; Heinemann, V; Hiddemann, W; Kentenich, CH; Malekmohammadi, M; Sommer, H; Stemmler, HJ | 1 |
| Buyse, M; Duchateau, L; Lohrisch, C; Piccart, MJ | 1 |
| Ando, A; Miyoshi, Y; Noguchi, S; Taguchi, T; Takamura, Y; Tamaki, Y | 1 |
| Guan, X; Li, L; Zou, Y | 1 |
| Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Hamm, C; Karanes, C; Klein, JL; Peters, WP | 1 |
| Barbaro, P; Console, G; Iacopino, P; Irrera, G; Martino, M; Messina, G; Morabito, F; Oliva, E; Palazzo, S; Pucci, G | 1 |
| Rosenblum, MD; Shivers, RR | 1 |
| Awada, A; Brassinne, C; de Valeriola, D; Freyer, G; Gil, T; Hennebert, P; Kerger, J; Piccart, M; Selleslags, J | 1 |
| Brugnatelli, S; Danova, M; De Bella, MT; Manuguerra, G; Palmeri, S; Riccardi, A; Vaglica, M | 1 |
| Glaspy, J; Hill, LR; Holmes, FA; Jones, SE; Liang, BC; Meza, L; Moore, M; Neumann, TA; O'Shaughnessy, JA; Savin, M; Shogan, J; Vukelja, S; Wiznitzer, I | 1 |
| Fleming, D; Hahl, M; Morkas, M | 1 |
| Arkad'eva, TV; Artamonova, EV; Davidenko, IS; Manziuk, LV; Poddubnaia, IV | 1 |
| Caruso, A; De Carolis, S; De Santis, M; Ferrazani, S; Lucchese, A | 1 |
| Frye, D; Hortobagyi, GN; Ibrahim, NK; Murray, JL; Rahman, Z; Valero, V | 1 |
| Mortimer, JE; Picus, J; Read, WL | 1 |
| Cohen, Y; Hertzanu, Y; Mermershtain, W; Schulman, H | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Collan, J; Franssila, K; Malmström, P; Mjaaland, I; Saksela, E; Sjöström, J; Skiöld-Petterson, D; Valvere, V; von Boguslawski, K; Wist, E; Østenstad, B | 1 |
| Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Ahmadi, MA; Arbuckle, R; Booser, D; Delpassand, E; Esmaeli, B; Esteva, F; Hortobagyi, G; Ibrahim, N; Valero, V | 1 |
| Bighin, C; Del, ML; Esposito, M; Lunardi, G; Schettini, G; Tolino, G; Vannozzi, MO; Venturini, M | 1 |
| Aihara, T; Kim, Y; Takatsuka, Y | 1 |
| Sun, Y | 1 |
| Ah-See, AK; Eggleton, SP; Eremin, O; Gilbert, FJ; Heys, SD; Hutcheon, AW; Miller, ID; Ogston, KN; Payne, S; Sarkar, TK; Smith, IC; Walker, LG | 1 |
| Maher, JF; Villalona-Calero, MA | 1 |
| Partridge, A; Winer, E | 1 |
| Bourlon-Cuellar, R; Candelaria, M; Noel-Ettiene, LM; Sánchez-Sánchez, JM; Zubieta, JL | 1 |
| Gnant, MF; Jakesz, R; Locker, GJ; Rudas, M; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
| Arun, B; Booser, D; Cristofanilli, M; Esmaeli, B; Esteva, FJ; Fritsche, HA; Guerra, LT; Hortobagyi, GN; Murray, JL; Pusztai, L; Smith, TL; Sneige, N; Valero, V | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Labonia, V; Landi, G; Mastro, AA; Nuzzo, F; Perrone, F; Rossi, E | 1 |
| Inaji, H; Kobayashi, H; Motomura, K; Noguchi, S; Taguchi, T; Takamura, Y | 1 |
| Alvarez, I; Andres, R; Escudero, P; Filipovich, E; Isla, D; Marti, JL; Mayordomo, JI; Polo, E; Saenz, A; Tres, A | 1 |
| Nabholtz, JM; Riva, A | 1 |
| O'Callaghan, C; Pegram, MD | 1 |
| Antila, K; Ekholm, E; Jalonen, J; Rantanen, V; Salminen, E; Syvänen, K | 1 |
| Thomssen, C | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Payrits, T; Raderer, M; Scheithauer, W; Schüll, B | 1 |
| Booser, DJ; Cristofanilli, M; Frye, DK; Hortobagyi, GN; Rivera, E; Rosales, MM; Valero, V | 1 |
| Emoto, T; Fujii, M; Fujikawa, M; Hamada, E; Komaki, T; Naka, Y; Yoshikawa, K; Yoshioka, Y | 1 |
| Ahmadi, MA; Arbuckle, R; Booser, D; Delpassand, E; Esmaeli, B; Esteva, FJ; Guerra, L; Hortobagyi, GN; Rivera, E; Valero, V | 1 |
| Angiolini, C; Baldini, A; Bergaglio, M; Canavese, G; Del Mastro, L; Garrone, O; Lambiase, A; Merlano, M; Rosso, R; Tolino, G; Venturini, M | 1 |
| Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S | 1 |
| Bengtsson, NO; Blomqvist, C; Heikkilä, R; Malmström, P; Ostenstad, B; Paavonen, T; Saksela, E; Sjöström, J; Tynninen, O; Valvere, V; von Boguslawski, K; Wist, E | 1 |
| Boulamatsis, D; Kanelopoulos, P; Kosmas, C; Tsavaris, N; Vadiaka, M | 1 |
| Arbuck, SG; Canetta, RM; Onetto, N; Rowinsky, EK | 1 |
334 review(s) available for docetaxel anhydrous and Breast Cancer
| Article | Year |
|---|---|
Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Isoxazoles | 2021 |
Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans | 2021 |
Docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Humans; Progression-Free Survival; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2021 |
A Meta-Analysis of the Efficacy of Albumin Paclitaxel versus Docetaxel in the Treatment of Breast Cancer.
Topics: Albumins; Asian People; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel | 2021 |
Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Nanoparticles; Paclitaxel; Randomized Controlled Trials as Topic; Solvents; Taxoids | 2022 |
The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Radiation recall dermatitis: A review of the literature.
Topics: Antimetabolites; Breast Neoplasms; Docetaxel; Female; Humans; Radiodermatitis | 2022 |
Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Polyphenols; Resveratrol; Stilbenes; Tumor Microenvironment; Water | 2022 |
Adjuvant Chemotherapy in Older Women With Early Breast Cancer.
Topics: Aged; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoplasm Recurrence, Local | 2023 |
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Receptors, Estrogen | 2023 |
Topics: Adolescent; Adult; Animals; Asthma; Atrial Fibrillation; Autoantibodies; Biomarkers; Breast Neoplasms; Child; Conjunctivitis, Allergic; Cornea; COVID-19; Cyclosporine; Cytokines; Death, Sudden, Cardiac; Defibrillators, Implantable; Diet; Disease Models, Animal; Docetaxel; Double-Blind Method; Dry Eye Syndromes; Educational Status; Emulsions; Female; Fluorescein Angiography; Fluoresceins; Focus Groups; Heart Failure; Hemothorax; Humans; Inflammation; Keratoconus; Male; Meibomian Glands; Mice; Middle Aged; Multiple Sclerosis; Myocardial Infarction; Myocardium; Nerve Fibers; Nigeria; Obesity; Overweight; Pandemics; Primary Prevention; Prospective Studies; Qualitative Research; Registries; Retinal Ganglion Cells; Retinal Vessels; Schools; Sirolimus; Tertiary Care Centers; Th1 Cells; Th2 Cells; Tomography, Optical Coherence; Troponin I; Tumor Necrosis Factor-alpha; United States; Ventricular Remodeling | 2022 |
Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Dermatoglyphics; Docetaxel; Female; Hand-Foot Syndrome; Humans | 2020 |
Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Genes, erbB-2; Humans; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2019 |
Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Docetaxel; Epistaxis; Exanthema; Female; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab | 2019 |
Comparative Effectiveness of Taxane-Containing Regimens for Treatment of HER2-Negative Metastatic Breast Cancer: A Network Meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Network Meta-Analysis; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate | 2019 |
Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aortitis; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Female; Fever; Filgrastim; Fluorodeoxyglucose F18; Granulocyte Colony-Stimulating Factor; Humans; Polyethylene Glycols; Positron Emission Tomography Computed Tomography; Trastuzumab | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
[Gastrointestinal symptoms revealing COVID-19 in Malian breast cancer patient undergoing chemotherapy].
Topics: Adult; Antineoplastic Agents, Phytogenic; Betacoronavirus; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Coronavirus Infections; COVID-19; Diarrhea; Docetaxel; Fatal Outcome; Female; HIV Infections; Humans; Liver Neoplasms; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spinal Neoplasms; Tomography, X-Ray Computed; Vomiting; Zoledronic Acid | 2020 |
Role of TDM-based dose adjustments for taxane anticancer drugs.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2021 |
Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Humans; Prognosis; Taxoids | 2021 |
The Role of Serotonin in Breast Cancer Stem Cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Docetaxel; Epithelial-Mesenchymal Transition; Female; Humans; Mice; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Phenotype; Receptors, Serotonin; Remission Induction; Serotonin; Sertraline; Signal Transduction | 2021 |
Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Hospitalization; Humans; Insurance Claim Review; Middle Aged; Paclitaxel; Patient Care; Retrospective Studies; Taxoids; Young Adult | 2017 |
Breast angiosarcoma without radiation history, putatively associated with subclinical lymphedema: A case report and review of the Japanese literature.
Topics: Axilla; Breast Neoplasms; Chemoradiotherapy; Docetaxel; External Fixators; Female; Hemangiosarcoma; Humans; Lymph Node Excision; Lymphedema; Mastectomy, Segmental; Middle Aged; Neoplasms, Second Primary; Spinal Diseases; Treatment Outcome | 2017 |
Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Proportional Hazards Models; Receptor, ErbB-2; Taxoids; Trastuzumab; Young Adult | 2017 |
Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Female; Humans; Models, Economic; Neoadjuvant Therapy; Neoplasm Staging; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Technology Assessment, Biomedical; Trastuzumab | 2018 |
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review.
Topics: Aged; Albumins; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cross Reactions; Docetaxel; Drug Hypersensitivity; Female; Humans; Paclitaxel; Taxoids | 2017 |
Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Molecular Targeted Therapy; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab | 2018 |
[A Case of Retroperitoneal Abscess Due to Acute Appendicitis during Neo-Adjuvant Chemotherapy for Breast Cancer].
Topics: Abdominal Abscess; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Taxoids; Trastuzumab | 2017 |
Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Docetaxel; Drugs, Chinese Herbal; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Quality of Life; Randomized Controlled Trials as Topic | 2018 |
Treatment of massive liver metastasis of breast cancer during pregnancy: first report of a complete remission with trastuzumab and review of literature.
Topics: Adult; Antineoplastic Agents, Immunological; Breast Neoplasms; Docetaxel; Female; Humans; Liver Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Trastuzumab | 2020 |
Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoprevention; Cyclophosphamide; Docetaxel; Epirubicin; Febrile Neutropenia; Female; Fluorouracil; Humans; Risk Factors; Treatment Outcome | 2018 |
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Female; Humans; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2019 |
Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Nervous System; Neutropenia; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2019 |
Adjuvant systemic therapies in breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Mastectomy; Paclitaxel; Practice Guidelines as Topic; Prognosis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
Trastuzumab emtansine in breast cancer.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
Primary angiosarcoma of the breast: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Developing Countries; Docetaxel; Female; Gemcitabine; Hemangiosarcoma; Humans; Lymph Node Excision; Magnetic Resonance Imaging; Mammaplasty; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Surgical Flaps; Taxoids; Thailand | 2013 |
[Impact of taxanes in the adjuvant setting of node-negative breast cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Methotrexate; Paclitaxel; Tamoxifen; Taxoids | 2013 |
[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gene Amplification; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neovascularization, Pathologic; Prognosis; Quinazolines; Receptor, ErbB-2; Taxoids; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Proteins; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome; Young Adult | 2015 |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Topics: Ado-Trastuzumab Emtansine; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Comorbidity; Docetaxel; Drug Administration Schedule; Evidence-Based Medicine; Female; Health Status Disparities; Healthcare Disparities; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Societies, Medical; Taxoids; Trastuzumab; Treatment Outcome; Triazoles; United States | 2014 |
Breast carcinoma with choriocarcinomatous features: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Choriocarcinoma; Chorionic Gonadotropin; Cisplatin; Combined Modality Therapy; Cyclobutanes; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Giant Cells; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Organoplatinum Compounds; Prognosis; Retrospective Studies; Taxoids | 2014 |
Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Female; Humans; Models, Economic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Edema; Female; Humans; Lymphedema; Mastectomy; Postoperative Complications; Risk Factors; Taxoids | 2016 |
Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2015 |
The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Staging; Odds Ratio; Pre-Exposure Prophylaxis; Risk; Taxoids | 2015 |
Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Humans; Platinum Compounds; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2015 |
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Management of patients treated with pertuzumab in the Australian clinical practice setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Bridged-Ring Compounds; Disease Management; Disease Progression; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2016 |
Pertuzumab and trastuzumab: the rationale way to synergy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Receptor, ErbB-2; Taxoids; Trastuzumab | 2016 |
[Fatal acute interstitial lung disease associated with docetaxel administration: about a case and review of the literature].
Topics: Acute Disease; Adult; Antineoplastic Agents; Breast Neoplasms; Diagnosis, Differential; Docetaxel; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Taxoids | 2016 |
Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoprevention; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Taxoids | 2017 |
A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2016 |
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Genes, erbB-2; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2008 |
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2008 |
Lessons learned from development of docetaxel.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Interactions; Female; Humans; Neoplasms; Pharmacogenetics; Taxoids | 2008 |
Novel targeting therapy concept for breast cancer treatment.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Gene Targeting; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Trastuzumab | 2008 |
Paclitaxel and docetaxel in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Consensus Development Conferences as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lapatinib; Paclitaxel; Publication Bias; Publishing; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Time; Trastuzumab | 2008 |
Capecitabine and docetaxel combination for the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2008 |
[Problems and future direction of preoperative systemic therapy for patients with operable breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Letrozole; Nitriles; Prednisone; Preoperative Care; Remission Induction; Survival Rate; Taxoids; Triazoles; Vincristine | 2008 |
Economic evaluation of docetaxel for breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Docetaxel; Female; Humans; Neoadjuvant Therapy; Taxoids | 2009 |
Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis.
Topics: Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2010 |
Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Clinical Trials as Topic; Docetaxel; Female; Fluorouracil; Genes, erbB-2; Humans; Immunoconjugates; Maytansine; Mice; Mice, SCID; Receptor, ErbB-2; Taxoids; Trastuzumab | 2010 |
Controversies in the management of adjuvant breast cancer with taxanes: review of the current literature.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Paclitaxel; Practice Guidelines as Topic; Taxoids | 2011 |
Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Male; Mice; Neutropenia; Prednisone; Prostatic Neoplasms; Rats; Taxoids | 2010 |
[Non-pegylated doxorubicin (Myocet®) as the less cardiotoxic alternative of free doxorubicin].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart Diseases; Humans; Neoplasms; Paclitaxel; Taxoids; Trastuzumab | 2010 |
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Platinum; Receptors, Estrogen; Taxoids | 2011 |
[Subacute cutaneous lupus erythematosus and cancer: two cases and literature review].
Topics: Adenocarcinoma; Aged; Antibodies, Antinuclear; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous; Mastectomy; Middle Aged; Paclitaxel; Paraneoplastic Syndromes; Ribonucleoproteins; Salvage Therapy; Tamoxifen; Taxoids; Trastuzumab | 2011 |
Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasms; Paclitaxel; Standard of Care; Taxoids | 2011 |
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2011 |
Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Taxoids | 2011 |
Docetaxel combined with targeted therapies in metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Indoles; Lapatinib; Pyrroles; Quinazolines; Sunitinib; Taxoids; Trastuzumab | 2012 |
Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Taxoids | 2012 |
Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Paclitaxel; Taxoids | 2012 |
[Pharmacoeconomic aspects of breast cancer management].
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Costs; Economics, Pharmaceutical; Female; Humans; Russia; Taxoids | 2011 |
Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm Staging; Odds Ratio; Randomized Controlled Trials as Topic; Taxoids; Young Adult | 2012 |
Pre-eclampsia following chemotherapy for breast cancer during pregnancy: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cesarean Section; Cyclophosphamide; Docetaxel; Female; HELLP Syndrome; Humans; Infant, Newborn; Male; Pre-Eclampsia; Pregnancy; Pregnancy Complications, Neoplastic; Taxoids | 2012 |
Surgical considerations in patients receiving neoadjuvant systemic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Meta-Analysis as Topic; Neoadjuvant Therapy; Sentinel Lymph Node Biopsy; Taxoids; Treatment Outcome | 2012 |
A case report of primary small cell carcinoma of the breast and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Small Cell; CD56 Antigen; Docetaxel; Female; Humans; Lymphatic Metastasis; Mammography; Nuclear Proteins; Phosphopyruvate Hydratase; Synaptophysin; Taxoids; Thyroid Nuclear Factor 1; Transcription Factors; Ultrasonography | 2012 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature.
Topics: Antineoplastic Agents; Birth Weight; Breast Neoplasms; Bridged-Ring Compounds; Cohort Studies; Docetaxel; Female; Gestational Age; Humans; Ovarian Neoplasms; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Retrospective Studies; Taxoids | 2012 |
Pertuzumab in HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; PubMed; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lapatinib; Mastectomy, Segmental; Paclitaxel; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sulfonamides; Taxoids; Trastuzumab | 2012 |
Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nomograms; Predictive Value of Tests; Risk Factors; Sentinel Lymph Node Biopsy; Taxoids; Treatment Outcome | 2012 |
Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Interactions; Humans; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.
Topics: Breast Neoplasms; Docetaxel; Female; Humans; Multidrug Resistance-Associated Protein 2; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; Precision Medicine; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids | 2012 |
Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2013 |
Lethal pneumonitis after docetaxel chemotherapy: case report and review of the literature.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Docetaxel; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Middle Aged; Taxoids | 2013 |
The current status of docetaxel for metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids | 2002 |
Integration of docetaxel into adjuvant breast cancer treatment regimens.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2002 |
Primary chemotherapy with docetaxel for the management of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2002 |
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Platinum Compounds; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2002 |
Gemcitabine and targeted therapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Docetaxel in the treatment of breast cancer: an update on recent studies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2002 |
Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Hematologic Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
[Radiation recall dermatitis after docetaxel and external beam radiotherapy. Report of two cases and review of the literature].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel; Radiodermatitis; Radiotherapy; Taxoids | 2002 |
Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
The European experience with docetaxel in the treatment of early-stage breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Europe; Female; Genes, p53; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Multicenter Studies as Topic; Paclitaxel; Platinum Compounds; Receptor, ErbB-2; Taxoids; Trastuzumab; Up-Regulation | 2002 |
Ongoing US cooperative group trials using taxanes in the adjuvant setting.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Risk Factors; Taxoids; Trastuzumab; United States | 2002 |
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Drug Synergism; Enzyme Induction; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Thymidine Phosphorylase; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
[Gemcitabine and breast cancer].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Combination versus sequential single-agent therapy in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Research Design; Taxoids; Trastuzumab | 2002 |
Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Taxoids | 2003 |
Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Paclitaxel; Taxoids | 2003 |
Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Survival Analysis; Taxoids; Treatment Outcome; United States | 2002 |
Adjuvant systemic therapy of early stage breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Enzyme Inhibitors; Female; Humans; Neoplasm Staging; Paclitaxel; Taxoids | 2003 |
Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vindesine; Vinorelbine | 2003 |
The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials as Topic; Docetaxel; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2003 |
Gemcitabine combined with docetaxel in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
[Gene therapy for breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Genes, erbB-2; Genes, MDR; Genes, p53; Genes, Tumor Suppressor; Genetic Therapy; Genetic Vectors; Humans; Interleukins; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Retroviridae; Taxoids | 2003 |
The evolving role of capecitabine in breast cancer.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Prodrugs; Taxoids; Trastuzumab; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2003 |
Exudative hyponychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: report of three cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Eruptions; Exudates and Transudates; Female; Fluorouracil; Humans; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 2003 |
Docetaxel-anthracycline combinations in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2003 |
Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2003 |
Neoadjuvant docetaxel in locally advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids | 2003 |
The role of taxanes in the adjuvant treatment of early stage breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2003 |
Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2003 |
Use and abuse of taxanes in the management of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bias; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Substance-Related Disorders; Taxoids | 2003 |
[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2003 |
Advances in the use of taxanes in the adjuvant therapy of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2003 |
[Primary systemic therapy of carcinoma of the breast - update of the geparduo studies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Randomized Controlled Trials as Topic; Taxoids | 2003 |
Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Neutrophils; Recombinant Proteins; Taxoids; Time Factors | 2003 |
Long-term suppression of lymphangitic lung metastasis from breast cancer using biweekly docetaxel: a case report.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Taxoids; Tomography, X-Ray Computed | 2003 |
The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
Topics: Animals; Breast Neoplasms; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids | 2003 |
The best use of chemotherapy in the adjuvant setting.
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2003 |
[Current status and perspectives of chemotherapy for anthracycline-pretreated breast cancer].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Retreatment; Survival Rate; Taxoids; Treatment Outcome | 2003 |
[Taxanes in primary systemic treatment of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Mastectomy, Segmental; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Rationale for the use of gemcitabine in breast cancer (Review).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Glutamates; Guanine; Humans; Pemetrexed; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2004 |
Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Humans; Neoplasm Metastasis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; State Medicine; Survival Rate; Taxoids; Treatment Outcome; United Kingdom | 2004 |
Taxanes in elderly breast cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
HERe-2 stay: the continuing importance of translational research in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Research Design; Taxoids; Trastuzumab; Up-Regulation | 2004 |
Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: general concepts and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Synergism; Female; Gemcitabine; Humans; Taxoids | 2004 |
Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Epirubicin; Gemcitabine; Humans; Neoadjuvant Therapy; Taxoids | 2004 |
[Update on docetaxel and breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Taxoids; Trastuzumab | 2004 |
Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids | 2004 |
Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2004 |
Gemcitabine and docetaxel in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Taxoids; Time Factors; Treatment Outcome | 2004 |
Management of excessive tearing as a side effect of docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Conjunctivitis; Constriction, Pathologic; Docetaxel; Female; Humans; Lacrimal Apparatus Diseases; Taxoids | 2005 |
Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Survival Rate; Taxoids | 2005 |
[The action and toxicity of taxanes].
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Taxoids | 2005 |
Docetaxel for treatment of solid tumours: a systematic review of clinical data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2005 |
Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer.
Topics: Activities of Daily Living; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Diabetes Mellitus, Type 1; Disease Progression; Docetaxel; Exercise Therapy; Female; Hand Strength; Humans; Middle Aged; Nurse's Role; Oncology Nursing; Pain; Pain Management; Pain Measurement; Patient Care Team; Peripheral Nervous System Diseases; Quality of Life; Severity of Illness Index; Taxoids | 2005 |
[Neoadjuvant treatment of early breast cancer: new drugs contribution].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2004 |
[Targeted therapies: last focus on EGF receptor inhibitors in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estradiol; Taxoids; Trastuzumab | 2004 |
Docetaxel administration schedule: from fever to tears? A review of randomised studies.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Therapy of breast cancer with molecular targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclooxygenase 2; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Paclitaxel; Prenylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab | 2005 |
The role of taxanes in the treatment of breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2005 |
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Taxoids | 2005 |
Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Maximum Tolerated Dose; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Taxanes in adjuvant breast cancer setting: which standard in Europe?
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Europe; Female; Humans; Paclitaxel; Taxoids | 2005 |
Docetaxel/trastuzumab combination therapy for the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2005 |
Docetaxel in the treatment of breast cancer: current experience and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Humans; Neoplasm Metastasis; Neoplasm Staging; Taxoids | 2005 |
Radiation recall dermatitis after docetaxel administration: absolute indication to replace the drug?
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Contraindications; Docetaxel; Female; Humans; Middle Aged; Radiation-Sensitizing Agents; Radiodermatitis; Taxoids | 2005 |
[Taxotere application in the management of breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Humans; Taxoids; Treatment Outcome | 2005 |
Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2005 |
Taxanes in the treatment of early breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Taxoids | 2005 |
Docetaxel: a review of its use in metastatic breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Humans; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2005 |
Recent findings with docetaxel in postoperative treatment for breast cancer.
Topics: Breast Neoplasms; Docetaxel; Female; Humans; Postoperative Care; Taxoids | 2005 |
Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2006 |
Optimizing adjuvant chemotherapy in early-stage breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2006 |
Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Metastasis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Tubulin Modulators | 2006 |
[Construction of optimal combined chemotherapy of anti-tumor drugs based on chronotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chronotherapy; Circadian Rhythm; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Taxoids | 2006 |
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
[Current status of adjuvant chemotherapy for breast cancer].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Menopause; Perioperative Care; Tamoxifen; Taxoids; Trastuzumab | 2006 |
[Molecular-targeted agents in breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Indoles; Lapatinib; Middle Aged; Paclitaxel; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab | 2006 |
Hematopoietic support with moderately myelosuppressive chemotherapy regimens: a nursing perspective.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Docetaxel; Drug Therapy, Combination; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2006 |
Overview of gemcitabine activity in advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids | 2006 |
Chemotherapy with taxanes in breast cancer during pregnancy: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Taxoids | 2006 |
Predictive factors for response to docetaxel in human breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Taxoids | 2006 |
Gemcitabine and taxanes in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2006 |
Usefulness of predictive tests for cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; ErbB Receptors; Gemcitabine; Genes, ras; Humans; Lung Neoplasms; Membrane Glycoproteins; Polymorphism, Single Nucleotide; Predictive Value of Tests; Randomized Controlled Trials as Topic; RNA, Messenger; Semaphorins; Taxoids; Ubiquitin-Protein Ligases | 2006 |
Capecitabine-docetaxel combination treatment.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Taxoids | 2006 |
[Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer].
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Contraindications; Docetaxel; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Pharmacogenetics and oncology treatment for breast cancer.
Topics: Aromatase Inhibitors; Biological Transport; Breast Neoplasms; Cytochrome P-450 CYP2D6; Docetaxel; Female; Gene Amplification; Genes, bcl-1; Glucuronosyltransferase; Humans; Paclitaxel; Pharmacogenetics; Tamoxifen; Taxoids | 2007 |
Docetaxel/anthracycline combinations for breast cancer treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Safety; Taxoids | 2007 |
Telling cells how to die: docetaxel therapy in cancer cell lines.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Death; Cell Line, Tumor; Docetaxel; Genes, cdc; Humans; Microtubules; Taxoids | 2007 |
Gemcitabine in the management of metastatic breast cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Heart Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2007 |
[Breast conserving surgery after preoperative chemotherapy].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Evidence-Based Medicine; Female; Humans; Mastectomy, Segmental; Paclitaxel; Preoperative Care; Prognosis; Sentinel Lymph Node Biopsy; Taxoids; Trastuzumab | 2007 |
[Optimal chemotherapy for advanced and recurrent breast cancer patients].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diphosphonates; Docetaxel; Female; Fluorouracil; Humans; Informed Consent; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Patient Care Team; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Silicates; Taxoids; Titanium; Trastuzumab | 2007 |
[Strategy in the treatment of anthracycline-resistant breast cancer].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Taxoids; Vinblastine; Vinorelbine | 2007 |
Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Models, Biological; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2007 |
Emerging therapeutic options for breast cancer chemotherapy during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Lapatinib; Oligohydramnios; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2008 |
Taxanes for adjuvant treatment of early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2007 |
Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2008 |
Role of gemcitabine in metastatic breast cancer patients: a short review.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Neoplasm Metastasis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Cognitive impairment with significant brain parenchymal volume loss following standard adjuvant chemotherapy in a patient with breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; Dementia; Docetaxel; Doxorubicin; Female; Humans; Magnetic Resonance Imaging; Mastectomy, Segmental; Memory Disorders; Middle Aged; Taxoids | 2007 |
Comparing methods for full versus single technology appraisal: a case study of docetaxel and paclitaxel for early breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Decision Making; Docetaxel; Early Diagnosis; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Uncertainty | 2008 |
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Taxoids; Vascular Endothelial Growth Factor A | 2008 |
Treatment of metastatic breast cancer: looking towards the future.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Medical Oncology; Neoplasm Metastasis; Paclitaxel; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
The taxane limbo: how low can we go?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Meta-Analysis as Topic; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Retrospective Studies; Taxoids | 2008 |
Docetaxel.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1995 |
[Taxenes: a new hope of clinical oncology in the 90-ies].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
[Recent advance in chemotherapy for breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Docetaxel; Female; Humans; Irinotecan; Mitoxantrone; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids | 1994 |
Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
Current status of Taxotere (docetaxel) as a new treatment in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Tolerance; Humans; Paclitaxel; Taxoids | 1995 |
New chemotherapeutic agents for breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1994 |
Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Dogs; Drug Screening Assays, Antitumor; Female; Humans; Mice; Ovarian Neoplasms; Paclitaxel; Rats; Taxoids; Tumor Cells, Cultured | 1994 |
The taxoids: paclitaxel and docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Hypersensitivity; Drug Interactions; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1994 |
The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1993 |
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lethal Dose 50; Lung Neoplasms; Microtubules; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1995 |
Taxoid compounds in breast cancer: current status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1995 |
Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 1995 |
Taxoids: effective agents in anthracycline-resistant breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids | 1995 |
Docetaxel (Taxotere) in combination: a step forward.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Clinical Trials as Topic; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1995 |
The role of taxanes in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Taxoids | 1996 |
Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
Docetaxel: a new defence in the management of breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Doxorubicin; Female; Humans; Liver Neoplasms; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 1995 |
Docetaxel (Taxotere) for advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
Docetaxel: a review of its pharmacology and clinical activity.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Eruptions; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Microtubules; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tubulin | 1996 |
Treatment of advanced breast cancer: current status.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1996 |
Treatment of patients with liver metastases.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Liver Neoplasms; Paclitaxel; Taxoids | 1996 |
The clinical rationale for developing docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Therapy, Combination; Humans; Paclitaxel; Taxoids | 1996 |
Taxoids in combination chemotherapy for metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
Metastatic breast cancer.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome | 1996 |
[Progress and perspectives in palliative therapy of breast carcinoma].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Female; Goserelin; Humans; Paclitaxel; Palliative Care; Tamoxifen; Taxoids | 1996 |
The international experience with docetaxel in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids | 1997 |
Docetaxel in breast cancer and a rationale for combination therapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Mice; Paclitaxel; Taxoids | 1997 |
[Development of a new tubulin-interacting agent, docetaxel (taxotere) in Japan].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin | 1997 |
Docetaxel. A review of its role in breast cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Paclitaxel; Remission Induction; Safety; Taxoids | 1997 |
Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Future perspectives of docetaxel (Taxotere) in front-line therapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Paclitaxel; Taxoids | 1997 |
Paclitaxel and docetaxel in breast and ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 1997 |
The taxoids: same roots, different drugs.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids | 1997 |
Docetaxel in combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance; Female; Humans; Paclitaxel; Taxoids | 1997 |
[A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1997 |
Review of docetaxel/doxorubicin combination in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1997 |
Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Metastasis; Nervous System Diseases; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 1997 |
Efficacy and safety of docetaxel in clinical trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Male; Paclitaxel; Taxoids | 1997 |
[Docetaxel (taxotere) for therapy of breast carcinoma. Highest effectiveness with moderate side effects].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Synergism; Female; Humans; Liver Neoplasms; Paclitaxel; Survival Rate; Taxoids | 1997 |
The taxoids. Comparative clinical pharmacology and therapeutic potential.
Topics: Alopecia; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids | 1998 |
Review of recent trials of chemotherapy for advanced breast cancer: the taxanes.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
The role of docetaxel in improving treatment outcomes in advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids | 1997 |
Docetaxel in combination with doxorubicin or vinorelbine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
Prospects with docetaxel in the treatment of patients with breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Taxanes in adjuvant and neoadjuvant therapies for breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1998 |
Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers; Breast Neoplasms; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Phenotype; Taxoids | 1998 |
Primary chemotherapy regimens and schedules.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids | 1998 |
Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Humans; Lymph Node Excision; Mastectomy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1998 |
[The effect of docetaxel on malignant tumors].
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1998 |
[Chemotherapy in metastasized breast carcinoma].
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoplasm Metastasis; Neoplasms, Second Primary; Paclitaxel; Palliative Care; Quality of Life; Survival Rate; Taxoids | 1998 |
Docetaxel: a taxoid for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1998 |
[Current developments in use of docetaxel (taxotere) in gynecologic oncology].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 1998 |
[Taxanes in the treatment of breast and ovarian cancers: current indications and results].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
An expanding role for docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Taxoids | 1998 |
Evolution in the treatment of advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
["Taxanes: an action mechanism at the cellular level, significant clinical progress in the treatment of cancers of the ovary and breast"].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Research Design; Taxoids | 1998 |
Taxanes in the treatment of breast cancer: a prodigy comes of age.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Neoplasm Proteins; Paclitaxel; Palliative Care; Survival Analysis; Taxoids; Tubulin; Vinca Alkaloids | 1999 |
A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Recently initiated studies: neoadjuvant treatments in the next century.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1999 |
[Taxotere as second-line for metastatic breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Monotherapy of metastatic breast cancer: a review of newer agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Paclitaxel; Palliative Care; Taxoids; Vinblastine; Vinorelbine | 1999 |
Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Economics, Pharmaceutical; Female; Humans; Paclitaxel; Taxoids | 1998 |
The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Mitomycin; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine | 1999 |
Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Single-agent docetaxel (Taxotere) in randomized phase III trials.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Failure | 1999 |
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Recent progress in the clinical development of docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Taxanes in combined-modality therapy for solid tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids | 1999 |
Expanding options in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
[New combination chemotherapies for breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Docetaxel: an update of its use in advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Economics, Pharmaceutical; Female; Humans; Metabolic Clearance Rate; Paclitaxel; Taxoids; Tissue Distribution; Tumor Cells, Cultured | 2000 |
The taxanes: an update.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2000 |
Docetaxel (Taxotere) in the treatment of cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Prostatic Neoplasms; Taxoids | 2000 |
Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Taxoids | 2000 |
Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Prognosis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2000 |
[Evidence for Taxotere treatment with solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Evidence-Based Medicine; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Stomach Neoplasms; Taxoids | 2000 |
[Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Evidence-Based Medicine; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
Chemotherapy-induced complete regression of choroidal metastases and subsequent isolated leptomeningeal carcinomatosis in advanced breast cancer: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Choroid Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Meningeal Neoplasms; Methotrexate; Mitoxantrone; Paclitaxel; Survival Analysis; Taxoids | 2000 |
[Neoadjuvant chemotherapy for locally advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Premedication; Tamoxifen; Taxoids | 2000 |
[Standard chemotherapy for metastatic breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Practice Guidelines as Topic; Prognosis; Taxoids | 2000 |
[Docetaxel hydrate for treatment of advanced breast cancers].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Paclitaxel; Taxoids | 2000 |
[Chemosensitivity test of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Taxoids; Tumor Cells, Cultured | 2000 |
State-of-the-art chemotherapy for advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2000 |
A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Quality of Life; Survival Analysis; Taxoids | 2000 |
Risks and benefits of taxanes in breast and ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Paclitaxel; Premedication; Taxoids | 2000 |
Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Genes, erbB-2; Humans; Paclitaxel; Taxoids; Trastuzumab | 2000 |
Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 2001 |
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Docetaxel; Drug Synergism; Genes, erbB-2; Heart Failure; Humans; Paclitaxel; Prognosis; Proto-Oncogene Mas; Taxoids; Trastuzumab | 2001 |
The platinum agents: a role in breast cancer treatment?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids; Trastuzumab | 2001 |
Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Genes, erbB-2; Humans; Paclitaxel; Taxoids; Trastuzumab | 2001 |
Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Methylprednisolone; Middle Aged; Paclitaxel; Taxoids; Thiotepa | 2001 |
Issues involved in research into the neoadjuvant treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Research; Taxoids | 2001 |
Docetaxel: overview of an active drug for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2001 |
Docetaxel and epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Paclitaxel; Taxoids | 2001 |
Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2001 |
Weekly docetaxel in breast cancer: applying clinical data to patient therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chronotherapy; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2001 |
Novel compounds in the therapy of breast cancer: opportunities for integration with docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Oligonucleotides, Antisense; Paclitaxel; Taxoids | 2001 |
Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Computer Simulation; Docetaxel; Humans; Lung Neoplasms; Models, Statistical; Neoplasms; Nonlinear Dynamics; Paclitaxel; Prospective Studies; Research Design; Taxoids | 2001 |
Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.
Topics: Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Italy; Meta-Analysis as Topic; Paclitaxel; Taxoids | 2001 |
New cytotoxic agents and schedules for advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Humans; Liposomes; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Trastuzumab; Vinblastine; Vinorelbine | 2001 |
Pharmacokinetic profiles of doxorubicin in combination with taxanes.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Drug Interactions; Humans; Paclitaxel; Taxoids | 2001 |
Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2001 |
Epirubicin in combination with the taxanes.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Epirubicin; Heart Diseases; Humans; Paclitaxel; Taxoids | 2001 |
[Recall dermatitis caused by re-exposure to docetaxel following irradiation of the brain. Case report and review of the literature].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Drug Eruptions; Female; Humans; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy Dosage; Taxoids | 2001 |
[Docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Paclitaxel; Taxoids | 2001 |
Interaction between Herceptin and taxanes.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Heart Diseases; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Nervous System Diseases; Neutropenia; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, ErbB-3; Salvage Therapy; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2001 |
Role of Herceptin in primary breast cancer: views from North America and Europe.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Interactions; Europe; Female; Humans; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; North America; Paclitaxel; Palliative Care; Pilot Projects; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Safety; Survival Analysis; Tamoxifen; Taxoids; Trastuzumab; Treatment Outcome | 2001 |
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Female; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Taxoids; Treatment Outcome | 2001 |
Cost effectiveness of treatment options in advanced breast cancer in the UK.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Decision Making, Computer-Assisted; Docetaxel; Female; Humans; Paclitaxel; Quality-Adjusted Life Years; Salvage Therapy; Taxoids; United Kingdom; Vinblastine; Vinorelbine | 2001 |
Taxanes and capecitabine in combination: rationale and clinical results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2002 |
Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Female; Genes, erbB-2; Humans; Infusions, Intravenous; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Use of taxanes in the treatment of patients with breast cancer has increased dramatically over the past 8 years.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Utilization; Female; Humans; Medical Oncology; Paclitaxel; Patient Selection; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Decision Making; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Prognosis; Research Design; Taxoids | 2001 |
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; In Situ Hybridization, Fluorescence; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab | 2001 |
Primary (neoadjuvant) chemotherapy with docetaxel in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Taxoids | 2001 |
Trials of new combinations of Herceptin in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2001 |
Taxol: the first of the taxanes, an important new class of antitumor agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Evaluation; Drug Evaluation, Preclinical; Drugs, Investigational; Female; Forecasting; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1992 |
854 trial(s) available for docetaxel anhydrous and Breast Cancer
| Article | Year |
|---|---|
Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans | 2022 |
Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasms, Second Primary; Receptor, ErbB-2; Republic of Korea; Retrospective Studies; Taxoids; Trastuzumab | 2022 |
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Diketopiperazines; Docetaxel; Double-Blind Method; Female; Filgrastim; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Polyethylene Glycols; Prostatic Neoplasms; Treatment Outcome | 2022 |
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Homologous Recombination; Humans; Triple Negative Breast Neoplasms | 2022 |
Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
Topics: Acrylamides; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab; Tumor Microenvironment | 2022 |
Prevention of taxane-associated acute pain syndrome with etoricoxib for patients with breast cancer: A phase II randomised trial.
Topics: Acute Pain; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Etoricoxib; Female; Humans; Neurotoxicity Syndromes; Taxoids | 2022 |
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Hormones; Humans; Immune Checkpoint Inhibitors; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab | 2022 |
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Docetaxel; Female; Humans; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab | 2022 |
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; East Asian People; Female; Humans; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab; Ventricular Function, Left | 2023 |
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2022 |
Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients - results from the Dutch Scalp Cooling Registry.
Topics: Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Hair; Humans; Hypothermia, Induced; Neoplasms; Paclitaxel; Registries; Scalp | 2023 |
Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neutropenia; Receptor, ErbB-2; Stomach Neoplasms | 2023 |
A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Docetaxel; Female; Humans; Micelles; Receptor, ErbB-2; Salivary Glands; Trastuzumab | 2023 |
Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2023 |
Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Quality of Life; Treatment Outcome | 2023 |
Topics: Adolescent; Adult; Animals; Asthma; Atrial Fibrillation; Autoantibodies; Biomarkers; Breast Neoplasms; Child; Conjunctivitis, Allergic; Cornea; COVID-19; Cyclosporine; Cytokines; Death, Sudden, Cardiac; Defibrillators, Implantable; Diet; Disease Models, Animal; Docetaxel; Double-Blind Method; Dry Eye Syndromes; Educational Status; Emulsions; Female; Fluorescein Angiography; Fluoresceins; Focus Groups; Heart Failure; Hemothorax; Humans; Inflammation; Keratoconus; Male; Meibomian Glands; Mice; Middle Aged; Multiple Sclerosis; Myocardial Infarction; Myocardium; Nerve Fibers; Nigeria; Obesity; Overweight; Pandemics; Primary Prevention; Prospective Studies; Qualitative Research; Registries; Retinal Ganglion Cells; Retinal Vessels; Schools; Sirolimus; Tertiary Care Centers; Th1 Cells; Th2 Cells; Tomography, Optical Coherence; Troponin I; Tumor Necrosis Factor-alpha; United States; Ventricular Remodeling | 2022 |
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Receptor, ErbB-2; Trastuzumab | 2023 |
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2023 |
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Treatment Outcome | 2023 |
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm, Residual; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2023 |
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome; Young Adult | 2020 |
Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Exercise Therapy; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Quality of Life; Survival Rate | 2019 |
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2020 |
A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Filgrastim; Humans; Middle Aged; Neutrophils; Pilot Projects; Polyethylene Glycols | 2020 |
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Invasiveness; Receptor, ErbB-2; Risk Factors; Trastuzumab | 2020 |
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Heart; Humans; Middle Aged; Prospective Studies; Receptor, ErbB-2; Trastuzumab; Young Adult | 2020 |
Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclobutanes; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Pilot Projects; Survival Analysis | 2019 |
A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Catheterization, Peripheral; Catheters, Indwelling; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Trastuzumab; Vascular Access Devices | 2020 |
A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients.
Topics: Adipose Tissue, Brown; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Trastuzumab; Treatment Outcome; Weight Gain | 2020 |
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Young Adult | 2020 |
Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Health Status; Humans; Middle Aged; Prognosis; Prospective Studies; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sweden; Taxoids; Time Factors; Young Adult | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Survival Rate; Thymidine Kinase; Tumor Burden | 2020 |
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Goserelin; Humans; Lymph Nodes; Middle Aged; Premenopause; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2020 |
A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Endostatins; Epirubicin; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Recombinant Proteins | 2020 |
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2020 |
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Double-Blind Method; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2020 |
Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome | 2020 |
A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Humans; Immunoglobulin Fc Fragments; Middle Aged; Neutropenia; Polyethylene Glycols | 2020 |
Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Half-Life; Hematologic Agents; Humans; Immunoglobulin Fc Fragments; Metabolic Clearance Rate; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols | 2021 |
The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Japan; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2021 |
Phase I study to evaluate the maximum tolerated dose of the combination of SH003 and docetaxel in patients with solid cancer: A study protocol.
Topics: Angelica; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Astragalus Plant; Breast Neoplasms; Clinical Trials, Phase I as Topic; Docetaxel; Humans; Lung Neoplasms; Phytotherapy; Plant Extracts; Trichosanthes | 2020 |
A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Treatment Outcome; Vinorelbine | 2020 |
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Prognosis; Survival Rate; Treatment Outcome | 2020 |
Study Protocol for Assessing the Efficacy of Compression Therapy Using Stockings and Sleeves to Prevent Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Compression Bandages; Docetaxel; Female; Humans; Middle Aged; Peripheral Nervous System Diseases | 2020 |
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Female; Humans; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Ventricular Function, Left | 2021 |
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Vaccines; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Membrane Glycoproteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Tumor Burden | 2021 |
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Humans; Poland; Receptor, ErbB-2; Trastuzumab | 2021 |
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans | 2021 |
Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antibiotics, Antineoplastic; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Breast Neoplasms; Cardiotoxicity; Carvedilol; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Incidence; Middle Aged; Risk Assessment; Stroke Volume; Tetrazoles; Ventricular Function, Left | 2021 |
The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine.
Topics: Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Prospective Studies; Retrospective Studies; Tumor Microenvironment | 2021 |
Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Progression-Free Survival; Stomach Neoplasms; Trastuzumab | 2021 |
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Quality of Life; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2021 |
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study).
Topics: Ado-Trastuzumab Emtansine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Japan; Receptor, ErbB-2; Trastuzumab | 2021 |
Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Breast Neoplasms; Docetaxel; Drug Interactions; Female; Half-Life; Humans; Middle Aged; Models, Biological; Neoplasm Staging; Receptor, ErbB-2; Trastuzumab | 2021 |
The effect of post-mastectomy radiation in women with one to three positive nodes enrolled on the control arm of BCIRG-005 at ten year follow-up.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Mastectomy, Segmental; Middle Aged; Postoperative Care; Proportional Hazards Models; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Agents; Body Image; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cancer Pain; Deoxycytidine; Docetaxel; Dyspnea; Epothilones; Fatigue; Female; Furans; Gemcitabine; Health Status; Heterocyclic Compounds, 4 or More Rings; Humans; Ketones; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Polyethylene Glycols; Quality of Life; Reproductive Health; Sleep Initiation and Maintenance Disorders; Taxoids; Vinblastine; Vinorelbine; Vomiting | 2017 |
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2017 |
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cyclophosphamide; Docetaxel; Early Diagnosis; Epirubicin; Female; Fluorouracil; Genes, erbB-2; Humans; Middle Aged; Neoadjuvant Therapy; Remission Induction; Survival Analysis; Taxoids | 2017 |
A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy.
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Onycholysis; Pharmaceutical Solutions; Prospective Studies; Taxoids; Treatment Outcome; Young Adult | 2017 |
Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study.
Topics: Adrenergic beta-Antagonists; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Placebos; Ramucirumab; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Taxoids | 2017 |
Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study.
Topics: Adult; Age of Onset; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Trastuzumab; Treatment Outcome | 2017 |
Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Receptor, ErbB-2; Taxoids; Trastuzumab | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Taxoids | 2017 |
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Taxoids; Trastuzumab | 2017 |
Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Japan; Middle Aged; Polyethylene Glycols; Prospective Studies; Taxoids; Treatment Outcome | 2018 |
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Emollients; Epirubicin; Female; Fluorouracil; Gonadotropin-Releasing Hormone; Hand-Foot Syndrome; Humans; Hydrotherapy; Hyperpigmentation; Lymphedema; Manual Lymphatic Drainage; Massage; Mastectomy; Middle Aged; Neoadjuvant Therapy; Pruritus; Quality of Life; Radiodermatitis; Radiotherapy, Adjuvant; Skin Care; Skin Diseases; Tamoxifen; Taxoids | 2018 |
Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Animals; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Hypothermia, Induced; Induction Chemotherapy; Middle Aged; Paclitaxel; Quality of Life; Scalp; Taxoids; Trastuzumab | 2018 |
Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy.
Topics: Actigraphy; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Muscle Stretching Exercises; Neoadjuvant Therapy; Neoplasm Staging; Sleep; Sleep Wake Disorders; Taxoids; Treatment Outcome; Yoga | 2018 |
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cancer Survivors; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Female; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids | 2018 |
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Peripheral Nervous System Diseases; Quality of Life; Taxoids | 2018 |
Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemoradiotherapy; Cyclophosphamide; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Mastectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Taxoids; Treatment Outcome | 2017 |
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppres
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Cyclophosphamide; Docetaxel; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Humans; Middle Aged; Neutropenia; Young Adult | 2018 |
Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Breast Neoplasms, Male; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Placebos; Receptor, ErbB-2; Trastuzumab; Young Adult | 2017 |
Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Hospitals, University; Humans; Incidence; Lenograstim; Neoplasm Staging; Pharmacoepidemiology; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Risk Factors; Severity of Illness Index; Spain; Taxoids | 2018 |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Breast Neoplasms; Canada; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Europe; Female; Humans; Maytansine; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; United States | 2018 |
A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Endostatins; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic; Positron Emission Tomography Computed Tomography; Prospective Studies; Quality of Life | 2018 |
Effect of Breast Irradiation on Cardiac Disease in Women Enrolled in BCIRG-001 at 10-Year Follow-Up.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Heart Failure; Humans; Middle Aged; Myocardial Infarction; Radiotherapy; Radiotherapy Dosage; Retrospective Studies; Stroke Volume; Taxoids; Time Factors | 2017 |
Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).
Topics: Acetylcarnitine; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Neurotoxicity Syndromes; Paclitaxel; Placebos; Taxoids; Treatment Outcome | 2018 |
Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Double-Blind Method; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab; Young Adult | 2018 |
A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Double-Blind Method; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Survival Rate; Trastuzumab; Young Adult | 2018 |
Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Confidence Intervals; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Lymph Node Excision; Lymph Nodes; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Postoperative Care; Young Adult | 2018 |
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2018 |
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Weight Gain; Weight Loss | 2018 |
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Time Factors; Trastuzumab | 2018 |
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Female; Germ-Line Mutation; Humans; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Prognosis; Receptor, ErbB-2; Receptor, ErbB-3; Support Vector Machine; Trastuzumab; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases | 2018 |
Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Genes, erbB-2; Heart Diseases; Humans; Injections, Subcutaneous; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Stroke Volume; Trastuzumab | 2018 |
The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoembryonic Antigen; Cell Count; Docetaxel; Epithelial-Mesenchymal Transition; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplastic Cells, Circulating; Phenotype; Prognosis; Receptor, ErbB-2; Treatment Outcome | 2019 |
Observation and analysis of clinical efficacy of breast-conserving therapy integrated with neoadjuvant chemotherapy on Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Docetaxel; Epirubicin; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Postoperative Complications; Quality of Life; Recurrence; Survival Analysis; Treatment Outcome | 2018 |
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Carbonic Anhydrase IX; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Young Adult | 2019 |
Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Docetaxel; Double-Blind Method; Doxorubicin; Female; Filgrastim; Hematologic Agents; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Polyethylene Glycols; Therapeutic Equivalency | 2019 |
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Progression-Free Survival; Receptor, ErbB-2; Sorafenib; Treatment Outcome | 2019 |
Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Non-Randomized Controlled Trials as Topic; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2019 |
A Dose-Escalating Pilot Study (NCT03017404) of Pegylated Liposomal Doxorubicin and Cyclophosphamide, Followed by Docetaxel Administration as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Nausea; Neoadjuvant Therapy; Neutropenia; Pilot Projects; Polyethylene Glycols; Stomatitis; Treatment Outcome | 2019 |
Early neutropenia on day 8 treated with adjuvant Docetaxel-based chemotherapy in early breast cancer patients: Putative mechanisms within the neutrophil pool system.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Neutrophils | 2019 |
The Chinese herb Xiaoaiping protects against breast cancer chemotherapy-induced alopecia and other side effects: a randomized controlled trial.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Middle Aged; Nausea; Prognosis; Prospective Studies; Protective Agents; Survival Rate; Vomiting | 2019 |
Effects of combined supervised intermittent aerobic, muscle strength and home-based walking training programs on cardiorespiratory responses in women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bicycling; Breast Neoplasms; Cardiorespiratory Fitness; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Exercise; Exercise Test; Female; Fluorouracil; Heart Rate; Home Care Services; Humans; Lactates; Middle Aged; Physical Exertion; Program Evaluation; Resistance Training; Walking | 2019 |
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab | 2019 |
Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Mastectomy, Segmental; Middle Aged; Prognosis; Prospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
High baseline Tie1 level predicts poor survival in metastatic breast cancer.
Topics: Adult; Aged; Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Prognosis; Progression-Free Survival; Prospective Studies; Receptor, TIE-1; Survival Analysis | 2019 |
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Predictive Value of Tests; Receptor, ErbB-2; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Double-Blind Method; Female; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab; Ventricular Dysfunction, Left | 2013 |
A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Receptor, IGF Type 1; Sarcoma; Taxoids; Treatment Outcome; Vomiting; Young Adult | 2013 |
Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follistatin; Humans; Imidazoles; Inhibins; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Time Factors; Transforming Growth Factor beta1; Treatment Outcome; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer.
Topics: Adult; Anthracyclines; Biomarkers; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Phosphorylation; Predictive Value of Tests; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Ribosomal Protein S6 Kinases, 90-kDa; Taxoids; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Medical Futility; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Taxoids; Treatment Outcome | 2013 |
The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carboplatin; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Black or African American; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Female; Humans; Lymph Nodes; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms; White People | 2015 |
Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Nanoparticles; Paclitaxel; Prognosis; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Hypertension; Inflammatory Breast Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Quality of Life; Receptor, ErbB-2; Surveys and Questionnaires; Taxoids; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
[Prevention of neutropenia during adjuvant taxotere therapy for breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caproates; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Hematologic Agents; Humans; Imidazoles; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Taxoids; Treatment Outcome | 2012 |
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Middle Aged; Molecular Targeted Therapy; Proportional Hazards Models; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2013 |
Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gene Expression; Humans; Middle Aged; Mucin-1; Neoadjuvant Therapy; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Survival; Taxoids; Treatment Outcome | 2013 |
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids; Treatment Outcome | 2013 |
Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Endostatins; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prospective Studies; Quality of Life; Taxoids; Young Adult | 2013 |
Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; DNA Topoisomerases, Type II; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2013 |
Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Early Detection of Cancer; Epirubicin; Female; Finland; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Multivariate Analysis; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Taxoids | 2013 |
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Staging; Quality of Life; Receptor, ErbB-2; Surveys and Questionnaires; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Response prediction to neoadjuvant chemotherapy: comparison between pre-therapeutic gene expression profiles and in vitro chemosensitivity assay.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Screening Assays, Antitumor; Epirubicin; Female; Gene Expression Profiling; Humans; In Vitro Techniques; Ki-67 Antigen; Neoadjuvant Therapy; Prospective Studies; Taxoids | 2013 |
Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Survival Rate; Taxoids; Young Adult | 2013 |
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Neoplasm Metastasis; Placebos; Quality of Life; Receptor, ErbB-2; Surveys and Questionnaires; Survival; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Trastuzumab; Young Adult | 2013 |
Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Taxoids | 2014 |
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2013 |
Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Double-Blind Method; Doxorubicin; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Polyethylene Glycols; Prognosis; Recombinant Proteins; Taxoids | 2013 |
Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Finland; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Humans; Middle Aged; Models, Biological; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Breast Neoplasms; Docetaxel; Electrocardiography; Female; Heart; Humans; Incidence; Middle Aged; Models, Biological; Neoplasm Proteins; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gene Amplification; Humans; Middle Aged; Neoplasm Staging; Poly-ADP-Ribose Binding Proteins; Polymerase Chain Reaction; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab; Young Adult | 2013 |
[Clinical paired study of comparing docetaxel plus capecitabine versus docetaxel plus epirubicin as first-line treatment in women with HER-2 negative advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Taxoids | 2013 |
Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Polyethylene Glycols; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Taxoids; Tomography, X-Ray Computed; Trastuzumab | 2013 |
Feasibility study of docetaxel and cyclophosphamide six- cycle therapy as adjuvant chemotherapy for Japanese human epidermal growth factor receptor 2-negative breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Taxoids | 2013 |
A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Diarrhea; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplastic Cells, Circulating; Neutropenia; Receptor, ErbB-2; Survival Rate; Taxoids; Thrombocytopenia; Young Adult | 2013 |
Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Time Factors | 2013 |
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuv
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Preoperative Care; Prognosis; Risk Factors; Taxoids; Treatment Outcome | 2013 |
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer.
Topics: Administration, Oral; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclosporine; Docetaxel; Drug Monitoring; Female; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Heart Failure; Humans; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2013 |
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Proportional Hazards Models; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Liposomes; Middle Aged; Nanotechnology; Taxoids; Young Adult | 2014 |
Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Etoposide; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Combinations; Female; Humans; Induction Chemotherapy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Risk Factors; Taxoids; Tegafur; Treatment Outcome; Tumor Burden | 2013 |
Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Obesity; Prognosis; Proportional Hazards Models; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2014 |
Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Breast Neoplasms; Docetaxel; Double-Blind Method; Fatigue; Female; Humans; Male; Middle Aged; Modafinil; Nausea; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Vomiting; Wakefulness-Promoting Agents | 2014 |
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Feasibility Studies; Female; Humans; Middle Aged; Taxoids | 2014 |
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Recombinant Proteins; Survival; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
The Kampo medicine Goshajinkigan prevents neuropathy in breast cancer patients treated with docetaxel.
Topics: Adult; Aged; Breast Neoplasms; Docetaxel; Drugs, Chinese Herbal; Female; Humans; Medicine, Kampo; Middle Aged; Nervous System Diseases; Taxoids; Vitamin B 12 | 2013 |
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dichloroacetic Acid; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxygen Consumption; Taxoids; Treatment Failure | 2014 |
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; tau Proteins; Taxoids | 2014 |
Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Taxoids; Trastuzumab | 2014 |
High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.
Topics: Angiopoietin-1; Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fibroblast Growth Factor 2; Humans; Interleukin-1alpha; Matrix Metalloproteinase 9; Neoadjuvant Therapy; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Platelet-Derived Growth Factor; Prospective Studies; Proto-Oncogene Proteins c-sis; Receptor, ErbB-2; Receptor, TIE-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Doxorubicin; Female; Humans; Imidazoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Receptor, ErbB-2; Taxoids; Treatment Outcome; Zoledronic Acid | 2014 |
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Docetaxel; Double-Blind Method; Female; Humans; Incidence; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Epothilones; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Proportional Hazards Models; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Prodrugs; Proportional Hazards Models; Taxoids; Treatment Outcome; Tubulin Modulators | 2014 |
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Indoles; Middle Aged; Oxindoles; Propionates; Pyrroles; Taxoids | 2014 |
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Postoperative Complications; Prognosis; Prospective Studies; Taxoids; Young Adult | 2014 |
Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Isoenzymes; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Retinal Dehydrogenase; Taxoids; Treatment Outcome | 2014 |
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Taxoids; Treatment Outcome; Young Adult | 2014 |
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunomagnetic Separation; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Taxoids | 2014 |
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2014 |
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Maytansine; Middle Aged; Receptor, ErbB-2; Retrospective Studies; RNA, Messenger; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplastic Cells, Circulating; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Neoadjuvant Therapy; Polyethylene Glycols; Receptor, ErbB-2; Receptors, Estrogen; Sample Size; Taxoids; Trastuzumab | 2014 |
Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: final results of a prospective phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy, Adjuvant; Docetaxel; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Prospective Studies; Taxoids; Treatment Outcome | 2014 |
Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; Breast Neoplasms; Docetaxel; Female; Humans; Immunohistochemistry; Middle Aged; Real-Time Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2014 |
Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Doxorubicin; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; ROC Curve; Taxoids; Treatment Outcome; Tumor Burden; Zoledronic Acid | 2014 |
Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cyclophosphamide; Cytochrome P-450 CYP2C9; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Glucuronosyltransferase; Humans; Leukocyte Count; Middle Aged; Neoadjuvant Therapy; Polymorphism, Single Nucleotide; Taxoids; Treatment Outcome | 2014 |
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Fatigue; Febrile Neutropenia; Female; Hand-Foot Syndrome; Humans; Hypertension; Immunoglobulin G; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ramucirumab; Stomatitis; Taxoids; Treatment Outcome | 2015 |
Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gene Expression Profiling; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Polymerase Chain Reaction; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2014 |
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; China; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Taxoids | 2014 |
The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.
Topics: Acyltransferases; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Transcription Factors; Trastuzumab | 2014 |
Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Keratins; Ki-67 Antigen; Middle Aged; Neoplastic Cells, Circulating; Norway; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Retreatment; Risk Factors; Taxoids; Time Factors; Treatment Failure | 2014 |
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast; Breast Neoplasms; Cohort Studies; Deoxycytidine; Docetaxel; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Salvage Therapy; Survival Analysis; Taxoids | 2015 |
Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2014 |
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER):
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab | 2014 |
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2015 |
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2015 |
Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Longitudinal Studies; Middle Aged; Peripheral Nervous System Diseases; Quality of Life; Self Report; Survivors; Taxoids; Young Adult | 2015 |
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Lymphatic Metastasis; Middle Aged; Naphthoquinones; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2015 |
Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2015 |
Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids | 2015 |
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Double-Blind Method; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab | 2015 |
Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2015 |
First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Polyethylene Glycols; Recombinant Fusion Proteins; Recombinant Proteins; Serum Albumin; Serum Albumin, Human; Taxoids | 2015 |
Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Prospective Studies; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2015 |
Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cell Hypoxia; Cell Proliferation; Docetaxel; Female; Gene Expression Profiling; Humans; Indoles; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Prospective Studies; Pyrroles; Sunitinib; Taxoids; Tomography, X-Ray Computed | 2015 |
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Grading; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids; Time Factors; Trastuzumab; Young Adult | 2015 |
Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Fusion Proteins; Recombinant Proteins; Serum Albumin; Serum Albumin, Human; Taxoids; Young Adult | 2015 |
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids | 2015 |
Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Treatment Outcome | 2015 |
Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Back Pain; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Double-Blind Method; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Male; Middle Aged; Musculoskeletal Pain; Myalgia; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2016 |
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; Treatment Outcome | 2015 |
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Predictive Value of Tests; Prospective Studies; Taxoids | 2015 |
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Longitudinal Studies; Middle Aged; Neoplasm Staging; Obesity; Paclitaxel; Taxoids | 2015 |
Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
Topics: Administration, Cutaneous; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Cost of Illness; Critical Care; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Length of Stay; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Risk Factors; Taxoids | 2016 |
Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Disease-Free Survival; Docetaxel; Female; Humans; Prospective Studies; Taxoids; Vinblastine; Vinorelbine | 2015 |
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Topics: Adult; Aged; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; United States | 2015 |
Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Maryland; Membrane Glycoproteins; Middle Aged; National Cancer Institute (U.S.); Neoplasm Metastasis; Proportional Hazards Models; Risk Factors; Taxoids; Texas; Time Factors; Treatment Outcome; United States | 2015 |
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Decision Support Techniques; Docetaxel; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Invasiveness; Receptor, ErbB-2; Taxoids; Trastuzumab; United States | 2016 |
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Odds Ratio; Taxoids; Treatment Outcome | 2015 |
Comparison of efficacy of neoadjuvant chemotherapy FEC 100 and Docetaxel 75 versus AC and Docetaxel in locally advanced breast cancer: a randomized clinical study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome; Young Adult | 2015 |
A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Breast Neoplasms; Cytochrome P-450 CYP2B6; Disease Progression; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Genotype; Humans; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Taxoids; Thiotepa | 2015 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Combinations; Edema; Fatigue; Female; Follow-Up Studies; Health Status; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Tegafur | 2016 |
Effects of Fresh Yellow Onion Consumption on CEA, CA125 and Hepatic Enzymes in Breast Cancer Patients: A Double- Blind Randomized Controlled Clinical Trial.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; CA-125 Antigen; Carcinoembryonic Antigen; Cyclophosphamide; Diet; Docetaxel; Double-Blind Method; Doxorubicin; Feeding Behavior; Female; Fluorouracil; Humans; Liver; Membrane Proteins; Methotrexate; Middle Aged; Onions; Placebos; Plant Preparations; Taxoids | 2015 |
High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; DNA Mutational Analysis; Docetaxel; Doxorubicin; Female; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids | 2015 |
A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutrophils; Polyethylene Glycols; Recombinant Fusion Proteins; Recombinant Proteins; Serum Albumin; Serum Albumin, Human; Taxoids | 2016 |
[A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Induction Chemotherapy; Lung Neoplasms; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2016 |
Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2017 |
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Taxoids | 2016 |
Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Models, Theoretical; Neoplasm Metastasis; Taxoids | 2016 |
Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Docetaxel; Female; Humans; Middle Aged; Morpholines; Nausea; Neoplasm Staging; Prospective Studies; Quality of Life; Salvage Therapy; Secondary Prevention; Serotonin 5-HT3 Receptor Antagonists; Spain; Surveys and Questionnaires; Taxoids; Time Factors; Treatment Outcome; Vomiting | 2016 |
Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Maximum Tolerated Dose; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2016 |
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epirubicin; Estrogen Receptor alpha; Female; Fluorouracil; Genetic Testing; Genomics; Humans; Immunohistochemistry; Ki-67 Antigen; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Prognosis; Receptor, ErbB-2; Receptors, Progesterone; Taxoids | 2016 |
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Survival Analysis; Taxoids | 2016 |
Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids | 2016 |
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Maytansine; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab | 2016 |
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR tr
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Prospective Studies; Quality of Life; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2016 |
Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients.
Topics: Breast Neoplasms; Cost-Benefit Analysis; Cyclophosphamide; Decision Trees; Docetaxel; Doxorubicin; Drug Monitoring; Early Diagnosis; Female; Humans; Models, Statistical; Neoadjuvant Therapy; Proportional Hazards Models; Quality-Adjusted Life Years; Taxoids | 2016 |
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Trastuzumab | 2016 |
Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Taxoids; Tissue Array Analysis; Transcriptome; Trastuzumab; Treatment Outcome; Young Adult | 2016 |
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Surface Area; Breast Neoplasms; Capecitabine; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Febrile Neutropenia; Female; Humans; Lymphatic Metastasis; Obesity; Taxoids | 2016 |
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HOR
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Taxoids; Young Adult | 2016 |
Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Asian People; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Gingivitis; Half-Life; Humans; Japan; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Ramucirumab; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2016 |
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mucin-1; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Taxoids | 2016 |
Phase II Study of Compliance and Morbidity with 4 Cycles of Taxotere Followed by 4 of Doxorubicin-Cyclophosphamide for Adjuvant Treatment of Operable Breast Cancer Patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Jordan; Middle Aged; Prospective Studies; Taxoids | 2016 |
HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Diarrhea; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Proanthocyanidins; Prognosis; Quality of Life; Taxoids; Trastuzumab; Young Adult | 2017 |
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Decision-Making; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Mastectomy, Segmental; Middle Aged; Molecular Typing; Neoadjuvant Therapy; Nitriles; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Tamoxifen; Taxoids; Treatment Outcome; Triazoles; Young Adult | 2017 |
A Phase I Trial of 100 mg/m2 Docetaxel in Patients with Advanced or Recurrent Breast Cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Clinical Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Taxoids; Young Adult | 2016 |
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Sweden; Taxoids | 2016 |
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Mammaplasty; Mastectomy; Prognosis; Prospective Studies; Surgical Wound Infection; Survival Rate; Taxoids | 2017 |
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Disease Progression; Docetaxel; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Middle Aged; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Analysis; Taxoids; Therapeutic Equipoise; Time Factors; Trastuzumab | 2017 |
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Double-Blind Method; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab; Young Adult | 2017 |
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Female; Humans; Immunohistochemistry; Mutation; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2017 |
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Prevalence; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Young Adult | 2017 |
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Health Resources; Humans; Kaplan-Meier Estimate; Netherlands; Paclitaxel; Quality-Adjusted Life Years; Receptor, ErbB-2; Taxoids | 2017 |
Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Cross-Over Studies; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Taxoids | 2009 |
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Failure | 2008 |
A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Taxoids | 2008 |
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Middle Aged; Protein Isoforms; Taxoids; Tubulin | 2008 |
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Taxoids | 2008 |
Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Dose escalation study of epirubicin and docetaxel in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids | 2008 |
Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Recurrence; Salvage Therapy; Survival Analysis; Taxoids | 2009 |
Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment.
Topics: Adult; Aged; Anthracyclines; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Taxoids; Treatment Failure; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Salvage Therapy; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2009 |
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Receptor, ErbB-2; Research Design; Taxoids; Trastuzumab | 2008 |
XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Immunotherapy; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Taxoids; Trastuzumab; Treatment Outcome | 2008 |
XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Docetaxel; Double-Blind Method; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Neutrophils; Recombinant Proteins; Taxoids; Treatment Outcome | 2008 |
Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Asthenia; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Eruptions; Female; Granulocyte Colony-Stimulating Factor; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Stomatitis; Taxoids | 2008 |
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Thionucleotides | 2008 |
[Phase II study of docetaxel plus epirubicin versus docetaxel plus cisplatin as first-line chemotherapy for advanced breast cancer].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Prospective Studies; Remission Induction; Taxoids; Young Adult | 2008 |
A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Docetaxel; Doxorubicin; Female; Genes, erbB-2; Humans; Liposomes; Middle Aged; Taxoids; Trastuzumab | 2009 |
Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Prognosis; Safety; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Mechanisms of stimulation of granulocytopoiesis with neupogen in patients with breast cancer during chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Differentiation; Cell Proliferation; Cells, Cultured; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoiesis; Humans; Middle Aged; Recombinant Proteins; Taxoids; Treatment Outcome; Up-Regulation | 2008 |
Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Clusterin; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Taxoids; Thionucleotides; Treatment Outcome | 2009 |
Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Taxoids | 2009 |
Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Models, Economic; Quality-Adjusted Life Years; Taxoids | 2009 |
Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Proliferating Cell Nuclear Antigen; Survivin; Taxoids | 2009 |
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Taxoids | 2009 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Comparison of 6 cycles versus 4 cycles of neoadjuvant epirubicin plus docetaxel chemotherapy in stages II and III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Taxoids | 2009 |
[CyberKnife and neoadjuvant chemotherapy for breast tumors: preliminary results].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Radiosurgery; Taxoids; Treatment Outcome | 2009 |
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Follow-Up Studies; Humans; Middle Aged; Prospective Studies; Receptor, ErbB-2; Taxoids | 2009 |
A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dibenzocycloheptenes; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Placebos; Quinolines; Recurrence; Taxoids | 2009 |
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Receptor, ErbB-2; Taxoids | 2009 |
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2009 |
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Survival Analysis; Taxoids | 2009 |
Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Feasibility Studies; Female; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Chemotherapy-induced tumor gene expression changes in human breast cancers.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Taxoids | 2009 |
Robotic stereotactic radioablation concomitant with neo-adjuvant chemotherapy for breast tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Protocols; Colorimetry; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Radiodermatitis; Radiosurgery; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Remission Induction; Robotics; Taxoids; Tumor Burden | 2009 |
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.
Topics: Abdominal Pain; Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; E-Selectin; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Logistic Models; Magnetic Resonance Imaging; Microvessels; Middle Aged; Multivariate Analysis; Preoperative Care; Stomatitis; Taxoids; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2009 |
Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids | 2010 |
Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Taxoids | 2009 |
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Belgium; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Early Diagnosis; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lethargy; Leukopenia; Middle Aged; Neutropenia; Proportional Hazards Models; Receptors, Estrogen; Taxoids; Treatment Outcome; United Kingdom | 2009 |
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Probability; Risk Assessment; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2009 |
Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome | 2009 |
nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Delivery Systems; Female; Humans; Middle Aged; Nanoparticles; Paclitaxel; Taxoids | 2010 |
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Demography; Docetaxel; Female; Hexanones; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Reactive Oxygen Species; Taxoids; Treatment Outcome | 2010 |
Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Doxorubicin; Estrogens; Female; Genes, erbB-2; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Progesterone; Prospective Studies; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Treatment Outcome; Young Adult | 2010 |
Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fever; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Mucositis; Neutropenia; Prospective Studies; Receptor, ErbB-2; Survival Analysis; Taxoids | 2010 |
Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Remission Induction; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2010 |
Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Taxoids | 2009 |
Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Female; Gene Expression; Genes, bcl-2; Humans; Middle Aged; Neoadjuvant Therapy; Preoperative Period; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Thionucleotides | 2009 |
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Frail Elderly; Humans; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2010 |
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracyclin
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Doxorubicin; Female; Heart Diseases; Humans; Middle Aged; Neoadjuvant Therapy; Polyethylene Glycols; Taxoids; Time Factors | 2009 |
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Receptor, ErbB-2; Taxoids; Trastuzumab | 2010 |
Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy.
Topics: Adult; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cluster Analysis; Docetaxel; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Middle Aged; Models, Biological; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Precision Medicine; Predictive Value of Tests; Prospective Studies; Proteomics; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2009 |
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.
Topics: Adult; Aged; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Obesity; Prognosis; Retrospective Studies; Taxoids; Treatment Outcome | 2010 |
Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Fluorouracil; Germany; Health Care Costs; Humans; Male; Methotrexate; Middle Aged; Prevalence; Taxoids; Treatment Outcome | 2009 |
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Carcinoma, Ductal; Cohort Studies; Cyclooxygenase 2; Cyclophosphamide; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; In Situ Hybridization; Middle Aged; Neoadjuvant Therapy; Nuclear Proteins; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Y-Box-Binding Protein 1 | 2009 |
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperati
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Recurrence; Taxoids; Time Factors | 2010 |
Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; DNA Topoisomerases, Type II; Docetaxel; Electrophoresis, Capillary; Epirubicin; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA Stability; RNA, Neoplasm; Taxoids; Time Factors; Treatment Outcome | 2010 |
Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2010 |
Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Multivariate Analysis; Reproducibility of Results; Taxoids; Treatment Outcome | 2009 |
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2010 |
[Equalization of breast cancer chemotherapy at general hospital( II )-evaluation of safety in FEC and TC regimens].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Ciprofloxacin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Hospitals, General; Humans; Japan; Middle Aged; Neutropenia; Taxoids | 2009 |
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Celecoxib; Cell Separation; Cyclophosphamide; Docetaxel; Early Detection of Cancer; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Time Factors; Trastuzumab; Young Adult | 2010 |
A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma in Situ; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Period; Taxoids; Treatment Outcome | 2010 |
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids; Treatment Outcome; United States | 2010 |
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Curcumin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Time Factors; Treatment Outcome | 2010 |
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Receptor, ErbB-2; Taxoids | 2009 |
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neutropenia; Taxoids | 2010 |
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Survival Rate; Taxoids; Trastuzumab; Young Adult | 2009 |
Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Docetaxel; Female; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Taxoids; Treatment Outcome | 2009 |
A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Taxoids; Treatment Outcome | 2009 |
TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Ramucirumab; Taxoids; Treatment Outcome | 2009 |
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cluster Analysis; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression; Gene Expression Profiling; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Pilot Projects; Taxoids | 2010 |
Development of a new G-CSF product based on biosimilarity assessment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2010 |
[Application of neoadjuvant chemotherapy for operable breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids | 2009 |
Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Docetaxel; Female; Humans; Lymph Nodes; Middle Aged; Models, Economic; Neoplasm Metastasis; Neoplasm Staging; Quality-Adjusted Life Years; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Fluorouracil; Humans; In Situ Hybridization, Fluorescence; International Agencies; Liver Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Soft Tissue Neoplasms; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2010 |
Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Risk Assessment; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2010 |
Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Radiotherapy, Adjuvant; Taxoids | 2010 |
Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2010 |
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxins; Disease Progression; Docetaxel; Doxorubicin; Female; Heart; Humans; Kaplan-Meier Estimate; Liposomes; Middle Aged; Neoplasm Metastasis; Stroke Volume; Taxoids; Trastuzumab; Ventricular Function, Left | 2010 |
A human epidermal growth factor receptor 2 expression-based approach to neoadjuvant chemotherapy for operable breast cancer.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Young Adult | 2010 |
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Germany; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Compliance; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2010 |
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Germany; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Compliance; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2010 |
Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Neoadjuvant Therapy; Patient Selection; Radiotherapy, Adjuvant; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Fluorescent Antibody Technique; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug Therapy, Combination; Female; Humans; Ketoconazole; Maximum Tolerated Dose; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Tegafur | 2010 |
Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2010 |
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; France; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Taxoids; Therapeutics; Time Factors; Trastuzumab | 2010 |
A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2010 |
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Drug Administration Schedule; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Placebos; Taxoids | 2010 |
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
Topics: Adenocarcinoma; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Premenopause; Survival Analysis; Taxoids | 2010 |
Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; ErbB Receptors; Female; Humans; Middle Aged; Neoadjuvant Therapy; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2010 |
Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Taxoids; Treatment Outcome | 2010 |
The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Polyethylene Glycols; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Trastuzumab; Young Adult | 2011 |
Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab | 2010 |
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Germany; Humans; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Phenotype; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Prospective Studies; Taxoids | 2011 |
A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Taxoids | 2010 |
Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Tumor Burden | 2011 |
[Feasibility of FEC 100 followed by DOC 100 as adjuvant chemotherapy for breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Feasibility Studies; Fluorouracil; Humans; Middle Aged; Taxoids | 2010 |
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Glutamates; Guanine; Humans; Middle Aged; Neoadjuvant Therapy; Pemetrexed; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome | 2011 |
NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Cytochrome P-450 CYP3A; Dexamethasone; Docetaxel; Female; Glucocorticoids; Humans; Midazolam; Middle Aged; Survival Analysis; Taxoids | 2011 |
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Europe; Female; Humans; Infusions, Intravenous; Logistic Models; Middle Aged; Patient Selection; Piperidines; Placebos; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; South Africa; Taiwan; Taxoids; Time Factors; Treatment Outcome | 2012 |
Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study.
Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Breast Neoplasms; Central Nervous System Stimulants; Cross-Over Studies; Docetaxel; Female; Humans; Methylphenidate; Middle Aged; Pilot Projects; Prospective Studies; Quality of Life; Severity of Illness Index; Spain; Surveys and Questionnaires; Taxoids; Time Factors; Treatment Outcome | 2012 |
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Complement System Proteins; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Plasma; Predictive Value of Tests; Taxoids; Validation Studies as Topic | 2010 |
Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Polyethylene Glycols; Taxoids | 2010 |
[A pilot study of weekly versus 3-week docetaxel in combination with capecitabine in patients with anthracycline-pretreated metastatic breast cancer].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Taxoids; Treatment Failure; Treatment Outcome | 2010 |
Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Young Adult | 2010 |
Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Decision Making; Docetaxel; Female; Gene Expression Profiling; Genetic Testing; Humans; Middle Aged; Retrospective Studies; Taxoids | 2011 |
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Taxoids | 2011 |
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeu
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease-Free Survival; Docetaxel; Female; Gene Amplification; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2011 |
Adjuvant docetaxel for high-risk, node-negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2010 |
A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Prospective Studies; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Receptor, ErbB-2; Signal Transduction; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2010 |
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2011 |
Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer.
Topics: Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Taxoids | 2010 |
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Combinations; Epirubicin; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Staging; Patient Selection; Taxoids; Treatment Outcome | 2011 |
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Neoadjuvant Therapy; Prognosis; Prospective Studies; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2011 |
Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Proportional Hazards Models; Quality of Life; Taxoids; Time Factors; Treatment Outcome | 2011 |
Very high quantitative tumor HER2 content and outcome in early breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Menstruation; Middle Aged; Prospective Studies; Quality of Life; Surveys and Questionnaires; Survival Rate; Tamoxifen; Taxoids; Treatment Outcome | 2011 |
[Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Taxoids; Thiotepa | 2011 |
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2012 |
Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Health Status; Humans; Kaplan-Meier Estimate; Methotrexate; Paclitaxel; Prospective Studies; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Skin Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Prospective Studies; Skin Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2010 |
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; DNA Mutational Analysis; Docetaxel; Female; Fluorouracil; Genomics; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2012 |
First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Hypertension; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2012 |
Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prospective Studies; Radiography; Radiopharmaceuticals; Sodium Isotopes; Taxoids; Treatment Outcome | 2011 |
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Genes, Neoplasm; Humans; Middle Aged; Multivariate Analysis; Taxoids; Treatment Outcome | 2011 |
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Endpoint Determination; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Plasminogen Activator Inhibitor 1; Prognosis; Prospective Studies; Risk Assessment; Taxoids; Urokinase-Type Plasminogen Activator; Young Adult | 2011 |
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypertension; Imidazoles; Indazoles; Middle Aged; Mucositis; Neoplasm Proteins; Neutropenia; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Taxoids; Thrombophilia | 2011 |
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast c
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Genes, erbB-2; Humans; Immunotherapy; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women wit
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Compliance; Quality of Life; Recurrence; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Taxoids; Young Adult | 2012 |
A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Heart Failure; Humans; Liposomes; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2011 |
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Taxoids; Treatment Outcome; Up-Regulation | 2011 |
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids | 2011 |
Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasms, Second Primary; Quality of Life; Selective Estrogen Receptor Modulators; Tamoxifen; Taxoids | 2011 |
Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; ErbB Receptors; Female; Gene Expression; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Receptor, ErbB-4; Taxoids; Up-Regulation | 2011 |
SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Pelvic Neoplasms; Taxoids; Treatment Outcome | 2011 |
A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Dexamethasone; Diuretics; Docetaxel; Dose-Response Relationship, Drug; Edema; Female; Follow-Up Studies; Humans; Middle Aged; Neutropenia; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2011 |
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; ErbB Receptors; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Taxoids; Young Adult | 2011 |
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Heart; Humans; Liposomes; Middle Aged; Neoplasm Metastasis; Taxoids | 2011 |
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.
Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Genotype; Glutamates; Guanine; Humans; Leukocyte Common Antigens; Lymphocytes; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pemetrexed; Polymorphism, Genetic; Sequence Analysis, DNA; Statistics, Nonparametric; Taxoids; Treatment Outcome | 2012 |
A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
Topics: Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Italy; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Prospective Studies; Survival Analysis; Taxoids | 2012 |
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Early Termination of Clinical Trials; Everolimus; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Sirolimus; Taxoids | 2012 |
Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neovascularization, Pathologic; Nitric Oxide; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Thrombospondin 1; Vascular Endothelial Growth Factor A | 2012 |
[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.
Topics: Adult; Aged; Antineoplastic Agents; Breast; Breast Neoplasms; Dideoxynucleosides; Docetaxel; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Kinetics; Middle Aged; Positron-Emission Tomography; Prospective Studies; Taxoids; Time Factors; Treatment Outcome; Tumor Burden | 2011 |
A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Ki-67 Antigen; Lymphatic Metastasis; Middle Aged; Prognosis; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression; Genetic Association Studies; Genotype; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Sequence Deletion; Taxoids; Treatment Outcome | 2012 |
Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Receptor, ErbB-2; Taxoids | 2011 |
[Clinical comparative study of neoadjuvant chemotherapy outcome in locally advanced breast cancer: docetaxel versus paclitaxel plus pirarubicin hydrochloride and cyclophosphamide].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Young Adult | 2011 |
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Finland; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Receptor, ErbB-2; Taxoids; Trastuzumab; Up-Regulation | 2012 |
An open-label multicenter safety, tolerability, and efficacy study of recombinant granulocyte colony-stimulating factor in the prevention of neutropenic complications in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Recombinant Proteins; Taxoids; Treatment Outcome | 2011 |
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Combinations; Female; Glutathione Disulfide; Humans; Immunity, Cellular; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Treatment Outcome; Young Adult | 2012 |
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Ventricular Dysfunction, Left; Young Adult | 2012 |
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Brazil; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Docetaxel; Europe; Female; Humans; Inflammation; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; Young Adult | 2012 |
Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Comorbidity; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Minor Surgical Procedures; Neoadjuvant Therapy; Neoplasm Metastasis; Placebos; Postoperative Hemorrhage; Taxoids | 2012 |
Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Cytochrome P-450 CYP3A; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neutropenia; Organic Anion Transporters, Sodium-Independent; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Republic of Korea; Retrospective Studies; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids | 2012 |
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Logistic Models; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2012 |
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2012 |
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Humans; Indoles; International Agencies; Middle Aged; Prospective Studies; Pyrroles; Receptor, ErbB-2; Sunitinib; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Administration Schedule; Drug Interactions; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Treatment Outcome | 2012 |
A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taiwan; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Adhesion Molecules; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Female; Humans; Leukocyte Disorders; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2012 |
A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Indoles; Middle Aged; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: The National Surgical Adjuvant Study of Breast Cancer 02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Edema; Female; Humans; Middle Aged; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Taxoids | 2012 |
Low expression of stathmin in tumor predicts high response to neoadjuvant chemotherapy with docetaxel-containing regimens in locally advanced breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; RNA, Messenger; RNA, Neoplasm; Stathmin; Taxoids | 2012 |
Circadian rhythms, symptoms, physical functioning, and body mass index in breast cancer survivors.
Topics: Activities of Daily Living; Adult; Affective Symptoms; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Body Mass Index; Breast Neoplasms; Circadian Rhythm; Cyclophosphamide; Depression; Docetaxel; Doxorubicin; Fatigue; Female; Humans; Middle Aged; Paclitaxel; Quality of Life; Sleep; Survivors; Taxoids | 2012 |
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Base Sequence; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Genes, p53; Humans; Ki-67 Antigen; Lymphatic Metastasis; Middle Aged; Mutation, Missense; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Sequence Analysis, DNA; Sequence Deletion; Survival Analysis; Taxoids; Tumor Suppressor Protein p53; Young Adult | 2012 |
Cost-utility analysis of adjuvant therapies for breast cancer in Iran.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Docetaxel; Double-Blind Method; Female; Humans; Iran; Middle Aged; Psychometrics; Quality-Adjusted Life Years; Statistics as Topic; Statistics, Nonparametric; Surveys and Questionnaires; Survival Analysis; Taxoids | 2012 |
[Docetaxel in combination with epirubicin as the first-line chemotherapy for advanced and recurrent breast cancer: a multicenter phase II study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Recurrence; Taxoids | 2012 |
Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Middle Aged; Neurotoxicity Syndromes; Paclitaxel; Paresthesia; Peripheral Nervous System Diseases; Quality of Life; Surveys and Questionnaires; Taxoids | 2012 |
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Survival Rate; Taxoids; Young Adult | 2012 |
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Hemorrhage; Humans; Hypertension; Middle Aged; Neutropenia; Paclitaxel; Proteinuria; Taxoids; Thromboembolism; Young Adult | 2012 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fever; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Remission Induction; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; ErbB Receptors; Female; Humans; Keratin-18; Keratin-8; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome | 2012 |
Feasibility of prior administration of cyclophosphamide in TC combination treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diarrhea; Docetaxel; Drug Administration Schedule; Eczema; Female; Humans; Middle Aged; Neutropenia; Prospective Studies; Taxoids; Treatment Outcome | 2014 |
Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2012 |
Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Neoadjuvant epirubicin/docetaxel (ET) concomitant chemotherapy for primary breast cancer with tumor diameter >=3.1 cm: results of the Kyushu ET therapy phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids | 2012 |
A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Fatigue; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Polyethylene Glycols; Preoperative Period; Recombinant Proteins; Taxoids; Thrombocytopenia; Treatment Outcome | 2013 |
Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients. A prospective, open, and unicentric Phase II clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Taxoids; Transaminases; Treatment Outcome; Vomiting | 2013 |
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Proto-Oncogene Proteins c-kit; Receptors, Platelet-Derived Growth Factor; Taxoids; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2012 |
[Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Premenopause; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vomiting | 2012 |
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Taxoids | 2013 |
A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Indoles; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Bevacizumab plus docetaxel and cisplatin for metastatic breast cancer: a pilot phase II study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Pilot Projects; Taxoids | 2012 |
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Topics: Adolescent; Adult; Aged; Anthracyclines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Karnofsky Performance Status; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2013 |
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Taxoids; Young Adult | 2013 |
Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome; Young Adult | 2013 |
Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Docetaxel; Endostatins; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Microvessels; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Radiography; Taxoids | 2013 |
Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Survival Analysis; Taxoids | 2013 |
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzene Derivatives; Breast Neoplasms; Docetaxel; Female; Humans; Maximum Tolerated Dose; Mice; Neoplasm Staging; Propionates; Receptors, Notch; Signal Transduction; Sulfones; Taxoids; Xenograft Model Antitumor Assays | 2013 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Lymphocytes, Tumor-Infiltrating; Methotrexate; Middle Aged; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Treatment Outcome | 2013 |
Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of su
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Docetaxel; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Thiotepa | 2013 |
Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neutropenia; Quality of Life; Taxoids; Treatment Outcome | 2014 |
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Taxoids | 2013 |
Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Republic of Korea; Taxoids; Treatment Outcome | 2013 |
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Maytansine; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Phenobarbital; Prospective Studies; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Taxoids | 2013 |
Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Taxoids | 2013 |
Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Prognosis; Survival Analysis; Taxoids | 2013 |
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Probability; Recombinant Proteins; Reference Values; Taxoids; Treatment Outcome | 2002 |
Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Cyclophosphamide; Disease Progression; Docetaxel; Doxorubicin; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Rate; Taxoids | 2002 |
Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Incidence; Meningeal Neoplasms; Meningitis; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Taxoids | 2002 |
Docetaxel secretion in tears: association with lacrimal drainage obstruction.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chromatography, High Pressure Liquid; Docetaxel; Female; Gas Chromatography-Mass Spectrometry; Humans; Infusions, Intravenous; Lacrimal Duct Obstruction; Middle Aged; Paclitaxel; Pilot Projects; Prospective Studies; Taxoids; Tears | 2002 |
Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Estramustine; Female; Humans; Microtubules; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival; Taxoids; Treatment Outcome; Venous Thrombosis | 2002 |
Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Paclitaxel; Taxoids; Tomography, Spiral Computed; Treatment Outcome | 2002 |
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction; Taxoids; Treatment Outcome | 2002 |
Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Double-Blind Method; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-3; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Recombinant Fusion Proteins; Recombinant Proteins; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prednisolone; Scotland; Survival Analysis; Taxoids; Time Factors; Treatment Outcome; Vincristine | 2002 |
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infections; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Delayed-Action Preparations; Docetaxel; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Neutrophils; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2003 |
Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cause of Death; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Pilot Projects; Risk Assessment; Salvage Therapy; Soft Tissue Neoplasms; Survival Analysis; Taxoids | 2002 |
Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Time Factors | 2003 |
Docetaxel with epirubicin--investigations on cardiac safety.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular System; Confidence Intervals; Docetaxel; Epirubicin; Female; Follow-Up Studies; Heart Function Tests; Humans; Middle Aged; Paclitaxel; Taxoids | 2003 |
A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Estramustine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Remission Induction; Survival Analysis; Taxoids | 2003 |
Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome | 2003 |
Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Menopause; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Spain; Taxoids; Treatment Outcome | 2003 |
Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Gene Expression; Genes, erbB-2; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids; Trastuzumab | 2003 |
A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Taxoids | 2003 |
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Palliative Care; Prospective Studies; Spain; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2003 |
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Health Status; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Evaluation; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial.
Topics: Adult; Aged; Ambulatory Care; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2003 |
Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Ifosfamide; Infusions, Intravenous; Middle Aged; Survival Analysis; Taxoids; Treatment Failure | 2003 |
[Clinical research of taxotere in treatment of metastatic breast cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2003 |
Phase I study of docetaxel and cyclophosphamide in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Incidence; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids | 2003 |
Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2003 |
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Budgets; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Metastasis; Ontario; Paclitaxel; Population Surveillance; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine; Women's Health | 2003 |
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.
Topics: Antineoplastic Agents, Phytogenic; Blood Cell Count; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Methylprednisolone; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Recurrence; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Hypothermia, Induced; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pulmonary Fibrosis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Prognosis; Quality of Life; Statistics as Topic; Survival Analysis; Taxoids | 2003 |
Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2003 |
Neoadjuvant docetaxel in locally advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids | 2003 |
Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Radiation Dosage; Radiation-Sensitizing Agents; Radiography; Taxoids; Treatment Outcome | 2003 |
[Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Fever; Fluorouracil; Hematologic Diseases; Humans; Hungary; Infections; Middle Aged; Sepsis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2003 |
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Recombinant Proteins; Taxoids | 2004 |
Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; France; Humans; Infusions, Intravenous; Italy; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Neutrophils; Recombinant Proteins; Taxoids; Time Factors | 2003 |
A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Taxoids; Treatment Outcome | 2003 |
Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Humans; Taxoids | 2003 |
Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Survival Rate; Taxoids; Time Factors | 2004 |
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Receptor, ErbB-2; Receptor, ErbB-3; Survival Analysis; Taxoids; Trastuzumab; United States; Up-Regulation | 2004 |
Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Respiratory System; Survival Analysis; Survival Rate; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2004 |
A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Up-Regulation | 2004 |
A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Colony-Forming Units Assay; Docetaxel; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Middle Aged; Neutropenia; Taxoids; Treatment Outcome | 2004 |
Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Frail Elderly; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2004 |
Trastuzumab and docetaxel for metastatic breast cancer: an experience from a cancer centre in India.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease Progression; Docetaxel; Female; Humans; India; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2004 |
Factors predicting docetaxel-related toxicity: experience at a single institution.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Health Status; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Regression Analysis; Stomach Neoplasms; Taxoids; Vomiting | 2004 |
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Feasibility Studies; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Staging; Patient Selection; Platinum Compounds; Receptor, ErbB-2; Research Design; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Up-Regulation | 2004 |
Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Taxoids; Thymidine Phosphorylase; Up-Regulation | 2004 |
Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Liposomes; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Infections; Leukocyte Count; Middle Aged; Mouth Mucosa; Mucous Membrane; Neutropenia; Regression Analysis; Skin; Taxoids | 2004 |
Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; Karnofsky Performance Status; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Prospective Studies; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2004 |
Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Salvage Therapy; Survival Analysis; Taxoids | 2004 |
Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Taxoids | 2004 |
Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Taxoids | 2004 |
Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support: a feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Fever; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Treatment Outcome | 2004 |
A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids; Thionucleotides; Treatment Outcome | 2004 |
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinases; Docetaxel; Enzyme Inhibitors; Female; Flavonoids; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Mouth Mucosa; Mucous Membrane; Neoplasm Metastasis; Phosphorylation; Piperidines; Retinoblastoma Protein; Taxoids; Time Factors; Tumor Suppressor Protein p53 | 2004 |
Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2004 |
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asthenia; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Europe; Female; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial BP-57.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Feasibility Studies; Female; Humans; Middle Aged; Taxoids; Treatment Outcome | 2004 |
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lymph Nodes; Middle Aged; Paclitaxel; Pilot Projects; Risk Factors; Survival Rate; Taxoids | 2004 |
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Prospective Studies; Survival Rate; Taxoids | 2004 |
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Topics: Adult; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Odds Ratio; Poly-ADP-Ribose Binding Proteins; Receptor, ErbB-2; Retrospective Studies; Taxoids; Treatment Outcome | 2004 |
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Neutropenia; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2004 |
Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged; Nail Diseases; Neoplasm Metastasis; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2004 |
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Prospective Studies; Taxoids | 2004 |
Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2004 |
Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Genes, erbB-2; Genetic Markers; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Liposomes; Maximum Tolerated Dose; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Radiography; Taxoids; Treatment Outcome | 2004 |
Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Heart; Humans; Hypersensitivity; Kidney; Liver; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nerve Tissue; Neutropenia; Radiography; Taxoids; Treatment Outcome | 2004 |
Monitoring the response of large (>3 cm) and locally advanced (T3-4, N0-2) breast cancer to neoadjuvant chemotherapy using (99m)Tc-Sestamibi uptake.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Image Interpretation, Computer-Assisted; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index; Taxoids; Technetium Tc 99m Sestamibi; Treatment Outcome | 2005 |
A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Japan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome | 2005 |
Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Taxoids; Time Factors; Treatment Failure; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
A phase I dose-escalating study of docetaxel plus folinic acid and 5-fluorouracil in anthracycline-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids | 2004 |
Prediction of docetaxel response in human breast cancer by gene expression profiling.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biopsy; Breast Neoplasms; Decision Making; DNA, Neoplasm; Docetaxel; Female; Forecasting; Gene Expression Profiling; Humans; Middle Aged; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2005 |
Neoadjuvant therapy with gemcitabine in breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Recombinant Proteins; Taxoids; Time Factors; Treatment Outcome | 2004 |
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Double-Blind Method; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Placebos; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2005 |
Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Salvage Therapy; Soft Tissue Neoplasms; Survival Analysis; Taxoids | 2005 |
Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Necrosis; Neoadjuvant Therapy; Neoplasm Invasiveness; Prognosis; Prospective Studies; Taxoids; Treatment Outcome | 2005 |
Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Filgrastim; Fluorouracil; Glucuronates; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pilot Projects; Polyethylene Glycols; Preoperative Care; Prospective Studies; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2005 |
First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2005 |
High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Prospective Studies; Severity of Illness Index; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2005 |
HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Tumor Suppressor Protein p53 | 2005 |
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Mastectomy, Segmental; Middle Aged; Neutropenia; Taxoids; Treatment Outcome | 2005 |
Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Colloids; Cyclophosphamide; Docetaxel; Doxorubicin; False Negative Reactions; Female; Humans; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Rosaniline Dyes; Sentinel Lymph Node Biopsy; Taxoids | 2005 |
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Epothilones; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Middle Aged; Nervous System; Paclitaxel; Taxoids; Treatment Outcome | 2005 |
Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Heart; Humans; Liposomes; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids | 2005 |
Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2005 |
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2005 |
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia; Taxoids | 2005 |
Capecitabine plus docetaxel combination therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Prospective Studies; Quality of Life; Sensitivity and Specificity; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Sepsis; Taxoids | 2005 |
Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Middle Aged; Multigene Family; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; RNA, Neoplasm; Sensitivity and Specificity; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; Neoplasm Metastasis; Neutropenia; Receptor, ErbB-2; Taxoids; Trastuzumab | 2005 |
[Bi-weekly chemotherapy with medium-dose docetaxel for advanced and recurrent breast cancers (The 15th study of Keiji Breast Cancer Study Group)].
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Marrow; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Floxuridine; Humans; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Quality of Life; Survival Analysis; Taxoids | 2005 |
Docetaxel and vinorelbine plus GM-CSF in malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Melanoma; Neoplasm Staging; Recombinant Proteins; Taxoids; Vinblastine; Vinorelbine | 2005 |
Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Humans; Neoplasm Metastasis; Taxoids | 2005 |
Sonographic evaluation of early-stage breast cancers that undergo neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Image Processing, Computer-Assisted; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity; Taxoids; Ultrasonography, Doppler, Color; Ultrasonography, Mammary | 2005 |
Preoperative second-line chemotherapy induces objective responses in primary breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Preoperative Care; Taxoids; Treatment Failure; Treatment Outcome | 2005 |
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cardiomyopathy, Dilated; Coronary Stenosis; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome | 2005 |
Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dimethoate; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Docetaxel; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Receptor, ErbB-2; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vomiting | 2005 |
Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Maximum Tolerated Dose; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Recombinant Proteins; Salvage Therapy; Taxoids | 2005 |
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Liposomes; Mastectomy, Segmental; Middle Aged; Taxoids; Treatment Outcome | 2005 |
Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: a phase II study.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lymph Node Excision; Middle Aged; Prospective Studies; Remission Induction; Skin; Taxoids | 2005 |
Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Glucuronates; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Receptor, ErbB-2; Remission Induction; Taxoids; Treatment Outcome | 2005 |
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chi-Square Distribution; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Logistic Models; Middle Aged; Paclitaxel; Proportional Hazards Models; Quality of Life; Taxoids; Treatment Outcome | 2005 |
A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liposomes; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Polyethylene Glycols; Prostatic Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome | 2005 |
Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Darbepoetin alfa; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Erythropoietin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ki-67 Antigen; Middle Aged; Neutropenia; Polyethylene Glycols; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome | 2005 |
Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
Topics: Adult; Age Distribution; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Greece; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Receptor, ErbB-2; Risk Assessment; Risk Factors; Sex Distribution; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
How reliable is MRI for predicting extent of residual breast cancer with different primary medical therapies?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Taxoids | 2005 |
Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab | 2006 |
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Genes, erbB-2; Humans; Middle Aged; Preoperative Care; Survival Analysis; Taxoids; Trastuzumab | 2006 |
Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Taxoids; Treatment Outcome | 2006 |
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Prodrugs; Prospective Studies; Remission Induction; Taxoids | 2005 |
Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids | 2005 |
Breath alcohol concentrations in Japanese outpatients following paclitaxel and docetaxel infusion.
Topics: Adult; Aged; Alcoholic Intoxication; Antineoplastic Agents, Phytogenic; Asian People; Breast Neoplasms; Breath Tests; Carcinoma, Non-Small-Cell Lung; Docetaxel; Ethanol; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Outpatients; Ovarian Neoplasms; Paclitaxel; Taxoids | 2005 |
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Breast Neoplasms; Dendritic Cells; Docetaxel; Female; Humans; Immunohistochemistry; Killer Cells, Natural; Macrophages; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; T-Lymphocytes; Taxoids; Trastuzumab | 2006 |
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Topics: Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Genes, erbB-2; Heart Diseases; Humans; Middle Aged; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2006 |
A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2006 |
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2006 |
Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Taxoids | 2006 |
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Taxoids | 2006 |
A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Oligonucleotides; Pancreatic Neoplasms; Prothrombin Time; Taxoids | 2006 |
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptors, Estrogen; Taxoids; Treatment Outcome | 2006 |
Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Time Factors; Treatment Outcome | 2006 |
Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Diseases; Humans; Liver Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Receptor, ErbB-2; Respiratory Tract Neoplasms; Risk Assessment; Skin Neoplasms; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2006 |
Treatment of metastatic breast cancer with vinorelbine and docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony sti
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neutropenia; Quality of Life; Taxoids | 2006 |
[Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study].
Topics: Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2006 |
Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2006 |
Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line; Chaperonin Containing TCP-1; Chaperonins; Chemotherapy, Adjuvant; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p53; GTP-Binding Proteins; GTPase-Activating Proteins; Humans; Molecular Chaperones; Neoplasm Proteins; Neoplasm Recurrence, Local; R-SNARE Proteins; RGS Proteins; RNA, Small Interfering; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2007 |
A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach.
Topics: Adenoviruses, Human; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Doxorubicin; Female; Gene Transfer Techniques; Genes, p53; Genetic Therapy; Genetic Vectors; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Survival Rate; Taxoids; Transgenes | 2006 |
Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.
Topics: 2-Methoxyestradiol; Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Estradiol; Fatigue; Female; Half-Life; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome; Tubulin Modulators; Urinalysis; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2007 |
Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Taxoids | 2006 |
TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Hospitals, Community; Humans; Middle Aged; Survival Rate; Taxoids; United Kingdom | 2007 |
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Genes, erbB-2; Humans; Middle Aged; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests; tau Proteins; Taxoids | 2007 |
A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Recombinant Proteins; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
[Multicenter phase II trial of thrice-weekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer--Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Middle Aged; Receptor, ErbB-2; Remission Induction; Taxoids; Trastuzumab | 2006 |
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 rando
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Premedication; Prospective Studies; Radionuclide Imaging; Remission Induction; Taxoids | 2006 |
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Tamoxifen; Taxoids; Treatment Outcome | 2006 |
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Prospective Studies; Survival Rate; Taxoids; Vomiting | 2006 |
[Docetaxel in the treatment of advanced breast cancer ].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Taxoids; Treatment Outcome; Vomiting | 2006 |
A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fever; Follow-Up Studies; Humans; Kidney; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2006 |
[Randomized controlled trial of two kinds of home-produced docetaxel in China for advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids | 2006 |
A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2007 |
Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Taxoids | 2006 |
Albumin-bound paclitaxel improves response rate vs docetaxel in metastatic breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2007 |
[The safety of docetaxel with cyclophosphamide (TC) therapy as adjuvant chemotherapy for Japanese women with operable breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphatic Metastasis; Middle Aged; Neutropenia; Taxoids; Treatment Outcome | 2007 |
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Polyethylene Glycols; Postmenopause; Premenopause; Preoperative Care; Recombinant Proteins; Taxoids | 2007 |
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Chromatography, High Pressure Liquid; DNA Primers; DNA, Neoplasm; Docetaxel; Doxorubicin; Genes, p53; Humans; Mutation; Predictive Value of Tests; Probability; Protein Biosynthesis; Taxoids | 2007 |
Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Ifosfamide; Middle Aged; Receptor, ErbB-2; Taxoids | 2007 |
[Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Remission Induction; Taxoids | 2007 |
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients.
Topics: Antineoplastic Agents; Biopsy; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Fixatives; Formaldehyde; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Paraffin Embedding; Patient Selection; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Tissue Fixation; Treatment Outcome; United Kingdom; United States | 2008 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cell Proliferation; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Genes, p53; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids | 2008 |
Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Glutamates; Guanine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pemetrexed; Taxoids; Treatment Outcome | 2007 |
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Taxoids | 2007 |
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2007 |
A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Female; Humans; Immune System; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Taxoids; Treatment Outcome | 2007 |
Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids | 2007 |
Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: further results from a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Palpation; Taxoids; Treatment Outcome | 2007 |
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Quinazolines; Taxoids; Treatment Outcome | 2007 |
Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; France; Humans; Middle Aged; Neoplasm Metastasis; Poland; Taxoids; Vinblastine; Vinorelbine | 2007 |
Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Humans; Middle Aged; Taxoids; Time Factors; Transforming Growth Factor beta1 | 2007 |
Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Taxoids | 2007 |
A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Taxoids | 2008 |
A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Retrospective Studies; Taxoids | 2008 |
A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Taxoids | 2008 |
The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; bcl-X Protein; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Taxoids; Tumor Suppressor Protein p53 | 2008 |
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Middle Aged; Prospective Studies; Survival Rate; Taxoids; Trastuzumab; Treatment Failure; Vinblastine; Vinorelbine | 2007 |
Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Pilot Projects; Sample Size; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2008 |
Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers.
Topics: Antineoplastic Agents; Breast Neoplasms; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Female; Genetic Markers; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Paclitaxel; Taxoids | 2008 |
PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.
Topics: 5' Untranslated Regions; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Blood Platelets; Breast Neoplasms; China; Constitutive Androstane Receptor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Doxorubicin; Exons; Female; Gene Expression Regulation, Neoplastic; Gene Frequency; Genotype; Hepatocyte Nuclear Factor 4; Humans; India; Malaysia; Middle Aged; Neutropenia; Polymorphism, Genetic; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Singapore; Taxoids; Time Factors; Transcription Factors; Treatment Outcome | 2008 |
Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome | 2008 |
An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy for anthracycline-naive patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Taxoids | 2007 |
Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Neutropenia; Paresthesia; Taxoids | 2007 |
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Patient Selection; Predictive Value of Tests; Receptors, Estrogen; Reproducibility of Results; ROC Curve; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2007 |
Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics.
Topics: Antineoplastic Agents; Breast Neoplasms; Constitutive Androstane Receptor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Genotype; Hepatocyte Nuclear Factor 4; Humans; Middle Aged; Polymorphism, Single Nucleotide; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Taxoids; Transcription Factors | 2007 |
How do patients want to learn of results of clinical trials? A survey of 1431 breast cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Health Knowledge, Attitudes, Practice; Health Status; Health Surveys; Humans; Middle Aged; Outcome and Process Assessment, Health Care; Patient Education as Topic; Surveys and Questionnaires; Taxoids | 2008 |
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Italy; Methotrexate; Patient Compliance; Taxoids; Treatment Outcome | 2008 |
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Odds Ratio; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Taxoids; Treatment Outcome | 2008 |
A phase I dose-escalating and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Taxoids; Vinblastine; Vinorelbine | 2007 |
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines; Taxoids; Treatment Outcome | 2008 |
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Survival Analysis; Taxoids | 2008 |
High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Topics: Adult; Aged; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Electrocardiography; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Receptor, ErbB-2; Stroke Volume; Taxoids; Treatment Outcome; Ultrasonography, Mammary; Up-Regulation; Ventricular Function, Left | 2008 |
Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Follow-Up Studies; Humans; Middle Aged; Prognosis; Survival Rate; Taxoids | 2008 |
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Premenopause; Quality of Life; Reproductive History; Surveys and Questionnaires; Survival Rate; Tamoxifen; Taxoids; Young Adult | 2009 |
Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Taxoids | 2008 |
Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Fluorouracil; Humans; Middle Aged; Taxoids | 2009 |
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Ki-67 Antigen; Logistic Models; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2008 |
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Receptors, Steroid; Taxoids | 2008 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Carcinoma, Lobular; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Liver Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2008 |
Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carrier Proteins; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Trastuzumab; Treatment Failure; Treatment Outcome | 2008 |
Biweekly docetaxel-containing chemotherapy may be the optimal schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Pilot Projects; Taxoids; Treatment Outcome | 2008 |
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
Topics: Adult; Aged; Alopecia; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Belgium; Boronic Acids; Bortezomib; Breast Neoplasms; Breast Neoplasms, Male; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Pyrazines; Spain; Taxoids; Treatment Outcome; United Kingdom; Vomiting | 2008 |
Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Thionucleotides | 2008 |
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2009 |
Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: phase I study of the Shiga Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Humans; Japan; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Taxoids | 2009 |
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Confidence Intervals; Docetaxel; Drug Tolerance; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Quality Control; Taxoids; Time Factors | 1995 |
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Eruptions; Europe; Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1994 |
[An early phase II clinical study of RP56976 (docetaxel) in patients with breast cancer].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Nausea; Paclitaxel; Remission Induction; Taxoids | 1994 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Asthenia; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Topics: Adult; Aged; Anthracyclines; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mitoxantrone; Paclitaxel; Taxoids | 1995 |
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Medullary; Carcinoma, Papillary; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids; Toxicity Tests | 1996 |
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cimetidine; Dexamethasone; Diphenhydramine; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Edema; Female; Humans; Injections, Intravenous; Leukopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel; Premedication; Taxoids | 1996 |
Docetaxel (Taxotere): an overview of first-line monotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 1995 |
Docetaxel (Taxotere) in combination: a step forward.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Clinical Trials as Topic; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1995 |
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 1996 |
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Taxoids | 1996 |
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 1996 |
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1996 |
Treatment of patients resistant to anthracycline therapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 1996 |
First-line treatment of metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Europe; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; North America; Paclitaxel; Taxoids | 1996 |
Taxoids in combination chemotherapy for metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Edema; Female; Flavonoids; Humans; Infusions, Intravenous; Lymphatic System; Middle Aged; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Taxoids; Water-Electrolyte Balance | 1997 |
Docetaxel in combination with doxorubicin: a phase I dose-finding study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pilot Projects; Survival Rate; Taxoids | 1997 |
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pilot Projects; Taxoids | 1997 |
Docetaxel combined with vinorelbine: phase I results and new study designs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Liver Neoplasms; Neoplasm Metastasis; Neutropenia; Paclitaxel; Research Design; Taxoids; Vinblastine; Vinorelbine | 1997 |
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Body Fluids; Breast Neoplasms; Cetirizine; Docetaxel; Drug Administration Schedule; Drug Eruptions; Edema; Europe; Female; Histamine H1 Antagonists; Humans; Methylprednisolone; Middle Aged; Paclitaxel; Pleural Effusion; Severity of Illness Index; Skin; Taxoids; Treatment Outcome; Water-Electrolyte Imbalance | 1997 |
Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Doxorubicin; Drug Administration Schedule; Estrogen Antagonists; Female; Fever; Humans; Infusions, Intravenous; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Tamoxifen; Taxoids | 1997 |
Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bacterial Infections; Breast Neoplasms; Cause of Death; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fever; Heart Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia | 1997 |
Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Constipation; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Mitomycins; Neoplasm Metastasis; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia; Vinblastine | 1997 |
Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclophosphamide; Dexamethasone; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Premedication; Remission Induction; Sarcoma; Taxoids | 1997 |
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fever; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1997 |
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bayes Theorem; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Taxoids | 1998 |
[Taxotere: the first drug better than acrdiamycin, the most frequently used drug in the treatment of metastasized breast cancer. Phase III study shows a better response than standard treatment].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 1997 |
A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1998 |
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Edema; Female; Fever; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Taxoids | 1998 |
Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Female; Glucocorticoids; Humans; Male; Middle Aged; Neoplasms; Nervous System Diseases; Paclitaxel; Prospective Studies; Taxoids | 1998 |
Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Mitomycin; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Vinblastine | 1998 |
Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Failure | 1998 |
Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids | 1998 |
Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
[Breast cancer: new therapeutic strategies].
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Multiple; Female; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Taxoids; Treatment Outcome | 1998 |
The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Ascites; Breast Neoplasms; Docetaxel; Edema; Humans; Hydroxyethylrutoside; Middle Aged; Paclitaxel; Pericardial Effusion; Pleural Effusion; Taxoids; Water-Electrolyte Imbalance | 1999 |
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lymphocyte Count; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Ventricular Function, Left | 1999 |
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 1999 |
Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Taxoids | 1999 |
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Health Status; Humans; Middle Aged; Mitomycins; Neutropenia; Paclitaxel; Patient Compliance; Proportional Hazards Models; Prospective Studies; Survival Analysis; Taxoids; Thrombocytopenia; Vinblastine | 1999 |
[Docetaxel therapy against anthracycline resistant breast cancer].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids | 1999 |
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Ventricular Function, Left | 1999 |
Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Middle Aged; Paclitaxel; Taxoids; Ventricular Function, Left | 1999 |
Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy. Hellenic Cooperative Interhospital Group in Oncology.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p185(HER2/neu) protein expression in breast cancer drill biopsies.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; DNA, Neoplasm; Docetaxel; Doxorubicin; Gene Amplification; Genes, erbB-2; Humans; Immunohistochemistry; Neoadjuvant Therapy; Paclitaxel; Polymerase Chain Reaction; Receptor, ErbB-2; Reproducibility of Results; Taxoids | 1999 |
Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 1999 |
Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Statistics, Nonparametric; Taxoids | 1999 |
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
[Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids | 1999 |
[Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.
Topics: Adult; Aged; Algorithms; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Paclitaxel; Patient Compliance; Taxoids; Treatment Failure | 1999 |
Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids | 1999 |
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Breast Neoplasms, Male; Chemical and Drug Induced Liver Injury; Docetaxel; Drug Resistance, Neoplasm; Female; Fever; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Risk Factors; Stomatitis; Taxoids; Treatment Outcome | 2000 |
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Alopecia; Antineoplastic Agents, Phytogenic; Area Under Curve; Aspartate Aminotransferases; Breast Neoplasms; Diarrhea; Docetaxel; Fatigue; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Taxoids; Time Factors | 2000 |
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Enterocolitis, Pseudomembranous; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Docetaxel administered on a weekly basis for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2000 |
[Efficacy of docetaxel for recurrent breast cancer: evaluation based on chemosensitivity test and clinical response].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Screening Assays, Antitumor; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2000 |
Intestinal side-effects of docetaxel/vinorelbine combination.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastroenteritis; Humans; Neutropenia; Paclitaxel; Risk Factors; Taxoids; Vinblastine; Vinorelbine | 2000 |
A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Dexamethasone; Docetaxel; Drug Resistance, Neoplasm; Female; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Prednisone; Taxoids | 2000 |
[Clinical efficacy of low-dose weekly docetaxel combined with oral 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced or metastatic breast cancer: a pilot trial].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Floxuridine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids | 2000 |
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Failure; Vinblastine; Vinorelbine | 2000 |
Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer.
Topics: Adult; Anthracyclines; Antineoplastic Agents, Phytogenic; Austria; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2000 |
Preliminary results of multicenter phase II trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Indonesia; Liver Neoplasms; Middle Aged; Paclitaxel; Remission Induction; Stroke Volume; Taxoids; Ventricular Function, Left | 2000 |
Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Netherlands; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Quality of Life; Taxoids | 2000 |
Phase II study of docetaxel in patients with liver metastases from breast cancer. UK study group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Patient Compliance; Survival Rate; Taxoids | 2000 |
Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2000 |
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids | 2000 |
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Chromatography, High Pressure Liquid; Cross-Over Studies; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Time Factors | 2000 |
[Intra-arterial infusion chemotherapy with docetaxel for locally advanced breast cancer and inflammatory breast cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intra-Arterial; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2000 |
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Disease Progression; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Stomatitis; Survival Analysis; Taxoids; Thiotepa; Thrombocytopenia; Transplantation Conditioning | 2000 |
Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2000 |
Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Taxoids | 2000 |
Docetaxel in patients with anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Middle Aged; Neutrophils; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Mobilization of peripheral blood stem cells in high-risk breast cancer patients using G-CSF after standard dose docetaxel.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Middle Aged; Paclitaxel; Taxoids | 2000 |
Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Remission Induction; Survival Analysis; Taxoids | 2001 |
Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Survival Analysis; Taxoids | 2001 |
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Incidence; Liver Neoplasms; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Taxoids | 2001 |
Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Hyperprolactinemia; Injections, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Prolactin; Remission Induction; Taxoids | 2001 |
[Effectiveness of doxorubicin-docetaxel or doxorubicin-cyclophosphamide combination in advanced breast cancer with distant metastasis].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Taxoids; Treatment Outcome | 2001 |
A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer.
Topics: Adult; Antigens, CD34; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Leukocyte Count; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Stem Cells; Taxoids | 2001 |
Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Taxoids | 2001 |
[Efficacy of weekly docetaxel therapy for advanced or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Tolerance; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2001 |
Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Analysis; Taxoids | 2001 |
Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2001 |
[Evaluation of efficacy and toxicity of docetaxel (Taxotere) in patients with advanced mammary gland cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2001 |
[A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Floxuridine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Patient Compliance; Preoperative Care; Prospective Studies; Tamoxifen; Taxoids | 2001 |
Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2001 |
Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mitoxantrone; Nausea; Neutropenia; Paclitaxel; Sepsis; Survival Rate; Taxoids | 2001 |
Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
[Effect of weekly docetaxel in patients with recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pilot Projects; Taxoids | 2001 |
Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Transplantation, Autologous; Treatment Outcome | 2001 |
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Taxoids | 2001 |
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Female; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Taxoids; Treatment Outcome | 2001 |
A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Interactions; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Metabolic Clearance Rate; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Dose-finding phase I study of simultaneous weekly infusion with doxorubicin and docetaxel in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2001 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
Weekly docetaxel (Taxotere) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Therapy, Combination; Female; Humans; Middle Aged; Neutrophils; Paclitaxel; Pilot Projects; Survival Rate; Taxoids; Vomiting | 2002 |
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; World Health Organization | 2002 |
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Delayed-Action Preparations; Docetaxel; Double-Blind Method; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Taxoids | 2002 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase II study of weekly docetaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distribution; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Linear Models; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prednisolone; Taxoids; Treatment Outcome; Vincristine | 2002 |
Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Menopause; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Prospective Studies; Survival Rate; Taxoids | 2002 |
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Paclitaxel; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; Up-Regulation | 2002 |
Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Docetaxel does not impair cardiac autonomic function in breast cancer patients previously treated with anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Circadian Rhythm; Docetaxel; Electrocardiography; Female; Heart Rate; Humans; Middle Aged; Paclitaxel; Taxoids | 2002 |
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Nausea; Nervous System Diseases; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Uracil | 2002 |
Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Intubation; Lacrimal Apparatus; Lacrimal Duct Obstruction; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Trastuzumab | 2002 |
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neovascularization, Pathologic; Paclitaxel; Prognosis; Taxoids; Time Factors; Treatment Outcome | 2002 |
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes.
Topics: Adult; Antibody Formation; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cytokines; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Growth Substances; Humans; Immunity, Cellular; Killer Cells, Lymphokine-Activated; Middle Aged; Paclitaxel; Taxoids | 2002 |
1394 other study(ies) available for docetaxel anhydrous and Breast Cancer
| Article | Year |
|---|---|
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Folate targeted hybrid lipo-polymeric nanoplexes containing docetaxel and miRNA-34a for breast cancer treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Folic Acid; Humans; MicroRNAs; Nanoparticles; Polymers | 2021 |
Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cannabidiol; Cell Line, Tumor; Cell Survival; Dactinomycin; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Irinotecan; MCF-7 Cells; Paclitaxel; Proteome; Proteomics; Vinorelbine | 2021 |
Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans | 2022 |
Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
A Retrospective Analysis of Metronomic Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Versus Docetaxel and Cyclophosphamide (TC) as Adjuvant Treatment in Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Retrospective Studies; Taxoids | 2022 |
Brazilian green propolis: A novel tool to improve the cytotoxic and immunomodulatory action of docetaxel on MCF-7 breast cancer cells and on women monocyte.
Topics: Breast Neoplasms; Docetaxel; Female; Humans; MCF-7 Cells; Monocytes; Propolis | 2022 |
Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Retrospective Studies | 2022 |
Reduction of breast tumor drug resistance by 2,3,5,4'-tetrahydroxystilbene for exhibition synergic chemotherapeutic effect.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glucosides; Humans; MCF-7 Cells; Stilbenes; Zebrafish | 2021 |
Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer-Associated Fibroblasts; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Receptor, ErbB-2; Trastuzumab | 2021 |
Docetaxel-related toxic optic neuropathy in a patient with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Toxic Optic Neuropathy | 2022 |
Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Mastectomy; Neoadjuvant Therapy; Retrospective Studies; Trastuzumab | 2022 |
Docetaxel monotherapy induces necrotic acute pancreatitis.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Pancreatitis | 2022 |
Marginal Corneal Infiltration Following Treatment for Metastatic Breast Cancer with Triple Chemotherapy of Trastuzumab, Pertuzumab & Docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Ki-67 Antigen; Taxoids; Trastuzumab | 2023 |
Correlation between CA12 and TFF3 and their prediction value of neoadjuvant chemotherapy response in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbonic Anhydrases; Docetaxel; Doxorubicin; Female; Humans; Neoadjuvant Therapy; Receptors, Estrogen; RNA, Messenger; Trefoil Factor-3 | 2022 |
Evaluation of a novel medical device for pegfilgrastim administration.
Topics: Activities of Daily Living; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Polyethylene Glycols; Recombinant Proteins | 2022 |
Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2022 |
Overexpression of microRNA-145 enhanced docetaxel sensitivity in breast cancer cells via inactivation of protein kinase B gamma-mediated phosphoinositide 3-kinase -protein kinase B pathway.
Topics: Breast Neoplasms; Cell Proliferation; Docetaxel; Female; Humans; MicroRNAs; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2022 |
Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark.
Topics: Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cohort Studies; Cytochrome P-450 CYP3A; Denmark; Docetaxel; Female; Humans; Liver-Specific Organic Anion Transporter 1; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; Taxoids | 2022 |
Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.
Topics: Androgen Antagonists; Breast Neoplasms; Docetaxel; Humans; Male; Phenotype; Prostatic Neoplasms, Castration-Resistant | 2022 |
nurP28, a New-to-Nature Zein-Derived Peptide, Enhances the Therapeutic Effect of Docetaxel in Breast Cancer Monolayers and Spheroids.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Peptides; Spheroids, Cellular; Zein | 2022 |
Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Chemokine CCL3; Docetaxel; Female; Humans; Macrophage Activation; Macrophages; Mice; Tumor Microenvironment | 2022 |
Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism.
Topics: Animals; Breast Neoplasms; Docetaxel; Endothelial Cells; Endothelium, Vascular; Female; Humans; Hypertension; Mice; NADPH Oxidase 4; NADPH Oxidases; Reactive Oxygen Species | 2022 |
Influence of alcohol sensitivity on bone metastases and skeletal-related events in primary operable breast cancer: A retrospective cohort study.
Topics: Aldehyde Dehydrogenase, Mitochondrial; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Docetaxel; Female; Humans; Retrospective Studies | 2022 |
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab | 2022 |
Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer.
Topics: Biosimilar Pharmaceuticals; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Female; Humans; Markov Chains; Neoplasms, Second Primary; Pharmaceutical Preparations; Quality-Adjusted Life Years; Receptor, ErbB-2; Trastuzumab | 2022 |
Single-Center Analysis of Pegfilgrastim-induced Aortitis Using a Drug Prescription Database and CT Findings.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aortitis; Breast Neoplasms; Cisplatin; Docetaxel; Drug Prescriptions; Esophageal Neoplasms; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Tomography, X-Ray Computed | 2022 |
Neural correlates in functional brain mapping among breast cancer survivors receiving different chemotherapy regimens: a qEEG/HEG-based investigation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Mapping; Breast Neoplasms; Cancer Survivors; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Neurotoxicity Syndromes; Paclitaxel | 2022 |
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clonal Evolution; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Neoadjuvant Therapy; Taxoids | 2022 |
Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Child; Docetaxel; Female; Humans; Lacrimal Apparatus Diseases; Macular Edema; Middle Aged; Optic Nerve Diseases; Paclitaxel; Retrospective Studies; Tamoxifen; Taxoids | 2022 |
Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Receptor, ErbB-2; Trastuzumab | 2022 |
Factors Associated with Absolute Neutrophil Count Dynamics and Docetaxel-Adryamicin-Cyclophosphamide (TAC) Chemotherapy Induced Neutropenia During Extended Filgrastim Administration in Breast Cancer Patients.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols | 2022 |
Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in Colombia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colombia; Cost-Benefit Analysis; Docetaxel; Female; Humans; Trastuzumab | 2022 |
Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort s
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; East Asian People; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Retrospective Studies | 2022 |
Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer.
Topics: Adult; Alopecia; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Paclitaxel; Prospective Studies; Scalp; Taxoids | 2022 |
Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life; Taxoids | 2022 |
[Two Cases of Therapy-Related Myeloid Neoplasms after Docetaxel with Cyclophosphamide Therapy for Breast Cancer].
Topics: Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2022 |
Optimal exposure to docetaxel in adjuvant chemotherapy for early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Hemoglobins; Humans; Neutropenia; Platinum; Taxoids | 2022 |
Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Epitopes; Female; Humans; Mice; Taxoids | 2022 |
Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction.
Topics: Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Methionine; Middle Aged; Neoadjuvant Therapy; Racemethionine | 2022 |
[Comparative Safety Study of Original and Generic Docetaxel without Alcohol in the Treatment of Breast Cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Edema; Ethanol; Female; Humans; Peripheral Nervous System Diseases; Retrospective Studies; Taxoids | 2022 |
Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cuba; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prospective Studies; Receptor, ErbB-2; Trastuzumab | 2023 |
An Evaluation of the Efficacy of Compression Therapy Using Sleeves and Stockings to Prevent Docetaxel-induced Peripheral Neuropathy in Breast Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Peripheral Nervous System Diseases; Retrospective Studies; Taxoids | 2022 |
Ethoxysanguinarine Induces Apoptosis, Inhibits Metastasis and Sensitizes cells to Docetaxel in Breast Cancer Cells through Inhibition of Hakai.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Humans | 2023 |
Boosting the Potential of Chemotherapy in Advanced Breast Cancer Lung Metastasis via Micro-Combinatorial Hydrogel Particles.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Hydrogels; Lung Neoplasms | 2023 |
Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors.
Topics: Administration, Oral; Antimitotic Agents; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Ritonavir; Taxoids | 2023 |
The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis.
Topics: Apoptosis; Breast Neoplasms; Carcinoma; Cell Proliferation; Docetaxel; Female; Humans; Molecular Docking Simulation; Prognosis; Proteomics; Receptors, Retinoic Acid | 2023 |
[A Case of Long-Term Survival of Breast Cancer with Extra-Regional Lymph Node Metastases].
Topics: Aged; Breast Diseases; Breast Neoplasms; Docetaxel; Female; Humans; Lymph Nodes; Lymphatic Metastasis | 2023 |
Half Dose Pegfilgrastim for Patients With Breast Cancer During Chemotherapy: A Case-series.
Topics: Breast Neoplasms; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Filgrastim; Humans | 2023 |
Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: a multicenter retrospective case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2023 |
Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lipopolysaccharides; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2023 |
Oligometastatic breast cancer to parotid gland with complete response.
Topics: Breast Neoplasms; Docetaxel; Female; Humans; Lymph Nodes; Parotid Gland; Trastuzumab | 2023 |
The Safety of Neoadjuvant Therapy with Polyethylene Glycol Liposome Adriamycin Combined with Docetaxel in Patients with Breast Cancer Complicated by Axillary Lymph Node Metastasis.
Topics: Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Liposomes; Lymphatic Metastasis; Neoadjuvant Therapy; Polyethylene Glycols; Stroke Volume; Taxoids; Trastuzumab; Troponin I; Ventricular Function, Left | 2023 |
A five arm natural history study of nasal vestibulitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Prospective Studies | 2023 |
Impact of Chemotherapy Regimens on Body Composition of Breast Cancer Women: A Multicenter Study across Four Brazilian Regions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Mass Index; Brazil; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Humans | 2023 |
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Ethanol; Female; Humans; Patients; Prospective Studies | 2023 |
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2023 |
Targeting human EGFR 2 (HER2) in salivary gland carcinoma.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Docetaxel; ErbB Receptors; Female; Humans; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Salivary Glands; Trastuzumab | 2023 |
CircRNA CircABCB1 Diminishes the Sensitivity of Breast Cancer Cells to Docetaxel by Sponging MiR-153-3p.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Docetaxel; Female; Humans; MicroRNAs; RNA, Circular | 2023 |
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records.
Topics: Breast Neoplasms; Docetaxel; Electronic Health Records; Female; Humans; Paclitaxel; Retrospective Studies; Taxoids; Trastuzumab | 2023 |
Hyaluronan-estradiol nanogels as potential drug carriers to target ER+ breast cancer cell line.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Curcumin; Docetaxel; Drug Carriers; Drug Delivery Systems; Estradiol; Female; Humans; Hyaluronic Acid; MCF-7 Cells; Nanogels; Nanoparticles | 2023 |
Transfer Learning for Early Prediction of Adverse Drug Reactions: Docetaxel and Alopecia in Breast Cancer as a Case Study.
Topics: Adverse Drug Reaction Reporting Systems; Alopecia; Breast Neoplasms; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Machine Learning | 2023 |
[A Case Study of Successful Breast Cancer Treatment after Recovery from Drug-Induced Interstitial Lung Disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Lung Diseases, Interstitial; Receptor, ErbB-2; Trastuzumab | 2023 |
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Leukocytes, Mononuclear; Mice; Mitosis; Receptor, ErbB-2; Receptors, CXCR4; Trastuzumab; Tumor Microenvironment | 2023 |
High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Docetaxel; Female; Humans; Retrospective Studies; Taxoids | 2023 |
Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Interactions; Female; Granulocyte Colony-Stimulating Factor; Humans; Insurance; Neutropenia; Taxoids | 2023 |
Impact of systemic dexamethasone dosage on docetaxel-induced oral mucositis in patients with breast cancer.
Topics: Breast Neoplasms; Dexamethasone; Docetaxel; Dysgeusia; Female; Humans; Retrospective Studies; Stomatitis | 2023 |
Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Retrospective Studies; Taxoids; Trastuzumab | 2023 |
[A Case of Breast Carcinoma That Changed Subtype to Squamous Cell Carcinoma after Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Cyclophosphamide; Docetaxel; Female; Humans; Liver Neoplasms; Mastectomy; Quality of Life | 2023 |
pH-triggered "PEG" sheddable and folic acid-targeted nanoparticles for docetaxel delivery in breast cancer treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Folic Acid; Humans; Hydrogen-Ion Concentration; Nanoparticles; Polyethylene Glycols | 2023 |
FTO-mediated epigenetic upregulation of LINC01559 confers cell resistance to docetaxel in breast carcinoma by suppressing miR-1343-3p.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Up-Regulation | 2023 |
Tumor-derived exosomes RNA expression profiling identifies the prognosis, immune characteristics, and treatment in HR+/HER2-breast cancer.
Topics: Breast Neoplasms; Docetaxel; Exosomes; Female; Humans; Paclitaxel; Prognosis | 2023 |
Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy.
Topics: Aged; Breast Neoplasms; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Intercellular Signaling Peptides and Proteins; Male; Medicare; Retrospective Studies; United States | 2023 |
Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Taxoids | 2023 |
Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Neoadjuvant Therapy; Platinum; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer.
Topics: Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Trastuzumab | 2023 |
Docetaxel-loaded PAMAM-based poly (γ-benzyl-l-glutamate)-b-d-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles in human breast cancer and human cervical cancer therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Dendrimers; Docetaxel; Drug Carriers; Drug Liberation; Female; HeLa Cells; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Uterine Cervical Neoplasms; Vitamin E | 2019 |
Melatonin Modulation of Radiation and Chemotherapeutics-induced Changes on Differentiation of Breast Fibroblasts.
Topics: Adipocytes; Antineoplastic Agents; Aromatase; Breast Neoplasms; Cancer-Associated Fibroblasts; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Docetaxel; Enzyme Activation; Female; Gene Expression Regulation; Humans; Mammary Glands, Human; Melatonin; PPAR gamma; Prostaglandin-Endoperoxide Synthases; Radiation, Ionizing; Vinorelbine | 2019 |
Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dendrimers; Docetaxel; Drug Interactions; Drug Liberation; Fluorescent Dyes; Humans; Paclitaxel; Receptor, ErbB-2; Surface Properties; Trastuzumab; Treatment Outcome | 2019 |
In utero exposure to breast cancer treatment: a population-based perinatal outcome study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Carboplatin; Case-Control Studies; Cesarean Section; Cohort Studies; Congenital Abnormalities; Continuous Positive Airway Pressure; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gestational Age; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Small for Gestational Age; Labor, Induced; New Zealand; Paclitaxel; Perinatal Death; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Premature Birth; Prospective Studies; Respiratory Distress Syndrome, Newborn; Stillbirth; Tamoxifen; Trastuzumab | 2019 |
CD44-Targeted Multifunctional Nanomedicines Based on a Single-Component Hyaluronic Acid Conjugate with All-Natural Precursors: Construction and Treatment of Metastatic Breast Tumors
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Lung Neoplasms; Mice; Molecular Targeted Therapy; Nanomedicine; Nanoparticles; Thioctic Acid; Tissue Distribution; Tyrosine; Xenograft Model Antitumor Assays | 2020 |
Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cross-Sectional Studies; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2019 |
Definitive alopecia post-docetaxel.
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2020 |
Coadministration of chemotherapy and PI3K/Akt pathway treatment with multistage acidity/CathB enzyme-responsive nanocarriers for inhibiting the metastasis of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Indazoles; Maleic Anhydrides; Mice; Nanoparticles; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Polyethyleneimine; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2019 |
Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy.
Topics: Activities of Daily Living; Adult; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cross-Sectional Studies; Docetaxel; Female; Hand-Foot Syndrome; Humans; Middle Aged; Surveys and Questionnaires; Taiwan | 2019 |
Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Breast Neoplasms; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Ornithine; Protein-Arginine Deiminase Type 2; Tamoxifen; Xenograft Model Antitumor Assays | 2019 |
An Exceptional Case of Bilateral Atrophic Squirrhus of Breast.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Trastuzumab | 2020 |
Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Computational Biology; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Mastectomy; MicroRNAs; Middle Aged; Prospective Studies; Retrospective Studies | 2019 |
Trastuzumab-conjugated nanoparticles composed of poly(butylene adipate-
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Coated Materials, Biocompatible; Docetaxel; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Screening Assays, Antitumor; Electroplating; Female; Humans; Nanoconjugates; Nanoparticles; Particle Size; Polyesters; Trastuzumab | 2019 |
Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab.
Topics: Adult; Agammaglobulinemia; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Gram-Positive Bacterial Infections; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2020 |
Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Claudin-5; Docetaxel; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Magnetic Resonance Imaging; Mice; Microscopy, Electron; Sequence Analysis, RNA; Tubulin; Xenograft Model Antitumor Assays | 2019 |
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2019 |
Distichiasis in association with entropion in metastatic HER2-positive breast cancer treated by pertuzumab, trastuzumab, and docetaxel combination chemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Entropion; Eyelids; Female; Humans; Receptor, ErbB-2; Taxoids; Trastuzumab | 2020 |
Development of conjugate-by-conjugate structured nanoparticles for oral delivery of docetaxel.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Chitosan; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Humans; Hydrogen-Ion Concentration; Hypromellose Derivatives; Intestinal Absorption; Nanoparticles; Particle Size; Vitamin E; X-Ray Diffraction | 2020 |
Pathologic response to neoadjuvant chemotherapy in HPV-associated oropharynx cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Oropharyngeal Neoplasms; Papillomavirus Infections; Treatment Outcome | 2020 |
MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin.
Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; MicroRNAs; Neoplasm Proteins | 2020 |
Responses of Blood System to Doxorubicin/Docetaxel Chemotherapy in Patients with Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Cell Lineage; Docetaxel; Doxorubicin; Erythrocytes; Erythropoiesis; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Leukopoiesis | 2019 |
A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.
Topics: Ado-Trastuzumab Emtansine; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Docetaxel; Female; Humans; Lapatinib; Markov Chains; Middle Aged; Neoplasm Metastasis; Quality-Adjusted Life Years; Receptor, ErbB-2; Taiwan; Trastuzumab | 2020 |
Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Netherlands; Retrospective Studies | 2019 |
Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Trastuzumab; Young Adult | 2020 |
Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: A retrospective cohort study on duration of prophylactic GCSF administration.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Middle Aged; Retrospective Studies | 2020 |
Improved chemotherapeutic efficacy against resistant human breast cancer cells with co-delivery of Docetaxel and Thymoquinone by Chitosan grafted lipid nanocapsules: Formulation optimization, in vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chitosan; Docetaxel; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Screening Assays, Antitumor; Female; Humans; Lipids; MCF-7 Cells; Nanocapsules; Neovascularization, Pathologic; Rats; Structure-Activity Relationship | 2020 |
Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Docetaxel; Female; Humans; Liposomes; Mice; Mice, Nude; Receptor, ErbB-2; Tissue Distribution; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Novel pH-triggered biocompatible polymeric micelles based on heparin-α-tocopherol conjugate for intracellular delivery of docetaxel in breast cancer.
Topics: alpha-Tocopherol; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Docetaxel; Drug Liberation; Female; Heparin; Humans; Hydrogen-Ion Concentration; MCF-7 Cells; Mice; Micelles | 2020 |
Co-encapsulation of docetaxel and thymoquinone in mPEG-DSPE-vitamin E TPGS-lipid nanocapsules for breast cancer therapy: Formulation optimization and implications on cellular and in vivo toxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanocapsules; Phosphatidylethanolamines; Polyethylene Glycols; Triple Negative Breast Neoplasms; Vitamin E | 2020 |
BAD sensitizes breast cancer cells to docetaxel with increased mitotic arrest and necroptosis.
Topics: Animals; Antineoplastic Agents; bcl-Associated Death Protein; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Genes, bcl-2; Humans; Mice; Mitosis; Necroptosis; Oxidative Phosphorylation; Prognosis; Promoter Regions, Genetic; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2020 |
Co-Delivery of Docetaxel and Salinomycin to Target Both Breast Cancer Cells and Stem Cells by PLGA/TPGS Nanoparticles.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Delivery Systems; Drug Liberation; Female; Humans; Liposomes; Male; MCF-7 Cells; Mice, Inbred BALB C; Nanoparticles; Neoplastic Stem Cells; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrans; Rats, Sprague-Dawley; Tissue Distribution; Vitamin E; Xenograft Model Antitumor Assays | 2019 |
Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2020 |
Computational Cancer Cell Models to Guide Precision Breast Cancer Medicine.
Topics: Breast Neoplasms; Cell Line, Tumor; Computer Simulation; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Evaluation, Preclinical; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Precision Medicine; Tamoxifen; Transcriptome | 2020 |
Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Disease Models, Animal; Docetaxel; Drug Carriers; Fatty Acids; Female; Hexoses; Inhibitory Concentration 50; Lipids; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nanoparticles; NIH 3T3 Cells; Particle Size; Poloxamer | 2020 |
Is HER2-positive metastatic breast cancer still an incurable disease?
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Docetaxel; Double-Blind Method; Humans; Receptor, ErbB-2; Trastuzumab | 2020 |
Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Decision Support Techniques; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Markov Chains; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Progression-Free Survival; Quality of Life; Receptor, ErbB-2; Trastuzumab | 2020 |
Regulation of docetaxel chemosensitivity by NR2F6 in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Repressor Proteins | 2020 |
Optimization of Docetaxel Loading Conditions in Liposomes: proposing potential products for metastatic breast carcinoma chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Docetaxel; Drug Liberation; Female; Humans; Liposomes; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; NIH 3T3 Cells; Particle Size; Rats | 2020 |
Optimal Tumor Reduction Rate and Modalities for Predicting pCR in Women With Breast Cancer.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Remission Induction; Trastuzumab; Triple Negative Breast Neoplasms; Tumor Burden; Ultrasonography | 2020 |
Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Humans; Maytansine; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Trastuzumab | 2020 |
Risk factors for breast cancer-related lymphedema: correlation with docetaxel administration.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Axilla; Body Mass Index; Breast Cancer Lymphedema; Breast Neoplasms; Breast Neoplasms, Male; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Male; Mastectomy; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Risk Factors; Sentinel Lymph Node Biopsy; Upper Extremity; Young Adult | 2020 |
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognitive Dysfunction; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Tamoxifen | 2020 |
Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Middle Aged; NAV1.7 Voltage-Gated Sodium Channel; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate | 2020 |
Taxotere-induced WNT16 Expression in Carcinoma-Associated Fibroblasts Might Associate with Progression and Chemoresistance of Breast Cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cancer-Associated Fibroblasts; Docetaxel; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Wnt Proteins | 2020 |
Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Hand-Foot Syndrome; Humans; Hyperpigmentation; Longitudinal Studies; Middle Aged; Mucositis; Nail Diseases; Prospective Studies; Review Literature as Topic; Skin Diseases | 2020 |
Delayed docetaxel extravasation in case of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2020 |
Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Female; Humans; Mice; Osteolysis; TNF Receptor-Associated Factor 6 | 2020 |
Quercetin Inhibits Lef1 and Resensitizes Docetaxel-Resistant Breast Cancer Cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Caveolin 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lymphoid Enhancer-Binding Factor 1; MCF-7 Cells; Neoplasm Metastasis; Neoplasm Proteins; Quercetin; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta; Vimentin | 2020 |
Exploring the Promising Potential of High Permeation Vesicle-Mediated Localized Transdermal Delivery of Docetaxel in Breast Cancer To Overcome the Limitations of Systemic Chemotherapy.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Disease Models, Animal; Docetaxel; Drug Carriers; Drug Compounding; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Particle Size; Permeability; Rats; Rats, Sprague-Dawley; Skin; Swine; Tissue Distribution; Transplantation, Homologous; Treatment Outcome; Tumor Burden | 2020 |
Radiation recall myelitis following capecitabine: First case report.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Carcinoma; Combined Modality Therapy; Docetaxel; Drug Substitution; Female; Humans; Hyperbaric Oxygenation; Letrozole; Middle Aged; Myelitis; Myositis; Prednisolone; Radiodermatitis; Radiotherapy, Adjuvant; Spinal Cord; Spinal Neoplasms; Thoracic Vertebrae | 2020 |
CHCHD2 decreases docetaxel sensitivity in breast cancer via activating MMP2.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Proliferation; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Matrix Metalloproteinase 2; Middle Aged; Transcription Factors | 2020 |
Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Randomized Controlled Trials as Topic; Receptors, Estrogen; Retrospective Studies; Survival Rate | 2020 |
Disulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Disulfiram; Docetaxel; Drug Synergism; Female; Humans; MCF-7 Cells; Reactive Oxygen Species | 2020 |
Docetaxel-induced acute myositis: a case report with review of literature.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Myositis | 2021 |
ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Nigeria; Trastuzumab | 2020 |
[Factors Contributing to the Occurrence of Edema in Breast Cancer Patients Receiving DTX Treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Edema; Humans; Receptor, ErbB-2; Taxoids; Trastuzumab | 2020 |
Two-weekly docetaxel in treatment of advanced breast cancer: A preliminary study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Progression-Free Survival; Treatment Outcome; Young Adult | 2020 |
Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer.
Topics: Adult; Age Factors; Alopecia; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Biopsy; Breast Neoplasms; Case-Control Studies; Docetaxel; Dose-Response Relationship, Drug; Enhancer Elements, Genetic; Female; Follow-Up Studies; Genetic Predisposition to Disease; Genome-Wide Association Study; Hair Follicle; Humans; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Retrospective Studies; Risk Factors | 2020 |
Melatonin Administered before or after a Cytotoxic Drug Increases Mammary Cancer Stabilization Rates in HER2/Neu Mice.
Topics: Anemia; Animals; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Disease Models, Animal; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Leukopenia; Melatonin; Mice; Mice, Transgenic; Receptor, ErbB-2 | 2020 |
Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2 | 2020 |
Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Polyethylene Glycols; Receptor, ErbB-2; Stroke Volume; Taxoids; Treatment Outcome; Ventricular Function, Left | 2020 |
Observational study of clinical toxicity with different formulations of docetaxel in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Longitudinal Studies; Prospective Studies; Taxoids | 2020 |
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2020 |
Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study.
Topics: Alberta; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Female; Humans; Lymph Nodes; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Treatment Outcome | 2020 |
Paired‑related homeobox 1 overexpression promotes multidrug resistance via PTEN/PI3K/AKT signaling in MCF‑7 breast cancer cells.
Topics: Breast Neoplasms; Cisplatin; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction | 2020 |
Nanoengineered Disruption of Heat Shock Protein 90 Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer.
Topics: Animals; Antineoplastic Agents, Immunological; Breast Neoplasms; Cell Line, Tumor; Cholesterol; Docetaxel; Drug Delivery Systems; Drug Liberation; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Killer Cells, Natural; Macrolides; Mice, Inbred BALB C; Molecular Targeted Therapy; Nanoparticles; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2020 |
Construction of long-circulation EpCAM targeted drug delivery system and its application in the diagnosis and treatment of breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Contrast Media; Docetaxel; Drug Carriers; Drug Delivery Systems; Drug Liberation; Epithelial Cell Adhesion Molecule; Female; Humans; Magnetic Iron Oxide Nanoparticles; Magnetic Resonance Imaging; Mice; Microspheres; Polyethylene Glycols | 2021 |
pH-Sensitive Nanoparticles Codelivering Docetaxel and Dihydroartemisinin Effectively Treat Breast Cancer by Enhancing Reactive Oxidative Species-Mediated Mitochondrial Apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Hydrogen-Ion Concentration; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mitochondria; Nanoparticles; Oxidative Stress; Reactive Oxygen Species; Signal Transduction | 2021 |
Incorporation of docetaxel and thymoquinone in borage nanoemulsion potentiates their antineoplastic activity in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Borago; Breast Neoplasms; Cell Proliferation; Docetaxel; Drug Delivery Systems; Emulsions; Female; Humans; Nanoparticles; Tumor Cells, Cultured | 2020 |
Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells.
Topics: Acrylamides; Aminoquinolines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoradiotherapy; Docetaxel; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2020 |
[Two Cases of Advanced HER2-Positive Locally Advanced Breast Cancer for Which Preoperative Chemotherapy with Pertuzumab, Trastuzumab, and Docetaxel Resulted in Good Response].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Trastuzumab | 2020 |
Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer.
Topics: Aged; Albumins; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2 | 2021 |
Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Risk Factors | 2021 |
Do all patients with breast cancer benefit from neoadjuvant chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Humans; Neoadjuvant Therapy; Patients | 2020 |
Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Chromosomes, Human, Pair 17; Docetaxel; Female; Gene Amplification; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2020 |
Anticancer potential of docetaxel-loaded cobalt ferrite nanocarrier: an in vitro study on MCF-7 and MDA-MB-231 cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Cobalt; Docetaxel; Drug Carriers; Drug Delivery Systems; Drug Liberation; Female; Ferric Compounds; Hemolysis; Humans; Magnetics; MCF-7 Cells; Nanoparticles; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Spectroscopy, Fourier Transform Infrared; Thermogravimetry; X-Ray Diffraction | 2021 |
[Comparison of the Incidence of Febrile Neutropenia in Doxorubicin/Cyclophosphamide(AC)and Docetaxel/Cyclophosphamide(TC) Perioperative Chemotherapies for Primary Breast Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Febrile Neutropenia; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Retrospective Studies | 2020 |
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome.
Topics: Anthracyclines; B7-H1 Antigen; Breast Neoplasms; Carcinoma, Ductal, Breast; CD8-Positive T-Lymphocytes; Cell Cycle Proteins; Cyclophosphamide; Disease-Free Survival; Docetaxel; Estrogen Receptor alpha; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunity, Innate; Interferon Regulatory Factors; Longitudinal Studies; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Neoplasm, Residual; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Tumor Microenvironment | 2020 |
Evaluation of ovarian reserve before and after chemotherapy.
Topics: Adolescent; Adult; Anti-Mullerian Hormone; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cyclophosphamide; Dacarbazine; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Female; Fertility Preservation; Fluorouracil; Hodgkin Disease; Humans; Longitudinal Studies; Luminescent Measurements; Ovarian Reserve; Prednisone; Procarbazine; Vinblastine; Vincristine; Young Adult | 2021 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases; Docetaxel; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Male; Middle Aged; Nail Diseases; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Taxoids; Tunisia | 2021 |
Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Therapy, Combination; Female; Humans; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Trastuzumab; Young Adult | 2021 |
[Two Cases of Breast Cancer with Extensive Invasion to Skin].
Topics: Bevacizumab; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Thoracic Wall | 2020 |
Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer.
Topics: Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Humans; Nanoparticles; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome | 2021 |
Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Infertility; Neoplasms; Paclitaxel; Pregnancy; Pregnant Women; Taxoids | 2021 |
pH sensitive liposomes assisted specific and improved breast cancer therapy using co-delivery of SIRT1 shRNA and Docetaxel.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; Hydrogen-Ion Concentration; Liposomes; Nanoparticles; Particle Size; RNA, Small Interfering; Sirtuin 1 | 2021 |
Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Humans; Hydrogen-Ion Concentration; Liposomes; Particle Size; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2021 |
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Female; Humans; Neoplasm Metastasis; Progression-Free Survival; Quality-Adjusted Life Years; Receptor, ErbB-2; Singapore; Trastuzumab | 2021 |
The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Female; Humans; Models, Economic; Neoplasm Metastasis; Quality-Adjusted Life Years; Receptor, ErbB-2; Reimbursement Mechanisms; Trastuzumab | 2021 |
Clinical impact of the biology of synchronous axillary lymph node metastases in primary breast cancer on preoperative treatment strategy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Large-Core Needle; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Retrospective Studies | 2021 |
Partial inclusion complex assisted crosslinked β-cyclodextrin nanoparticles for improving therapeutic potential of docetaxel against breast cancer.
Topics: Antineoplastic Agents; beta-Cyclodextrins; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Nanoparticles | 2022 |
Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Integrin beta3; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Survival Analysis | 2021 |
Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008-2012.
Topics: Alberta; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Lymph Nodes; Taxoids | 2021 |
Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2-negative breast cancer patients treated with docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Patient-Specific Modeling; Receptor, ErbB-2 | 2021 |
Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Minnesota; Neoplasms; Paclitaxel | 2021 |
Efficient in vitro and in vivo docetaxel delivery mediated by pH-sensitive LPHNPs for effective breast cancer therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Particle Size; Tissue Distribution | 2021 |
Novel decorated nanostructured lipid carrier for simultaneous active targeting of three anti-cancer agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Carriers; Drug Liberation; Female; Humans; Lipids; Methotrexate; Nanostructures; Tumor Cells, Cultured | 2021 |
Effect of 3 mg versus 6 mg pegfilgrastim on the prevention of febrile neutropenia in breast cancer patients receiving docetaxel and cyclophosphamide: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Polyethylene Glycols; Prospective Studies; Retrospective Studies | 2021 |
Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Meglumine; Middle Aged; Neoadjuvant Therapy; Organometallic Compounds; Predictive Value of Tests; Prospective Studies; Trastuzumab; Tumor Burden | 2021 |
Dendronized hyaluronic acid-docetaxel conjugate as a stimuli-responsive nano-agent for breast cancer therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dendrimers; Docetaxel; Drug Carriers; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Mice, Inbred BALB C; Mice, Nude; Nanostructures; Xenograft Model Antitumor Assays | 2021 |
Docetaxel encapsulation in nanoscale assembly micelles of folate-PEG-docetaxel conjugates for targeted fighting against metastatic breast cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Folic Acid; Humans; Mice; Mice, Inbred BALB C; Micelles; Polyethylene Glycols | 2021 |
Abnormal Long Non-Coding RNAs Expression Patterns Have the Potential Ability for Predicting Survival and Treatment Response in Breast Cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; RNA, Long Noncoding; Survival Analysis; Transcriptome | 2021 |
Co-Adjuvant Therapy Efficacy of Catechin and Procyanidin B2 with Docetaxel on Hormone-Related Cancers In Vitro.
Topics: Antineoplastic Agents; Biflavonoids; Breast Neoplasms; Catechin; Docetaxel; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Humans; In Vitro Techniques; Male; MCF-7 Cells; Proanthocyanidins; Prostatic Neoplasms | 2021 |
Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Breast Neoplasms; Docetaxel; Female; Humans; Male; Middle Aged; Models, Statistical; Progression-Free Survival; Proportional Hazards Models; Receptor, ErbB-2; Survival Rate; Tumor Burden | 2021 |
Deep Penetration of Nanolevel Drugs and Micrometer-Level T Cells Promoted by Nanomotors for Cancer Immunochemotherapy.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Docetaxel; Female; Humans; Immunotherapy; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Nanostructures; Nitric Oxide; T-Lymphocytes; Tumor Microenvironment | 2021 |
Chemotherapeutic effects on breast tumor hemodynamics revealed by eigenspectra multispectral optoacoustic tomography (eMSOT).
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Female; Hemodynamics; Humans; Hypoxia; Mice; Mice, SCID; Oxygen; Photoacoustic Techniques; Tomography; Tomography, Optical; Tomography, X-Ray Computed; Tumor Microenvironment | 2021 |
Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Retrospective Studies | 2022 |
Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Lipids; Mice; Micelles; Oligopeptides; Triple Negative Breast Neoplasms | 2021 |
Synergistic inhibition of migration and invasion of breast cancer cells by dual docetaxel/quercetin-loaded nanoparticles via Akt/MMP-9 pathway.
Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Docetaxel; Female; Hyaluronic Acid; Imines; Lactic Acid; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice, Inbred BALB C; Nanoparticles; Polyethylenes; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Proto-Oncogene Proteins c-akt; Quercetin; Taxoids; Wound Healing | 2017 |
WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 CYP3A; Docetaxel; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; Mutation; Prognosis; Taxoids; Up-Regulation; WT1 Proteins | 2017 |
Central Macular Thickness Monitoring after a Taxane-Based Therapy in Visually Asymptomatic Patients.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Esophageal Neoplasms; Female; Humans; Macula Lutea; Macular Edema; Male; Middle Aged; Ovarian Neoplasms; Taxoids; Tomography, Optical Coherence; Visual Acuity | 2017 |
Activation of hypoxia-inducible factor-1α by prolonged in vivo hyperinsulinemia treatment potentiates cancerous progression in estrogen receptor-positive breast cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hyperinsulinism; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin; Insulin Resistance; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Reactive Oxygen Species; Receptors, Estrogen; Signal Transduction; Taxoids; Ubiquitination; Xenograft Model Antitumor Assays | 2017 |
Her-2 expression regulated by downregulation of miR-9 and which affects chemotherapeutic effect in breast cancer.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice, Inbred C57BL; MicroRNAs; Receptor, ErbB-2; Taxoids | 2017 |
A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Remission Induction; Taxoids; Trastuzumab | 2017 |
Formulation of a Sustained Release Docetaxel Loaded Cockle Shell-Derived Calcium Carbonate Nanoparticles against Breast Cancer.
Topics: Animal Shells; Animals; Antineoplastic Agents; Breast Neoplasms; Calcium Carbonate; Cardiidae; Cell Survival; Delayed-Action Preparations; Docetaxel; Drug Carriers; Drug Compounding; Drug Liberation; Female; Humans; MCF-7 Cells; Nanoparticles; Particle Size; Surface Properties; Taxoids | 2017 |
Potentiation of docetaxel sensitivity by miR-638 via regulation of STARD10 pathway in human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Phosphoproteins; Signal Transduction; Taxoids | 2017 |
[Generic drugs controversy in oncology].
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Compounding; Drugs, Generic; Enterocolitis; Febrile Neutropenia; Female; Humans; Legislation, Drug; Medical Oncology; Taxoids; United States | 2017 |
Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients.
Topics: Antineoplastic Agents; Biomarkers; Breast Neoplasms; China; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; Humans; India; Malaysia; Orosomucoid; Predictive Value of Tests; Prognosis; Stomatitis; Taxoids | 2018 |
βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Brain; Breast Neoplasms; Cattle; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; Microtubules; RNA, Small Interfering; Taxoids; Tubulin; Tubulin Modulators | 2017 |
Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Everolimus; Female; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mice, Inbred BALB C; Mice, Nude; PC-3 Cells; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; Vascular Endothelial Growth Factor A | 2017 |
Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?
Topics: Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Humans | 2017 |
Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Maytansine; Receptor, ErbB-2; Salivary Ducts; Taxoids; Trastuzumab | 2017 |
New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Female; Fingolimod Hydrochloride; Humans; Lymphopenia; Mice; Nanoparticles; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Co-delivery of docetaxel and silibinin using pH-sensitive micelles improves therapy of metastatic breast cancer.
Topics: Acrylic Resins; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Hydrogen-Ion Concentration; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Polyethylene Glycols; Silybin; Silymarin; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 2017 |
Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.
Topics: Administrative Claims, Healthcare; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Comparative Effectiveness Research; Cyclophosphamide; Databases, Factual; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Medicare; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Propensity Score; Retrospective Studies; SEER Program; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; United States | 2017 |
A prospective study of docetaxel-associated pain syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Cancer Pain; Docetaxel; Female; Humans; Incidence; Middle Aged; Myalgia; Prospective Studies; Surveys and Questionnaires; Taxoids | 2018 |
The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles.
Topics: A549 Cells; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Coumarins; Docetaxel; Female; Humans; Hyaluronic Acid; Male; MCF-7 Cells; Mice; Nanoparticles; Polymers; Tamoxifen; Taxoids; Thiazoles | 2017 |
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; T-Lymphocytes, Cytotoxic; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2017 |
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Pyrimidines; Quinazolines; Receptor, ErbB-2; Survival Analysis; Taxoids; Thiophenes; Trastuzumab; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Surface modification of docetaxel nanocrystals with HER2 antibody to enhance cell growth inhibition in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Humans; MCF-7 Cells; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Taxoids | 2017 |
Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Bridged-Ring Compounds; Chromatin; Colchicine; Docetaxel; Drug Resistance, Neoplasm; Humans; MCF-7 Cells; Microtubules; Taxoids; Vinca Alkaloids | 2017 |
Long-term peripheral neuropathy symptoms in breast cancer survivors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Cancer Survivors; Cross-Sectional Studies; Docetaxel; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Prevalence; Retrospective Studies; Taxoids | 2017 |
Changes in ischemia-modified albumin in myocardial toxicity induced by anthracycline and docetaxel chemotherapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cyclophosphamide; Docetaxel; Electrocardiography; Epirubicin; Female; Humans; Middle Aged; Serum Albumin; Serum Albumin, Human; Taxoids | 2017 |
Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; Lipids; Liposomes; Nanoparticles; Receptor, ErbB-2; Trastuzumab | 2018 |
NanoMIL-100(Fe) containing docetaxel for breast cancer therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Carriers; Drug Liberation; Humans; Iron; MCF-7 Cells; Micelles; Models, Molecular; Molecular Conformation; Nanostructures; Organometallic Compounds; Taxoids | 2018 |
Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Maytansine; Mexico; Receptor, ErbB-2; Taxoids; Trastuzumab | 2017 |
Ocular metastasis from breast carcinoma simulating anterior scleritis: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Diagnosis, Differential; Docetaxel; Doxorubicin; Eye Neoplasms; Eye Pain; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Scleritis; Taxoids; Tomography, X-Ray Computed | 2017 |
Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutrophils; Randomized Controlled Trials as Topic; Taxoids | 2017 |
Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drugs, Generic; Excipients; Female; Hospitals, University; Humans; Incidence; Japan; Logistic Models; Middle Aged; Multivariate Analysis; Retrospective Studies; Solubility; Taxoids; Therapeutic Equivalency | 2017 |
Self-delivering prodrug-nanoassemblies fabricated by disulfide bond bridged oleate prodrug of docetaxel for breast cancer therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Disulfides; Docetaxel; Female; Humans; Mice, Inbred BALB C; Nanostructures; Oleic Acid; Prodrugs; Taxoids | 2017 |
Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cardiotoxicity; Chemoradiotherapy, Adjuvant; Docetaxel; Doxorubicin; Drug Eruptions; Female; Humans; Mastectomy, Segmental; Middle Aged; Prospective Studies; Radiation Dose Hypofractionation; Trastuzumab; Treatment Outcome; Ventricular Function, Left | 2018 |
Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Humans; Markov Chains; Neoplasm Metastasis; Quality-Adjusted Life Years; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab | 2018 |
Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; Tumor Microenvironment | 2017 |
Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 7; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Female; Humans; Mice, Inbred BALB C; Micelles; RNA, Small Interfering; Taxoids | 2017 |
Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Survivors; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Insurance Claim Review; Lymph Node Excision; Mastectomy; Middle Aged; Office Visits; Paclitaxel | 2018 |
Taxane Followed by Anthracycline or Vice Versa: Impact of Sequential Order on Breast Cancer Recurrence?-Reply.
Topics: Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Docetaxel; Epirubicin; Humans; Neoplasm Recurrence, Local; Taxoids | 2018 |
Taxane Followed by Anthracycline or Vice Versa: Impact of Sequential Order on Breast Cancer Recurrence?
Topics: Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Docetaxel; Epirubicin; Humans; Neoplasm Recurrence, Local; Taxoids | 2018 |
Near-infrared remotely triggered drug-release strategies for cancer treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA; Docetaxel; Drug Delivery Systems; Drug Liberation; Female; Gold; Humans; Infrared Rays; Lapatinib; Lasers; Nanoshells; Quinazolines; Serum Albumin, Human; Taxoids | 2017 |
Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Incidence; Lymphedema; Middle Aged; Prospective Studies | 2018 |
Investigating the role of tumor-infiltrating lymphocytes in advanced HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Lymphocytes, Tumor-Infiltrating; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2018 |
Symptom clusters using the Brief Pain Inventory in patients with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Cancer Pain; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Pain Measurement; Prospective Studies; Quality of Life; Taxoids | 2017 |
The Relationship Between Peripheral Neuropathy Induced by Docetaxel and Systemic Inflammation-based Parameters in Patients with Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Blood Platelets; Breast Neoplasms; Docetaxel; Female; Humans; Inflammation; Leukocyte Count; Lymphocytes; Middle Aged; Monocytes; Neutrophils; Peripheral Nervous System Diseases; Platelet Count; Retrospective Studies; Taxoids | 2017 |
Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Nanoparticles; Neoplastic Stem Cells; RNAi Therapeutics; Taxoids | 2017 |
Novel sulforaphane-enabled self-microemulsifying delivery systems (SFN-SMEDDS) of taxanes: Formulation development and in vitro cytotoxicity against breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Docetaxel; Drug Delivery Systems; Emulsions; Excipients; Female; Humans; Isothiocyanates; MCF-7 Cells; Paclitaxel; Solubility; Sulfoxides; Taxoids | 2018 |
Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Colony-Stimulating Factors; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Receptor, ErbB-2; Trastuzumab | 2018 |
Melatonin enhances the apoptotic effects and modulates the changes in gene expression induced by docetaxel in MCF‑7 human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Docetaxel; Female; Humans; MCF-7 Cells; Melatonin; Taxoids; Transcriptome | 2018 |
Resensitization of Akt Induced Docetaxel Resistance in Breast Cancer by 'Iturin A' a Lipopeptide Molecule from Marine Bacteria Bacillus megaterium.
Topics: Antifungal Agents; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bacillus megaterium; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lipopeptides; Peptides, Cyclic; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured | 2017 |
Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
Topics: Acute Disease; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Leukemia, Myeloid; Medicare; Myelodysplastic Syndromes; Neoplasm Staging; Registries; Risk Factors; SEER Program; Taxoids; Texas; United States | 2018 |
CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cytochrome P-450 CYP1A1; Docetaxel; Female; Genetic Markers; Humans; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Progression-Free Survival; Survival Analysis; Thiotepa | 2018 |
Docetaxel/cyclophosphamide chemotherapy in older patients with breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Retrospective Studies | 2018 |
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Disease-Free Survival; Docetaxel; Female; Humans; Italy; Middle Aged; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2018 |
The role of PET and MRI in evaluating the feasibility of skin-sparing mastectomy following neoadjuvant therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Taxoids | 2018 |
Simultaneous Targeting of Differentiated Breast Cancer Cells and Breast Cancer Stem Cells by Combination of Docetaxel- and Sulforaphane-Loaded Self-Assembled Poly(D, L-lactide-co-glycolide)/Hyaluronic Acid Block Copolymer-Based Nanoparticles.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Female; Humans; Hyaluronic Acid; Isothiocyanates; Lactic Acid; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplastic Stem Cells; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Sulfoxides; Taxoids | 2016 |
Nanoparticles with Optimal Ratiometric Co-Delivery of Docetaxel with Gambogic Acid for Treatment of Multidrug-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Male; MCF-7 Cells; Nanoparticles; Rats; Rats, Sprague-Dawley; Taxoids; Xanthones; Xenograft Model Antitumor Assays | 2016 |
[Effect of Pegfilgrastim Primary Prophylactic Administration on Relative Dose Intensity(RDI)in Postoperative Adjuvant Chemotherapy(TC Therapy)for Breast Cancer - A Single-Center, Retrospective Study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Filgrastim; Humans; Middle Aged; Neutropenia; Polyethylene Glycols; Retrospective Studies; Taxoids | 2017 |
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Maytansine; Meningeal Neoplasms; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab | 2018 |
Synthesis, in vitro characterization, and anti-tumor effects of novel polystyrene-poly(amide-ether-ester-imide) co-polymeric micelles for delivery of docetaxel in breast cancer in Balb/C mice.
Topics: Amides; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Delivery Systems; Drug Liberation; Ether; Female; Humans; Imides; MCF-7 Cells; Mice; Mice, Inbred BALB C; Micelles; Particle Size; Polyesters; Polyethylene Glycols; Polymers; Polystyrenes; Taxoids | 2018 |
The microbial flora of taxane therapy-associated nail disease in cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Bacteria; Breast Neoplasms; Dermatomycoses; Docetaxel; Female; Fungi; Humans; Paclitaxel; Paronychia; Skin Diseases, Bacterial; Taxoids | 2018 |
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Endoribonucleases; Female; Humans; Mice; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Response Elements; Saccharomyces cerevisiae; Signal Transduction; Unfolded Protein Response; X-Box Binding Protein 1; Xenograft Model Antitumor Assays | 2018 |
[A Case of a Bulky Axillary Ectopic Breast Cancer Which Successfully Resected after Chemotherapy(Docetaxel)].
Topics: Aged; Antineoplastic Agents; Axilla; Breast Neoplasms; Docetaxel; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Neoadjuvant Therapy; Taxoids | 2018 |
LMTK3 confers chemo-resistance in breast cancer.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; DNA Breaks, Double-Stranded; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Histones; Humans; Membrane Proteins; Mice, Nude; Protein Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cell Proliferation; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Docetaxel; Female; HT29 Cells; Humans; Liposomes; Mice; Nanomedicine; Polylactic Acid-Polyglycolic Acid Copolymer; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Development of novel biotinylated chitosan-decorated docetaxel-loaded nanocochleates for breast cancer targeting.
Topics: Animals; Antineoplastic Agents; Biotin; Breast Neoplasms; Chelating Agents; Chitosan; Delayed-Action Preparations; Docetaxel; Drug Carriers; Drug Design; Humans; MCF-7 Cells; Molecular Targeted Therapy; Nanostructures; Phosphatidylglycerols; Rats; Tissue Distribution | 2018 |
Chemo-sensitivity of Two-dimensional Monolayer and Three-dimensional Spheroid of Breast Cancer MCF-7 Cells to Daunorubicin, Docetaxel, and Arsenic Disulfide.
Topics: Antineoplastic Agents; Arsenicals; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Spheroids, Cellular; Sulfides; Taxoids; Tissue Scaffolds | 2018 |
Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Follow-Up Studies; Humans; Immunohistochemistry; Middle Aged; Multigene Family; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Taxoids; Trastuzumab; Treatment Outcome | 2018 |
Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Meglumine; Middle Aged; Neoadjuvant Therapy; Organometallic Compounds; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Tumor Burden | 2018 |
Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management.
Topics: Albumins; Anacardic Acids; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Clathrin; Deoxycytidine; Docetaxel; Drug Carriers; Female; Gemcitabine; Hemolysis; Humans; Macromolecular Substances; MCF-7 Cells; Nanoparticles; Neoplasm Transplantation; Particle Size; Polymers; Protein Conformation; Rats; Rats, Sprague-Dawley | 2018 |
Co-delivery of docetaxel and gemcitabine using PEGylated self-assembled stealth nanoparticles for improved breast cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Micelles; Nanoparticles; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Engineering fast dissolving sodium acetate mediated crystalline solid dispersion of docetaxel.
Topics: Antineoplastic Agents; Breast Neoplasms; Calorimetry, Differential Scanning; Cell Survival; Chromatography, Liquid; Crystallization; Crystallography, X-Ray; Docetaxel; Dose-Response Relationship, Drug; Drug Compounding; Dynamic Light Scattering; Female; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; MCF-7 Cells; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Particle Size; Powder Diffraction; Sodium Acetate; Solubility; Tandem Mass Spectrometry; Taxoids; Technology, Pharmaceutical; Water | 2018 |
Esophageal Metastases from Breast Carcinoma: a Rare Delayed Metastases After 15 Years.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Docetaxel; Dose Fractionation, Radiation; Esophageal Mucosa; Esophageal Neoplasms; Esophagoscopy; Female; Humans; Lymph Node Excision; Mastectomy, Segmental; Middle Aged; Positron Emission Tomography Computed Tomography; Time Factors; Treatment Outcome | 2019 |
Chemotherapy-induced erythrodysesthesia of the breast.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Magnetic Resonance Imaging; Middle Aged | 2018 |
Therapeutic efficacy of lipid emulsions of docetaxel-linoleic acid conjugate in breast cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Emulsions; Female; Linoleic Acid; Male; Mice; Mice, Inbred BALB C; Rats, Sprague-Dawley; Taxoids; Treatment Outcome; Tumor Burden | 2018 |
Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Prospective Studies | 2018 |
A transfer learning approach via procrustes analysis and mean shift for cancer drug sensitivity prediction.
Topics: Algorithms; Antineoplastic Agents; Area Under Curve; Bortezomib; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Computational Biology; Databases, Factual; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Machine Learning; Multiple Myeloma; Triple Negative Breast Neoplasms | 2018 |
Colored body images reveal the perceived intensity and distribution of pain in women with breast cancer treated with adjuvant taxanes: a prospective multi-method study of pain experiences.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Pain; Pain Measurement; Prospective Studies; Taxoids | 2018 |
Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Delivery Systems; Endocytosis; Female; Humans; Liposomes; Particle Size; Proof of Concept Study; Receptor, ErbB-2; Taxoids; Trastuzumab | 2018 |
Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies | 2019 |
Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Polyethylene Glycols; Taxoids | 2018 |
Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Docetaxel; Endothelial Cells; Female; Humans; Lymphangiogenesis; Lymphatic Metastasis; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-3 | 2018 |
Acute Generalized Exanthematous Pustulosis Induced by Docetaxel and Recurrent With Letrozole: A Case Report.
Topics: Acute Generalized Exanthematous Pustulosis; Adrenal Cortex Hormones; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Letrozole; Middle Aged; Tamoxifen; Treatment Outcome | 2018 |
Treatment of HER2-positive early breast cancer: How to best balance efficacy and toxicity?
Topics: Breast Neoplasms; Carboplatin; Colony-Stimulating Factors; Docetaxel; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab | 2018 |
Precisely albumin-hitchhiking tumor cell-activated reduction/oxidation-responsive docetaxel prodrugs for the hyperselective treatment of breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Liberation; Female; Humans; Male; Mice, Inbred BALB C; Oxidation-Reduction; Prodrugs; Protein Binding; Rats, Sprague-Dawley; Serum Albumin; Tissue Distribution | 2018 |
Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells
Topics: Animals; Aptamers, Nucleotide; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chitosan; CHO Cells; Cricetinae; Cricetulus; Docetaxel; Drug Liberation; Gene Expression Regulation, Neoplastic; Gene Silencing; Heparin; Humans; Mucin-1; Nanoparticles; Neoplasm Metastasis; Particle Size; Receptor, IGF Type 1; Receptors, Somatomedin; RNA, Small Interfering; Serum; Static Electricity | 2019 |
Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors.
Topics: Amino Alcohols; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cell-Free System; Docetaxel; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Hydrazines; Ligands; Mice; Models, Molecular; Phosphotransferases (Alcohol Group Acceptor); Pyrazoles; Xenograft Model Antitumor Assays | 2018 |
Use of pertuzumab and trastuzumab during pregnancy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fetus; Humans; Oligohydramnios; Pregnancy; Pregnancy Complications, Neoplastic; Trastuzumab; Young Adult | 2018 |
Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; CX3C Chemokine Receptor 1; Disease Progression; Docetaxel; Doxorubicin; Drug Synergism; Female; Humans; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Cells, Circulating; Prognosis; Small Molecule Libraries; Xenograft Model Antitumor Assays | 2018 |
Docetaxel-Induced Myositis.
Topics: Aged; Biopsy; Breast Neoplasms; Docetaxel; Female; Humans; Magnetic Resonance Imaging; Muscles; Myositis; Taxoids | 2020 |
Polymeric nanocapsules embedded with ultra-small silver nanoclusters for synergistic pharmacology and improved oral delivery of Docetaxel.
Topics: Administration, Oral; Animals; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Metal Nanoparticles; Mice; Nanocapsules; Particle Size; Silver | 2018 |
Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients.
Topics: Adult; Aged; Alleles; Breast Neoplasms; Cytochrome P-450 CYP3A; Docetaxel; Female; Genotype; Humans; Middle Aged; Neoadjuvant Therapy; Pharmacogenetics; Pharmacogenomic Testing | 2018 |
Synthesis and
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Esters; Ethers; Female; Humans; Magnetic Resonance Spectroscopy; Maleates; Mice, Inbred BALB C; Micelles; Nylons; Particle Size; Polystyrenes; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Resins, Synthetic; Selective Estrogen Receptor Modulators; Spectroscopy, Fourier Transform Infrared | 2018 |
Ginsenoside Rg5 induces apoptosis and autophagy via the inhibition of the PI3K/Akt pathway against breast cancer in a mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Proteins; Breast Neoplasms; Disease Models, Animal; Docetaxel; Female; Gene Expression Regulation; Ginsenosides; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Panax; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Hospitalization; Humans; Linear Models; Neoplasm Staging; Retrospective Studies; SEER Program; Survival Analysis | 2018 |
Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carboplatin; Cell Proliferation; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Drug Screening Assays, Antitumor; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Young Adult | 2018 |
Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Genes, erbB-2; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Proportional Hazards Models; Taxoids | 2018 |
LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt/β-catenin pathway.
Topics: 3' Untranslated Regions; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Receptors, G-Protein-Coupled; Taxoids; Wnt Signaling Pathway | 2019 |
3,3'-Diindolylmethane enhances apoptosis in docetaxel-treated breast cancer cells by generation of reactive oxygen species.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Indoles; Reactive Oxygen Species | 2018 |
Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Chitosan; Docetaxel; Drug Carriers; Female; Glycoconjugates; Humans; Kidney; Liver; Lung; Molecular Targeted Therapy; Nanoparticles; Rats; Receptor, ErbB-2; Trastuzumab; Tumor Burden; Vitamin E; Xenograft Model Antitumor Assays | 2019 |
Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial.
Topics: Adult; Aged; Breast Neoplasms; Cytochrome P-450 CYP1B1; Docetaxel; Doxorubicin; Female; Genetic Association Studies; Humans; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic | 2018 |
Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Genotype; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Odds Ratio; Polymorphism, Single Nucleotide; Receptors, Fibroblast Growth Factor; Treatment Outcome | 2018 |
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2019 |
Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cohort Studies; Docetaxel; Female; Humans; Incidence; Medicare; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; SEER Program; United States | 2019 |
Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Middle Aged; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2018 |
Chemosensitizer and docetaxel-loaded albumin nanoparticle: overcoming drug resistance and improving therapeutic efficacy.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Nanoparticles; Quercetin; Rats; Serum Albumin, Bovine | 2018 |
Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Nestin; Phosphoric Monoester Hydrolases; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies | 2019 |
Evidence for L-Dopa Decarboxylase Involvement in Cancer Cell Cytotoxicity Induced by Docetaxel and Mitoxantrone.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetinae; Cricetulus; Docetaxel; Dopa Decarboxylase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; MCF-7 Cells; Mitoxantrone; Prostatic Neoplasms; Protein Isoforms | 2018 |
Predicting chemo-brain in breast cancer survivors using multiple MRI features and machine-learning.
Topics: Adult; Algorithms; Anisotropy; Antineoplastic Agents; Brain; Brain Mapping; Breast Neoplasms; Cancer Survivors; Case-Control Studies; Cognition Disorders; Docetaxel; Epirubicin; Female; Fourier Analysis; Humans; Machine Learning; Magnetic Resonance Imaging; Middle Aged; Regression Analysis; Young Adult | 2019 |
From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Docetaxel; Drug Delivery Systems; Female; Humans; Liposomes; Mice; Mice, Nude; Spheroids, Cellular; Tissue Distribution; Trastuzumab | 2018 |
Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; MCF-7 Cells; Nanoparticles; Particle Size; Peptides; Polymers; Surface Properties | 2018 |
Studying of the Mechanisms of Combined Effect of Dexamethasone, Doxorubicin, and Docetaxel on Breast Cancer Cells.
Topics: Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Movement; Dexamethasone; Docetaxel; Doxorubicin; Female; Humans; S100 Calcium-Binding Protein A4 | 2018 |
Correlation of circulating pro-angiogenic miRNAs with cardiotoxicity induced by epirubicin/cyclophosphamide followed by docetaxel in patients with breast cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Cardiotoxicity; Cell-Free Nucleic Acids; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; MicroRNAs; Middle Aged; Troponin I | 2018 |
Patterns of Regression in Breast Cancer after Primary Systemic Treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Prognosis | 2019 |
Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; China; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Taxoids | 2019 |
Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Glucuronosyltransferase; Humans; Logistic Models; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Prospective Studies; Stroke Volume | 2019 |
Activation of polymeric nanoparticle intracellular targeting overcomes chemodrug resistance in human primary patient breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Carriers; Drug Delivery Systems; Drug Resistance, Multiple; Female; Humans; Nanoparticles; Nanotechnology; Polylactic Acid-Polyglycolic Acid Copolymer; Tumor Cells, Cultured | 2018 |
lncRNA profile study reveals the mRNAs and lncRNAs associated with docetaxel resistance in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; High-Throughput Nucleotide Sequencing; Humans; RNA, Long Noncoding; RNA, Messenger | 2018 |
Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India.
Topics: Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Docetaxel; Female; Humans; India; Logistic Models; Middle Aged; Neoadjuvant Therapy; Polymorphism, Single Nucleotide; Prospective Studies; Real-Time Polymerase Chain Reaction; Treatment Outcome | 2019 |
[Two Cases of Unresectable/Advanced Breast Cancer with Pathological Complete Response after Combination Chemotherapy with Pertuzumab. Trastuzumab, and Docetaxel].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Receptor, ErbB-2; Taxoids; Trastuzumab | 2018 |
Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Breast Neoplasms; Case-Control Studies; Constitutive Androstane Receptor; Docetaxel; Female; Glucuronosyltransferase; Humans; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Prognosis; Receptors, Cytoplasmic and Nuclear | 2019 |
Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; I-kappa B Kinase; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Serine-Threonine Kinases; RAW 264.7 Cells | 2019 |
Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Movement; Disease Progression; Docetaxel; Female; Gene Knockout Techniques; Heterografts; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Seminal Plasma Proteins | 2019 |
Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cardiotoxicity; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Denmark; Docetaxel; Epirubicin; Female; Heart Failure; Humans; Incidence; Longitudinal Studies; Mastectomy, Segmental; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Risk; Stroke Volume; Trastuzumab | 2019 |
The impact of Catechol-O-methyl transferase knockdown on the cell proliferation of hormone-responsive cancers.
Topics: 2-Methoxyestradiol; Aromatase; Breast Neoplasms; Catechol O-Methyltransferase; Catechols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Hormones; Humans; Male; Nitriles; Phosphorylation; Prostatic Neoplasms; Receptors, Estrogen; RNA, Small Interfering; Transcription Factor RelA | 2019 |
Novel hyaluronic acid-modified temperature-sensitive nanoparticles for synergistic chemo-photothermal therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Contrast Media; Docetaxel; Drug Carriers; Drug Liberation; Female; Fluorescent Dyes; Humans; Hyaluronic Acid; Infrared Rays; Injections, Intravenous; Lung; Lung Neoplasms; Mice, Inbred BALB C; Nanoparticles; Particle Size; Phospholipids; Photoacoustic Techniques; Polymers; Pyrroles; Temperature; Theranostic Nanomedicine | 2019 |
4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinase Kinases; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Proteins; Tamoxifen | 2019 |
Aspartic acid tagged carbon nanotubols as a tool to deliver docetaxel to breast cancer cells: Reduced hemotoxicity with improved cytotoxicity.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Drug Liberation; Drug Synergism; Humans; Nanotubes, Carbon; Rats, Wistar | 2019 |
Docetaxel and alpha-lipoic acid co-loaded nanoparticles for cancer therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Lipids; Mammary Neoplasms, Animal; MCF-7 Cells; Mice; Nanoparticles; Thioctic Acid | 2019 |
A Different Kind of Relapse: Ethanol as an Additive in Chemotherapy Formulations.
Topics: Alcohol Abstinence; Alcoholism; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Compounding; Ethanol; Female; Humans; Lost to Follow-Up; Middle Aged; Patient Dropouts; Patients; Physicians; Recurrence; Treatment Outcome | 2019 |
Combination of Human Umbilical Vein Endothelial Cell Vaccine and Docetaxel Generates Synergistic Anti-Breast Cancer Effects.
Topics: Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Docetaxel; Female; Human Umbilical Vein Endothelial Cells; Humans | 2019 |
Impact of protocol change on individual factors related to course of adverse reactions to chemotherapy for breast cancer.
Topics: Abdominal Pain; Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Brazil; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Cytochrome P-450 CYP2B6; Diarrhea; Docetaxel; Doxorubicin; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genetic Predisposition to Disease; Humans; Longitudinal Studies; Middle Aged; Pharmacogenomic Testing; Polymorphism, Single Nucleotide | 2020 |
Retrospective comparison of two consecutive cohorts of adjuvant chemotherapy regimens of cyclophosphamide with either docetaxel or paclitaxel in older patients with early breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Paclitaxel; Retrospective Studies | 2019 |
Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Oncologists; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Self Report; Young Adult | 2019 |
Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa.
Topics: Breast Neoplasms; Cost-Benefit Analysis; Developing Countries; Docetaxel; Female; Humans; Middle Aged; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; South Africa; United Kingdom | 2019 |
Chemotherapy-Induced Extracellular Vesicle miRNAs Promote Breast Cancer Stemness by Targeting
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Vesicles; Female; Homeodomain Proteins; Humans; MCF-7 Cells; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplastic Stem Cells; Transcription Factors; Xenograft Model Antitumor Assays | 2019 |
Epirubicin chemotherapy in women with breast cancer: Alternating arms for intravenous administration to reduce chemical phlebitis.
Topics: Administration, Intravenous; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Injection Site Reaction; Middle Aged; Phlebitis; Prospective Studies | 2019 |
Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Liberation; Female; Mice; Mice, Inbred BALB C; Micelles; Polymers; RAW 264.7 Cells; Transplantation, Homologous; Treatment Outcome | 2019 |
Vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Liposomes; MCF-7 Cells; Particle Size; Polyethylene Glycols; Succinates; Vitamin E | 2019 |
Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Emergencies; Female; Fever; Hospitalization; Humans; Infections; Kaplan-Meier Estimate; Logistic Models; Mastectomy; Mastectomy, Segmental; Middle Aged; Neutropenia; New South Wales; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Trastuzumab | 2019 |
Role of docosahexaenoic acid in enhancement of docetaxel action in patient-derived breast cancer xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dietary Supplements; Disease Models, Animal; Docetaxel; Docosahexaenoic Acids; Drug Synergism; Female; Humans; Mice; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Single-Cell Analysis Reveals a Preexisting Drug-Resistant Subpopulation in the Luminal Breast Cancer Subtype.
Topics: Antineoplastic Agents; Breast Neoplasms; Caveolin 1; Caveolin 2; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoid Enhancer-Binding Factor 1; MCF-7 Cells; MicroRNAs; Neoplastic Stem Cells; Single-Cell Analysis; Vimentin; Wnt Signaling Pathway | 2019 |
The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Mice; Transcriptome; Xenograft Model Antitumor Assays | 2019 |
G protein-coupled receptor kinase 5 modifies cancer cell resistance to paclitaxel.
Topics: Acetylation; Apoptosis; Biocatalysis; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; G-Protein-Coupled Receptor Kinase 3; G-Protein-Coupled Receptor Kinase 5; G-Protein-Coupled Receptor Kinases; HeLa Cells; Histone Deacetylase 6; Histones; Humans; MAP Kinase Signaling System; Paclitaxel; Phosphorylation; Phosphoserine; Protein Binding; Tubulin | 2019 |
Sensitization of MDA-MBA231 breast cancer cell to docetaxel by myricetin loaded into biocompatible lipid nanoparticles via sub-G1 cell cycle arrest mechanism.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Drug Liberation; Fatty Acids; Flavonoids; G1 Phase Cell Cycle Checkpoints; Humans; Nanoparticles | 2020 |
Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Carriers; Female; Humans; Mice; Nanoparticles; NIH 3T3 Cells; Polyethylene Glycols; Prodrugs; Taxoids; Trastuzumab; Vitamin E | 2013 |
Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
Topics: AC133 Antigen; Amyloid Precursor Protein Secretases; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokines; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Glycoproteins; Humans; Hyaluronan Receptors; Membrane Proteins; Mice; Mice, SCID; Multidrug Resistance-Associated Protein 2; Nerve Tissue Proteins; Peptides; Receptor, Notch1; Signal Transduction; Taxoids; Tetrahydronaphthalenes; Time Factors; Valine; Xenograft Model Antitumor Assays | 2013 |
Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epirubicin; Female; HMGB1 Protein; Humans; Neoadjuvant Therapy; Taxoids; Tumor Cells, Cultured | 2013 |
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Caspase 3; Cell Line, Tumor; Deoxycytidine; Docetaxel; Down-Regulation; Doxorubicin; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Panobinostat; Receptor, ErbB-2; Survivin; Taxoids | 2012 |
The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cyclophosphamide; Decitabine; DNA Methylation; DNA, Neoplasm; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heparan Sulfate Proteoglycans; Humans; Methylation; MicroRNAs; Neoplasm Proteins; RNA, Neoplasm; Taxoids | 2013 |
Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Coumarins; Docetaxel; Drug Carriers; Half-Life; Humans; Liposomes; Male; Microscopy, Confocal; Particle Size; Polyethylene Glycols; Rats, Sprague-Dawley; Receptor, ErbB-2; Spectroscopy, Fourier Transform Infrared; Taxoids; Thiazoles; Trastuzumab; Vitamin E | 2013 |
Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; False Negative Reactions; False Positive Reactions; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Statistics, Nonparametric; Taxoids; Trastuzumab; Treatment Outcome; Tumor Burden; Young Adult | 2013 |
Metabolomics reveals metabolic targets and biphasic responses in breast cancer cells treated by curcumin alone and in association with docetaxel.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Comet Assay; Curcumin; Docetaxel; Female; Glutathione; Glutathione Transferase; Humans; Inflammation; Magnetic Resonance Spectroscopy; MCF-7 Cells; Metabolomics; Multivariate Analysis; Oxidative Stress; Taxoids; Treatment Outcome | 2013 |
[Gastric metastasis from breast cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Carrier Proteins; Docetaxel; Doxorubicin; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Glycoproteins; Humans; Mastectomy, Modified Radical; Membrane Transport Proteins; Multimodal Imaging; Positron-Emission Tomography; Stomach Neoplasms; Taxoids; Tomography, X-Ray Computed | 2013 |
Ulinastatin exerts synergistic effects with taxotere and inhibits invasion and metastasis of breast cancer by blocking angiogenesis and the epithelial-mesenchymal transition.
Topics: Aged; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Glycoproteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Random Allocation; Taxoids; Trypsin Inhibitors; Xenograft Model Antitumor Assays | 2013 |
A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; Docetaxel; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Kaplan-Meier Estimate; Kinesins; MCF-7 Cells; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Proteins; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA Interference; Talin; Taxoids; Xenograft Model Antitumor Assays | 2013 |
Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Drug Monitoring; Female; Humans; Neoplasms; Paclitaxel; Pharmacogenetics; Precision Medicine; Taxoids | 2013 |
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2013 |
Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Receptor, ErbB-2; Taxoids; Thrombotic Microangiopathies; Trastuzumab | 2013 |
New advances in taxane therapy: the next generation.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Polyglutamic Acid; Taxoids | 2004 |
[Combination therapy herceptin+taxotere/Herceptin+navelbine].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Docetaxel; Female; Humans; In Situ Hybridization, Fluorescence; Neoplasm Staging; Pilot Projects; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2002 |
Oil-filled lipid nanoparticles containing 2'-(2-bromohexadecanoyl)-docetaxel for the treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Mice; Mice, Inbred BALB C; Nanoparticles; Oils; Taxoids; Tissue Distribution; Treatment Outcome | 2013 |
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Docetaxel; Female; Humans; Mutation; Phosphatidylinositol 3-Kinases; Prognosis; Receptor, ErbB-2; Sequence Analysis, DNA; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Hand-foot syndrome caused by docetaxel with no recurrence after switch to paclitaxel, a different taxane.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Secondary Prevention; Taxoids | 2014 |
Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Dexamethasone; Docetaxel; Female; Humans; Incidence; Lacrimal Apparatus Diseases; Lacrimal Duct Obstruction; Middle Aged; Prevalence; Prospective Studies; Taxoids | 2013 |
Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Docetaxel; Female; Genotype; Humans; Neoadjuvant Therapy; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Taxoids; Treatment Outcome | 2013 |
Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases.
Topics: Adult; Aged; Breast Neoplasms; Docetaxel; Female; Humans; Liver; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Pilot Projects; Taxoids | 2014 |
Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab | 2013 |
Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: a retrospective cohort analysis.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Taxoids | 2013 |
Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Middle Aged; Paclitaxel; Skin Diseases; Survival Rate; Taxoids | 2013 |
Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diarrhea; Docetaxel; Drug Eruptions; Epirubicin; Feasibility Studies; Female; Humans; Middle Aged; Myalgia; Neutropenia; Pilot Projects; Taxoids | 2013 |
Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Staging; Neutrophils; Retrospective Studies; Risk Factors; Taxoids | 2013 |
Is catheter rupture rare after totally implantable access port implantation via the right internal jugular vein? Report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheterization, Central Venous; Catheters, Indwelling; Docetaxel; Equipment Failure; Female; Humans; Jugular Veins; Middle Aged; Motion; Neck; Neoplasm Recurrence, Local; Stress, Mechanical; Surgery, Computer-Assisted; Taxoids; Ultrasonography, Interventional; Vinblastine; Vinorelbine | 2014 |
Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clusterin; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids | 2013 |
Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Case-Control Studies; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Female; Genetic Predisposition to Disease; Genotype; Global Health; Humans; Inactivation, Metabolic; Lebanon; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Poverty; Taxoids; Trastuzumab | 2013 |
Prostate apoptosis response-4 is involved in the apoptosis response to docetaxel in MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; BH3 Interacting Domain Death Agonist Protein; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Taxoids; Transfection | 2013 |
Temporal changes in standard and tissue Doppler imaging echocardiographic parameters after anthracycline chemotherapy in women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Echocardiography, Doppler; Female; Fluorouracil; Heart Diseases; Humans; Middle Aged; Prospective Studies; Stroke Volume; Taxoids; Time Factors; Ventricular Dysfunction, Left | 2013 |
Bullous reaction at docetaxel infusion site.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Hand Dermatoses; Humans; Infusions, Intravenous; Skin Diseases, Vesiculobullous; Taxoids | 2014 |
Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Calorimetry, Differential Scanning; Cell Survival; Chromatography, Gel; Coumarins; Docetaxel; Female; Humans; Inhibitory Concentration 50; Lactic Acid; Magnetic Resonance Spectroscopy; Mannitol; MCF-7 Cells; Molecular Weight; Nanoparticles; Particle Size; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Static Electricity; Taxoids; Thermogravimetry; Thiazoles; Vitamin E; Xenograft Model Antitumor Assays | 2013 |
The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Hyaluronic Acid; Hydroxyquinolines; Lipid Bilayers; MCF-7 Cells; Mice; Nanoparticles; Silicon Dioxide; Taxoids | 2013 |
[Padma 28 in cytostatic-induced dysesthesia and edema of the hands--a case from practice].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Hand; Humans; Lymph Node Excision; Lymphedema; Mastectomy; Medicine, Tibetan Traditional; Microcirculation; Middle Aged; Paresthesia; Phytotherapy; Plant Extracts; Sensory Receptor Cells; Taxoids | 2013 |
Erosive conjunctival and corneal inflammatory changes in a patient receiving weekly docetaxel for breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Conjunctivitis; Diagnosis, Differential; Docetaxel; Drug Administration Schedule; Female; Humans; Keratitis; Taxoids | 2014 |
PPARβ mRNA expression, reduced by n-3 PUFA diet in mammary tumor, controls breast cancer cell growth.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Fatty Acids, Omega-3; Female; Humans; Mammary Neoplasms, Animal; Peroxisome Proliferator-Activated Receptors; PPAR-beta; Rats; RNA, Messenger; Taxoids | 2013 |
Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis.
Topics: Actins; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Female; Humans; Immunohistochemistry; Mice; Nanoparticles; Stromal Cells; Taxoids; Xenograft Model Antitumor Assays | 2013 |
Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Clinical Trials, Phase I as Topic; Cytochrome P-450 CYP3A; Docetaxel; Doxorubicin; Drug Interactions; Female; Half-Life; Humans; Intestine, Small; Lapatinib; Membrane Transport Modulators; Mice; Mice, Inbred Strains; Neoplasm Metastasis; Quinazolines; Taxoids; Tissue Distribution; Topoisomerase II Inhibitors; Tubulin Modulators | 2013 |
HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Paclitaxel; Pennsylvania; Peripheral Nervous System Diseases; Retrospective Studies; Taxoids | 2013 |
Candidate markers that associate with chemotherapy resistance in breast cancer through the study on Taxotere-induced damage to tumor microenvironment and gene expression profiling of carcinoma-associated fibroblasts (CAFs).
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carcinoma; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Docetaxel; Drug Resistance, Neoplasm; Female; Fibroblasts; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Taxoids; Transcriptome; Tumor Microenvironment | 2013 |
MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; PTEN Phosphohydrolase; RNA Interference; Taxoids | 2013 |
Reduction of toxicity by reversing the order of infusion of docetaxel and cyclophosphamide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Follow-Up Studies; Hematologic Diseases; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Taxoids; Young Adult | 2013 |
Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disulfiram; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Neoplastic Stem Cells; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2013 |
Taxane associated subacute cutaneous lupus erythematosus.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease Progression; Docetaxel; Female; Humans; Lupus Erythematosus, Cutaneous; Middle Aged; Taxoids | 2013 |
The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Esthetics; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Reoperation; Retrospective Studies; Taxoids; Tumor Burden | 2013 |
Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Breast Neoplasms; DNA Primers; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Taxoids; Vascular Endothelial Growth Factor A | 2014 |
Systematic expression analysis of genes related to multidrug-resistance in isogenic docetaxel- and adriamycin-resistant breast cancer cell lines.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; MCF-7 Cells; Taxoids | 2013 |
Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Markov Chains; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Denmark; Docetaxel; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Peripheral Nervous System Diseases; Risk Factors; Taxoids; Young Adult | 2013 |
Synthesis and characterization of lipid immuno-nanocapsules for directed drug delivery: selective antitumor activity against HER2 positive breast-cancer cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colloids; Deoxycholic Acid; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; Inhibitory Concentration 50; MCF-7 Cells; Nanocapsules; Olive Oil; Particle Size; Plant Oils; Poloxamer; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
Biodegradable self-assembled nanoparticles of poly (D,L-lactide-co-glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Breast Neoplasms; Carbohydrate Sequence; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Flow Cytometry; Humans; Hyaluronan Receptors; Hyaluronic Acid; Lactic Acid; Male; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Taxoids | 2014 |
Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Recombinant Proteins; Survival Analysis; Taxoids; Young Adult | 2013 |
First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Drug Costs; Female; France; Hospital Costs; Hospitals, Private; Hospitals, University; Humans; Kaplan-Meier Estimate; Middle Aged; National Health Programs; Neoplasm Metastasis; Paclitaxel; Public Sector; Retrospective Studies; Taxoids; Time Factors; Transportation; Trastuzumab; Treatment Outcome | 2014 |
Trastuzumab-induced systemic capillary leak syndrome in a breast cancer patient.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Capillary Leak Syndrome; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Taxoids; Trastuzumab | 2014 |
Development and in vitro characterization of docetaxel-loaded ligand appended solid fat nanoemulsions for potential use in breast cancer therapy.
Topics: Antineoplastic Agents; Biological Transport; Breast Neoplasms; Cholesterol; Docetaxel; Drug Carriers; Drug Discovery; Emulsions; Folic Acid; HeLa Cells; Humans; Ligands; Nanoparticles; Phosphatidylcholines; Polyethylene Glycols; Sonication; Taxoids; Triglycerides | 2015 |
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Deoxycytidine; Disease Progression; DNA Copy Number Variations; Docetaxel; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Response to neoadjuvant treatment of invasive ductal breast carcinomas including outcome evaluation: MRI analysis by an automatic CAD system in comparison to visual evaluation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cohort Studies; Cyclophosphamide; Diagnosis, Computer-Assisted; Docetaxel; Doxorubicin; Female; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Mammography; Mastectomy; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2014 |
Chemotherapy-induced acral erythema with involvement of the face and neck: A case report.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Face; Female; Hand-Foot Syndrome; Humans; Neck; Pyridoxine; Skin; Taxoids; Trastuzumab; Vitamin B Complex; Young Adult | 2016 |
[Potential indications for helical tomotherapy in breast cancers].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Funnel Chest; Hodgkin Disease; Humans; Middle Aged; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Obesity; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Taxoids | 2014 |
IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2.
Topics: Antineoplastic Agents; Biopsy; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Interleukin-17; Lymphocytes, Tumor-Infiltrating; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Receptors, Estrogen; Taxoids | 2013 |
Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients.
Topics: Aged; Anecdotes as Topic; Antineoplastic Agents; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Drugs, Generic; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Retrospective Studies; Taxoids | 2014 |
A higher body mass index and fat mass are factors predictive of docetaxel dose intensity.
Topics: Adipose Tissue; Antineoplastic Agents, Phytogenic; Body Mass Index; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Taxoids | 2013 |
Inhibitory effects of mild hyperthermia plus docetaxel therapy on ER(+/-) breast cancer cells and action mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Cycle; Docetaxel; Hot Temperature; HSP70 Heat-Shock Proteins; Humans; MAP Kinase Signaling System; MCF-7 Cells; Receptors, Estrogen; Taxoids | 2013 |
Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Hypoxia; Docetaxel; Doxorubicin; Female; Humans; Male; Mice; Mice, Nude; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
A pilot study: application of hemoglobin and cortisol levels, and a memory test to evaluate the quality of life of breast cancer patients on chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Cyclophosphamide; Docetaxel; Erythrocyte Count; Female; Hemoglobins; Humans; Hydrocortisone; Leukocyte Count; Memory Disorders; Pilot Projects; Quality of Life; Surveys and Questionnaires; Taxoids; Treatment Outcome; Young Adult | 2013 |
[Nausea, vomiting and quality of life in women with breast cancer receiving chemotherapy].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Nausea; Prospective Studies; Quality of Life; Severity of Illness Index; Socioeconomic Factors; Surveys and Questionnaires; Taxoids; Trastuzumab; Vomiting | 2013 |
PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Messenger; Taxoids | 2014 |
CD24 polymorphisms cannot predict pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; CD24 Antigen; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Taxoids | 2014 |
[A case of chest wall recurrence after mastectomy for breast cancer that showed response to chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Mastectomy; Middle Aged; Recurrence; Taxoids; Thoracic Neoplasms; Thoracic Wall | 2013 |
[A case of acute appendicitis which occurred during chemotherapy for breast cancer].
Topics: Acute Disease; Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Mastectomy, Segmental; Sentinel Lymph Node Biopsy; Taxoids | 2013 |
Early predictive value of non-response to docetaxel in neoadjuvant chemotherapy in breast cancer using 18F-FDG-PET.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Taxoids | 2014 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
CD44-targeted docetaxel conjugate for cancer cells and cancer stem-like cells: a novel hyaluronic acid-based drug delivery system.
Topics: Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Solubility; Taxoids; Water | 2014 |
Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; M Phase Cell Cycle Checkpoints; MCF-7 Cells; Microtubules; Paclitaxel; Protein Isoforms; Taxoids; Time Factors; Tubulin; Tubulin Modulators | 2014 |
Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Letrozole; Meta-Analysis as Topic; Nitriles; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Triazoles | 2013 |
High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Vaccines; CD4-Positive T-Lymphocytes; Cell Differentiation; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Leukapheresis; Melanoma; Neoadjuvant Therapy; T-Lymphocyte Subsets; Taxoids; Uveal Neoplasms | 2014 |
Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Size; Body Surface Area; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Obesity; Odds Ratio; Retrospective Studies; Taxoids | 2014 |
Carboxymethylcellulose-based and docetaxel-loaded nanoparticles circumvent P-glycoprotein-mediated multidrug resistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carboxymethylcellulose Sodium; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Phenotype; Polymers; RNA, Messenger; Taxoids | 2014 |
Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Papilledema; Taxoids; Vision Disorders; Visual Fields | 2014 |
Enrichment of breast cancer stem-like cells by growth on electrospun polycaprolactone-chitosan nanofiber scaffolds.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chitosan; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Nanofibers; Nanomedicine; Neoplastic Stem Cells; Polyesters; Taxoids; Tissue Scaffolds; Tumor Stem Cell Assay | 2014 |
Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; CpG Islands; Cyclophosphamide; DNA Methylation; DNA Repair; Docetaxel; Female; Fluorouracil; Homologous Recombination; Humans; Methotrexate; Middle Aged; Neoadjuvant Therapy; Taxoids; Triple Negative Breast Neoplasms | 2013 |
Reducing febrile neutropenia rates in early breast cancer. Experience of two UK cancer centres.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Medical Audit; Middle Aged; Retrospective Studies; Risk Factors; Taxoids; Young Adult | 2014 |
Uptake and cytotoxicity of docetaxel-loaded hyaluronic acid-grafted oily core nanocapsules in MDA-MB 231 cancer cells.
Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Female; Humans; Hyaluronic Acid; Mice; Nanocapsules; NIH 3T3 Cells; Reactive Oxygen Species; Taxoids | 2014 |
A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Nomograms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; ROC Curve; Survival Rate; Taxoids | 2014 |
MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells.
Topics: Apc4 Subunit, Anaphase-Promoting Complex-Cyclosome; Apoptosis; Breast Neoplasms; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Taxoids | 2014 |
Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infection Control; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polyethylene Glycols; Prednisone; Recombinant Proteins; Risk Factors; Rituximab; Taxoids; Vincristine; Young Adult | 2014 |
Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Contrast Media; Docetaxel; Female; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Sensitivity and Specificity; Software; Subtraction Technique; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Targeted poly (L-γ-glutamyl glutamine) nanoparticles of docetaxel against folate over-expressed breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Chemistry, Pharmaceutical; Docetaxel; Drug Carriers; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; MCF-7 Cells; Mice, Inbred BALB C; Microscopy, Confocal; Microscopy, Electron, Scanning; Nanoparticles; Nanotechnology; Peptides; Polyglutamic Acid; Proton Magnetic Resonance Spectroscopy; Solubility; Taxoids; Technology, Pharmaceutical; Time Factors; Tissue Distribution; Tumor Burden | 2014 |
Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Estradiol; Female; Fluorouracil; Follicle Stimulating Hormone; Humans; Incidence; Induction Chemotherapy; Menstruation; Middle Aged; Premenopause; Primary Ovarian Insufficiency; Prospective Studies; Retrospective Studies; Tamoxifen; Taxoids; Young Adult | 2014 |
Influence of surface chemistry on cytotoxicity and cellular uptake of nanocapsules in breast cancer and phagocytic cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Excipients; Female; Humans; Macrophages; Nanocapsules; Particle Size; Phagocytes; Surface Properties; Taxoids | 2014 |
Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer.
Topics: Adult; Affect; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Cohort Studies; Computers, Handheld; Cyclophosphamide; Data Collection; Depression; Docetaxel; Doxorubicin; Fatigue; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Sleep; Taxoids | 2014 |
Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organometallic Compounds; Predictive Value of Tests; Prospective Studies; Republic of Korea; Taxoids; Treatment Outcome | 2014 |
Neutropenic enterocolitis affecting the transverse colon: an unusual complication of chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colectomy; Colon, Transverse; Cyclophosphamide; Docetaxel; Enterocolitis, Neutropenic; Female; Humans; Ileostomy; Taxoids; Tomography, X-Ray Computed | 2014 |
Correlation of tumor-infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Forkhead Transcription Factors; Humans; Immunohistochemistry; Immunophenotyping; Lymphocyte Subsets; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Stromal Cells; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Taxoids; Tumor Microenvironment | 2014 |
In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Ki-67 Antigen; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2014 |
PEG-PCL based micelle hydrogels as oral docetaxel delivery systems for breast cancer therapy.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Hydrogels; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Micelles; Nanoparticles; Particle Size; Polyesters; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Taxoids; X-Ray Diffraction | 2014 |
Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Docetaxel; Drug Administration Schedule; Female; Health Care Costs; Humans; Markov Chains; Monte Carlo Method; Neoplasm Staging; New Zealand; Paclitaxel; Quality-Adjusted Life Years; Survival Analysis; Taxoids | 2014 |
Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Retrospective Studies; Taxoids | 2015 |
Relationship between chemotherapy and prognosis in different subtypes of node-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Logistic Models; Medicare; Middle Aged; Neoplasm Staging; Paclitaxel; Registries; Risk Assessment; Risk Factors; SEER Program; Selection Bias; Taxoids; Texas; United States | 2014 |
Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Carriers; Female; Lung Neoplasms; Mice, Inbred BALB C; Micelles; Nanoparticles; Neoadjuvant Therapy; Polyesters; Polyethylene Glycols; Polymers; Taxoids; Time Factors; Tumor Burden | 2014 |
Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Breast Neoplasms; Cell Proliferation; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; MCF-7 Cells; Methotrexate; Multidrug Resistance-Associated Protein 2; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Taxoids; Tubulin | 2014 |
Perspectives of nanoemulsion assisted oral delivery of docetaxel for improved chemotherapy of cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Emulsions; Ethanol; Excipients; Female; Hot Temperature; Humans; Inhibitory Concentration 50; Lecithins; MCF-7 Cells; Mice; Microscopy, Electron, Transmission; Nanoparticles; Nanotechnology; Particle Size; Poloxamer; Polyethylene Glycols; Solubility; Soybean Oil; Surface Properties; Surface-Active Agents; Taxoids; Technology, Pharmaceutical; Ultrasonics | 2016 |
Is there any cumulative dose for trastuzumab?
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Echocardiography; Female; Heart Diseases; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Taxoids; Trastuzumab; Triazoles | 2015 |
[Expression of ABCG2 and p-glycoprotein in residual breast cancer tissue after chemotherapy and their correlation with epithelial-mesenchymal transition].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cadherins; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Epithelial-Mesenchymal Transition; Female; Humans; MCF-7 Cells; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; RNA, Messenger; Taxoids; Vimentin | 2014 |
Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Mice, SCID; Multidrug Resistance-Associated Proteins; Neoplasm Transplantation; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Tissue Array Analysis; Tumor Burden | 2014 |
Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Microtubules; Mitosis; Protein Stability; Taxoids; Tubulin Modulators | 2014 |
Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
Topics: Adjuvants, Pharmaceutic; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemoprevention; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Taxoids | 2014 |
PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Epirubicin; ErbB Receptors; Female; Follow-Up Studies; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids | 2014 |
Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuz
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Proliferation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Female; Gene Amplification; HSP90 Heat-Shock Proteins; Humans; Ki-67 Antigen; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
Deformable registration for quantifying longitudinal tumor changes during neoadjuvant chemotherapy.
Topics: Anatomic Landmarks; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Contrast Media; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Neoadjuvant Therapy; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Cell Proliferation; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Exosomes; Female; Flow Cytometry; Humans; Taxoids; Tumor Cells, Cultured | 2014 |
Collateral damage: taxane-induced colonic perforation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Colectomy; Colonic Diseases; Colostomy; Docetaxel; Enterocolitis; Female; Humans; Intestinal Perforation; Neoadjuvant Therapy; Predictive Value of Tests; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cantharidin; Cyclophosphamide; Docetaxel; Drug Combinations; Drugs, Chinese Herbal; Epirubicin; Female; Humans; Middle Aged; Postoperative Period; Quality of Life; Retrospective Studies; Taxoids | 2014 |
Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Docetaxel; Female; Humans; Inhibitor of Apoptosis Proteins; Real-Time Polymerase Chain Reaction; Survivin; Taxoids; Vinblastine | 2014 |
[Evaluation of breath alcohol concentration after the administration of alcohol-based docetaxel].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Breath Tests; Docetaxel; Ethanol; Female; Humans; Infusions, Intravenous; Middle Aged; Taxoids | 2014 |
Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: are signal intensity-time curves adequate?
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Taxoids; Young Adult | 2014 |
Clinical features of docetaxel chemotherapy-related lymphedema.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Lymphedema; Middle Aged; Taxoids | 2014 |
Brown adipose tissue activity in relation to weight gain during chemotherapy in breast cancer patients: a pilot study.
Topics: Adipose Tissue, Brown; Adult; Antibodies, Monoclonal, Humanized; Body Mass Index; Breast Neoplasms; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Pilot Projects; Positron-Emission Tomography; Taxoids; Tomography, X-Ray Computed; Trastuzumab; Weight Gain | 2014 |
Drug response of captured BT20 cells and evaluation of circulating tumor cells on a silicon nanowire platform.
Topics: Biosensing Techniques; Breast Neoplasms; Docetaxel; Female; Humans; MCF-7 Cells; Microfluidic Analytical Techniques; Nanowires; Neoplastic Cells, Circulating; Silicon; Streptavidin; Taxoids | 2015 |
Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Metabolic Syndrome; Middle Aged; Risk; Taxoids; Treatment Outcome | 2016 |
Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Mammaplasty; Mastectomy, Subcutaneous; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Perforator Flap; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
Taxane-induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy.
Topics: Apoptosis; Breast Neoplasms; Bridged-Ring Compounds; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; MCF-7 Cells; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Signal Transduction; Taxoids | 2015 |
Enhancing therapeutic effects of docetaxel-loaded dendritic copolymer nanoparticles by co-treatment with autophagy inhibitor on breast cancer.
Topics: Animals; Antineoplastic Agents; Autophagy; Breast Neoplasms; Chloroquine; Dendrimers; Disease Models, Animal; Docetaxel; Drug Carriers; Female; Humans; Lysosomes; MCF-7 Cells; Mice, SCID; Nanoparticles; Phagosomes; Taxoids; Treatment Outcome | 2014 |
Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Israel; Middle Aged; Retrospective Studies; Taxoids | 2014 |
Drug-induced subacute cutaneous lupus erythematosus associated with docetaxel chemotherapy: a case report.
Topics: Antibodies, Antinuclear; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Docetaxel; Drug Eruptions; Female; Humans; Lupus Erythematosus, Cutaneous; Middle Aged; Neoplasm Staging; Severity of Illness Index; Sjogren's Syndrome; Taxoids; Treatment Outcome | 2014 |
Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Carriers; Female; Gene Expression Regulation, Neoplastic; Humans; Lipids; Mice; Mice, Nude; Nanoparticles; Taxoids; Xenograft Model Antitumor Assays | 2014 |
Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Body Mass Index; Breast Neoplasms; Case-Control Studies; Confidence Intervals; Cyclophosphamide; Docetaxel; Epirubicin; Female; Glutathione S-Transferase pi; Haplotypes; Humans; Middle Aged; Odds Ratio; Oxidative Stress; Peripheral Nervous System Diseases; Polymorphism, Genetic; Taxoids | 2015 |
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cytochrome P-450 CYP3A; Docetaxel; Doxorubicin; Female; Gene Frequency; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Taxoids | 2015 |
Docetaxel modulates the delayed rectifier potassium current (IK) and ATP-sensitive potassium current (IKATP) in human breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Delayed Rectifier Potassium Channels; Docetaxel; Female; Humans; KATP Channels; MCF-7 Cells; Membrane Potentials; Patch-Clamp Techniques; Taxoids | 2015 |
A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Protocols; Cost of Illness; Docetaxel; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Myalgia; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Taxoids | 2015 |
Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Cell Line, Tumor; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression; Gene Knockdown Techniques; Hepatocyte Nuclear Factor 3-alpha; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2015 |
BRCA2-associated therapy-related acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Genes, BRCA2; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Taxoids | 2015 |
Length of chemotherapy and use of bevacizumab for breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Taxoids | 2014 |
Neutropenic fever rates with adjuvant docetaxel and cyclophosphamide in early breast cancer: audit from regional cancer centre in New South Wales.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Audit; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Humans; New South Wales; Retrospective Studies; Taxoids | 2014 |
Theranostic vitamin E TPGS micelles of transferrin conjugation for targeted co-delivery of docetaxel and ultra bright gold nanoclusters.
Topics: Animals; Breast Neoplasms; Cell Line; Docetaxel; Drug Carriers; Flow Cytometry; Gold; Humans; Metal Nanoparticles; Mice; Mice, SCID; Micelles; Microscopy, Electron, Transmission; NIH 3T3 Cells; Particle Size; Polyethylene Glycols; Taxoids; Transferrin; Vitamin E | 2015 |
CLEOPATRA holds strong in final analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Neoadjuvant Therapy; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
SNPs and taxane toxicity in breast cancer patients.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Cytochrome P-450 CYP3A; DNA-Binding Proteins; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Endonucleases; Female; Genetic Association Studies; Humans; Middle Aged; Mucositis; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids | 2014 |
Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Humans; Hyperglycemia; Infections; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; Taxoids; Young Adult | 2015 |
[Use of pertuzumab and docetaxel desensitization in oncological patient; apropos of a case].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Female; Humans; Middle Aged; Taxoids | 2014 |
β-elemene reverses chemoresistance of breast cancer via regulating MDR-related microRNA expression.
Topics: Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Sesquiterpenes; Taxoids | 2014 |
C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study.
Topics: Adenylate Kinase; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Ceramides; Cisplatin; Docetaxel; Drug Synergism; ErbB Receptors; Female; HEK293 Cells; Humans; Hydroxamic Acids; MAP Kinase Kinase 4; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Paclitaxel; Proteolysis; Taxoids; TOR Serine-Threonine Kinases; Vorinostat | 2015 |
Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens for breast cancer.
Topics: Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Docetaxel; Drugs, Investigational; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Retrospective Studies; Taxoids; Trastuzumab | 2015 |
Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways.
Topics: ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cell Membrane Permeability; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; MCF-7 Cells; Microarray Analysis; Neoplasm Proteins; Signal Transduction; Taxoids | 2015 |
Dose-dense nonpegylated liposomal Doxorubicin and docetaxel combination in breast cancer: dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Polyethylene Glycols; Taxoids | 2015 |
Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Emergency Service, Hospital; Female; Hospitalization; Humans; Middle Aged; Ontario; Paclitaxel; Retrospective Studies; Taxoids | 2015 |
Taxane-based regimens as adjuvant treatment for breast cancer: a retrospective study in egyptian cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Egypt; Female; Humans; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Young Adult | 2015 |
Development of docetaxel nanocapsules for improving in vitro cytotoxicity and cellular uptake in MCF-7 cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemistry, Pharmaceutical; Docetaxel; Drug Compounding; Drug Delivery Systems; Drug Liberation; Female; Humans; MCF-7 Cells; Microscopy, Electron, Transmission; Nanocapsules; Particle Size; Taxoids | 2015 |
Co-delivery of docetaxel and Poloxamer 235 by PLGA-TPGS nanoparticles for breast cancer treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Resistance, Multiple; Female; Humans; Lactic Acid; MCF-7 Cells; Nanoparticles; Particle Size; Poloxamer; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Taxoids; Vitamin E | 2015 |
Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Docetaxel; Epirubicin; Febrile Neutropenia; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Premedication; Quality-Adjusted Life Years; Taxoids | 2015 |
Activation of neuroimmune pathways increases therapeutic effects of radiotherapy on poorly differentiated breast carcinoma.
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Docetaxel; Female; Mice; Mice, Inbred BALB C; Substance P; Taxoids; Treatment Outcome | 2015 |
Knockdown of UbcH10 enhances the chemosensitivity of dual drug resistant breast cancer cells to epirubicin and docetaxel.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Immunohistochemistry; MCF-7 Cells; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Taxoids; Ubiquitin-Conjugating Enzymes | 2015 |
Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2015 |
Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Follow-Up Studies; Hair; Humans; Hypothermia, Induced; Middle Aged; Prospective Studies; Scalp; Taxoids; Treatment Outcome | 2015 |
PCK3145 inhibits proliferation and induces apoptosis in breast and colon cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Colonic Neoplasms; Docetaxel; Female; HT29 Cells; Humans; MAP Kinase Signaling System; MCF-7 Cells; Organoplatinum Compounds; Oxaliplatin; Peptide Fragments; Prostatic Secretory Proteins; Receptors, Laminin; Taxoids | 2015 |
Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2015 |
β2-AR signaling controls trastuzumab resistance-dependent pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Nude; Receptor, ErbB-2; Receptors, Adrenergic, beta-2; Signal Transduction; Taxoids; Trastuzumab | 2016 |
miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Nucleocytoplasmic Transport Proteins; RNA, Messenger; Taxoids | 2015 |
[Pertuzumab+trastuzumab+DTX therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Databases, Genetic; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Bilateral cystoid macular edema following docetaxel chemotherapy in a patient with retinitis pigmentosa: a case report.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Electroretinography; Female; Fluorescein Angiography; Fundus Oculi; Humans; Macular Edema; Middle Aged; Retinitis Pigmentosa; Taxoids; Tomography, Optical Coherence; Visual Acuity | 2015 |
Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Female; Humans; Mice; Micelles; Rats; Rats, Sprague-Dawley; Taxoids | 2015 |
Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cross-Sectional Studies; Docetaxel; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Sensitivity and Specificity; Taxoids; Tomography, X-Ray Computed; Trastuzumab | 2015 |
Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; DNA Copy Number Variations; Docetaxel; Drug Synergism; Female; Gene Amplification; Gene Expression; Humans; Microtubules; p21-Activated Kinases; Prognosis; Protein Kinase Inhibitors; Signal Transduction; Taxoids; Tubulin Modulators | 2015 |
Efficacy and prognosis of neoadjuvant chemotherapy is correlated with breast cancer molecular classification.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Neoplasm Grading; Precision Medicine; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Manganese oxide and docetaxel co-loaded fluorescent polymer nanoparticles for dual modal imaging and chemotherapy of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Liberation; Female; Fluoresceins; Fluorescent Dyes; Humans; Magnetic Phenomena; Magnetic Resonance Imaging; Manganese Compounds; Mice, SCID; Microscopy, Fluorescence; Nanoparticles; Oxides; Particle Size; Polymers; Taxoids; Tissue Distribution; Tumor Burden | 2015 |
Docetaxel-induced Haemorrhagic Interstitial Pneumonitis - An Acute Life-threatening Adverse Effect.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Hemorrhage; Humans; Lung Diseases, Interstitial; Taxoids | 2015 |
Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; France; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Survivors; Taxoids; Trastuzumab | 2015 |
Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cytochromes c; Docetaxel; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Male; Octreotide; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, Somatostatin; Taxoids | 2015 |
Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients.
Topics: Adult; Breast Neoplasms; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Health Personnel; Humans; Male; Medication Adherence; Middle Aged; Premedication; Surveys and Questionnaires; Taxoids | 2015 |
New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Cardiotoxicity; Cardiovascular Diseases; Cyclophosphamide; Docetaxel; Doxorubicin; Echocardiography; Electroencephalography; Enzyme-Linked Immunosorbent Assay; Female; Galectin 3; Heart; Humans; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Sensitivity and Specificity; Taxoids; Tumor Necrosis Factor-alpha; Young Adult | 2015 |
Translocation and toxicity of docetaxel multi-walled carbon nanotube conjugates in mammalian breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Female; Humans; MCF-7 Cells; Nanocapsules; Nanoconjugates; Nanotubes, Carbon; Particle Size; Subcellular Fractions; Taxoids; Treatment Outcome | 2014 |
Participation of autophagy in the cytotoxicity against breast cancer cells by cisplatin.
Topics: Adenine; Antineoplastic Agents; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Methotrexate; Taxoids | 2015 |
Peloruside A Inhibits Growth of Human Lung and Breast Tumor Xenografts in an Athymic nu/nu Mouse Model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Humans; Inhibitory Concentration 50; Lactones; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
A 3D-microtissue-based phenotypic screening of radiation resistant tumor cells with synchronized chemotherapeutic treatment.
Topics: Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Docetaxel; Doxorubicin; Female; Fibroblasts; Humans; Radiation Tolerance; Taxoids; Vinblastine | 2015 |
Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Down-Regulation; Female; Humans; MicroRNAs; Neoplastic Stem Cells; Phosphoric Diester Hydrolases; Pyrophosphatases; Taxoids | 2015 |
Mammographic breast density: Predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Density; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mammary Glands, Human; Mammography; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Decision Support Techniques; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Primary Prevention; Quality-Adjusted Life Years; Risk Factors; Taxoids | 2016 |
Regulation of BAX/BCL2 gene expression in breast cancer cells by docetaxel-loaded human serum albumin nanoparticles.
Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Female; Gene Expression; Humans; MCF-7 Cells; Nanoparticles; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Serum Albumin; Taxoids | 2015 |
Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Letrozole; Middle Aged; Nitriles; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2015 |
Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Taxoids | 2016 |
Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Taxoids; Trastuzumab | 2016 |
Preoperative chemotherapy for T2 breast cancer is associated with improved surgical outcome.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Retrospective Studies; Taxoids; Trastuzumab | 2015 |
Preparation and therapeutic application of docetaxel-loaded poly(d,l-lactide) nanofibers in preventing breast cancer recurrence.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Mice; Mice, Inbred BALB C; Nanofibers; Neoplasm Recurrence, Local; Polyesters; Taxoids; X-Ray Diffraction | 2016 |
The Influence Of Obesity On Results Of AT (Doxorubicin Plus Docetaxel) Neoadjuvant Chemotherapy In Locally Advanced Breast Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Obesity; Prognosis; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Docetaxel-induced scleroderma: a case report and its role in the production of extracellular matrix.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cells, Cultured; Chemotherapy, Adjuvant; Docetaxel; Extracellular Matrix; Extracellular Matrix Proteins; Female; Fibroblasts; Fibrosis; Humans; Middle Aged; Scleroderma, Diffuse; Skin | 2017 |
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; C-Reactive Protein; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factors; Humans; Indoles; Interleukin-6; Middle Aged; Neoplasm Metastasis; Oxindoles; Propionates; Pyrroles; Taxoids; Vascular Endothelial Growth Factor A | 2016 |
[Analysis of the Side Effects of Docetaxel with Cyclophosphamide (TC Therapy)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Humans; Middle Aged; Taxoids | 2015 |
Biotin/Folate-decorated Human Serum Albumin Nanoparticles of Docetaxel: Comparison of Chemically Conjugated Nanostructures and Physically Loaded Nanoparticles for Targeting of Breast Cancer.
Topics: Antineoplastic Agents, Phytogenic; Biotin; Breast Neoplasms; Docetaxel; Female; Folic Acid; Humans; Nanoparticles; Serum Albumin; Taxoids | 2016 |
Dose intensity and toxicity associated with Taxotere formulation: a retrospective study in a population of breast cancer patients treated with docetaxel as an adjuvant or neoadjuvant chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Taxoids; Tubulin Modulators | 2015 |
Regulating the surface poly(ethylene glycol) density of polymeric nanoparticles and evaluating its role in drug delivery in vivo.
Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Lactones; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Polyesters; Polyethylene Glycols; RAW 264.7 Cells; Surface Properties; Taxoids | 2015 |
β-Elemene Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Coculture Techniques; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Exosomes; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Luciferases; MCF-7 Cells; Oligonucleotide Array Sequence Analysis; PTEN Phosphohydrolase; Sesquiterpenes; Taxoids | 2015 |
Prognostic significance of nodal involvement region in clinical stage IIIc breast cancer patients who received primary systemic treatment, surgery, and radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clavicle; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Doxorubicin; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mammary Glands, Human; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Rate; Taxoids | 2015 |
Dual-Ligand Modified Polymer-Lipid Hybrid Nanoparticles for Docetaxel Targeting Delivery to Her2/neu Overexpressed Human Breast Cancer Cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Diffusion; Docetaxel; Humans; Ligands; Lipids; Nanocapsules; Polymers; Receptor, ErbB-2; tat Gene Products, Human Immunodeficiency Virus; Taxoids; Treatment Outcome | 2015 |
MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; MCF-7 Cells; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Receptor, Notch1; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Taxoids | 2015 |
Microencapsulated Multicellular Tumor Spheroids as a Tool to Test Novel Anticancer Nanosized Drug Delivery Systems In Vitro.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Cells, Immobilized; Docetaxel; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Humans; Methotrexate; Nanoparticles; Spheroids, Cellular; Taxoids | 2015 |
Enhanced Antitumor Efficacy and Reduced Toxicity of Docetaxel Loaded Estradiol Functionalized Stealth Polymeric Nanoparticles.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Docetaxel; Drug Carriers; Estradiol; Female; HeLa Cells; Humans; Mice; Nanoparticles; Photoelectron Spectroscopy; Polyesters; Polyethylene Glycols; Polymers; Rats; Rats, Sprague-Dawley; Taxoids; Tumor Cells, Cultured | 2015 |
Interstitial lung disease associated with docetaxel in a patient treated for breast cancer - a case report.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Lung Diseases, Interstitial; Middle Aged; Taxoids; Tomography, X-Ray Computed | 2015 |
Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Patient Outcome Assessment; Peripheral Nervous System Diseases; Prospective Studies; Taxoids | 2016 |
Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Phenotype; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survivin; Taxoids; Up-Regulation | 2016 |
Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Glucose; Blood Proteins; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Echocardiography; Female; Follow-Up Studies; Heart Diseases; Humans; Iodine Radioisotopes; Lipids; Middle Aged; Neoadjuvant Therapy; Observer Variation; Radiopharmaceuticals; Radiotherapy, Adjuvant; Reproducibility of Results; Risk Factors; Taxoids; Tomography, Emission-Computed, Single-Photon | 2015 |
Glutathione S-transferase polymorphisms influence chemotherapy response and treatment outcome in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Genetic Association Studies; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Kaplan-Meier Estimate; Middle Aged; Polymorphism, Single Nucleotide; Proportional Hazards Models; Taxoids; Thiotepa; Treatment Outcome | 2015 |
FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance.
Topics: Antibiotics, Antineoplastic; Base Sequence; Binding Sites; Breast Neoplasms; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; MCF-7 Cells; Middle Aged; Prognosis; Promoter Regions, Genetic; Protein Binding; Survivin; Taxoids; X-Linked Inhibitor of Apoptosis Protein | 2015 |
Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoprevention; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Febrile Neutropenia; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Hospitalization; Humans; Middle Aged; Neoplasm Staging; Portugal; Retrospective Studies; Taxoids | 2015 |
Minkowski functionals: An MRI texture analysis tool for determination of the aggressiveness of breast cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biopsy; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Therapy; Epirubicin; Female; Humans; Image Processing, Computer-Assisted; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Prognosis; Reproducibility of Results; Retrospective Studies; Software; Statistics, Nonparametric; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
[Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Liposomes; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 2015 |
[Administration Order of FEC-DOC in Breast Cancer Adjuvant Chemotherapy Has an Effect on Toxicity].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Staging; Taxoids | 2015 |
Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Taxoids; Tegafur | 2015 |
MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; MicroRNAs; Microtubule-Associated Proteins; Phosphoproteins; Taxoids; Xenograft Model Antitumor Assays | 2015 |
Pluronic F-127 Stabilised Docetaxel Nanocrystals Improve Apoptosis by Mitochondrial Depolarization in Breast Cancer Cells: Pharmacokinetics and Toxicity Assessment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Diffusion; Docetaxel; Drug Compounding; Drug Stability; Drug Synergism; Excipients; Female; Humans; Materials Testing; MCF-7 Cells; Membrane Potential, Mitochondrial; Mice; Nanoparticles; Particle Size; Poloxamer; Rats, Wistar; Taxoids; Treatment Outcome | 2015 |
Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs.
Topics: Apoptosis; Breast Neoplasms; Coculture Techniques; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Exosomes; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Taxoids; Tumor Microenvironment; Wnt Signaling Pathway | 2016 |
Nuclear localization of the caspase-3-cleaved form of p73 in anoikis.
Topics: Anoikis; Breast Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Docetaxel; Doxorubicin; Female; Humans; MCF-7 Cells; Taxoids; Transfection; Tumor Protein p73; Tumor Suppressor Protein p53 | 2016 |
Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Hepatocyte Growth Factor; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Taxoids | 2016 |
Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Postoperative Period; Renal Dialysis; Renal Insufficiency, Chronic; Taxoids | 2015 |
Preparation of Engineered Salmonella Typhimurium-Driven Hyaluronic-Acid-Based Microbeads with Both Chemotactic and Biological Targeting Towards Breast Cancer Cells for Enhanced Anticancer Therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Line, Tumor; Chemotaxis; Docetaxel; Drug Liberation; Endocytosis; Female; Flow Cytometry; Genetic Engineering; Hyaluronic Acid; Lactic Acid; Maleimides; Mice; Microspheres; Movement; Nanoparticles; NIH 3T3 Cells; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Proton Magnetic Resonance Spectroscopy; Salmonella typhimurium; Taxoids | 2016 |
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Topics: Animals; Antibodies, Blocking; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Bridged-Ring Compounds; Cell Line, Tumor; Cells, Cultured; Docetaxel; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Mice, SCID; NK Cell Lectin-Like Receptor Subfamily K; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Trastuzumab; Xenograft Model Antitumor Assays | 2016 |
Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Models, Animal; Docetaxel; Female; Mice; Mice, Knockout; Ritonavir; Taxoids; Treatment Outcome; Tumor Burden | 2016 |
Methylation of RASSF10 promotes cell proliferation and serves as a docetaxel resistant marker in human breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; DNA Methylation; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Signal Transduction; Taxoids; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2015 |
Cooperative Treatment of Metastatic Breast Cancer Using Host-Guest Nanoplatform Coloaded with Docetaxel and siRNA.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Docetaxel; Endocytosis; Female; Gene Knockdown Techniques; Gold; Humans; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Nanotubes; RNA, Small Interfering; Spectrophotometry, Ultraviolet; Static Electricity; Taxoids; Temperature; Time Factors | 2016 |
MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Calcium-Binding Proteins; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Female; HEK293 Cells; Human Umbilical Vein Endothelial Cells; Humans; Intercellular Signaling Peptides and Proteins; MCF-7 Cells; Mice; Mice, Nude; Neoplastic Stem Cells; Neovascularization, Pathologic; Neovascularization, Physiologic; Receptor, Notch1; Taxoids; Time Factors; Xenograft Model Antitumor Assays | 2016 |
Multiparametric MR imaging of tumor response to intraarterial chemotherapy in orthotopic xenograft models of human metastatic brain tumor.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Contrast Media; Diffusion Magnetic Resonance Imaging; Docetaxel; Female; Humans; Immunoenzyme Techniques; Injections, Intra-Arterial; Mice; Mice, Inbred BALB C; Mice, Nude; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cell Cycle Proteins; Class I Phosphatidylinositol 3-Kinases; Cyclophosphamide; DNA Mutational Analysis; Docetaxel; Epirubicin; Gene Expression; Humans; Middle Aged; Mutation; Phosphoproteins; PTEN Phosphohydrolase; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2016 |
Functionalized graphene oxide-based thermosensitive hydrogel for near-infrared chemo-photothermal therapy on tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Docetaxel; Female; Graphite; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; MCF-7 Cells; Mice; Mice, Inbred BALB C; Oxides; Photochemotherapy; Taxoids; Temperature | 2016 |
An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Gene Expression; Genomics; Hemangioendothelioma; Hormones; Humans; Indoles; Microvessels; Middle Aged; Prognosis; Pyrroles; Sunitinib; Taxoids; Transcription, Genetic | 2016 |
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
Topics: Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; MCF-7 Cells; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Taxoids | 2016 |
A digestive allergic reaction with hypereosinophilia imputable to docetaxel in a breast cancer patient: a case report.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Hypersensitivity; Eosinophilia; Female; Gastrointestinal Tract; Humans; Taxoids | 2015 |
Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCε/δ-induced ERK pathways.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mammary Neoplasms, Experimental; Methylnitrosourea; Phosphorylation; Protein Kinase C-delta; Protein Kinase C-epsilon; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; RNA Interference; Signal Transduction; Taxoids; Time Factors; Transfection; Tumor Burden | 2016 |
Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Jurkat Cells; Male; Mice; Mice, Inbred BALB C; Programmed Cell Death 1 Receptor; Prostatic Neoplasms; T-Lymphocytes, Cytotoxic; Taxoids; Tumor Escape | 2016 |
Comparison of Doctors' and Breast Cancer Patients' Perceptions of Docetaxel, Epirubicin, and Cyclophosphamide (TEC) Toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Oncologists; Perception; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Spain; Taxoids | 2016 |
Folic acid functionalized long-circulating co-encapsulated docetaxel and curcumin solid lipid nanoparticles: In vitro evaluation, pharmacokinetic and biodistribution in rats.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Curcumin; Docetaxel; Drug Carriers; Drug Liberation; Female; Folic Acid; Humans; Lipids; MCF-7 Cells; Nanoparticles; Rats; Rats, Wistar; Taxoids; Tissue Distribution | 2016 |
[Association between the expression of IGF1R and estrogen receptor and efficacy of neoadjuvant chemotherapy in beast cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Immunohistochemistry; Neoadjuvant Therapy; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Somatomedin; Taxoids | 2015 |
Docetaxel-based adjuvant therapy for breast cancer patients in Asia-Pacific region: Results from 5 years follow-up on Asia-Pacific Breast Initiative-I.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Humans; Longitudinal Studies; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Taxoids | 2016 |
Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach.
Topics: Adult; Aged; Aging; Antineoplastic Agents, Phytogenic; Asian People; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Models, Biological; Taxoids | 2016 |
Nasopharyngeal metastasis of breast carcinoma with HER 2 discordance: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Molecular Targeted Therapy; Nasal Obstruction; Nasopharyngeal Neoplasms; Rare Diseases; Receptor, ErbB-2; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2018 |
MicroRNA expression profiles of drug-resistance breast cancer cells and their exosomes.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Exosomes; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; MCF-7 Cells; MicroRNAs; Microscopy, Electron; Taxoids; Vinblastine; Vinorelbine | 2016 |
RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carboplatin; Caspase 3; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Ovarian Neoplasms; RNA Stability; RNA, Ribosomal, 18S; RNA, Ribosomal, 28S; Taxoids | 2016 |
Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia- Pacific Breast Initiatives I and II.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Longitudinal Studies; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Safety; Survival Rate; Taxoids; Young Adult | 2016 |
Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells.
Topics: Amiloride; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; Lysosomes; Necrosis; Reactive Oxygen Species; Taxoids | 2016 |
Disulfide-Linked Amphiphilic Polymer-Docetaxel Conjugates Assembled Redox-Sensitive Micelles for Efficient Antitumor Drug Delivery.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Disulfides; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Humans; Lung Neoplasms; Micelles; Oxidation-Reduction; Polymers; Taxoids; Tumor Cells, Cultured | 2016 |
Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Taxoids | 2016 |
MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3β/β-Catenin Signaling Pathway.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; MicroRNAs; Signal Transduction; Taxoids | 2016 |
DTC chemotherapy regimen is associated with higher incidence of premature ovarian failure in women of reproductive age with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Estradiol; Female; Fluorouracil; Follicle Stimulating Hormone; Humans; Ifosfamide; Incidence; Luteinizing Hormone; Middle Aged; Primary Ovarian Insufficiency; Reproduction; Taxoids | 2016 |
Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Taxoids | 2016 |
Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Real-Time Polymerase Chain Reaction; Survival Rate; Taxoids; Trastuzumab | 2016 |
[Predictive and prognostic value of monitoring lymphocyte subsets in peripheral blood before and after chemotherapy in patients with metastatic breast cancer].
Topics: Breast Neoplasms; Docetaxel; Female; Flow Cytometry; Humans; Lymphocyte Count; Neoplasm Metastasis; Prognosis; Survival Rate; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Taxoids | 2016 |
Sensitizing basal-like breast cancer to chemotherapy using nanoparticles conjugated with interference peptide.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Homeodomain Proteins; Humans; Nanoparticles; Peptides; Taxoids | 2016 |
Curcumin-docetaxel co-loaded nanosuspension for enhanced anti-breast cancer activity.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Breast Neoplasms; Curcumin; Docetaxel; Female; Humans; Male; MCF-7 Cells; Mice; Nanoparticles; Particle Size; Solubility; Suspensions; Taxoids; Tissue Distribution | 2016 |
Long-term cognitive impairment of breast cancer patients after chemotherapy: A functional MRI study.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cognitive Dysfunction; Cyclophosphamide; Docetaxel; Doxorubicin; Executive Function; Female; Gyrus Cinguli; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Middle Aged; Neuropsychological Tests; Occipital Lobe; Prefrontal Cortex; Stroop Test; Taxoids; Temporal Lobe | 2016 |
Diffuse psoriasis induced by docetaxel in a 62-year-old woman with breast carcinoma.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Eruptions; Female; Humans; Middle Aged; Psoriasis; Taxoids | 2016 |
Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Multivariate Analysis; Neoadjuvant Therapy; Neutrophils; Prognosis; Proportional Hazards Models; Retrospective Studies; ROC Curve; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
Topics: Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Early Detection of Cancer; Estrogen Receptor alpha; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Observer Variation; Prognosis; Random Allocation; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Receptors, Progesterone; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2016 |
Formulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cell Survival; Docetaxel; Drug Compounding; Drug Delivery Systems; Drug Stability; Emulsions; Ethylene Glycols; Female; Humans; Male; MCF-7 Cells; Mice, Inbred BALB C; Polyethylene Glycols; Polymers; Propylene Glycols; Rats; Rats, Sprague-Dawley; Solubility; Taxoids; Vitamin E; Xenograft Model Antitumor Assays | 2016 |
Magnetic polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol micelles for docetaxel delivery in breast cancer: an in vitro study on two cell lines of breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Caprolactam; Cell Line, Tumor; Docetaxel; Female; Humans; Micelles; Polyethylene Glycols; Polyvinyls; Spectroscopy, Fourier Transform Infrared; Taxoids | 2017 |
Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Contrast Media; Coordination Complexes; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Taxoids | 2016 |
Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Recurrence; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Evolution, Molecular; Exome; Female; Gene Expression Profiling; Genetic Variation; Genomics; High-Throughput Nucleotide Sequencing; Humans; Mutation; Taxoids; Workflow | 2016 |
[A Retrospective Analysis of Epiphora Due to Docetaxel].
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Lacrimal Apparatus Diseases; Middle Aged; Retrospective Studies; Taxoids | 2016 |
Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Registries; Retrospective Studies; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Postural Balance; Taxoids | 2016 |
Self-assembled nanoparticles based on chondroitin sulfate-deoxycholic acid conjugates for docetaxel delivery: Effect of degree of substitution of deoxycholic acid.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Chondroitin Sulfates; Deoxycholic Acid; Docetaxel; Drug Carriers; Drug Delivery Systems; Drug Liberation; Female; Humans; Hydrophobic and Hydrophilic Interactions; Nanoparticles; Polymers; Taxoids; Tumor Cells, Cultured | 2016 |
Docetaxel-Chitosan nanoparticles for breast cancer treatment: cell viability and gene expression study.
Topics: Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; Breast Neoplasms; Cell Survival; Chitosan; Docetaxel; Female; Gene Expression; Humans; MCF-7 Cells; Microscopy, Electron, Scanning; Nanoparticles; Proto-Oncogene Proteins c-bcl-2; Proton Magnetic Resonance Spectroscopy; Real-Time Polymerase Chain Reaction; Spectroscopy, Fourier Transform Infrared; Taxoids | 2016 |
TXR1 and TSP1 expression varies by the molecular subtypes of breast cancer patients who received previous docetaxel-based first-line chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Blotting, Western; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Real-Time Polymerase Chain Reaction; Repressor Proteins; Taxoids | 2016 |
Liquid crystalline nanoparticles encapsulating cisplatin and docetaxel combination for targeted therapy of breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cisplatin; Docetaxel; Humans; Nanoparticles; Taxoids | 2016 |
Serotonin transporter antagonists target tumor-initiating cells in a transgenic mouse model of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Synergism; Female; Humans; Mammary Neoplasms, Experimental; Mice, Transgenic; Neoplastic Stem Cells; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sertraline; Spheroids, Cellular; Taxoids | 2016 |
Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast; Breast Neoplasms; Contrast Media; Docetaxel; Epirubicin; Female; Humans; Image Enhancement; Middle Aged; Neoadjuvant Therapy; Reproducibility of Results; Taxoids; Treatment Outcome; Ultrasonography, Mammary | 2017 |
Folate-PEG-decorated docetaxel lipid nanoemulsion for improved antitumor activity.
Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Docetaxel; Drug Carriers; Drug Delivery Systems; Emulsions; Female; Folic Acid; HeLa Cells; Humans; Lipids; MCF-7 Cells; Mice, Inbred BALB C; Nanoparticles; Polyethylene Glycols; Taxoids | 2016 |
Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional Portuguese cohort study.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Hospitals; Humans; Middle Aged; Neoplasm Staging; Portugal; Retrospective Studies; Taxoids | 2016 |
Comparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Critical Care; Docetaxel; Drugs, Generic; Febrile Neutropenia; Female; Hospital Mortality; Hospitalization; Humans; Incidence; Middle Aged; Retrospective Studies; Taxoids | 2017 |
RGD(Arg-Gly-Asp) internalized docetaxel-loaded pH sensitive liposomes: Preparation, characterization and antitumor efficacy in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Docetaxel; Female; Hydrogen-Ion Concentration; In Vitro Techniques; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Oligopeptides; Rats; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Division; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; G2 Phase; Humans; MCF-7 Cells; Phenotype; Pterocarpans; Taxoids | 2016 |
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Tumor Burden | 2016 |
Mild photothermal therapy/photodynamic therapy/chemotherapy of breast cancer by Lyp-1 modified Docetaxel/IR820 Co-loaded micelles.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Emulsions; Female; Hyperthermia, Induced; Indocyanine Green; Infrared Rays; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Molecular Targeted Therapy; Nanocapsules; Peptides, Cyclic; Photochemotherapy; Photosensitizing Agents; Phototherapy; Taxoids; Treatment Outcome | 2016 |
Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
Topics: Acute Coronary Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Incidence; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pulmonary Embolism; Retrospective Studies; Risk Factors; Sentinel Lymph Node Biopsy; Stroke; Taxoids; Thromboembolism; Venous Thrombosis | 2016 |
Antitumor effect of Deoxypodophyllotoxin on human breast cancer xenograft transplanted in BALB/c nude mice model.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drugs, Chinese Herbal; Etoposide; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Podophyllotoxin; Taxoids; Xenograft Model Antitumor Assays | 2016 |
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle Proteins; Clinical Trials, Phase II as Topic; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Inhibitor of Apoptosis Proteins; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Survivin; Taxoids; Trans-Activators; Treatment Outcome; Trefoil Factor-1 | 2016 |
[A Case of Luminal-HER2 Advanced Breast Cancer with Liver Metastasis Showed Pathological Complete Response to the Therapy with Pertuzumab plus Trastuzumab plus Docetaxel].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Phenobarbital; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Databases, Factual; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Insurance, Health; Middle Aged; Neutropenia; Retrospective Studies; Taxoids; Trastuzumab; Young Adult | 2016 |
Novel Methodology for Comparing Standard-of-Care Interventions in Patients With Cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Febrile Neutropenia; Female; Humans; Randomized Controlled Trials as Topic; Standard of Care; Taxoids | 2016 |
Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Base Sequence; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genes, BRCA1; Humans; MCF-7 Cells; MicroRNAs; RNA, Neoplasm; Signal Transduction; Taxoids | 2016 |
Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Hungary; Middle Aged; Prospective Studies; Receptor, ErbB-2; Taxoids | 2017 |
Assessment of early treatment response to neoadjuvant chemotherapy in breast cancer using non-mono-exponential diffusion models: a feasibility study comparing the baseline and mid-treatment MRI examinations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diffusion Magnetic Resonance Imaging; Docetaxel; Epirubicin; Feasibility Studies; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Reproducibility of Results; Taxoids | 2017 |
Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Elasticity Imaging Techniques; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Tumor Burden; Ultrasonography, Mammary | 2016 |
Generic docetaxel chemotherapy induced skin toxicities in breast cancer patient.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Eruptions; Drugs, Generic; Female; Humans; Middle Aged; Skin Diseases; Taxoids | 2016 |
Anti-Invasive and Anti-Proliferative Synergism between Docetaxel and a Polynuclear Pd-Spermine Agent.
Topics: Animals; Avian Proteins; Breast Neoplasms; Cell Movement; Cell Proliferation; Chick Embryo; Chickens; Docetaxel; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Neovascularization, Pathologic; Palladium; Spermine; Taxoids; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Topics: Adolescent; Adult; Age Factors; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Longitudinal Studies; Middle Aged; Multicenter Studies as Topic; Patient Compliance; Practice Guidelines as Topic; Prospective Studies; Quality of Life; Surveys and Questionnaires; Taxoids; Young Adult | 2017 |
MiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel.
Topics: Adaptor Proteins, Vesicular Transport; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Movement; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; MicroRNAs; Neoplasm Invasiveness; Taxoids; Tumor Stem Cell Assay; Up-Regulation | 2017 |
Biocompatible hyperbranched polyglycerol modified β-cyclodextrin derivatives for docetaxel delivery.
Topics: Adenocarcinoma; beta-Cyclodextrins; Breast Neoplasms; Cell Line; Delayed-Action Preparations; Docetaxel; Drug Screening Assays, Antitumor; Erythrocytes; Female; Glycerol; Hemolysis; Humans; Polymers; Taxoids | 2017 |
Co-delivery of docetaxel and verapamil by reduction-sensitive PEG-PLGA-SS-DTX conjugate micelles to reverse the multi-drug resistance of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Survival; Docetaxel; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; MCF-7 Cells; Micelles; Microscopy, Electron, Transmission; Polyesters; Polyethylene Glycols; Rats; Rats, Wistar; Solubility; Succinimides; Taxoids; Verapamil | 2017 |
Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Lymphedema; Middle Aged; Retrospective Studies; Taxoids | 2017 |
Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2017 |
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Letrozole; Lymph Node Excision; Lymph Nodes; Mastectomy; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy; Ribs; Taxoids; Triazoles; Zoledronic Acid | 2017 |
Successful management of synchronous recurrent breast carcinoma with chronic myelogenous leukemia: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2017 |
Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Logistic Models; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Trastuzumab | 2017 |
MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Female; Follow-Up Studies; Gene Amplification; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Prognosis; Proto-Oncogene Proteins c-myc; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids | 2017 |
Taxan-associated nail toxicity.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Nail Diseases; Taxoids | 2017 |
Preclinical evaluation of taxane-binding peptide-modified polymeric micelles loaded with docetaxel in an orthotopic breast cancer mouse model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Evaluation, Preclinical; Emulsions; Female; Mice; Micelles; Nanocapsules; Peptides; Polymers; Protein Binding; Taxoids; Treatment Outcome | 2017 |
Pseudocirrhosis in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Diagnosis, Differential; Docetaxel; Doxorubicin; Fatal Outcome; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Mastectomy; Taxoids; Trastuzumab | 2018 |
Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2017 |
Personalized chemotherapy selection for breast cancer using gene expression profiles.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Therapy; Female; Humans; Male; Models, Biological; Paclitaxel; Precision Medicine; Taxoids; Transcriptome | 2017 |
Prostate apoptosis response 4 (PAR4) expression modulates WNT signaling pathways in MCF7 breast cancer cells: A possible mechanism underlying PAR4-mediated docetaxel chemosensitivity.
Topics: Apoptosis Regulatory Proteins; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Proteins; Taxoids; Wnt Signaling Pathway | 2017 |
Improved Bioavailability and Antitumor Effect of Docetaxel by TPGS Modified Proniosomes: In Vitro and In Vivo Evaluations.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Caco-2 Cells; Disease Models, Animal; Docetaxel; Drug Carriers; Humans; Liposomes; Mice; Taxoids; Treatment Outcome; Vitamin E | 2017 |
Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Hepatectomy; Humans; Letrozole; Liver Neoplasms; Male; Markov Chains; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Quality-Adjusted Life Years; Survival Rate; Taxoids; Triazoles | 2017 |
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Bridged-Ring Compounds; Diagnostic Imaging; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Microtubules; Taxoids; Tubulin; Tumor Cells, Cultured | 2017 |
Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Oxindoles; Propionates; Pyrroles; Quality of Life; Taxoids | 2017 |
The APE1 redox inhibitor E3330 reduces collective cell migration of human breast cancer cells and decreases chemoinvasion and colony formation when combined with docetaxel.
Topics: Antineoplastic Agents; Benzoquinones; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; DNA-(Apurinic or Apyrimidinic Site) Lyase; Docetaxel; Female; Humans; Neoplasm Invasiveness; Oxidation-Reduction; Propionates; Taxoids | 2017 |
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Menopause; Middle Aged; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Receptors, Estrogen; Taxoids | 2008 |
[Adjuvant chemotherapy for breast cancer and targeted therapies].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab | 2008 |
Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.
Topics: Adult; Aged; BRCA1 Protein; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Taxoids | 2008 |
Sentinel lymph node biopsy after neoadjuvant chemotherapy in a patient with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Axilla; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; False Negative Reactions; Feasibility Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Sentinel Lymph Node Biopsy; Taxoids | 2008 |
[A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Humans; Magnetic Resonance Imaging; Neoadjuvant Therapy; Taxoids | 2008 |
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Paclitaxel; Proportional Hazards Models; Taxoids | 2008 |
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Humans; Paclitaxel; Taxoids | 2008 |
A case of osteonecrosis of the jaw in a breast cancer patient with bone metastases receiving long-term treatment with bisphosphonates.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Docetaxel; Female; Humans; Jaw Diseases; Osteonecrosis; Spinal Neoplasms; Taxoids; Tomography, X-Ray Computed; Trastuzumab | 2009 |
Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Middle Aged; Neutropenia; Recombinant Proteins; Retrospective Studies; Taxoids | 2008 |
RPN2 gene confers docetaxel resistance in breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hexosyltransferases; Humans; In Situ Nick-End Labeling; Proteasome Endopeptidase Complex; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Taxoids | 2008 |
[Low dose-intensity docetaxel monotherapy for patients with anthracycline-resistant metastatic breast cancer in poor physical status].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukopenia; Lymphatic Metastasis; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids | 2008 |
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Breast Neoplasms; Docetaxel; Doxorubicin; Gene Expression Profiling; Humans; Neoadjuvant Therapy; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A | 2008 |
[Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].
Topics: Adult; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Exanthema; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Neutropenia; Receptor, ErbB-2; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab | 2008 |
hTERT gene expression levels and telomerase activity in drug resistant MCF-7 cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Proliferation; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Humans; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Taxoids; Telomerase; Tumor Cells, Cultured; Vincristine | 2008 |
Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Docetaxel; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Taxoids; Xenograft Model Antitumor Assays | 2009 |
A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Cluster Analysis; Computer Simulation; Docetaxel; Environment; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Likelihood Functions; Logistic Models; Male; Models, Genetic; Models, Statistical; Monte Carlo Method; Pharmacogenetics; Phenotype; Prostatic Neoplasms; Reproducibility of Results; Tamoxifen; Taxoids; Treatment Outcome | 2008 |
Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Amplification; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Taxoids; Transcription, Genetic | 2008 |
Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distribution; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Heart Diseases; Humans; Methotrexate; Middle Aged; Neoplasm Staging; Pilot Projects; Prospective Studies; Radiotherapy Dosage; Taxoids; Treatment Outcome | 2009 |
Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Topics: Adult; Albumins; Antineoplastic Agents; Attitude of Health Personnel; Breast Neoplasms; Canada; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2009 |
How should we prescribe lapatinib to our patients: once daily or twice daily, and at what dose?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lapatinib; Polyethylene Glycols; Quinazolines; Recombinant Proteins; Taxoids | 2009 |
Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Retrospective Studies; Sensitivity and Specificity; Sentinel Lymph Node Biopsy; Taxoids | 2008 |
Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling.
Topics: Antineoplastic Agents; Biopsy; Breast Neoplasms; DNA, Complementary; Docetaxel; Female; Gene Expression Profiling; Genome, Human; Humans; Neoplasm Proteins; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Postmenopause; Predictive Value of Tests; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2009 |
Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hospitalization; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Cycle; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Inhibitory Concentration 50; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Taxoids | 2009 |
[Combination of docetaxel and capecitabine for the treatment of anthracycline-resistant advanced breast carcinoma].
Topics: Adult; Aged; Agranulocytosis; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Remission Induction; Survival Rate; Taxoids; Vomiting | 2008 |
[Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Remission Induction; Survival Rate; Taxoids | 2008 |
Anthracyclines and early breast cancer: the end of an era?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Receptor, ErbB-2; Taxoids | 2009 |
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Taxoids | 2009 |
3'-Deoxy-3'-[(18)F]fluorothymidine (FLT) uptake in breast cancer cells as a measure of proliferation after doxorubicin and docetaxel treatment.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Doxorubicin; Female; Fluorine Radioisotopes; Humans; Radiopharmaceuticals; S Phase; Taxoids; Thymidine | 2009 |
Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer.
Topics: Alopecia; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2009 |
[Acute abdomen in a chemotherapy treated breast cancer patient].
Topics: Abdomen, Acute; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Taxoids | 2009 |
NICE updates guidance on early and advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Early Diagnosis; Female; Humans; Mastectomy; Practice Guidelines as Topic; Taxoids; United Kingdom | 2009 |
Neutropenic enterocolitis and docetaxel neoadjuvant chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Enterocolitis, Neutropenic; Female; Humans; Middle Aged; Taxoids | 2009 |
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Glucose intolerance during adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dexamethasone; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Glucose Intolerance; Humans; Hyperglycemia; Hyperinsulinism; Middle Aged; Taxoids | 2009 |
A novel mixed micelle gel with thermo-sensitive property for the local delivery of docetaxel.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Fluorescent Dyes; Gels; Humans; Inhibitory Concentration 50; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Molecular Weight; Ovarian Neoplasms; Poloxamer; Polysorbates; Random Allocation; Rhodamines; Taxoids; Temperature; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Topics: Adult; Alleles; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cyclophosphamide; Cytochrome P-450 CYP3A; Docetaxel; Etoposide; Female; Genotype; Humans; Middle Aged; Polymorphism, Single Nucleotide; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2009 |
Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium.
Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cytochromes c; Docetaxel; Genes, bcl-2; Humans; Membrane Potential, Mitochondrial; Organophosphorus Compounds; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Tubulin Modulators | 2009 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Epidemiologic study to assess patient involvement in choice of adjuvant chemotherapy for breast cancer (PROSA Study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Patient Participation; Patient Satisfaction; Prospective Studies; Spain; Taxoids | 2009 |
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Ki-67 Antigen; Lymphatic Metastasis; Middle Aged; Prognosis; Receptors, Estrogen; Taxoids; Treatment Outcome | 2009 |
[Examination about the influence for daily life that nail and skin disorders induced by docetaxel in patients with breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Nail Diseases; Quality of Life; Skin Diseases; Surveys and Questionnaires; Taxoids | 2009 |
[Correlations between hormonal receptor and HER2 status or nuclear grades and response rate in breast cancer treated with neoadjuvant chemotherapy of docetaxel alone].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2009 |
[Pneumocystis pneumonia in two breast cancer patients treated with docetaxel: an unusual adverse event of chemotherapy].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Pneumonia, Pneumocystis; Taxoids | 2010 |
QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outc
Topics: Actins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Taxoids | 2009 |
Transcriptome changes induced by docetaxel in human mammary cell lines expressing different levels of ERBB2.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Gene Expression Regulation, Neoplastic; Humans; Polymerase Chain Reaction; Receptor, ErbB-2; Taxoids; Transcription, Genetic | 2009 |
3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Docetaxel; Down-Regulation; Drug Therapy, Combination; Female; Humans; Indoles; Inhibitor of Apoptosis Proteins; Luciferases; Male; Mice; Microtubule-Associated Proteins; Neoplasm Metastasis; Plasmids; Prostatic Neoplasms; Survivin; Taxoids | 2009 |
Unravelling the mystery of the TACT trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Randomized Controlled Trials as Topic; Research Design; Taxoids; United Kingdom | 2009 |
Docetaxel-induced Stevens-Johnson syndrome with regenerating epidermis composed of atypical keratinocytes.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Epidermis; Female; Humans; Keratinocytes; Middle Aged; Stevens-Johnson Syndrome; Taxoids | 2009 |
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2009 |
Improvement in docetaxel-induced nail changes associated with cyclooxygenase-2 inhibitor treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclooxygenase 2 Inhibitors; Docetaxel; Female; Humans; Meloxicam; Middle Aged; Nail Diseases; Taxoids; Thiazines; Thiazoles | 2009 |
[A case of triple negative chest wall recurrent breast cancer treated with capecitabine and docetaxel combination therapy (XT therapy)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Positron-Emission Tomography; Taxoids; Thoracic Neoplasms; Thoracic Wall; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[Effects of neoadjuvant chemotherapy of docetaxel combined with and epirubicin or pirarubicin on breast cancer: clinical analysis of 160 cases].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Logistic Models; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Young Adult | 2009 |
Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Feasibility Studies; Female; Humans; Japan; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2009 |
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Enzyme Inhibitors; Humans; Indazoles; Lapatinib; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sulfonamides; Taxoids; Trastuzumab; Xenograft Model Antitumor Assays | 2009 |
Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; DNA, Neoplasm; Docetaxel; Dose-Response Relationship, Drug; Female; Glutathione; Humans; Metabolic Networks and Pathways; Metabolomics; Mitosis; Neoplasm Proteins; Nuclear Magnetic Resonance, Biomolecular; Phospholipids; Taxoids | 2010 |
Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cluster Analysis; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Paclitaxel; Taxoids; Vincristine | 2010 |
Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids; Treatment Outcome | 2010 |
Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical | 2009 |
Hand-foot syndrome after treatment with docetaxel.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Foot Dermatoses; Hand Dermatoses; Humans; Syndrome; Taxoids | 2009 |
Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Synergism; Enzyme Activation; Female; Humans; Lung Neoplasms; Matrix Metalloproteinase 1; Matrix Metalloproteinase Inhibitors; Mice; Mice, Nude; Peptides; Proto-Oncogene Proteins c-akt; Receptor, PAR-1; RNA, Small Interfering; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2009 |
Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Taxoids; Thrombocytopenia; Trastuzumab | 2009 |
Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Contrast Media; Docetaxel; Female; Humans; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Taxoids; Transplantation, Heterologous | 2010 |
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Fever; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Taxoids | 2009 |
Methylation mediated silencing of TMS1 in breast cancer and its potential contribution to docetaxel cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; CARD Signaling Adaptor Proteins; Cytoskeletal Proteins; DNA Methylation; Docetaxel; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Tumor Cells, Cultured | 2009 |
Re: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Ki-67 Antigen; Lymph Nodes; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids | 2009 |
Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome | 2010 |
Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Female; Fluorouracil; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; Taxoids; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2009 |
Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cell Proliferation; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Ki-67 Antigen; Logistic Models; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Tamoxifen; Taxoids; Tumor Suppressor Protein p53 | 2010 |
Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Disease-Free Survival; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Sunitinib in breast cancer: friend or foe.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Indoles; Pyrroles; Sunitinib; Taxoids | 2009 |
Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Indoles; Liver Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Pyrroles; Sunitinib; Taxoids; Tomography, X-Ray Computed | 2009 |
[A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Inflammation; Middle Aged; Oxonic Acid; Skin Neoplasms; Taxoids; Tegafur; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Gene Expression Profiling; Humans; Middle Aged; Oligonucleotide Array Sequence Analysis; Receptor, ErbB-2; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Trastuzumab | 2009 |
Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bacterial Toxins; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Escherichia coli Proteins; Female; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Humans; Membrane Proteins; Paclitaxel; Spheroids, Cellular; Taxoids; Transfection | 2010 |
[Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Informed Consent; Middle Aged; Neutropenia; Quality of Life; Recombinant Proteins; Taxoids; Time Factors | 2009 |
Overexpression of kinesins mediates docetaxel resistance in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Immunoblotting; Kinesins; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Tubulin; Tumor Cells, Cultured | 2009 |
An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Taxoids; United Kingdom | 2009 |
Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; China; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Taxoids | 2009 |
Case of fulminant colitis after docetaxel therapy for breast carcinoma in a patient with underlying ulcerative colitis.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Colitis, Ulcerative; Docetaxel; Female; Humans; Taxoids | 2009 |
Effects of decitabine on the expression of selected endogenous control genes in human breast cancer cells.
Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Taxoids | 2010 |
Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Taxoids; Thrombotic Microangiopathies; Trastuzumab; Treatment Outcome | 2010 |
Have we reached a plateau in adjuvant breast cancer therapy?
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Research Design; Taxoids | 2009 |
What does similarity mean in clinical trials?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids | 2009 |
Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Longitudinal Studies; Taxoids; Vitamin D; Vitamin D Deficiency | 2010 |
A remarkable case of cutaneous metastatic breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Humans; Mammaplasty; Mastectomy, Modified Radical; Middle Aged; Neoadjuvant Therapy; Nitriles; Radiography; Skin Neoplasms; Taxoids; Triazoles | 2009 |
Neutropenic enterocolitis associated with docetaxel therapy in a patient with breast cancer.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Enterocolitis, Neutropenic; Female; Humans; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Taxoids | 2009 |
Bilateral phrenic nerve paralysis as a manifestation of paraneoplastic syndrome.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paralysis; Paraneoplastic Syndromes, Nervous System; Phrenic Nerve; Respiratory Insufficiency; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2010 |
Axillary sentinel node biopsy after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Sentinel Lymph Node Biopsy; Taxoids | 2010 |
Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD24 Antigen; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorescent Antibody Technique; Glutamates; Guanine; Humans; Hyaluronan Receptors; Middle Aged; Neoadjuvant Therapy; Pemetrexed; Taxoids | 2010 |
Mees lines and Beau lines after chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cytarabine; Daunorubicin; Docetaxel; Female; Humans; Leukemia, Myeloid, Acute; Nail Diseases; Taxoids | 2010 |
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
Topics: Adult; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Genes, BRCA1; Humans; Methotrexate; Middle Aged; Neoadjuvant Therapy; Registries; Taxoids | 2010 |
[A case of advanced breast cancer with multiple bone metastases responding to docetaxel and high-dose toremifene as fourth-line chemo-endocrine therapy].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Taxoids; Toremifene | 2009 |
Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Sphingosine-1-phosphate: a potential therapeutic agent against human breast cancer.
Topics: Aldehyde-Lyases; Apoptosis; Breast Neoplasms; Cell Proliferation; Docetaxel; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lysophospholipids; Phosphotransferases (Alcohol Group Acceptor); RNA, Messenger; Sphingosine; Taxoids | 2011 |
[Tolerability and safety of docetaxel plus cyclophosphamide as adjuvant chemotherapy for axillary lymph node-negative breast cancer--JECBC04 trial].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Tolerance; Female; Humans; Middle Aged; Multicenter Studies as Topic; Taxoids | 2010 |
Comment on pegylated liposomal Doxorubicin plus docetaxel in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Metastasis; Polyethylene Glycols; Survival Analysis; Taxoids | 2010 |
Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
[Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids | 2009 |
What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Maximum Tolerated Dose; Polyethylene Glycols; Taxoids; Treatment Outcome | 2010 |
Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cryoelectron Microscopy; Docetaxel; Drug Carriers; Drug Compounding; Drug Stability; Female; Humans; Hydrogen-Ion Concentration; Lipids; Mice; Molecular Structure; Nanoparticles; Solubility; Taxoids; Xenograft Model Antitumor Assays | 2010 |
Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; BRCA1 Protein; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; DNA Damage; DNA Repair; Docetaxel; Epirubicin; Female; Histones; Humans; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Outcome Assessment, Health Care; Predictive Value of Tests; Prognosis; Proteins; Rad51 Recombinase; Taxoids; Ubiquitin | 2010 |
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Retrospective Studies; Risk Factors; Taxoids; Treatment Outcome | 2011 |
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Endothelium, Vascular; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
[Efficacy of FEC and trastuzumab/docetaxel combination therapy for metastatic breast cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Trastuzumab | 2010 |
Severe interstitial pneumonitis associated with the administration of taxanes.
Topics: Adrenal Cortex Hormones; Aged; Breast Neoplasms; Docetaxel; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Taxoids; Tomography, X-Ray Computed | 2010 |
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Diphosphonates; Docetaxel; Double-Blind Method; Drug Synergism; Female; Genes, erbB-2; Humans; Incidence; Jaw Diseases; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Oral Hygiene; Osteonecrosis; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2010 |
Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Tetrazolium Salts; Thiazoles; Time Factors | 2010 |
The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2010 |
Drug resistant breast cancer cells overexpress ETS1 gene.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Matrix Metalloproteinase 1; Oncogenes; Paclitaxel; Proto-Oncogene Protein c-ets-1; Taxoids; Vincristine | 2010 |
Multifunctional nanoparticles of biodegradable copolymer blend for cancer diagnosis and treatment.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Docetaxel; Female; Humans; Lactic Acid; Mice; Nanoparticles; NIH 3T3 Cells; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quantum Dots; Taxoids; Vitamin E | 2010 |
[An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Skin Neoplasms; Taxoids; Tomography, X-Ray Computed; Vitamin B 6 | 2010 |
Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Docetaxel; Estrogen Receptor alpha; Female; Humans; Middle Aged; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Taxoids | 2010 |
Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer.
Topics: Adult; Aged; Anthracyclines; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neutropenia; Prognosis; Taxoids; Treatment Outcome | 2010 |
GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Endoplasmic Reticulum Chaperone BiP; Female; Heat-Shock Proteins; Humans; Lymphatic Metastasis; Menopause; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Taxoids; Treatment Outcome | 2011 |
[Safety and tolerability of docetaxel with cyclophosphamide for early breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Neoplasm Staging; Taxoids | 2010 |
[Two elderly patients with advanced breast cancer successfully treated by tri-weekly docetaxel].
Topics: Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoplasm Staging; Taxoids; Tomography, X-Ray Computed | 2010 |
Bone metastasis of a breast cancer detected by 3'-deoxy-3'-18F-fluorothymidine PET/CT.
Topics: Adult; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Dideoxynucleosides; Docetaxel; Epirubicin; Female; Humans; Positron-Emission Tomography; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Taxane-based chemotherapy for node-positive breast cancer--take-home lessons.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Humans; Receptor, ErbB-2; Survival Rate; Taxoids | 2010 |
Photosensitive rash in association with porphyrin biosynthesis possibly induced by docetaxel and trastuzumab therapy in a patient with metastatic breast carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dermatitis, Phototoxic; Docetaxel; Exanthema; Female; Humans; Middle Aged; Neoplasm Metastasis; Porphyrins; Taxoids; Trastuzumab | 2010 |
Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fertility; Fluorouracil; Humans; Incidence; Logistic Models; Middle Aged; Odds Ratio; Retrospective Studies; Risk Assessment; Risk Factors; Tamoxifen; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2010 |
BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Immunohistochemistry; Lymphatic Metastasis; Multicenter Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Taxoids | 2010 |
nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
Topics: Albumins; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cytotoxins; Docetaxel; Drug Therapy, Combination; Female; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids; Treatment Outcome | 2010 |
Carboplatin and docetaxel-induced acute pancreatitis: brief report.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neoplasm Staging; Pancreatitis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Tomography, X-Ray Computed | 2010 |
Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Polymorphism, Genetic; Postmenopause; Premenopause; Taxoids | 2010 |
Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Chi-Square Distribution; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2C8; Cytochrome P-450 Enzyme System; Docetaxel; Drug Hypersensitivity; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Italy; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Odds Ratio; Paclitaxel; Phenotype; Polymorphism, Single Nucleotide; Retrospective Studies; Risk Assessment; Risk Factors; Taxoids; Treatment Outcome | 2010 |
Acute localized exanthematous pustulosis induced by docetaxel.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antineoplastic Agents; Biopsy; Breast Neoplasms; Cheek; Docetaxel; Female; Humans; Taxoids | 2010 |
[Safety and tolerance of docetaxel (especially 75 mg/m2) with cyclophosphamide (TC therapy) as adjuvant chemotherapy for Japanese patients with operable breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Taxoids | 2010 |
Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
Neoadjuvant treatment in young women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Sentinel Lymph Node Biopsy; Taxoids; Treatment Outcome | 2010 |
Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cell Division; Cell Survival; Cytoplasm; Docetaxel; Female; Humans; Male; Phosphorylation; Prostatic Neoplasms; Sp1 Transcription Factor; Taxoids; Transcription, Genetic; Treatment Outcome; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role?
Topics: Antineoplastic Agents; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Delayed-Action Preparations; Docetaxel; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Female; Humans; Inhibitory Concentration 50; Kinetics; Male; Micelles; Nanoparticles; Polyesters; Prostatic Neoplasms; Solubility; Taxoids | 2010 |
Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Cyclin D1; Docetaxel; Epirubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; NM23 Nucleoside Diphosphate Kinases; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Young Adult | 2011 |
Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; In Situ Hybridization, Fluorescence; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; ROC Curve; Statistics, Nonparametric; Taxoids | 2010 |
ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; NM23 Nucleoside Diphosphate Kinases; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Young Adult | 2011 |
Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Chi-Square Distribution; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Logistic Models; Mastectomy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Odds Ratio; Patient Selection; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2012 |
Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Humans; Markov Chains; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Salvage Therapy; Spain; Taxoids | 2010 |
[Feasibility of adjuvant docetaxel plus cyclophosphamide therapy for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Feasibility Studies; Female; Humans; Middle Aged; Taxoids | 2010 |
Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up).
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Pilot Projects; Taxoids | 2011 |
Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Taxoids | 2011 |
Health-related quality of life after chemotherapy cycle in breast cancer in Iran.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cognition Disorders; Cohort Studies; Cyclophosphamide; Docetaxel; Double-Blind Method; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Health Status; Humans; Iran; Middle Aged; Nausea; Quality of Life; Taxoids | 2011 |
Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cholecalciferol; Docetaxel; Drug Eruptions; Dysgeusia; Female; Humans; Middle Aged; Stomatitis; Taxoids; Trastuzumab; Treatment Outcome; Vitamin D; Vitamin D Deficiency; Vitamins | 2011 |
Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fever; Humans; Maximum Tolerated Dose; Medical Audit; Middle Aged; Neutropenia; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Therapy, Computer-Assisted; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2010 |
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Clinical Trials, Phase II as Topic; Docetaxel; Enzyme Activation; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Taxoids; Transfection; Trastuzumab | 2011 |
3,3'-Diindolylmethane enhances taxotere-induced growth inhibition of breast cancer cells through downregulation of FoxM1.
Topics: Animals; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Forkhead Box Protein M1; Forkhead Transcription Factors; Humans; Indoles; Mice; Mice, Nude; Taxoids; Xenograft Model Antitumor Assays | 2011 |
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Docetaxel; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Insulin-Like Growth Factor I; Mice; Mice, Inbred NOD; Mice, SCID; NIH 3T3 Cells; Pyrazoles; Receptor, ErbB-2; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Triazines; Xenograft Model Antitumor Assays | 2011 |
MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Mucin-1; Neoplastic Cells, Circulating; Receptors, Progesterone; RNA, Messenger; Taxoids; Thiotepa | 2011 |
[A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Lymph Node Excision; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel; Tamoxifen; Taxoids; Tegafur; Trastuzumab; Uracil | 2010 |
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Complement System Proteins; Docetaxel; Epirubicin; Female; Humans; Neoadjuvant Therapy; Taxoids | 2011 |
Questioning the value of (99m)Tc-HYNIC-annexin V based response monitoring after docetaxel treatment in a mouse model for hereditary breast cancer.
Topics: Animals; Annexin A5; Breast Neoplasms; Disease Models, Animal; Docetaxel; Mice; Organotechnetium Compounds; Radionuclide Imaging; Taxoids | 2011 |
The First Description of Docetaxel-Induced Recall Inflammatory Skin Reaction After Previous Drug Extravasation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Docetaxel; Drug Eruptions; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Neoplasm Metastasis; Recurrence; Taxoids | 2011 |
Oncogramme, a new promising method for individualized breast tumour response testing for cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Keratins; Precision Medicine; Prognosis; Taxoids; Tumor Cells, Cultured | 2011 |
Effects of EpCAM overexpression on human breast cancer cell lines.
Topics: Antigens, Neoplasm; Antineoplastic Agents; beta Catenin; Breast Neoplasms; Cell Adhesion Molecules; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Docetaxel; Epithelial Cell Adhesion Molecule; Female; Gene Expression Profiling; Humans; Microscopy, Confocal; Protein Processing, Post-Translational; Signal Transduction; Subcellular Fractions; Taxoids; Wnt Proteins | 2011 |
DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diffusion Magnetic Resonance Imaging; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Prospective Studies; Remission Induction; Taxoids | 2012 |
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cytochrome P-450 CYP3A; Docetaxel; Drug Interactions; Female; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Taxoids; Treatment Outcome | 2011 |
Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Docetaxel; Female; Humans; Luciferases; Luminescent Agents; Mice; Mice, Nude; Protein Serine-Threonine Kinases; Pyrazoles; Reproducibility of Results; Taxoids; Transfection | 2011 |
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Tumor Suppressor Protein p53 | 2011 |
Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Estriol; Estrogen Antagonists; Female; Humans; Ifosfamide; Leuprolide; Lymphatic Metastasis; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triazoles; Tumor Necrosis Factor Ligand Superfamily Member 15 | 2011 |
Adjuvant docetaxel for node-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Intention to Treat Analysis; Neoplasm Recurrence, Local; Recurrence; Taxoids | 2011 |
Adjuvant docetaxel for node-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Receptor, ErbB-2; Receptors, Granulocyte Colony-Stimulating Factor; Taxoids; Up-Regulation | 2011 |
miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Topics: Antineoplastic Agents; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Cyclin D1; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; Reproducibility of Results; Taxoids | 2012 |
[A case of possible retroperitoneal metastasis of breast cancer successfully treated with oral S-1 and cyclophosphamide therapy after TC therapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Retroperitoneal Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2011 |
Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Trastuzumab; Treatment Outcome | 2010 |
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Synergism; Female; Fluorouracil; Humans; Models, Theoretical; Neoplasm Metastasis; Taxoids | 2011 |
Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Cell Line, Tumor; Cluster Analysis; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; HEK293 Cells; Humans; Kinesins; Middle Aged; Neoplasm Staging; Paclitaxel; Protein Binding; Taxoids; Vincristine | 2012 |
Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Tumor Suppressor Protein p53 | 2011 |
Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2011 |
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Plastic Surgery Procedures; Polyethylene Glycols; Ribs; Taxoids; Thoracic Wall | 2011 |
Dermatopathologic effects of taxane therapy.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Biopsy; Breast Neoplasms; Bridged-Ring Compounds; Cell Cycle; Docetaxel; Female; Humans; Leiomyosarcoma; Male; Mitosis; Paclitaxel; Skin; Skin Diseases; Taxoids | 2011 |
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Cytoplasm; Disease-Free Survival; Docetaxel; Doxorubicin; ErbB Receptors; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Multicenter Studies as Topic; Neoadjuvant Therapy; Poly(ADP-ribose) Polymerases; Prognosis; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome | 2011 |
A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Metaplasia; Middle Aged; Multimodal Imaging; Preoperative Care; Prognosis; Taxoids | 2014 |
CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cytochrome P-450 CYP3A; Disease Progression; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2011 |
Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners?
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Guidelines as Topic; Humans; Imidazoles; Indazoles; Multicenter Studies as Topic; Neoplasm Proteins; Precision Medicine; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Research Design; Taxoids; Vascular Endothelial Growth Factor A | 2011 |
An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD24 Antigen; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Humans; Hyaluronan Receptors; Isoenzymes; Neoplastic Stem Cells; Phenotype; Prognosis; Retinal Dehydrogenase; Taxoids | 2011 |
Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Geriatric Assessment; Humans; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
Acute generalized exanthematous pustulosis induced by docetaxel.
Topics: Acute Generalized Exanthematous Pustulosis; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Eruptions; Female; Humans; Middle Aged; Taxoids | 2011 |
Dielectrophoresis-based cellular microarray chip for anticancer drug screening in perfusion microenvironments.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Docetaxel; Drug Evaluation, Preclinical; Electrodes; Electrophoresis; Female; Humans; Microarray Analysis; Microfluidic Analytical Techniques; Taxoids | 2011 |
Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Rate; Survivors; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Triple-negative breast cancer: are the imaging findings different between responders and nonresponders to neoadjuvant chemotherapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Breast Neoplasms; Cyclophosphamide; Diagnostic Imaging; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Necrosis; Neoadjuvant Therapy; Sentinel Lymph Node Biopsy; Taxoids; Treatment Outcome | 2011 |
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Docetaxel and adjuvant treatment of breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Taxoids | 2011 |
SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.
Topics: Anthracyclines; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Lobular; Docetaxel; Female; HSP70 Heat-Shock Proteins; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Neoplasm, Residual; Prognosis; Randomized Controlled Trials as Topic; Serpins; Taxoids; Treatment Outcome | 2012 |
Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey.
Topics: Acetamides; Breast Neoplasms; Chemotherapy, Adjuvant; Dexamethasone; Docetaxel; Erythema; Famotidine; Female; Glucocorticoids; Hand-Foot Syndrome; Histamine H2 Antagonists; Humans; Incidence; Logistic Models; Multivariate Analysis; Neoadjuvant Therapy; Piperidines; Pyridines; Ranitidine; Retrospective Studies; Steroids; Surveys and Questionnaires; Taxoids | 2011 |
Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Nomograms; Prognosis; Taxoids; Treatment Outcome; Young Adult | 2011 |
Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Protein Isoforms; Statistics as Topic; Taxoids | 2012 |
Curative-intent stereotactic body radiation therapy for residual breast cancer liver metastasis after systemic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Radiosurgery; Taxoids | 2014 |
Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression; Genes, erbB-2; Humans; Immunochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Poly-ADP-Ribose Binding Proteins; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Health Care Costs; Humans; Methotrexate; Middle Aged; Prognosis; Quality-Adjusted Life Years; Taxoids | 2011 |
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD4-Positive T-Lymphocytes; Docetaxel; Female; Genes, erbB-2; Humans; Lymphoid Tissue; Middle Aged; Neoadjuvant Therapy; Prognosis; T-Box Domain Proteins; Taxoids; Trastuzumab | 2011 |
Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Female; Humans; Membrane Proteins; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Sulfonamides; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computer Simulation; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Female; Gene Expression Profiling; Genetic Association Studies; Humans; Inhibitory Concentration 50; Middle Aged; Models, Biological; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Phenotype; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Tubulin Modulators | 2012 |
Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERK.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Therapy, Combination; Female; Glycoproteins; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 3; Neoplasm Invasiveness; Phosphorylation; Real-Time Polymerase Chain Reaction; Receptors, Urokinase Plasminogen Activator; RNA, Messenger; Taxoids; Trypsin Inhibitors; Urokinase-Type Plasminogen Activator | 2011 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
[Administration of dicarbamin in the course of taxotere-assisted chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caproates; Docetaxel; Drug Administration Schedule; Female; Humans; Imidazoles; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Prostatic Neoplasms; Protective Agents; Taxoids; Treatment Outcome | 2011 |
Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Taxoids | 2012 |
TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Denmark; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Retrospective Studies; Taxoids | 2011 |
Chemo-enzymatic synthesis of ester-linked docetaxel-monosaccharide conjugates as water-soluble prodrugs.
Topics: Antineoplastic Agents; beta-Galactosidase; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Docetaxel; Esters; Female; Fungal Proteins; Glycoconjugates; Glycosylation; Humans; Hydrolysis; Lactase; Magnetic Resonance Spectroscopy; Monosaccharides; Prodrugs; Solubility; Taxoids; Water; Xylosidases | 2011 |
Encapsulation of docetaxel into PEGylated gold nanoparticles for vectorization to cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Docetaxel; Drug Carriers; Female; Gold; Humans; Magnetic Resonance Spectroscopy; Metal Nanoparticles; Polyethylene Glycols; Solubility; Spectrophotometry, Ultraviolet; Taxoids | 2011 |
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Prognosis; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Androgen; Taxoids | 2011 |
Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Cytoplasm; Docetaxel; Doxorubicin; Epithelial Cells; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; tau Proteins; Taxoids | 2011 |
[A case of effective combination therapy with docetaxel, cyclophosphamide and trastuzumab as primary systemic therapy for locally advanced HER2-positive breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab | 2011 |
Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Humans; Lung Neoplasms; Microscopy, Electron, Scanning; Nanomedicine; Nanoparticles; Polyethylene Glycols; Polyglactin 910; Receptor, ErbB-2; Taxoids; Trastuzumab | 2011 |
Nanoformulation of D-α-tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran-glycolide) diblock copolymer for breast cancer therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Female; Humans; Magnetic Resonance Spectroscopy; Mice; Mice, SCID; Microscopy, Electron, Scanning; Nanoparticles; Polyesters; Polyethylene Glycols; Polyglycolic Acid; Random Allocation; Taxoids; Vitamin E; Xenograft Model Antitumor Assays | 2011 |
Lethal human neutropenic entercolitis caused by Clostridium chauvoei in the United States: tip of the iceberg?
Topics: Adult; Breast Neoplasms; Clostridium chauvoei; Clostridium Infections; DNA, Bacterial; Docetaxel; Enterocolitis, Neutropenic; Fatal Outcome; Female; Humans; RNA, Ribosomal, 16S; Taxoids; United States | 2012 |
Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distribution; Constipation; Cost Savings; Dexamethasone; Docetaxel; Female; Humans; Middle Aged; Nausea; Ondansetron; Practice Guidelines as Topic; Sleep Initiation and Maintenance Disorders; Taxoids; Vomiting | 2012 |
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab | 2012 |
The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Texas; Trastuzumab; Treatment Outcome | 2011 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Medullary; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Female; Genetic Therapy; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Mice, Nude; Oligodeoxyribonucleotides, Antisense; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Gene Expression Profiling; Humans; Ki-67 Antigen; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2012 |
Docetaxel/Cyclophosphamide-induced ultraviolet recall dermatitis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Chemotherapy, Adjuvant; Cyclophosphamide; Dermatitis; Docetaxel; Female; Humans; Recurrence; Sunburn; Taxoids | 2011 |
Resolution of extensive leptomeningeal metastasis and clinical spinal cord compression from breast cancer using weekly docetaxel chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Central Nervous System; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Meningeal Neoplasms; Middle Aged; Spinal Cord Compression; Taxoids | 2012 |
Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fever; Humans; Leukocyte Count; Middle Aged; Models, Biological; Neutropenia; Neutrophils; Retrospective Studies; Risk Assessment; Taxoids | 2012 |
An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Microarray Analysis; MicroRNAs; Proto-Oncogene Proteins c-akt; Taxoids | 2011 |
The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Fever; Humans; Middle Aged; Models, Biological; Neutropenia; Risk Factors; Taxoids | 2012 |
Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cardiovascular Diseases; Cyclophosphamide; Docetaxel; Doxorubicin; Echocardiography; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Taxoids; Troponin I; Ventricular Function, Left | 2011 |
Stable and efficient delivery of docetaxel by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphile.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Docetaxel; Drug Carriers; Drug Compounding; Drug Stability; Female; Humans; Injections, Intravenous; Lethal Dose 50; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Micelles; Peptides; Photolysis; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Stomach Neoplasms; Taxoids; Technology, Pharmaceutical; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Taxane doublets for metastatic breast cancer: do we need another cytotoxic pair or another approach?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Receptor, ErbB-2; Taxoids | 2011 |
Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Gloves, Protective; Humans; Hypothermia, Induced; Japan; Middle Aged; Nail Diseases; Taxoids | 2012 |
Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapy.
Topics: Animals; Anthracenes; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Green Fluorescent Proteins; Humans; Mice; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sphingosine; Taxoids; Tyrphostins; Versicans | 2011 |
In vitro mechanistic study of cell death and in vivo performance evaluation of RGD grafted PEGylated docetaxel liposomes in breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Female; Liposomes; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Nanocapsules; Oligopeptides; Polyethylene Glycols; Rabbits; Taxoids; Tissue Distribution; Treatment Outcome | 2012 |
Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?
Topics: 14-3-3 Proteins; BH3 Interacting Domain Death Agonist Protein; Biomarkers; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Proteomics; Taxoids | 2012 |
Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphocyte Count; Mastectomy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy.
Topics: Adult; Age Factors; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Hemoglobins; Humans; Incidence; Logistic Models; Mastectomy; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Taxoids | 2012 |
Cross-sensitivity between taxanes in patients with breast cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Docetaxel; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Premedication; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
Letter: Docetaxel-induced supravenous serpentine dermatitis.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Eruptions; Erythema; Female; Forearm; Humans; Hyperpigmentation; Injections, Intravenous; Middle Aged; Mometasone Furoate; Pregnadienediols; Pruritus; Taxoids; Veins | 2011 |
HER2 therapy--an abundance of riches.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Male; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
The extraction of pharmacogenetic and pharmacogenomic relations--a case study using PharmGKB.
Topics: Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Citalopram; Computational Biology; Cytochrome P-450 CYP2C19; Databases, Factual; Databases, Genetic; Docetaxel; Female; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Knowledge Bases; Obesity; Pharmacogenetics; Pharmacokinetics; Protein Interaction Mapping; Taxoids; Urocortins | 2012 |
Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Regression Analysis; Taxoids; Trastuzumab | 2012 |
Breast cancer: Increasing therapy options for HER2-positive early breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cyclophosphamide; Disease Progression; Docetaxel; Female; Genes, erbB-2; Humans; Taxoids; Time Factors; Trastuzumab | 2011 |
The synergistic effect of herceptin and docetaxel in polylactide-D-α-tocopheryl polyethylene glycol succinate (PLA-TPGS) nanoparticles.
Topics: Adsorption; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Docetaxel; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Synergism; Endocytosis; Female; Humans; Light; Microscopy, Confocal; Microscopy, Electron, Scanning; Molecular Targeted Therapy; Nanoparticles; Nanotechnology; Polyethylene Glycols; Scattering, Radiation; Succinates; Taxoids; Technology, Pharmaceutical; Time Factors; Trastuzumab | 2011 |
Effect of ulinastatin on growth inhibition, apoptosis of breast carcinoma cells is related to a decrease in signal conduction of JNk-2 and NF-κB.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 9; NF-kappa B; Signal Transduction; Taxoids; Transplantation, Heterologous | 2012 |
Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Cycloheximide; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; MCF-7 Cells; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Protein Synthesis Inhibitors; Proteolysis; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Signal Transduction; Taxoids; Transcriptional Activation; Tumor Necrosis Factor-alpha | 2012 |
Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Pennsylvania; Peripheral Nervous System Diseases; Self Care; Taxoids; Young Adult | 2012 |
Reactions of granulocytic lineage of hemopoiesis and mechanisms of their development in combined treatment with adriablastin and taxotere.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Breast Neoplasms; Cell Proliferation; Docetaxel; Doxorubicin; Female; Granulocytes; Hematopoiesis; Humans; Neutrophils; Taxoids | 2011 |
[The role of nanotechnology in creating novel antitumor agents].
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Design; Female; Humans; Liposomes; Nanoparticles; Nanostructures; Nanotechnology; Neoplasms; Paclitaxel; Tamoxifen; Taxoids | 2011 |
[Use of Taxotere in neoadjuvant therapy of breast cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
[Use of Taxotere in adjuvant chemotherapy of breast cancer].
Topics: Anemia, Hypochromic; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Erythrocyte Transfusion; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Taxoids; Treatment Outcome | 2011 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Survival Rate; Taxoids | 2013 |
Polymeric micelles based on poly(ethylene glycol) block poly(racemic amino acids) hybrid polypeptides: conformation-facilitated drug-loading behavior and potential application as effective anticancer drug carriers.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Human Umbilical Vein Endothelial Cells; Humans; Micelles; Molecular Conformation; Particle Size; Peptides; Polyethylene Glycols; Stereoisomerism; Taxoids | 2012 |
The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy.
Topics: Actigraphy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Fatigue; Female; Fluorouracil; Humans; Longitudinal Studies; Middle Aged; Paclitaxel; Prospective Studies; Sleep; Sleep Wake Disorders; Taxoids | 2012 |
Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; China; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2011 |
Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Female; Humans; Liposomes; Polyethylene Glycols; Quantum Dots; Radiation-Sensitizing Agents; Taxoids; Vitamin E | 2012 |
Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sentinel Lymph Node Biopsy; Taxoids; Tomography, X-Ray Computed | 2013 |
Cutis verticis gyrata secondary to infiltrating ductal carcinoma breast.
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Hypertrophy; Lung Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Scalp Dermatoses; Severity of Illness Index; Skin; Taxoids | 2012 |
[A case of breast cancer with chronic renal failure successfully treated with TC therapy as adjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Creatinine; Cyclophosphamide; Docetaxel; Female; Humans; Kidney Failure, Chronic; Middle Aged; Neoplasm Staging; Sentinel Lymph Node Biopsy; Taxoids | 2012 |
[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Topics: Adult; Agranulocytosis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Leukopenia; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Remission Induction; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
[Correlation of expression of Survivin, BCRP and HER-2 genes with therapeutic response of TE regimen neoadjuvant chemotherapy in breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Inhibitor of Apoptosis Proteins; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Receptor, ErbB-2; Remission Induction; RNA, Messenger; Survivin; Taxoids | 2011 |
Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Costs and Cost Analysis; Cyclophosphamide; Databases, Factual; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome; Young Adult | 2012 |
Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Feasibility Studies; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Preoperative Care; Quality of Life; Taxoids; Treatment Outcome | 2012 |
Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Menstrual Cycle; Methotrexate; Middle Aged; Multivariate Analysis; Premenopause; Prognosis; Proportional Hazards Models; Retrospective Studies; Taxoids; Young Adult | 2012 |
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; BRCA1 Protein; Breast Neoplasms; Cisplatin; Docetaxel; Female; Gene Expression Profiling; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Randomized Controlled Trials as Topic; Taxoids | 2012 |
A study of Docetaxel-induced effects in MCF-7 cells by means of Raman microspectroscopy.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Nucleolus; Docetaxel; Female; Humans; Spectrum Analysis, Raman; Taxoids | 2012 |
[Support of hematological homeostasis during chemotherapy with taxanes].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caproates; Docetaxel; Female; Fever; Follow-Up Studies; Homeostasis; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Protective Agents; Severity of Illness Index; Stomach Neoplasms; Taxoids; Tongue Neoplasms | 2011 |
Effects of the combination of RAD001 and docetaxel on breast cancer stem cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Everolimus; Female; Humans; Immunohistochemistry; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Nude; Sirolimus; Stem Cells; Taxoids; Tetrazolium Salts; Thiazoles | 2012 |
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Genotype; Humans; Middle Aged; Neoplasm Metastasis; Pharmacogenetics; Prognosis; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
Non-genetic risk factors and predicting efficacy for docetaxel--drug-induced liver injury among metastatic breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chi-Square Distribution; Docetaxel; Female; Hepatitis B; Humans; Liver Neoplasms; Logistic Models; Middle Aged; Multivariate Analysis; Odds Ratio; Premenopause; Retrospective Studies; Risk Assessment; Risk Factors; Taxoids | 2012 |
Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vinblastine; Vinorelbine | 2012 |
Non-invasive quantification of tumor vascular architecture during docetaxel-chemotherapy.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Mammary Neoplasms, Experimental; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Rats; Regional Blood Flow; Taxoids; Treatment Outcome; Tumor Burden; Ultrasonography | 2012 |
Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Meta-Analysis as Topic; Middle Aged; Morocco; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2012 |
Predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2α expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Dexamethasone; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Glutathione S-Transferase pi; Humans; Inhibitor of Apoptosis Proteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Poly-ADP-Ribose Binding Proteins; Prognosis; Prospective Studies; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Survivin; Taxoids | 2013 |
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Taxoids; Treatment Outcome; Young Adult | 2012 |
Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2013 |
Expression of β-tubulin III and survivin in advance stage breast cancer correlates with chemotherapeutic effects of docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Inhibitor of Apoptosis Proteins; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Survivin; Taxoids; Tubulin | 2012 |
Novel hydrophilic taxane analogues inhibit growth of cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Proliferation; Docetaxel; Female; Flow Cytometry; Humans; Hydrophobic and Hydrophilic Interactions; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2012 |
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Heart Failure; Humans; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy.
Topics: Acid Phosphatase; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone and Bones; Breast Neoplasms; Calcium; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Collagen; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Isoenzymes; Middle Aged; Neoadjuvant Therapy; Osteoprotegerin; Peptide Fragments; Prevalence; RANK Ligand; Retrospective Studies; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase; Taxoids; TNF-Related Apoptosis-Inducing Ligand; Vitamin D; Vitamin D Deficiency | 2012 |
Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Ficusin; Fluorouracil; Humans; Middle Aged; Minoxidil; Prospective Studies; Spironolactone; Taxoids; Ultraviolet Therapy; Vitamins | 2012 |
Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer.
Topics: Adult; Antineoplastic Agents; Apoptosis; Base Sequence; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Docetaxel; Down-Regulation; Epigenesis, Genetic; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Logistic Models; Multivariate Analysis; Neoplasms, Ductal, Lobular, and Medullary; Promoter Regions, Genetic; Sequence Analysis, DNA; Taxoids; Tubulin Modulators; Tumor Suppressor Proteins | 2012 |
Dual HER2 blockade slows metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Survival; Docetaxel; Drug Synergism; Female; Humans; Indazoles; Mice; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Sulfonamides; Taxoids | 2012 |
Additive effects of ulinastatin and docetaxel on growth of breast cancer xenograft in nude mice and expression of PGE2, IL-10, and IL-2 in primary breast cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; Dinoprostone; Docetaxel; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Female; Glycoproteins; Humans; Interleukin-10; Interleukin-2; Mice; Mice, Nude; Neoplasm Transplantation; Receptors, Prostaglandin E, EP2 Subtype; RNA, Messenger; Taxoids; Trypsin Inhibitors; Up-Regulation | 2012 |
Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Docetaxel; Female; Gene Expression Profiling; Humans; Mevalonic Acid; Mice; Mice, SCID; Neoplasms, Basal Cell; Neoplastic Stem Cells; Taxoids | 2012 |
Novel drug delivery system based on docetaxel-loaded nanocapsules as a therapeutic strategy against breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Humans; Hydrophobic and Hydrophilic Interactions; Lipids; M Phase Cell Cycle Checkpoints; MCF-7 Cells; Nanocapsules; Taxoids | 2012 |
Case records of the Massachusetts General Hospital. Case 16-2012. A 32-year-old woman with HER2-positive breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mastectomy; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Melphalan; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Treatment Failure | 2012 |
Nitroxide pirolin reduces oxidative stress generated by doxorubicin and docetaxel in blood plasma of rats bearing mammary tumor.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Antioxidants; Breast Neoplasms; Carcinogens; Cyclic N-Oxides; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Hydrogen Peroxide; Oxidative Stress; Protein Carbonylation; Rats; Rats, Sprague-Dawley; Sulfhydryl Compounds; Superoxide Dismutase; Taxoids; Thiobarbituric Acid Reactive Substances | 2012 |
Novel hydrophilic docetaxel (CQMU-0519) analogue inhibits proliferation and induces apoptosis in human A549 lung, SKVO3 ovarian and MCF7 breast carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Caspases; Cell Line, Tumor; Colorimetry; Docetaxel; Enzyme Activation; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Taxoids | 2012 |
Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Sectional Studies; Cyclophosphamide; Denmark; Docetaxel; Epirubicin; Female; Fluorouracil; Foot; Hand; Humans; Lymph Node Excision; Mastectomy; Middle Aged; Multivariate Analysis; Neuralgia; Pain Measurement; Prevalence; Prospective Studies; Radiotherapy; Risk Factors; Sensation Disorders; Severity of Illness Index; Surveys and Questionnaires; Taxoids | 2012 |
Cutaneous metastases from breast carcinoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biopsy; Breast Neoplasms; Docetaxel; Drug Therapy, Combination; Female; Humans; Skin Neoplasms; Taxoids; Trastuzumab | 2011 |
HER2 testing in patients with breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Immunohistochemistry; Lapatinib; Maytansine; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Particle Size; Phosphatidylethanolamines; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Solubility; Taxoids | 2012 |
Safe chemotherapy and hormone therapy for treating early breast cancer in a glucose 6-phosphate dehydrogenase-deficient patient: case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Letrozole; Middle Aged; Nitriles; Taxoids; Triazoles | 2012 |
Taxus baccata allergy in a breast cancer patient.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Immunologic; Drug Hypersensitivity; Female; Humans; Taxoids; Taxus | 2012 |
Effects of docetaxel, doxorubicin and cyclophosphamide on human breast cancer cell line MCF-7.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Colorimetry; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Synergism; Female; Humans; Taxoids | 2012 |
MRI evaluation of neoadjuvant low-dose fractionated radiotherapy with concurrent chemotherapy in patients with locally advanced breast cancer.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Clinical Protocols; Combined Modality Therapy; Diffusion Magnetic Resonance Imaging; Docetaxel; Doxorubicin; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Taxoids | 2012 |
Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Taxoids; Trastuzumab | 2012 |
Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Approval; Female; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; United States; United States Food and Drug Administration | 2012 |
First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2012 |
A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Stability; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Micelles; Molecular Imaging; Nanoparticles; Spectrometry, Fluorescence; Taxoids; Tissue Distribution; Xenograft Model Antitumor Assays | 2012 |
Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies.
Topics: Adaptation, Psychological; Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dysgeusia; Feeding and Eating Disorders; Female; Flavoring Agents; Humans; Interviews as Topic; Middle Aged; Paclitaxel; Qualitative Research; Spices; Taste; Taxoids; Young Adult | 2013 |
Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model.
Topics: Adipose Tissue; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Mice; Mice, SCID; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Small Molecule Libraries; STAT3 Transcription Factor; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer.
Topics: Adult; Aged; Anthracyclines; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Clinical Trials as Topic; Dendritic Cells; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Macrophages; Middle Aged; Multivariate Analysis; T-Lymphocytes; Taxoids; Treatment Outcome; Young Adult | 2012 |
Syndrome of inappropriate anti-diuretic hormone secretion secondary to carboplatin after docetaxel-carboplatin-trastuzumab combination for early stage HER-2 positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Receptor, ErbB-2; Receptors, IgG; Survival Rate; Taxoids; Trastuzumab | 2012 |
Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxel.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Fatty Acids, Nonesterified; Female; Gene Expression; Glucose; Gonanes; Humans; Lipogenesis; Medroxyprogesterone Acetate; Phospholipids; Progestins; Receptors, Progesterone; Stearoyl-CoA Desaturase; Taxoids; Triglycerides | 2012 |
[Sensitivity to chemotherapeutic drugs of polyploid tumor cells induced by a spindle poison nocodazole].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Fluorouracil; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Nocodazole; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Polyploidy; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Taxoids; Vincristine | 2012 |
Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Cognition; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Neuropsychological Tests; Paclitaxel; Prognosis; Stress, Psychological; Taxoids | 2014 |
Optimize administration protocol of capecitabine plus docetaxel combination in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Databases as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Models, Statistical; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2012 |
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; HMGB1 Protein; Humans; Mucin-1; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor for Advanced Glycation End Products; Taxoids; Trastuzumab | 2013 |
Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Germ-Line Mutation; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Receptor, ErbB-2; Taxoids; Vascular Endothelial Growth Factor A | 2012 |
Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Dendritic Cells; DNA-Binding Proteins; Docetaxel; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; Immunomodulation; Neoplasm Metastasis; Peptides, Cyclic; Taxoids | 2012 |
Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Medullary; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymph Node Excision; Mastectomy; Middle Aged; Morocco; Neoplasm Grading; Neoplasm Staging; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Receptor, Notch1; Recurrence; Signal Transduction; Spheroids, Cellular; Taxoids; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Neovascularization, Pathologic; Receptor, ErbB-2; Severity of Illness Index; Taxoids; Transforming Growth Factor beta1 | 2012 |
Potential application value of contrast-enhanced ultrasound in neoadjuvant chemotherapy of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Contrast Media; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Ultrasonography, Doppler, Color; Ultrasonography, Mammary | 2012 |
Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxanthine Phosphoribosyltransferase; Kallikreins; Methotrexate; RNA, Messenger; Taxoids | 2013 |
Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Proportional Hazards Models; Taxoids; Treatment Outcome; Tumor Burden | 2013 |
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Protein Structure, Tertiary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Protein Array Analysis; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Taxoids | 2013 |
MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression.
Topics: Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Dual-Specificity Phosphatases; Extracellular Signal-Regulated MAP Kinases; Female; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Phosphatases; Mitogen-Activated Protein Kinases; Neoplasm Recurrence, Local; Neoplasm, Residual; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); RNA Interference; Taxoids | 2012 |
Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Protein Array Analysis; Proteomics; Taxoids | 2013 |
Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Chemical and Drug Induced Liver Injury; Docetaxel; Female; Gene Frequency; Humans; Interleukin-10; Middle Aged; Polymorphism, Single Nucleotide; Taxoids; Tumor Necrosis Factor-alpha | 2013 |
The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Marrow Cells; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Synergism; Female; Gemcitabine; Humans; Mice; Taxoids; Triterpenes; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid | 2012 |
Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cause of Death; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fever; Fluorouracil; Humans; Malaysia; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.
Topics: Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Contrast Media; Cyclophosphamide; Diastole; Docetaxel; Doxorubicin; Echocardiography; Echocardiography, Three-Dimensional; Female; Heart Ventricles; Humans; Middle Aged; Paclitaxel; Prospective Studies; Reproducibility of Results; Stroke Volume; Systole; Taxoids; Trastuzumab; Ventricular Function, Left | 2013 |
SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Chloride-Bicarbonate Antiporters; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression; Humans; Membrane Proteins; Neoadjuvant Therapy; Nerve Tissue Proteins; Oncogene Proteins; Receptor, Angiotensin, Type 1; Receptor, ErbB-2; RNA, Messenger; Sulfate Transporters; Taxoids; Transcortin; Treatment Outcome | 2013 |
Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Odds Ratio; Receptor, ErbB-2; Taxoids | 2012 |
Aberrant Keap1 methylation in breast cancer and association with clinicopathological features.
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; DNA Methylation; Docetaxel; Epirubicin; Female; Humans; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Kelch-Like ECH-Associated Protein 1; Middle Aged; Promoter Regions, Genetic; Risk Factors; Taxoids | 2013 |
Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neoplasm, Residual; Taxoids; Treatment Outcome; Young Adult | 2012 |
Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; DNA; Docetaxel; Epirubicin; Female; Follow-Up Studies; Humans; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2013 |
[A case report of liver metastasis of breast cancer successfully treated by hepatic arterial infusion of docetaxel and systemic administration of nab-paclitaxel].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2012 |
[A case of recurrent breast cancer in which gemcitabine-docetaxel therapy was successful for a long period].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Recurrence; Taxoids; Time Factors | 2012 |
[A clinical study of reasonable doses of docetaxel salvage therapy for patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Taxoids; Young Adult | 2012 |
Noninvasive identification of viable cell populations in docetaxel-treated breast tumors using ferritin-based magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Membrane; Dietary Supplements; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Ferritins; Green Fluorescent Proteins; Humans; Immunohistochemistry; Iron; Magnetic Resonance Imaging; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Taxoids | 2013 |
Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.
Topics: Animals; Antinematodal Agents; Autoantigens; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Embryo, Mammalian; Feedback, Physiological; Female; Fibroblasts; HCT116 Cells; Humans; Intracellular Signaling Peptides and Proteins; Mammary Neoplasms, Animal; MCF-7 Cells; Membrane Proteins; Mice; Mice, Knockout; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine | 2013 |
The depletion of interleukin-8 causes cell cycle arrest and increases the efficacy of docetaxel in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Integrin beta3; Interleukin-8; Middle Aged; RNA Interference; RNA, Small Interfering; Taxoids | 2013 |
Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoates; Bone Marrow; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Resistance; Female; Humans; Hydrazines; Mastectomy, Segmental; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Estrogen; Receptors, Fc; Recombinant Fusion Proteins; Remission Induction; Splenectomy; Taxoids; Thrombocytopenia; Thrombopoietin | 2013 |
Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Keratin-19; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids | 2013 |
[Clinical utility of adjuvant TC regimen].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Taxoids | 2012 |
Efficient downregulation of ErbB-2 induces TACC1 upregulation in breast cancer cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Down-Regulation; Female; Fetal Proteins; Gene Expression Regulation, Neoplastic; Humans; Microtubule-Associated Proteins; Nuclear Proteins; Receptor, ErbB-2; Taxoids; Up-Regulation | 2013 |
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Calreticulin; Carcinoembryonic Antigen; Cell Line, Tumor; Colorectal Neoplasms; Cytotoxicity, Immunologic; Dendritic Cells; Docetaxel; eIF-2 Kinase; Female; HMGB1 Protein; Humans; Immunotherapy; Male; Mucin-1; Prostate-Specific Antigen; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; T-Lymphocytes, Cytotoxic; Taxoids | 2013 |
Docetaxel improves survival and reduces risk of relapse in node-positive early-stage breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Paclitaxel; Postoperative Care; Secondary Prevention; Survival Rate; Taxoids | 2002 |
[One case of locally advanced breast cancer in which multidisciplinary treatment, chiefly, therapy with preoperative intraarterial infusion of docetaxel (TXT), was successful].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Docetaxel; Female; Floxuridine; Humans; Infusions, Intra-Arterial; Medroxyprogesterone Acetate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2002 |
In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disulfiram; Docetaxel; Drug Interactions; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epirubicin; Female; Humans; Paclitaxel; Razoxane; Taxoids; Tretinoin; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |
Docetaxel-induced nail changes--a neurogenic mechanism: a case report.
Topics: Afferent Pathways; Arm; Brachial Plexus; Breast Neoplasms; Docetaxel; Efferent Pathways; Female; Humans; Middle Aged; Motor Neurons; Nail Diseases; Neoplasm Invasiveness; Neural Conduction; Neurologic Examination; Neurons, Afferent; Paclitaxel; Paralysis; Parasympathetic Nervous System; Sensory Thresholds; Skin; Sympathetic Nervous System; Taxoids; Vibration | 2002 |
Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Squamous Cell; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Which dosing scheme is suitable for the taxanes? An in vitro model.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Cell Survival; Docetaxel; Female; Humans; Indicators and Reagents; Paclitaxel; Taxoids; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2002 |
[A case of recurrent breast cancer with chronic renal failure treated on an outpatient basis].
Topics: Ambulatory Care; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Kidney Failure, Chronic; Lung Neoplasms; Middle Aged; Paclitaxel; Radiotherapy Dosage; Renal Dialysis; Taxoids; Thoracic Neoplasms | 2002 |
[Patient with bone metastasis of breast cancer who were improved by weekly DXR/TXT therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Middle Aged; Paclitaxel; Taxoids | 2002 |
Meeting highlights 38th annual meeting of the American Society of Clinical Oncology. Advances in adjuvant chemotherapy for management of breast cancer: the emerging role of docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Medical Oncology; Middle Aged; Paclitaxel; Taxoids | 2002 |
Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: biological synergy or an artefact of trial design?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
Radiation recall dermatitis from docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Paclitaxel; Radiodermatitis; Radiotherapy, Adjuvant; Recurrence; Taxoids | 2002 |
In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Flow Cytometry; Gene Expression Regulation; Genes, erbB-2; Humans; Immunohistochemistry; Paclitaxel; Probability; Sensitivity and Specificity; Statistics, Nonparametric; Taxoids; Trastuzumab; Tumor Cells, Cultured | 2002 |
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2002 |
Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Eruptions; Erythema; Female; Foot; Hand; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Skin Diseases; Sweat Gland Diseases; Syndrome; Taxoids | 2002 |
High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Central Nervous System Neoplasms; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Taxoids | 2002 |
Advances in breast oncology: the 2002 ASCO meeting.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Docetaxel; Evidence-Based Medicine; Female; Humans; Nitriles; Paclitaxel; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids; Technology Assessment, Biomedical; Triazoles | 2002 |
Pegfilgrastim: the promise of pegylation fulfilled.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2003 |
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Microtubules; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pilot Projects; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis; tau Proteins; Taxoids; Treatment Outcome; Tubulin | 2002 |
Fatal herpes simplex virus hepatitis complicating chemotherapy with weekly docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Fatal Outcome; Female; Hepatitis, Viral, Human; Herpes Simplex; Humans; Liver Failure; Middle Aged; Paclitaxel; Taxoids | 2003 |
Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression; Genes, erbB-2; Humans; Paclitaxel; Taxoids; Transfection; Tumor Cells, Cultured | 2003 |
[A case of advanced recurrent breast cancer responding to treatment with weekly docetaxel combined with doxorubicin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Floxuridine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mastectomy, Modified Radical; Medroxyprogesterone Acetate; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids | 2003 |
Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Chemotherapy, Adjuvant; Cyclin D3; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cyclophosphamide; Docetaxel; Enzyme Inhibitors; Epirubicin; Female; Fluorouracil; Gene Expression; Genes, p53; Genes, Tumor Suppressor; Humans; Ki-67 Antigen; Methotrexate; Middle Aged; Paclitaxel; Preoperative Care; Receptors, Steroid; Taxoids; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins | 2003 |
Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Docetaxel; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Paclitaxel; Radiography; Rats; Rats, Inbred F344; Taxoids; Time Factors; Treatment Outcome | 2002 |
The use of putative placebo in active control trials: two applications in a regulatory setting.
Topics: Angina, Unstable; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as Topic; Confidence Intervals; Data Interpretation, Statistical; Docetaxel; Doxorubicin; Enoxaparin; Female; Fibrinolytic Agents; Humans; Myocardial Infarction; Odds Ratio; Paclitaxel; Placebos; Randomized Controlled Trials as Topic; Taxoids; Therapeutic Equivalency | 2003 |
Semi-synthesis of an O-glycosylated docetaxel analogue.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Chemistry; Breast Neoplasms; Cattle; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Glycosylation; Humans; In Vitro Techniques; Indicators and Reagents; Paclitaxel; Taxoids; Tubulin; Tumor Cells, Cultured | 2003 |
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
Topics: Apoptosis; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; DNA Fragmentation; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Neoplasm Transplantation; Paclitaxel; Taxoids; Time Factors; Tumor Cells, Cultured | 2003 |
Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Mitomycin; Oligonucleotides; Oligonucleotides, Antisense; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Signal Transduction; Taxoids; Time Factors | 2003 |
Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Docetaxel; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Multicenter Studies as Topic; Narcotics; Neoplasm Metastasis; Paclitaxel; Pain; Pain Measurement; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Taxoids | 2003 |
Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2003 |
Two strategies may enhance breast cancer treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Genetic Testing; Humans; Immunotherapy; Mice; Paclitaxel; Taxoids | 2003 |
Delayed seroma formation secondary to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Exudates and Transudates; Female; Humans; Mammaplasty; Middle Aged; Recurrence; Taxoids; Time Factors | 2003 |
Cholestatic jaundice and pseudomembranous colitis following combination therapy with doxorubicin and docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Enterocolitis, Pseudomembranous; Female; Humans; Jaundice, Obstructive; Middle Aged; Taxoids | 2003 |
[Regression of an uveal metastatic tumor from breast cancer during chemotherapy--a case report].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Choroid Neoplasms; Combined Modality Therapy; Diphosphonates; Docetaxel; Doxorubicin; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Paclitaxel; Pamidronate; Tamoxifen; Taxoids; Time Factors; Ultrasonography; Visual Acuity | 2003 |
Cystic maculopathy with normal capillary permeability secondary to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Permeability; Docetaxel; Fatal Outcome; Female; Fluorescein Angiography; Humans; Macular Edema; Middle Aged; Paclitaxel; Retinal Vessels; Taxoids; Visual Acuity | 2003 |
Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere).
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Conjunctivitis; Docetaxel; Female; Humans; Lacrimal Duct Obstruction; Middle Aged; Paclitaxel; Taxoids | 2003 |
NICE recommends new treatment for breast and bowel cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Practice Guidelines as Topic; Taxoids; Tegafur; Uracil | 2003 |
Successful treatment of thrombocytopenia due to marrow metastases of breast cancer with weekly docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Bone Marrow Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2003 |
Reversible life-threatening encephalopathy in the absence of hepatic failure following conventional doses of docetaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Breast Neoplasms; Docetaxel; Female; Humans; Liver Failure; Paclitaxel; Taxoids | 2003 |
Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dacryocystorhinostomy; Docetaxel; Female; Humans; Intubation; Lacrimal Apparatus; Lacrimal Duct Obstruction; Middle Aged; Nasal Mucosa; Paclitaxel; Silicone Elastomers; Taxoids | 2003 |
Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Dacryocystorhinostomy; Docetaxel; Drainage; Esophageal Neoplasms; Female; Humans; Intubation; Lacrimal Duct Obstruction; Lung Neoplasms; Male; Middle Aged; Nasolacrimal Duct; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Taxoids; Texas | 2003 |
[A case of postoperative recurrent breast cancer with multiple lung metastases that completely responded to combination therapy of docetaxel (TXT) and medroxyprogesterone acetate (MPA)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Medroxyprogesterone Acetate; Middle Aged; Paclitaxel; Postoperative Period; Remission Induction; Taxoids | 2003 |
Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diphosphonates; Docetaxel; Genes, erbB-2; Humans; Imidazoles; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Taxoids; Transfection; Zoledronic Acid | 2003 |
Predictive cancer genomics--what do we need?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Genomics; Humans; Neoadjuvant Therapy; Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Sequence Analysis, DNA; Taxoids | 2003 |
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast; Breast Neoplasms; Docetaxel; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2003 |
Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Base Sequence; Breast Neoplasms; DNA Primers; DNA, Complementary; Docetaxel; Female; Humans; Middle Aged; Models, Genetic; Molecular Sequence Data; Polymerase Chain Reaction; Postmenopause; Premenopause; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Sequence Homology, Nucleic Acid; Taxoids; Treatment Outcome; Tubulin | 2003 |
Osteonecrosis of the jaws associated with cancer chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Jaw Diseases; Middle Aged; Osteonecrosis; Paclitaxel; Taxoids | 2003 |
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
Topics: Annexin A5; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Northern; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Chromatin; Coloring Agents; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Deoxycytidine; Detergents; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Epothilones; Flow Cytometry; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Multienzyme Complexes; Phosphorylation; Precipitin Tests; Proteasome Endopeptidase Complex; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sepharose; Taxoids; Tetrazolium Salts; Thiazoles; Time Factors; Trastuzumab | 2003 |
The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Docetaxel; Female; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
[Two cases of recurrent breast cancer successfully treated with paclitaxel weekly therapy].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids | 2003 |
[So that survival chances in breast cancer are improved. Finding a "clinical trial opportunity" for your patients].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Patient Selection; Prognosis; Quality Assurance, Health Care; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2003 |
[Cryoimmunological therapy with local injection of OK-432 against advance or recurrent breast cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cryosurgery; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Injections, Intralesional; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Picibanil; Taxoids | 2003 |
Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Taxoids | 2003 |
[New: gemzar plus taxan in metastatic breast carcinoma. Optimal combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Genes, erbB-2; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Trastuzumab; Treatment Outcome | 2003 |
All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells.
Topics: Breast Neoplasms; Cell Death; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mitogen-Activated Protein Kinases; Phosphorylation; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tretinoin | 2004 |
The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Mammography; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Taxoids; Tomography, X-Ray Computed | 2004 |
[Current studies reveal significant survival advantage. Breast cancer therapy with herceptin].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Survival Rate; Taxoids; Trastuzumab | 2003 |
Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bayes Theorem; Breast Neoplasms; Docetaxel; Enzyme Inhibitors; Health Care Rationing; Health Expenditures; Humans; Influenza, Human; Middle Aged; Models, Economic; Neuraminidase; Randomized Controlled Trials as Topic; Taxoids; United Kingdom | 2004 |
Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere).
Topics: Antifungal Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cerulenin; Docetaxel; Drug Resistance, Neoplasm; Fatty Acid Synthases; Female; Genes, erbB-2; Humans; Taxoids; Transfection | 2004 |
A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Fatal Outcome; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Liver Neoplasms; Receptor, ErbB-2; Taxoids; Tomography, X-Ray Computed; Trastuzumab | 2004 |
Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer.
Topics: Androstadienes; Angiopoietin-1; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neovascularization, Pathologic; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tamoxifen; Taxoids; Triazoles; Vascular Endothelial Growth Factor A | 2004 |
Docetaxel extravasation into the normal breast during breast cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Blister; Breast; Breast Neoplasms; Docetaxel; Extravasation of Diagnostic and Therapeutic Materials; Female; Histamine H1 Antagonists; Humans; Hydrocortisone; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
Weekly taxanes--a leap forward or a minute progress?
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Evaluation of antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Cadherins; Cell Line, Tumor; Decitabine; DNA; Docetaxel; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Proteins; Serpins; Taxoids; Time Factors | 2004 |
Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Life Tables; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Prednisone; Prognosis; Receptors, Progesterone; Risk; Survival Analysis; Tamoxifen; Taxoids; Transcription Factors; Vincristine | 2004 |
Is docetaxel now an essential component of neoadjuvant breast chemotherapy?
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Endpoint Determination; Female; Humans; Neoadjuvant Therapy; Reproducibility of Results; Survival Analysis; Taxoids | 2004 |
Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression.
Topics: Antineoplastic Agents, Phytogenic; Antioxidants; Breast Neoplasms; Cell Division; Docetaxel; Drug Synergism; Drug Therapy, Combination; Female; gamma-Linolenic Acid; Humans; Lipid Peroxidation; Oxidative Stress; Receptor, ErbB-2; Taxoids; Tumor Cells, Cultured; Vitamin E | 2004 |
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine | 2004 |
[Clinical observation of electrocardiographic changes in response to taxotere combined with adriamycin treatment for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Electrocardiography; Female; Humans; Male; Middle Aged; Taxoids | 2004 |
[Retrospective analysis on efficacy and toxicity of paclitaxel-containing treatments in patients with advanced or recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab; Vomiting, Anticipatory | 2004 |
Promising combination therapies with gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Synergism; Gemcitabine; Histones; Humans; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Tumor Stem Cell Assay | 2004 |
Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Gene Amplification; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Erythema multiforme major following docetaxel.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Erythema Multiforme; Female; Humans; Hydrocortisone; Taxoids; Treatment Outcome | 2005 |
Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Prospective Studies; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Determination of fraction unbound docetaxel using microequilibrium dialysis.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dialysis; Docetaxel; Female; Humans; Taxoids | 2004 |
Limited cerebrospinal fluid penetration of docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Breast Neoplasms; Chromatography, Liquid; Docetaxel; Humans; Infusions, Intravenous; Taxoids | 2004 |
Falsely low pulse oximetry values in patients receiving docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Diagnostic Errors; Docetaxel; Female; Humans; Middle Aged; Monitoring, Intraoperative; Nails; Oximetry; Taxoids | 2004 |
Differential effects of doxorubicin and docetaxel on nitric oxide production and inducible nitric oxide synthase expression in MCF-7 human breast cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Nitric Oxide; Nitric Oxide Synthase; Taxoids; Tumor Cells, Cultured | 2004 |
Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2004 |
Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Drug Resistance, Neoplasm; Humans; Oligonucleotide Array Sequence Analysis; RNA, Messenger; Taxoids; Tumor Suppressor Proteins | 2004 |
Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Retrospective Studies; Sentinel Lymph Node Biopsy; Taxoids | 2004 |
Quality of life in women with advanced breast cancer treated with docetaxel.
Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Health Status; Humans; Interpersonal Relations; Karnofsky Performance Status; Middle Aged; Quality of Life; Surveys and Questionnaires; Taxoids | 2004 |
Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Bone Neoplasms; Breast Neoplasms; Cell Proliferation; Colony-Forming Units Assay; Disease Progression; DNA Fingerprinting; Docetaxel; Drug Resistance, Neoplasm; Female; Genetic Variation; Humans; Luciferases; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; Mice, Nude; Organ Specificity; Proto-Oncogene Proteins c-bcl-2; Taxoids; Transfection; Tumor Cells, Cultured | 2004 |
[Adjuvant chemotherapy with taxoid-containing drugs in breast cancer: soon to be expected in the Netherlands].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2004 |
Colitis in patients with breast carcinoma treated with taxane-based chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Colitis; Colonoscopy; Docetaxel; Female; Humans; Paclitaxel; Radiography; Taxoids | 2004 |
[A case of liver metastases of breast cancer successfully treated by combination chemotherapy using hepatic arterial infusion of docetaxel and systemic administration of trastuzumab].
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Mastectomy, Segmental; Taxoids; Tegafur; Trastuzumab; Uracil | 2004 |
[Chemotherapy-associated enterocolitis--a rare but potentially lethal side effect of adjuvant breast cancer treatment: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Enterocolitis, Necrotizing; Epirubicin; Fatal Outcome; Female; Humans; Intestinal Pseudo-Obstruction; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Reoperation; Taxoids; Treatment Failure | 2004 |
Advances in taxane therapy for metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bone Marrow; Breast Neoplasms; Chemistry, Pharmaceutical; Docetaxel; Drug Hypersensitivity; Heart Diseases; Humans; Nausea; Paclitaxel; Taxoids; Treatment Outcome; Vomiting; Water-Electrolyte Imbalance | 2004 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid | 2004 |
Images in clinical medicine. Beau's lines.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Nails, Malformed; Taxoids | 2004 |
Successful combination therapy with trastuzumab and Paclitaxel for adriamycin- and docetaxel-resistant inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Doxorubicin; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Paclitaxel; Pleural Effusion, Malignant; Taxoids; Trastuzumab; Treatment Outcome | 2004 |
[A case of local advanced breast cancer with multiple lung metastases successfully treated with multimodal therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Mastectomy; Middle Aged; Palliative Care; Quality of Life; Taxoids; Trastuzumab; Ulcer | 2004 |
[Enhancement of FG020326 on sensitivity of MCF-7/ADR cells to taxotere via enhancing activation of caspase-8 and caspase-3].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase 3; Caspase 8; Caspases; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Taxoids | 2004 |
Acute interstitial pneumopathy associated with docetaxel hypersensitivity.
Topics: Acute Disease; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal; Docetaxel; Dose-Response Relationship, Drug; Drug Hypersensitivity; Female; Humans; Lung Diseases, Interstitial; Taxoids | 2004 |
[Role of taxanes in treatment of breast cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Data Interpretation, Statistical; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Taxoids; Time Factors; Trastuzumab | 2004 |
Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers.
Topics: Aged; Antineoplastic Agents, Phytogenic; Aromatase; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclooxygenase 2; Docetaxel; Down-Regulation; Female; Gene Expression Regulation, Enzymologic; Humans; Interleukin-6; Membrane Proteins; Middle Aged; Neoadjuvant Therapy; Postmenopause; Prostaglandin-Endoperoxide Synthases; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Tumor Necrosis Factor-alpha | 2004 |
[Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Floxuridine; Humans; Middle Aged; Preoperative Care; Taxoids | 2004 |
HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 17; Disease Progression; Docetaxel; Female; Genes, erbB-2; Humans; Middle Aged; Monosomy; Taxoids; Time Factors; Trastuzumab | 2005 |
Stability of the HER2 gene after primary chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cyclophosphamide; DNA, Neoplasm; Docetaxel; Epirubicin; Female; Fluorouracil; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mastectomy; Middle Aged; Neoplasm Staging; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2005 |
Docetaxel-induced onycholysis.
Topics: Adult; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nail Diseases; Risk Assessment; Severity of Illness Index; Taxoids; Toes | 2004 |
Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Taxoids | 2005 |
Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Erythropoietin; Female; Humans; Incidence; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Skin Diseases; Taxoids | 2005 |
Herceptin and chemotherapy combination active in advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Receptor, ErbB-2; Taxoids; Trastuzumab | 2004 |
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Taxoids | 2005 |
Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2005 |
Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2005 |
Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Survival; Docetaxel; Extracellular Signal-Regulated MAP Kinases; Female; Fibroblast Growth Factor 2; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperidines; Taxoids; Tumor Cells, Cultured | 2005 |
[Study of three-weekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab | 2005 |
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cytoskeleton; DNA Mutational Analysis; Docetaxel; Drug Resistance, Neoplasm; Female; Genes, BRCA1; Germ-Line Mutation; Humans; Microtubules; Spindle Apparatus; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2005 |
Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Calcium Channel Blockers; Cell Line, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 7; Docetaxel; Drug Resistance, Neoplasm; Female; Genome, Human; Humans; Nucleic Acid Hybridization; Taxoids; Verapamil | 2005 |
Docetaxel-induced myositis: report of a novel side-effect.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Myositis; Taxoids | 2005 |
[Onycholysis due to docetaxel in breast cancer treatment].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Nail Diseases; Taxoids | 2005 |
A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice.
Topics: Animals; Anions; Antibodies, Monoclonal; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Synergism; Endothelial Cells; Female; Humans; Lung Neoplasms; Mice; Mice, SCID; Neovascularization, Pathologic; Phosphatidylserines; Phospholipids; Taxoids; Xenograft Model Antitumor Assays | 2005 |
Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Down-Regulation; Fatty Acids, Omega-3; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Receptor, ErbB-2; Taxoids; Tumor Cells, Cultured | 2005 |
[Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2005 |
A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study.
Topics: Age Factors; Aged; Bone Neoplasms; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Geriatric Assessment; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Risk Assessment; Skin Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
TAC--a new standard in adjuvant therapy for breast cancer?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Survival Analysis; Taxoids | 2005 |
Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Cyclophosphamide; Disease Progression; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epirubicin; Female; Fluorometry; Fluorouracil; Humans; Methotrexate; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Quality Control; Retrospective Studies; Taxoids; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Mutation; Protein Isoforms; Receptors, Estrogen; RNA, Messenger; Sequence Analysis, DNA; Taxoids; Tubulin | 2005 |
Multiple cutaneous acral metastases in a woman with breast adenocarcinoma treated with pegylated liposomal doxorubicin: incidental or aetiological association?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Fatal Outcome; Female; Fingers; Humans; Liposomes; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Skin Neoplasms; Taxoids; Toes | 2005 |
Botulinum toxin for palliative treatment of epiphora in a patient with canalicular obstruction.
Topics: Antineoplastic Agents, Phytogenic; Botulinum Toxins, Type A; Breast Neoplasms; Docetaxel; Female; Humans; Injections; Lacrimal Apparatus; Lacrimal Apparatus Diseases; Lacrimal Duct Obstruction; Middle Aged; Neuromuscular Agents; Palliative Care; Taxoids | 2005 |
The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer.
Topics: Adipocytes; Animals; Breast Neoplasms; Cell Death; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Humans; Interferon-gamma; Interleukin-6; Interleukin-8; Lactones; Mice; Mice, Nude; Neoplasm Metastasis; Sesquiterpenes; Survival Rate; Taxoids; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2005 |
Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Taxoids | 2005 |
Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Paclitaxel; RNA, Messenger; Taxoids; Time Factors; Verapamil | 2005 |
Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Docetaxel; Doxorubicin; Drug Synergism; Genistein; Humans; Lung Neoplasms; Male; Neoplasms; NF-kappa B; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids | 2005 |
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Humans; Pilot Projects; Preoperative Care; Taxoids | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Fluorouracil; Humans; Lymphatic Metastasis; Neutropenia; Sepsis; Taxoids | 2005 |
Adjuvant docetaxel for node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Neutropenia; Taxoids | 2005 |
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Topics: Acetylation; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Blotting, Western; Breast Neoplasms; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Drug Synergism; Flow Cytometry; G2 Phase; Gene Amplification; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Receptor, ErbB-2; Signal Transduction; Survivin; Taxoids; Trastuzumab; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vorinostat; X-Linked Inhibitor of Apoptosis Protein | 2005 |
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diagnostic Imaging; Docetaxel; Doxorubicin; Female; Humans; Magnetic Resonance Imaging; Mammography; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Palpation; Predictive Value of Tests; Sensitivity and Specificity; Taxoids; Ultrasonography, Mammary | 2005 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Docetaxel; Erythema; Fatal Outcome; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged; Paresthesia; Taxoids; Vitamin E | 2006 |
Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Retrospective Studies; Taxoids | 2006 |
Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Doxorubicin; Drug Carriers; Feasibility Studies; Female; Humans; Liposomes; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab | 2005 |
[Cost-effectiveness analysis of capecitabine in combination with docetaxel in comparison to docetaxel monotherapy in advanced or metastatic breast cancer in France].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Fluorouracil; France; Hospital Costs; Humans; Middle Aged; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Docetaxel; Female; Flow Cytometry; Humans; Mitosis; Nucleoproteins; Taxoids | 2005 |
Taxanes and breast cancer: shifting priorities.
Topics: Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2005 |
Early onset of oral aphthous ulcers with weekly docetaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Stomatitis, Aphthous; Taxoids | 2005 |
[Response rates following neoadjuvant chemotherapy and breast preserving treatment in patients with locally advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Docetaxel; Epirubicin; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Taxoids; Treatment Outcome | 2005 |
Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Taxoids | 2005 |
[A case of advanced breast cancer with multiple lung and liver metastases successfully treated with multi-disciplinary therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Docetaxel; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Taxoids; Trastuzumab; Treatment Outcome | 2005 |
High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer.
Topics: Antineoplastic Agents, Phytogenic; BRCA1 Protein; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Taxoids; Thioredoxins; Tumor Suppressor Protein p53 | 2005 |
[Improved quality of life in a patient with carcinomatous meningitis from invasive lobular carcinoma treated with intrathecal MTX and Ara-C in combination with systemic docetaxel].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Cerebrospinal Fluid; Cytarabine; Docetaxel; Drug Administration Schedule; Female; Humans; Injections, Spinal; Meningeal Neoplasms; Meningitis; Methotrexate; Quality of Life; Taxoids | 2005 |
Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
Topics: Administration, Oral; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Docetaxel; Europe; Female; Humans; Ibandronic Acid; Lapatinib; Quinazolines; Taxoids; Trastuzumab | 2005 |
Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Doxorubicin; Electrophoretic Mobility Shift Assay; Enzyme Activation; ErbB Receptors; Female; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; In Situ Nick-End Labeling; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Microtubule-Associated Proteins; Neoadjuvant Therapy; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Receptors, Estrogen; Risk Factors; src-Family Kinases; STAT3 Transcription Factor; Survivin; Taxoids | 2006 |
Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Breast; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Lobular; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose Fractionation, Radiation; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neutropenia; Pilot Projects; Taxoids | 2006 |
Radiation-induced angiosarcoma of the breast shows major response to docetaxel after failure of anthracycline-based chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Hemangiosarcoma; Humans; Neoplasms, Radiation-Induced; Taxoids; Treatment Outcome | 2006 |
Choroidal metastasis from breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Choroid Neoplasms; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Taxoids | 2006 |
[Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Breast Neoplasms, Male; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Lymphatic Metastasis; Male; Mastectomy, Segmental; Middle Aged; Nausea; Taxoids; Vomiting, Anticipatory | 2006 |
[A case of postoperative pulmonary metastasis of breast cancer treated with docetaxel and cyclophosphamide therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Segmental; Middle Aged; Postoperative Period; Taxoids; Tomography, X-Ray Computed | 2006 |
Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Endpoint Determination; Epirubicin; Female; Fluorouracil; Humans; Survival; Taxoids | 2005 |
Breast cancer in pregnancy: are taxanes safe?
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Child Development; Docetaxel; Female; Humans; Infant; Male; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects; Safety; Taxoids | 2006 |
Panmucositis and chemosensitisation associated with betel quid chewing during dose-dense adjuvant breast cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Areca; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Herb-Drug Interactions; Humans; Mastication; Methotrexate; Middle Aged; Mucositis; Taxoids | 2006 |
Trialists should tell participants results, but how?
Topics: Antineoplastic Agents, Phytogenic; Bioethics; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Communication; Docetaxel; Female; Humans; Taxoids; Treatment Outcome | 2006 |
Docetaxel administered during pregnancy for inflammatory breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fetal Development; Fluorouracil; Humans; Inflammation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Taxoids | 2006 |
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2006 |
[Advances in the treatment of breast carcinoma. New therapy schedules with astonishing success quotas].
Topics: Age Factors; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Female; Humans; Mammography; Meta-Analysis as Topic; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Risk; Tamoxifen; Taxoids; Time Factors; Trastuzumab; Triazoles | 2006 |
Determination of docetaxel and Paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Chromatography, High Pressure Liquid; Docetaxel; Drug Stability; Female; Half-Life; Humans; Paclitaxel; Quality Control; Reproducibility of Results; Spectrophotometry, Ultraviolet; Taxoids; Temperature | 2006 |
Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Erythema; Female; Foot; Hand; Humans; Syndrome; Taxoids | 2006 |
[Inhibitory effect of antisense oligodeoxynucleotides targeting HER-2 mRNA on growth of breast cancer: experiment in vivo with mice].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Oligodeoxyribonucleotides, Antisense; Receptor, ErbB-2; RNA, Messenger; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2006 |
Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dihydrouracil Dehydrogenase (NAD+); Docetaxel; Drug Combinations; Drug Synergism; Female; Humans; Mice; Mice, SCID; Oxonic Acid; Taxoids; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2006 |
Clinical experience with docetaxel for Chinese breast cancer patients: hematological toxicity profiles.
Topics: Adult; Aged; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; China; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Immunohistochemistry; Incidence; Mastectomy, Segmental; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids | 2006 |
Taxane-containing chemotherapy in the treatment of early breast cancer patients.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2006 |
[Breast cancer. Coverage from the 28th San Antonio Breast Cancer Symposium].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Mastectomy, Segmental; Radiotherapy, Adjuvant; Taxoids; Texas; Trastuzumab | 2006 |
Docetaxel-induced nasal septal perforation.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Nasal Septum; Nose Diseases; Ovarian Neoplasms; Rupture, Spontaneous; Taxoids | 2006 |
A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229).
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Vaccines; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Poxviridae; Randomized Controlled Trials as Topic; Research Design; Taxoids | 2006 |
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Docetaxel; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Signal Transduction; Survivin; Taxoids | 2006 |
Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Incidence; Lacrimal Apparatus Diseases; Lacrimal Duct Obstruction; Middle Aged; Prospective Studies; Severity of Illness Index; Taxoids | 2006 |
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alleles; Antineoplastic Agents; Breast Neoplasms; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Garlic; Genotype; Humans; Injections, Intravenous; Middle Aged; Predictive Value of Tests; Prospective Studies; Taxoids; Time Factors; Treatment Outcome | 2006 |
Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Docetaxel; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2006 |
[Biweekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Prognosis; Receptor, ErbB-2; Remission Induction; Survival Rate; Taxoids; Trastuzumab | 2006 |
The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone.
Topics: Adult; Aged; Ambulatory Care; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Ciprofloxacin; Clinical Trials, Phase II as Topic; Docetaxel; Doxorubicin; Feasibility Studies; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Japan; Middle Aged; Neoadjuvant Therapy; Neutropenia; Recombinant Proteins; Retrospective Studies; Risk Assessment; Taxoids; Telephone; Treatment Outcome | 2007 |
MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo.
Topics: Antineoplastic Agents; Benzamides; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Enzyme Inhibitors; Female; Humans; Kinetics; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Taxoids | 2006 |
NICE approves docetaxel for early breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Taxoids | 2006 |
[Examination of the safety of docetaxel/cyclophosphamide combination therapy for advanced recurrent breast cancer].
Topics: Adult; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Skin Neoplasms; Stomatitis; Taxoids | 2006 |
Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Remission Induction; Retrospective Studies; Taxoids; Treatment Outcome | 2006 |
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Topics: Aged; Aging; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2006 |
Trastuzumab/docetaxel-induced nail dystrophy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Fatal Outcome; Female; Humans; Middle Aged; Nail Diseases; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2006 |
Antitumor activity of edotecarin in breast carcinoma models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbazoles; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Indoles; Inhibitory Concentration 50; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Rats; Rats, Sprague-Dawley; Taxoids; Topoisomerase I Inhibitors | 2007 |
[Breast carcinoma and bone chondrosarcoma: a new syndrome?].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Chondrosarcoma; Combined Modality Therapy; Cyclophosphamide; Diagnosis, Differential; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Mammography; Middle Aged; Phenotype; Radiography, Thoracic; Radiotherapy Dosage; Ribs; Syndrome; Taxoids; Tomography, X-Ray Computed | 2006 |
Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Cell Cycle; Cell Proliferation; Diploidy; Docetaxel; Dose-Response Relationship, Drug; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mitosis; Taxoids; Tumor Cells, Cultured | 2007 |
[Efficacy and toxicity of combination treatment with epirubicin (EPI) plus docetaxel (DOC) in advanced breast cancer].
Topics: Adult; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Taxoids | 2006 |
Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Keratin-18; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2006 |
Chemotherapy influences inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) activity on 3D breast cancer cell line.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Doxorubicin; Humans; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Spheroids, Cellular; Taxoids | 2006 |
Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Taxoids | 2007 |
[HER-2 and ER expression in prediction of chemo-sensitivity of taxane for advanced breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Immunohistochemistry; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Remission Induction; Retrospective Studies; Taxoids | 2006 |
[Docetaxel combined with cisplatin in the treatment of anthracycline-resistant advanced breast cancer].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Neutropenia; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2006 |
[Docetaxel-induced acute pulmonary capillary-leak syndrome mimicking cardiogenic oedema].
Topics: Acute Disease; Anticoagulants; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Leak Syndrome; Diagnosis, Differential; Docetaxel; Dose-Response Relationship, Drug; Edema, Cardiac; Female; Heparin, Low-Molecular-Weight; Humans; Lung Neoplasms; Methylprednisolone; Middle Aged; Pulmonary Edema; Pulmonary Embolism; Recurrence; Respiration, Artificial; Spinal Neoplasms; Taxoids; Tinzaparin | 2007 |
[Two cases of radiofrequency ablation (RFA) therapy for control of liver metastases from breast cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Catheter Ablation; Docetaxel; Fatal Outcome; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymphatic Metastasis; Mastectomy; Middle Aged; Paclitaxel; Taxoids; Trastuzumab | 2006 |
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Pleural Effusion, Malignant; Pleural Neoplasms; Quality of Life; Remission Induction; Taxoids; Toremifene | 2007 |
[A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Inflammation; Mammography; Middle Aged; Remission Induction; Taxoids; Tomography, X-Ray Computed; Ultrasonography, Mammary | 2007 |
MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms.
Topics: Algorithms; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Mice; Mice, SCID; Taxoids; Water | 2007 |
Role of intercellular communications in breast cancer multicellular tumor spheroids after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Communication; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Connexin 43; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; Membrane Proteins; Microscopy, Electron, Scanning Transmission; Models, Biological; Occludin; Sensitivity and Specificity; Spheroids, Cellular; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 2006 |
Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2007 |
Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle Proteins; Cyclophosphamide; Docetaxel; Epirubicin; Female; Geminin; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Protein Serine-Threonine Kinases; RNA, Messenger; Taxoids; Treatment Outcome; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases | 2007 |
HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.
Topics: Adult; Aged; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Epirubicin; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Taxoids; Tumor Suppressor Protein p53 | 2007 |
Docetaxel-induced onycholysis: the role of subungual hemorrhage and suppuration.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Hemorrhage; Humans; Male; Middle Aged; Nail Diseases; Stomach Neoplasms; Suppuration; Taxoids | 2007 |
Adjuvant docetaxel-based treatment for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Radiation-Sensitizing Agents; Taxoids | 2007 |
[The efficacy and safety of docetaxel for elderly advanced breast cancer patients].
Topics: Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Edema; Female; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Remission Induction; Taxoids | 2007 |
[Assessment of neoadjuvant chemotherapy in breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Logistic Models; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Taxoids; Vinblastine; Vinorelbine | 2006 |
The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Genes, erbB-2; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids | 2007 |
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Germ-Line Mutation; Humans; Middle Aged; Neoadjuvant Therapy; Patient Selection; Poland; Registries; Taxoids; Treatment Outcome; Tubulin Modulators | 2008 |
Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Keratin-18; Models, Genetic; Necrosis; Neoplasm Metastasis; Reproducibility of Results; Taxoids; Time Factors; Treatment Outcome | 2007 |
[Surgery for advanced breast cancer from the viewpoint of medical oncologist].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Taxoids | 2007 |
A new model of patient tumor-derived breast cancer xenografts for preclinical assays.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cyclophosphamide; Disease Models, Animal; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Nucleic Acid Hybridization; Oligopeptides; Taxoids; Trastuzumab | 2007 |
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Predictive Value of Tests; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Thymidine Phosphorylase | 2007 |
Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Docetaxel; Enzyme-Linked Immunosorbent Assay; Glycerylphosphorylcholine; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Mice, SCID; Phosphorus Isotopes; Phosphorylcholine; Taxoids; Transplantation, Heterologous | 2007 |
Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Cell Proliferation; Docetaxel; Doxorubicin; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Ki-67 Antigen; Models, Biological; Paclitaxel; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Spheroids, Cellular; Tamoxifen; Taxoids; Tissue Distribution; Tumor Burden; Tumor Cells, Cultured | 2007 |
Trastuzumab use for metastatic breast cancer in pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachial Plexus Neuropathies; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Infant, Newborn; Lung Neoplasms; Neoplasm Staging; Oligohydramnios; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Taxoids; Trastuzumab | 2007 |
Neoadjuvant combination for stage II-III breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Humans; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Trastuzumab | 2007 |
A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
Topics: Adenoviridae; Animals; Antigens, CD; Antigens, Differentiation; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Combined Modality Therapy; CTLA-4 Antigen; Cyclophosphamide; Dendritic Cells; Deoxycytidine; Docetaxel; Doxorubicin; Female; Flow Cytometry; Galactosylceramides; Gemcitabine; Genetic Vectors; Glucocorticoid-Induced TNFR-Related Protein; Humans; Immunization; Immunotherapy; Mice; Myeloid Cells; Peptide Fragments; Receptor, ErbB-2; Receptors, Nerve Growth Factor; Receptors, Tumor Necrosis Factor; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Taxoids; Transfection; Vaccines, DNA | 2007 |
Sclerodermiform aspect of arm lymphoedema after treatment with docetaxel for breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Arm; Breast Neoplasms; Docetaxel; Female; Humans; Lymphedema; Middle Aged; Scleroderma, Localized; Taxoids | 2007 |
Toxic effects differ in combination treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 2007 |
[Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neutropenia; Paclitaxel; Postoperative Period; Retrospective Studies; Taxoids | 2007 |
Docetaxel weekly with metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2007 |
Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphatic Metastasis; Middle Aged; Nausea; Neoplasm Metastasis; Retrospective Studies; Taxoids; Treatment Outcome; Vomiting | 2007 |
Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Prognosis; Reproducibility of Results; Taxoids; Treatment Outcome | 2007 |
Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation.
Topics: Adenocarcinoma; Alkanes; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carbamates; Cell Line, Tumor; Cell Survival; Dimerization; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Fluorescent Antibody Technique, Indirect; Glutamic Acid; Glycine; Humans; Lactones; Models, Molecular; Mutation, Missense; Paclitaxel; Protein Structure, Quaternary; Pyrones; Taxoids; Transfection; Tubulin; Tubulin Modulators | 2007 |
Docetaxel plus cyclophosphamide in adjuvant breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Receptor, ErbB-2; Risk; Taxoids | 2007 |
Acute lung injury associated with docetaxel and bevacizumab.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Humans; Lung Diseases, Interstitial; Neoplasm Metastasis; Respiratory Distress Syndrome; Taxoids; Tomography, X-Ray Computed | 2007 |
Potentiation of the anti-tumour effect of docetaxel by conjugated linoleic acids (CLAs) in breast cancer cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Linoleic Acids, Conjugated; Pilot Projects; Stereoisomerism; Taxoids | 2007 |
Evaluation of therapeutic efficacy of capecitabine on human breast carcinoma tissues and cell lines in vitro.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Female; Flow Cytometry; Fluorouracil; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Luminescence; Taxoids; Tetrazolium Salts | 2007 |
Retroviral integration site analysis and the fate of transduced clones in an MDR1 gene therapy protocol targeting metastatic breast cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cells; Humans; Neoplasm Metastasis; Retroviridae; Taxoids; Virus Integration | 2007 |
Enhancement of the solubility and efficacy of poorly water-soluble drugs by hydrophobically-modified polysaccharide derivatives.
Topics: Animals; Antineoplastic Agents, Phytogenic; Benzophenones; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Docetaxel; Dose-Response Relationship, Drug; Drug Compounding; Ethanol; Female; Glucans; Humans; Hydrophobic and Hydrophilic Interactions; Macrophages; Mice; Nanostructures; Pharmaceutical Vehicles; Photosensitizing Agents; Polysorbates; Solubility; Solvents; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Surface Tension; Taxoids; Water | 2007 |
Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Health Care Costs; Humans; Quality-Adjusted Life Years; Taxoids | 2008 |
Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Nucleus; Cell Proliferation; Combined Modality Therapy; Docetaxel; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Mastectomy; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids | 2008 |
Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2007 |
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Staging; Phenotype; Prognosis; Taxoids | 2007 |
Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Retrospective Studies; Taxoids | 2007 |
MDRView: a visualization of the polymorphisms of MDR1(ABCB1) GENE in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Polymorphism, Single Nucleotide; Software; Taxoids | 2007 |
Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; British Columbia; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
[Poor outcome neutropenic enterocolitis after treatment with docetaxel in a breast cancer patient].
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Enterocolitis, Neutropenic; Female; Humans; Taxoids; Treatment Outcome | 2007 |
Translation, please.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Patient Selection; Predictive Value of Tests; Receptors, Estrogen; Reproducibility of Results; Research Design; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2007 |
Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Female; Fibronectins; Genetic Vectors; Humans; Inhibitor of Apoptosis Proteins; MAP Kinase Kinase Kinase 5; Metabolic Networks and Pathways; Microtubule-Associated Proteins; Neoplasm Proteins; Oligonucleotides; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Survivin; Taxoids | 2008 |
Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Fibronectins; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Taxoids; Transfection; Tumor Cells, Cultured | 2008 |
Primary chemotherapy with sequential docetaxel followed by docetaxel and epirubicin in large operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Taxoids | 2007 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2008 |
Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Time Factors | 2009 |
Taxane analogues against breast cancer: a quantitative structure-activity relationship study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Quantitative Structure-Activity Relationship; Taxoids; Thermodynamics | 2008 |
Flagellate erythema induced by docetaxel.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Eruptions; Erythema; Female; Humans; Middle Aged; Taxoids; Treatment Outcome | 2008 |
CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance.
Topics: Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cytochrome P-450 CYP1B1; Docetaxel; Drug Resistance; Enzyme Induction; Gene Expression; Humans; Organ Specificity; RNA, Small Interfering; Taxoids | 2008 |
Measuring the cost of chemotherapy is important, but it is not enough.
Topics: Antineoplastic Agents; Breast Neoplasms; Complementary Therapies; Cost of Illness; Cost-Benefit Analysis; Docetaxel; Drug Costs; Humans; Neutropenia; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Analysis; Taxoids; Therapies, Investigational | 2008 |
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Genes, erbB-2; Humans; Liver Neoplasms; Middle Aged; Remission Induction; Taxoids; Trastuzumab | 2008 |
[Prediction of response to docetaxel in breast cancer].
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Pharmacological; Breast Neoplasms; Docetaxel; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Prognosis; Taxoids | 2008 |
Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Monitoring; Estrogens; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Progesterone; Prognosis; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel.
Topics: Adult; Amenorrhea; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Incidence; Middle Aged; Retrospective Studies; Taxoids | 2008 |
Dramatic response of acute monoblastic leukemia to a single dose of docetaxel.
Topics: Bone Marrow Examination; Breast Neoplasms; Docetaxel; Female; Humans; Leukemia, Monocytic, Acute; Middle Aged; Neoplasms, Second Primary; Remission Induction; Taxoids | 2008 |
Modeling resistance index of taxoids to MCF-7 cell lines using ANN together with electrotopological state descriptors.
Topics: Algorithms; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Female; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Neural Networks, Computer; Paclitaxel; Predictive Value of Tests; Principal Component Analysis; Quantitative Structure-Activity Relationship; Reproducibility of Results; Software; Taxoids | 2008 |
Anticancer therapy in patients with porphyrias: evidence today.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Epoetin Alfa; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Letrozole; Middle Aged; Nitriles; Porphyria, Acute Intermittent; Porphyria, Variegate; Recombinant Proteins; Risk Assessment; Taxoids; Triazoles; Uterine Neoplasms | 2008 |
Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Japan; Mastectomy; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2008 |
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Genotype; Humans; Middle Aged; Paclitaxel; Polymorphism, Genetic; Receptor, ErbB-2; Receptors, IgG; Signal Transduction; Taxoids; Trastuzumab; Treatment Outcome | 2008 |
[An advanced metastatic breast cancer patient successfully treated with combination therapy including docetaxel, doxorubicin and cyclophosphamide (TAC) as salvage therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Salvage Therapy; Taxoids; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[A case of triple negative recurrent breast cancer successfully treated with capecitabine+docetaxel combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Recurrence; Taxoids; Time Factors; Tomography, X-Ray Computed | 2008 |
[The clinical study on neoadjuvant chemotherapy with combination of docetaxel and pharmorubicin for locally advanced breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome | 2008 |
[Transcatheter treatment of liver metastases from breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Angiography; Antineoplastic Agents; Breast Neoplasms; Chemoembolization, Therapeutic; Docetaxel; Doxorubicin; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Korea; Middle Aged; Taxoids; Treatment Outcome | 2009 |
European oncologists' preferences for the management of breast cancer: case presentations and expert commentary.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Genes, erbB-2; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Tamoxifen; Taxoids; Trastuzumab | 2008 |
Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Markov Chains; Medical Oncology; Monte Carlo Method; Quality-Adjusted Life Years; Recurrence; Taxoids; Treatment Outcome | 2009 |
Re: Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Lymphatic Metastasis; Taxoids | 2008 |
Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells.
Topics: Antineoplastic Agents; Aurora Kinase A; Aurora Kinases; Breast Neoplasms; Cell Adhesion; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Humans; Protein Serine-Threonine Kinases; RNA, Small Interfering; Taxoids; Tumor Cells, Cultured | 2008 |
[Collagen gel droplet-embedded culture drug sensitivity test in human breast cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Collagen; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gels; Humans; Male; Paclitaxel; Taxoids | 2008 |
[Effect of neoadjuvant chemotherapy on ERCC1 gene expression in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; DNA-Binding Proteins; Docetaxel; Endonucleases; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2008 |
Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids | 2009 |
Paclitaxel in doxorubicin-resistant metastatic breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
An overview of phase II studies of docetaxel in patients with metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
Taxoids.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cisplatin; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; Lethal Dose 50; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Tumor Cells, Cultured | 1995 |
Effects of the microtubule-disturbing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Kinetics; Neoplasm Proteins; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vinblastine; Vincristine | 1994 |
Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Docetaxel; Drug Resistance; Drug Screening Assays, Antitumor; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1994 |
Taxotere shows significant antitumor activity in anthracycline-resistant breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance; Female; Humans; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
Docetaxel: current status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Taxoids | 1995 |
Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro.
Topics: Adenocarcinoma; Aminopterin; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Synergism; Humans; Paclitaxel; Prospective Studies; Taxoids; Tumor Cells, Cultured | 1996 |
Taxoids: new weapons against cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Microtubules; Molecular Structure; Neoplasms; Ovarian Neoplasms; Paclitaxel; Phytotherapy; Taxoids; Trees | 1996 |
Response to dexamethasone in patients with fluid retention after docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Edema; Female; Glucocorticoids; Humans; Paclitaxel; Taxoids | 1996 |
Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Docetaxel; Drug Carriers; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel and gemcitabine released for cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Approval; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids; United States; United States Food and Drug Administration | 1996 |
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Melanoma, Experimental; Mice; Mice, Nude; Molecular Structure; Ovarian Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 1996 |
Management of advanced breast cancer: patient needs, challenges and new treatment options. Introduction.
Topics: Aging; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Research; Taxoids | 1996 |
Conclusion: the place of docetaxel (Taxotere) in future therapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
Synthesis and structure-activity relationships of nonaromatic taxoids: effects of alkyl and alkenyl ester groups on cytotoxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Esters; Female; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Ovarian Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 1997 |
Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Ascites; Breast Neoplasms; Docetaxel; Edema; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pleural Effusion; Taxoids; Treatment Failure; Treatment Outcome | 1997 |
Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions.
Topics: Administration, Oral; Anti-Asthmatic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cromolyn Sodium; Docetaxel; Drug Hypersensitivity; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1996 |
[Docetaxel in lymphangiosis carcinomatosa].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids; Tomography, X-Ray Computed | 1997 |
Docetaxel-induced subungual hemorrhage.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Breast Neoplasms, Male; Docetaxel; Female; Hemorrhage; Humans; Male; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 1997 |
Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Female; Humans; Leukemia; Mitosis; Paclitaxel; Structure-Activity Relationship; Taxoids; Triterpenes; Tumor Cells, Cultured | 1997 |
Ataxia following docetaxel infusion.
Topics: Antineoplastic Agents, Phytogenic; Ataxia; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1997 |
Introduction: taxoids and the management of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1997 |
[Docetaxel symposium].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1997 |
Docetaxel: today's results and tomorrow's promises.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
Docetaxel chemotherapy induces transverse superficial loss of the nail plate.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Nail Diseases; Paclitaxel; Taxoids | 1997 |
Another taxane takes center stage in San Antonio.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Estrogen Antagonists; Female; Genes, BRCA1; Humans; Mutation; Paclitaxel; Taxoids | 1998 |
[Breast cancer with liver metastasis responsive to docetaxel: case report].
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1998 |
Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Paclitaxel; Receptor, ErbB-2; Taxoids; Tumor Cells, Cultured | 1998 |
Lack of CNS penetration of docetaxel in a patient with leptomeningeal carcinomatosis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Arachnoid; Blood-Brain Barrier; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Meningeal Neoplasms; Paclitaxel; Taxoids | 1998 |
[Taxoids in ovarian and breast carcinoma: the role of the medical profession and the government].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Costs; Drug Utilization; Female; Guidelines as Topic; Humans; Paclitaxel; Physician's Role; Policy Making; Public Policy; Taxoids | 1998 |
[Provision of taxoids in 1996: inequality of care].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Budgets; Clinical Trials as Topic; Docetaxel; Drug Costs; Drug Utilization; Female; Health Care Rationing; Hospitals; Humans; Netherlands; Ovarian Neoplasms; Paclitaxel; Population Surveillance; Surveys and Questionnaires; Taxoids | 1998 |
In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Breast Neoplasms; Cisplatin; Cyclodextrins; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1998 |
Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Paclitaxel; Pancreatic Neoplasms; Polymerase Chain Reaction; RNA, Messenger; tau Proteins; Taxoids; Tubulin | 1998 |
[Yellow nails].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Eruptions; Female; Hand Dermatoses; Humans; Middle Aged; Nail Diseases; Paclitaxel; Pigmentation Disorders; Taxoids | 1998 |
Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Microtubules; Middle Aged; Mitosis; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Tubulin | 1998 |
Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 1998 |
Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Interactions; Epirubicin; Female; Humans; Mice; Paclitaxel; Taxoids | 1998 |
Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Neoplasms; Paclitaxel; Taxoids | 1998 |
Is there a place for "dose-dense" weekly schedules of the taxoids?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Humans; Paclitaxel; Palliative Care; Taxoids | 1998 |
Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Costs and Cost Analysis; Disease Progression; Docetaxel; Female; Humans; Markov Chains; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Taxoids; Western World | 1998 |
Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids | 1999 |
Paclitaxel and docetaxel. Innovation, but at what cost?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Costs and Cost Analysis; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1995 |
Cost utility in second-line metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
Topics: Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1996 |
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Division; Cetuximab; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Flow Cytometry; Humans; Oligonucleotides; Oligonucleotides, Antisense; Oligoribonucleotides, Antisense; Paclitaxel; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Nail changes secondary to docetaxel (Taxotere).
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 1999 |
[Low-dose weekly administration of docetaxel for metastatic breast cancer].
Topics: Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
The role of taxanes in the management of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Evidence-Based Medicine; Humans; Medical Oncology; Paclitaxel; Taxoids | 1999 |
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
Telomerase enzyme activity and RNA expression in adriamycin-resistant human breast carcinoma MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Carcinoma; Cell Count; Cell Division; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis, Agar Gel; Female; Fluorouracil; Gene Expression; Humans; Paclitaxel; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Taxoids; Telomerase; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |
Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Diphosphonates; Docetaxel; Drug Synergism; Humans; Ibandronic Acid; Neoplasm Invasiveness; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
[Multi-drug resistant breast cancer responding to chemotherapy with docetaxel (taxotere: TXT)].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Quality of Life; Taxoids | 1999 |
[A breast cancer patient with docetaxel-resistant pleural recurrence with remarkable response to doxifluridine and cyclophosphamide].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cranial Irradiation; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pleural Neoplasms; Quality of Life; Taxoids | 1999 |
[Pharmacological study of weekly docetaxel in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1999 |
[Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report].
Topics: Aged; Alendronate; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1999 |
[A case of recurrent breast cancer successfully treated with docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 1999 |
Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Health Care Costs; Humans; Middle Aged; Paclitaxel; Quality-Adjusted Life Years; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
Taxane-induced glaucoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Fatal Outcome; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Paclitaxel; Recurrence; Taxoids | 1999 |
[A case report: effective trans-arterial neoadjuvant chemotherapy with docetaxel for a local advanced breast cancer patient].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Infusions, Intra-Arterial; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids | 1999 |
[A case of multiple liver metastases from breast cancer successfully treated with intra-arterial administration of docetaxel].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymph Node Excision; Middle Aged; Paclitaxel; Taxoids | 1999 |
[A case of hepatic arterial infusion chemotherapy with docetaxel for liver metastasis from breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 1999 |
Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Breast Neoplasms; Chromatography, High Pressure Liquid; Docetaxel; Drug Synergism; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
[Administration of docetaxel in cases of recurrent breast carcinoma with malignant pleural effusion controlled by intrapleural administration of OK-432].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Picibanil; Pleura; Pleural Effusion, Malignant; Taxoids | 1999 |
Taxing the taxanes: overused or undersold?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Synergism; Estramustine; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel and epirubicin plus G-CSF mobilize hematopoietic progenitors in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Paclitaxel; Taxoids | 1999 |
A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cells, Cultured; Culture Media, Serum-Free; Cyclophosphamide; Dendritic Cells; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-4; Leukapheresis; Leukocyte Count; Lymphocyte Culture Test, Mixed; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neutropenia; Paclitaxel; Taxoids | 1999 |
[A trial for neoadjuvant chemotherapy of transarterial infusion of docetaxel in locally advanced breast cancer].
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intra-Arterial; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2000 |
Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema.
Topics: Anthropometry; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Permeability; Carcinoma; Docetaxel; Double-Blind Method; Edema; Electronics, Medical; Female; Flavonoids; Humans; Leg; Lymphedema; Mastectomy; Optics and Photonics; Ovarian Neoplasms; Paclitaxel; Placebos; Randomized Controlled Trials as Topic; Taxoids; Venous Insufficiency; Weight Loss | 2000 |
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Palliative Care; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
Complete regression of choroidal metastases from breast cancer after docetaxel-based systemic chemotherapy.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Choroid Neoplasms; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Paclitaxel; Recombinant Proteins; Skin Neoplasms; Taxoids; Treatment Outcome | 2000 |
Can HER2 status predict response to cancer therapy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Taxoids; Trastuzumab | 2000 |
Cutaneous fibrosis induced by docetaxel: a case report.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Eruptions; Female; Fibrosis; Humans; Paclitaxel; Skin; Taxoids | 2000 |
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carboplatin; Cell Division; Cell Line; Cell Line, Transformed; Cell Survival; Cisplatin; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Doxorubicin; Epithelial Cells; Etoposide; Female; Genes, erbB-2; Humans; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Receptor, ErbB-2; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Injections, Intraperitoneal; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Weight Loss | 2000 |
Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prednisolone; Radiopharmaceuticals; Sensitivity and Specificity; Taxoids; Tomography, Emission-Computed; Vincristine | 2000 |
[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Humans; Injections, Intra-Arterial; Leucovorin; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Taxoids | 2000 |
Taxane-based therapy for breast cancer: combination or sequential therapy?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Paclitaxel; Taxoids | 2000 |
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Docetaxel; Enterocolitis; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Taxoids; Tomography, X-Ray Computed | 2000 |
Colitis and docetaxel-based chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colitis; Diarrhea; Docetaxel; Estramustine; Female; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2000 |
[A case of advanced breast cancer associated with humoral hypercalcemia that responded to medroxyprogesterone acetate and docetaxel].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Hypercalcemia; Lymph Nodes; Lymphatic Metastasis; Medroxyprogesterone Acetate; Neoplasm Invasiveness; Paclitaxel; Taxoids | 2000 |
[A case of head metastases of breast cancer successfully treated with radiation therapy and docetaxel].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Mastectomy, Radical; Meningeal Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Skin Neoplasms; Skull Neoplasms; Taxoids | 2000 |
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antigens, Nuclear; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Docetaxel; Female; Fluorouracil; Humans; Immunohistochemistry; Ki-67 Antigen; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Paraffin Embedding; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Randomized Controlled Trials as Topic; Taxoids; Tumor Suppressor Protein p53 | 2000 |
Mesenteric venous thrombosis attributed to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Mesenteric Vascular Occlusion; Mesenteric Veins; Middle Aged; Osteolysis; Paclitaxel; Sternum; Taxoids; Venous Thrombosis | 2000 |
[Effective chemotherapy with docetaxel in a patient with breast cancer who had progressed after high-dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT)].
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Taxoids | 2000 |
In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; DNA Fragmentation; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Interactions; Female; Humans; Mitosis; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Taxoids; Tumor Cells, Cultured | 2000 |
Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Radiodermatitis; Recurrence; Taxoids | 2000 |
[A case of effective chemotherapy using CAF followed by docetaxel for advanced breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2000 |
Docetaxel effectively mobilizes peripheral blood CD34+ cells.
Topics: Adult; Antigens, CD34; Antineoplastic Agents, Phytogenic; Blood Component Removal; Breast Neoplasms; Cell Count; Docetaxel; Drug Evaluation; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged; Paclitaxel; Prospective Studies; Taxoids; Time Factors | 2000 |
Docetaxel in the management of breast and non-small-cell lung cancers. ASCO 2000, 22nd annual San Antonio Breast Cancer Symposium, and ECCO 10. Abstracts.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2000 |
Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Paclitaxel; Remission Induction; Salvage Therapy; Taxoids | 2000 |
[Antitumor activity of UFT and docetaxel on human breast carcinoma xenografts].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Paclitaxel; Succinate Dehydrogenase; Taxoids; Tegafur; Transplantation, Heterologous; Uracil; Xenograft Model Antitumor Assays | 2000 |
Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Dexamethasone; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids | 2000 |
[A case of locally advanced breast cancer successfully resected after selective intra-arterial chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Paclitaxel; Taxoids | 2000 |
Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support.
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lymphatic Metastasis; Paclitaxel; Pulmonary Edema; Radiography; Taxoids | 2000 |
Mobilization of hematopoietic progenitor cells with a combination of docetaxel, adriamycin, 5-fluorouracil and filgrastim in breast cancer patients.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Paclitaxel; Recombinant Proteins; Taxoids | 2001 |
Changes in findings of mammography, ultrasonography and contrast-enhanced computed tomography of three histological complete responders with primary breast cancer before and after neoadjuvant chemotherapy: case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Mammography; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Postmenopause; Taxoids; Tomography, X-Ray Computed; Ultrasonography, Mammary | 2000 |
Severe syndrome of inappropriate antidiuretic hormone secretion with docetaxel treatment in metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Inappropriate ADH Syndrome; Paclitaxel; Taxoids | 2000 |
Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Child; Child, Preschool; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2001 |
Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Mammography; Middle Aged; Paclitaxel; Reproducibility of Results; Taxoids; Tomography, Emission-Computed | 2001 |
[Two cases of advanced and metastatic breast cancers treated by docetaxel in combination with intra-arterial infusion of adriamycin].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
[A case of breast cancer 5 cm in diameter treated with a breast preserving approach after preoperative intra-arterial chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Injections, Intra-Arterial; Middle Aged; Paclitaxel; Taxoids | 2001 |
[A case of recurrent breast cancer successfully treated with docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Clinical picture: nail changes secondary to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 2001 |
Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Models, Animal; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Paclitaxel; Taxoids; Thymidine Phosphorylase; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2001 |
[A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
Topics: Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2001 |
[Fulminant hepatocellular necrosis following administration of docetaxel].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Liver Failure; Middle Aged; Necrosis; Paclitaxel; Taxoids | 2001 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine | 1995 |
Hypertrophic osteoarthropathy associated with docetaxel treatment.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Diagnosis, Differential; Docetaxel; Female; Humans; Lung Neoplasms; Mastectomy; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Paclitaxel; Taxoids | 2001 |
[Efficacy of docetaxel for anthracycline-resistant metastatic breast cancer].
Topics: Alopecia; Anthracyclines; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2001 |
Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Chi-Square Distribution; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Middle Aged; Neoplasm Proteins; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; RNA, Neoplasm; Taxoids; Transcription Factors | 2001 |
Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Breast Neoplasms; Cell Survival; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Flow Cytometry; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Immunohistochemistry; Immunomagnetic Separation; Keratins; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Risk Factors; Stem Cells; Taxoids; Time Factors; Tumor Cells, Cultured | 2001 |
[Effect of G-CSF (nartograstim) on neutropenia (leukopenia) induced by taxane in metastatic breast cancer--time-course changes in neutrophil and leukocyte counts].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Neutropenia; Neutrophils; Paclitaxel; Retrospective Studies; Taxoids | 2001 |
Docetaxel induced cardiotoxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids; Ventricular Dysfunction, Left | 2001 |
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Colonic Neoplasms; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Immunotoxins; Inhibitory Concentration 50; Lewis Blood Group Antigens; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids | 2001 |
Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Sternum; Taxoids | 2001 |
[Treatment outcomes with vinorelbine for metastatic breast cancer patients previously treated with both doxorubicin and docetaxel].
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
[A patient with recurrent breast cancer whose liver metastasis regressed following combined use of weekly docetaxel and MPA.5'-DFUR].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Liver Neoplasms; Medroxyprogesterone Acetate; Paclitaxel; Taxoids | 2001 |
From the Food and Drug Administration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diethylhexyl Phthalate; Docetaxel; Female; Financing, Government; Fluorouracil; Heart Failure; Humans; Male; Orphan Drug Production; Pacemaker, Artificial; Paclitaxel; Spermatogenesis; Taxoids; Testis; United States; United States Food and Drug Administration | 2001 |
Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver Neoplasms; Paclitaxel; Salvage Therapy; Taxoids | 2001 |
[Therapeutic effect of multimodal therapy, such as cryosurgery, locoregional immunotherapy and systemic chemotherapy against far advanced breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cisplatin; Combined Modality Therapy; Cryosurgery; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Immunotherapy; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Picibanil; Taxoids | 2001 |
[Docetaxel was effective as neoadjuvant chemotherapy for patients after failure of trans-arterial neoadjuvant chemotherapy with CEF in 2 cases of advanced breast cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Failure | 2001 |
[A case of locally advanced breast cancer successfully treated with wide resection and reconstruction of chest wall with A-O metallic plates].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Mastectomy; Middle Aged; Paclitaxel; Plastic Surgery Procedures; Quality of Life; Surgical Mesh; Survivors; Taxoids | 2001 |
[Local therapy for stage IV advanced breast cancer with brain metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Quality of Life; Radiosurgery; Tamoxifen; Taxoids | 2001 |
[Taxane-based palliative chemotherapy for metastatic breast cancer: matched pair analysis to compare the efficacy and safety of docetaxel and paclitaxel].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Disease-Free Survival; Docetaxel; Female; Humans; Matched-Pair Analysis; Middle Aged; Paclitaxel; Palliative Care; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cachexia; Docetaxel; Drug Interactions; Female; Floxuridine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Paclitaxel; Taxoids; Tegafur; Thymidine Phosphorylase; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
[Cardiac conduction abnormalities after neoadjuvant chemotherapy with doxorubicin and docetaxel for primary breast carcinoma: a case report].
Topics: Aged; Anesthesia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Heart Block; Humans; Intraoperative Complications; Mastectomy, Segmental; Paclitaxel; Postoperative Complications; Taxoids | 2001 |
[Hepatic infusion of docetaxel using PEIT for a patient with stage IV breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Ethanol; Fadrozole; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Injections, Intralesional; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2001 |
[A case of breast cancer with multiple metastases effectively treated with long-term administration of docetaxel, aclarubicin and UFT].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Tegafur; Uracil | 2001 |
Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dacryocystorhinostomy; Docetaxel; Drug Administration Schedule; Female; Glass; Humans; Infusions, Intravenous; Intubation; Lacrimal Duct Obstruction; Middle Aged; Nasolacrimal Duct; Paclitaxel; Silicone Elastomers; Taxoids; Tears | 2001 |
Taxanes in the adjuvant treatment of breast cancer: why not yet?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Meta-Analysis as Topic; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Taxoids | 2001 |
Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA Primers; Docetaxel; Female; Humans; Middle Aged; Mixed Function Oxygenases; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Taxoids | 2002 |
[Clinical observation of taxotere in the treatment of advanced non-small-cell lung cancer and breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow.
Topics: Adult; Anthracyclines; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Breast Neoplasms; Cell Separation; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Infection Control; Infections; Inflammation; Melphalan; Middle Aged; Mitoxantrone; Mucous Membrane; Multivariate Analysis; Neutropenia; Paclitaxel; Patient Selection; Retrospective Studies; Risk; Taxoids; Thiotepa; Transplantation Conditioning | 2001 |
'Rings' of F-actin form around the nucleus in cultured human MCF7 adenocarcinoma cells upon exposure to both taxol and taxotere.
Topics: Actins; Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Nucleus; Cell Survival; Cytoskeleton; Docetaxel; Female; Humans; Immunohistochemistry; Microfilament Proteins; Microtubules; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2000 |
Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2001 |
Challenges in oncology. Case 2. Radiation recall associated with docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Paclitaxel; Radiation Injuries; Radiotherapy; Skin; Taxoids | 2002 |
[Combination of taxotere and doxorubicin in chemotherapy of disseminated breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2001 |
Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Neoplasm Staging; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Taxoids; Treatment Outcome | 2000 |
Severe interstitial pneumonitis associated with docetaxel administration.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Prognosis; Prostatic Neoplasms; Respiration, Artificial; Taxoids; Uterine Neoplasms | 2002 |
Massive cavitation of solid pulmonary metastatic lesions in a breast cancer patient: a case report.
Topics: Adult; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Lung; Lung Neoplasms; Paclitaxel; Taxoids | 2002 |
Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Lacrimal Apparatus Diseases; Lacrimal Duct Obstruction; Middle Aged; Paclitaxel; Taxoids | 2002 |
Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Paclitaxel; Taxoids | 2002 |
Clinical trials of new anticancer agents in recent years in China.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Clinical Trials as Topic; Colorectal Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Male; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
Gastrointestinal pneumatosis after docetaxel chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Emphysema; Female; Humans; Middle Aged; Paclitaxel; Pneumatosis Cystoides Intestinalis; Stomach Diseases; Taxoids; Tomography, X-Ray Computed | 2002 |
Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Collagen; Cyclophosphamide; Docetaxel; Drug Screening Assays, Antitumor; Epirubicin; Female; Gels; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Taxoids | 2002 |
Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
Monotherapy with paclitaxel as third-line chemotherapy against anthracycline-pretreated and docetaxel-refractory metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Multiple; Female; Follow-Up Studies; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Neoplasm Staging; Paclitaxel; Risk Assessment; Taxoids; Treatment Failure; Treatment Outcome | 2002 |
[A case report of both CAF and docetaxel-resistant breast cancer responding to paclitaxel weekly therapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2002 |